<SEC-DOCUMENT>0001640334-18-000968.txt : 20180515
<SEC-HEADER>0001640334-18-000968.hdr.sgml : 20180515
<ACCEPTANCE-DATETIME>20180515071350
ACCESSION NUMBER:		0001640334-18-000968
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180515
DATE AS OF CHANGE:		20180515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nemus Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		18833045

	BUSINESS ADDRESS:	
		STREET 1:		130 NORTH MARINA DRIVE
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90803
		BUSINESS PHONE:		(949) 396-0330

	MAIL ADDRESS:	
		STREET 1:		130 NORTH MARINA DRIVE
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nmus_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html><head><title>nmus_10q.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>UNITED STATES</b></font></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>SECURITIES AND EXCHANGE COMMISSION</b></font></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>Washington, D.C. 20549</b></font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="5">FORM 10-Q</font></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">(Mark One)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p><font style="FONT-FAMILY: Wingdings">x</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><b>QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr>
<tr height="15">
<td></td>
<td></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify">For the quarterly period ended <b>March 31, 2018</b></p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>or</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Wingdings">o</font> </p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr>
<tr height="15">
<td></td>
<td></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify">For the transition period from ___________ to&nbsp;___________</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Commission File Number: <b><u>000-55136</u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="45%" align="center" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center"><b><font size="5">Nemus Bioscience, Inc.</font></b></p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter)</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="45%">
<p style="MARGIN: 0px" align="center"><b>Nevada</b></p></td>
<td width="10%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="45%">
<p style="MARGIN: 0px" align="center"><b>45-0692882</b></p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center">(State or other jurisdiction</p>
<p style="MARGIN: 0px" align="center">of incorporation or organization)</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="center">(I.R.S. Employer</p>
<p style="MARGIN: 0px" align="center">Identification No.)</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="100%">
<p style="MARGIN: 0px" align="center"><b><u>130 North Marina Drive, Long Beach, CA 90803</u></b></p></td></tr>
<tr height="15">
<td valign="top" width="100%">
<p style="MARGIN: 0px" align="center">(Address of principal executive offices) (Zip Code)</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="100%">
<p style="MARGIN: 0px" align="center"><b><u>(949) 396-0330</u></b></p></td></tr>
<tr height="15">
<td valign="top" width="100%">
<p style="MARGIN: 0px" align="center">(Registrant's telephone number, including area code)</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>________________________________________________</b></p>
<p style="MARGIN: 0px" align="center">(Former name or former address, if changed since last report)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <font face="Wingdings">x</font> Yes&nbsp;&nbsp;&nbsp; <font face="Wingdings">o</font> No</p>
<p style="MARGIN: 0px" align="right">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <font face="Wingdings">x</font> Yes&nbsp;&nbsp;&nbsp; <font face="Wingdings">o</font> No</p>
<p style="MARGIN: 0px" align="right">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the registrant is a large accelerated file, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0">
<tr height="15">
<td valign="top" width="20%">
<p style="MARGIN: 0px" align="justify">Large accelerated filer</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Wingdings">o</font></p></td>
<td valign="top" width="25%">
<p style="MARGIN: 0px" align="justify">Accelerated filer</p></td>
<td valign="top" width="10%">
<p style="MARGIN: 0px" align="justify"><font face="Wingdings">o</font></p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Non-accelerated filer</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Wingdings"><font style="FONT-FAMILY: Wingdings">&#168;</font> </font>(Do not check if a smaller reporting company)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Smaller reporting company</p></td>
<td valign="top">
<p><font style="FONT-FAMILY: Wingdings">x</font></p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify">Emerging growth company</p></td>
<td>
<p><font style="FONT-FAMILY: Wingdings">x</font></p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font face="Wingdings">x</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <font face="Wingdings">o</font> Yes&nbsp;&nbsp;&nbsp; <font face="Wingdings">x</font> No</p>
<p style="MARGIN: 0px" align="right">&nbsp;</p>
<p style="MARGIN: 0px">As of May 10, 2018, there were 132,601,579 shares of the issuer's $0.001 par value common stock issued and outstanding.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">
<table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px" align="center"><b><a name="toc">TABLE OF CONTENTS</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td colspan="5">
<p style="MARGIN: 0px" align="center"><b><a href="#PART I - FINANCIAL INFORMATION">PART I&#8212;FINANCIAL INFORMATION</a></b></p></td></tr>
<tr height="15">
<td width="10%"></td>
<td></td>
<td width="1%"></td>
<td width="9%"></td>
<td width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 1. Financial Statements">Item 1.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 1. Financial Statements">Financial Statements:</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">4</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#BAL">Consolidated Balance Sheets as of March 31, 2018 (Unaudited) and December 31, 2017</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">4</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#soo">Consolidated Statements of Operations for the Three Months Ended March 31, 2018 and 2017 (Unaudited)</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">5</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#cash">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017 (Unaudited)</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">6</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#note">Notes to the Unaudited Consolidated Financial Statements</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">7</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.">Item 2.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">26</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 3. Quantitative and Qualitative Disclosures about Market Risk.">Item 3.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 3. Quantitative and Qualitative Disclosures about Market Risk.">Quantitative and Qualitative Disclosures about Market Risk</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">29</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 4. Controls and Procedures.">Item 4.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 4. Controls and Procedures.">Controls and Procedures</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">29</p></td>
<td></td></tr>
<tr height="15" bgcolor="#ffffff">
<td></td>
<td></td>
<td></td>
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td colspan="4">
<p style="MARGIN: 0px" align="center"><b><a href="#PART II - OTHER INFORMATION">PART II &#8211; OTHER INFORMATION</a></b></p></td>
<td></td></tr>
<tr height="15" bgcolor="#ffffff">
<td></td>
<td></td>
<td></td>
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 1. Legal Proceeding">Item 1.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 1. Legal Proceeding">Legal Proceedings</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 1A. Risk Factors.">Item 1A.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 1A. Risk Factors.">Risk Factors</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.">Item 2.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 3. Defaults Upon Senior Securities.">Item 3.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 3. Defaults Upon Senior Securities.">Defaults Upon Senior Securities</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 4. Mine Safety Disclosures.">Item 4.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 4. Mine Safety Disclosures.">Mine Safety Disclosures</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 5. Other Information.">Item 5.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 5. Other Information.">Other Information</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 6. Exhibits.">Item 6.</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify"><a href="#Item 6. Exhibits.">Exhibits</a></p></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">30</p></td>
<td></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak4b291fef-9880-4c89-aa87-0bc1d262db46" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>FORWARD-LOOKING STATEMENTS</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Statements in this Quarterly Report on Form 10-Q that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, you can identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," "will," "would" or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section titled "Risk Factors" including, without limitation, risks relating to:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px" align="justify">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need;</p></td></tr>
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">the early stage of our product candidates presently under development;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="left"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">our ability to retain or hire key scientific or management personnel;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">our dependence on the University of Mississippi, third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">our ability to develop successful sales and marketing capabilities in the future as needed;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">competition in our industry; and</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">regulatory developments in the United States and foreign countries.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreake818c42b-dcb1-41bc-bbe6-77b73ce88cde" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="PART I - FINANCIAL INFORMATION">PART I - FINANCIAL INFORMATION</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><a name="Item 1. Financial Statements"><b><u>Item 1. Financial Statements</u></b><b><u></u></b></a></p>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px">
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><a name="BAL">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</a></b></p></td></tr>
<tr>
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>CONSOLIDATED BALANCE SHEETS</b></p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>ASSETS</b></p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(Unaudited)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>March 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>December 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2018</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Current assets</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash and cash equivalents </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2,945,312</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">259,955</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Restricted cash </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">4,428</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">4,428</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Prepaid expenses </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" align="right">206,317</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" align="right">291,428</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total current assets </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">3,156,057</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">555,811</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Property and equipment, net </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">2,134</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">1,407</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total assets </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" align="right">3,158,191</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" align="right">557,218</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED </b></p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>STOCK AND STOCKHOLDERS' DEFICIT </b></p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(Unaudited)</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>March 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>December 31, </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" colspan="2">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2018</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" colspan="2">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Current liabilities </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">98,757</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">100,921</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable to related party </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">100,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accrued payroll and related expenses </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">45,704</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">54,512</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accrued expenses </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">78,237</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">143,826</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Provision for conversion of Series B preferred stock </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">6,715</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Convertible debt </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">235,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Provision for conversion of convertible debt </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">265,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total current liabilities </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">322,698</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">805,974</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Noncurrent liabilities </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Warrant liabilities </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">8,589,472</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">551,322</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total noncurrent liabilities </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">8,589,472</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">551,322</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total liabilities </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" align="right">8,912,170</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" align="right">1,357,296</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Commitments and contingencies </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">(Note 3) </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Redeemable Convertible Series B Preferred Stock, $0.001 par value, 20 </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top" colspan="2">
<p style="MARGIN: 0px 0px 0px 15px">million shares authorized; none issued and outstanding as of March 31, 2018 </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" colspan="3">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">and 2,833.55 issued and outstanding as of December 31, 2017, </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">net of $347,091 of issuance costs </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">822,201</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Convertible Series D Preferred Stock, $0.001 par value, 20 million </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">shares authorized; none issued and outstanding as of March 31, 2018, </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">and 200 issued and outstanding as of December 31, 2017, </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">net of $30,557 of issuance costs </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">169,446</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Convertible Series F Preferred Stock, $0.001 par value, 20 million </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">shares authorized; none issued and outstanding as of March 31, 2018 </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">and 2,000 issued and outstanding as of December 31, 2017, </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">net of $118,855 of issuance costs </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">-</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">1,777,781</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Stockholders&#8217; deficit </b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock, $0.001 par value; 236 million shares authorized; </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">132,414,079 issued and outstanding as of March 31, 2018 </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">and 33,622,829 issued and outstanding as of December 31, 2017 </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">132,414</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">33,623</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Additional paid-in-capital </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">15,375,360</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">9,444,831</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Warrants </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">982,911</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">982,911</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated deficit </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">(22,244,664</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">)</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">(14,030,871</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total stockholders&#8217; deficit </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">(5,753,979</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">)</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" align="right">(3,569,506</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total liabilities and stockholders&#8217; deficit </p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" align="right">3,158,191</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" align="right">557,218</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">See accompanying notes to the unaudited consolidated financial statements. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak318b734f-01cd-41a4-b03e-0cc2ce4bc2c5" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">4</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><a name="soo">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</a></b></p></td></tr>
<tr>
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p></td></tr>
<tr>
<td valign="top" colspan="11">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(unaudited)</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Three months </b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Three months </b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>March 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>March 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2018</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Operating expenses</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Research and development</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">25,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">92,100</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">General and administrative</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,226,361</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,288,053</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">Total operating expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,251,361</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,380,153</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Operating loss</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(1,251,361</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(1,380,153</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Interest expense</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">3,100</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Other expense (income)</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Change in fair value of warrant liability</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(1,162,493</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(12,561</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Fair value of warrant liability in excess of proceeds</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">7,174,634</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Change in fair value of conversion rights of Series B preferred stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(85,205</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Change in fair value of conversion rights of convertible debt</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">185,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Financing transaction costs</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">137,191</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Loss on extinguishment of convertible&nbsp;debt</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">590,392</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Amortization of convertible&nbsp;debt discount</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">34,608</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Net Loss before income taxes</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(8,213,793</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">(1,282,387</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Provision for income taxes</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">831</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Net loss</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(8,213,793</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(1,283,218</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Less: Preferred deemed dividend</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign="bottom" width="9%" align="right">711,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Net loss applicable to common shareholders</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">(8,213,793</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign="bottom" width="9%" align="right">(1,994,218</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Basic earnings per common share</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.09</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.09</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Diluted earnings per common share</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.09</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">(0.09</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Weighted average shares of common stock outstanding</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px"><b>Basic</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">88,632,979</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">23,247,530</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px"><b>Diluted</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">88,632,979</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">23,247,530</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">See accompanying notes to the unaudited consolidated financial statements.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak55966c4e-c618-49a0-b7d6-7dc8afc68c1e" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">5</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" colspan="12">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><a name="cash">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</a></b></p></td></tr>
<tr>
<td valign="top" colspan="12">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p></td></tr>
<tr>
<td valign="top" colspan="12">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>(unaudited)</b></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp; </p>
<p style="MARGIN: 0px">
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Three months </b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Three months </b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>ended</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>March 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>March 31,</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2018</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>2017</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Cash flows from operating activities:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Net loss </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(8,213,793</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">(1,283,218</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Adjustments to reconcile net loss to net cash </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 30px">used in operating activities:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Depreciation</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">331</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">2,428</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Stock-based compensation expense</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">229,609</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">152,169</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Amortization of warrants and stock issued for services (1)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Change in fair value of conversion rights of Series B preferred stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(85,205</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Change in fair value of conversion rights of convertible debt</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">185,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Change in fair value of warrant liabilities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(1,162,493</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(12,561</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Fair value of warrant liability in excess of proceeds</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">7,174,634</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Loss on extinguishment of&nbsp;convertible debt</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">590,392</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Amortization of convertible&nbsp;debt discount</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">34,608</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Common stock issued for services</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">187,550</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 45px">Changes in assets and liabilities:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Prepaid expenses (1)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">85,111</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">43,994</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Accounts payable</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(2,164</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(47,486</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Accounts payable to related party</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">100,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Accrued payroll and related expenses</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(8,808</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">(48,368</td>
<td valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Accrued license and patent reimbursement fees</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">16,250</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Accrued expenses and other liabilities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(65,589</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">253,042</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 75px">Net cash used in operating activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(1,053,162</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(816,405</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Cash flows from investing activities:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Purchases of property and equipment</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(1,059</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Net cash used in investing activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">(1,059</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Cash flows from financing activities:</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from Series D preferred stock issuance, net of $183,343 issuance costs (2)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,131,857</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from Common stock issuance, net of $9,122 issuance costs</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">3,240,878</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from Warrant exercises</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">98,700</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from Convertible debt issuance</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">400,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 60px">Net cash provided by financing activities</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">3,739,578</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">1,131,857</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Net increase in cash, cash equivalents and restricted cash</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">2,685,357</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">315,452</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Cash, cash equivalents and restricted cash</b>,<b> beginning of period</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">264,383</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">102,320</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><b>Cash, cash equivalents and restricted cash, end of period</b></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">2,949,740</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">417,772</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><i>Supplemental disclosures of cash-flow information:</i></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Reconciliation of cash, cash equivalents and restricted cash:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash and cash equivalents</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">2,945,312</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">380,272</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Restricted cash</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">4,428</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">37,500</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Total cash, cash equivalents and restricted cash shown in the consolidated</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">statements of cash flows</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">2,949,740</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">417,772</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Cash paid during the period for:</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Interest</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Income taxes</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">-</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%" align="right">1,631</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><i>Supplemental disclosures of non-cash financing activities:</i></p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Conversion of outstanding preferred stock into common stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,947,227</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">880,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Conversion of outstanding preferred stock subject to redemption into common stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">828,916</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">405,625</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px 0px 0px 15px">Fair value of common stock issued in extinguishment of convertible debt </p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">1,710,000</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">&nbsp;-</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px 0px 0px 15px">Fair value of warrants issued in connection with Emerald financing</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">10,424,634</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">-</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px 0px 0px 15px">Release of warrant liabilities due to exercise of warrants</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="right">&nbsp;1,223,991</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">&nbsp;-</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px 0px 0px 0in"><i>&nbsp;</i></p>
<p style="MARGIN: 0px 0px 0px 0in"><i>Supplemental disclosures of non-cash financing and investing activities:</i></p>
<p style="MARGIN: 0px 0px 0px 0in"><em></em>&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%" colspan="2">
<p style="MARGIN: 0px 0px 0px 0in">(1)</p></td>
<td valign="top" colspan="7">
<p style="MARGIN: 0px 0px 0px 0in">During the three months ended March 31, 2017, warrants issued to service providers for consulting services were valued at $30,000 and were recorded as a Prepaid expense and amortized over the service period.</p></td></tr>
<tr height="15">
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="7">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="top" colspan="2">
<p style="MARGIN: 0px 0px 0px 0in">(2)</p></td>
<td valign="top" colspan="7">
<p style="MARGIN: 0px 0px 0px 0in">During the three months ended March 31, 2017 preferred deemed dividends of $536,000 was recognized on Series D Preferred Stock and $175,000 on Series C Preferred Stock.</p></td></tr></table>&nbsp;
<p style="MARGIN: 0px 0px 0px 0in" align="center">See accompanying notes to the unaudited consolidated financial statements. </p>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak54ee428f-d419-489a-8cbe-b8e7c0b022fb" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">6</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="note">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</a></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>1. Nature of Operations, Business Activities and Summary of Significant Accounting Policies</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Nature of Operations and Basis of Presentation</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi (&#8220;UM&#8221;) is federally permitted and licensed to cultivate cannabis for research purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;our&#8221; refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. (&#8220;LGL&#8221;), together with its wholly-owned subsidiary, Nemus, a California corporation (&#8220;Nemus&#8221;). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Long Beach, California. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald&#8221;) discussed in note 4 below in which Emerald purchased a majority of the equity interest in Nemus resulting in a change in control. The current Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, have tendered their resignation and Emerald has appointed its nominees to the new Board.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of March 31, 2018, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Use of Estimates</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense and equity securities with embedded features as discussed below.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Liquidity and Going Concern</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has incurred operating losses and negative cash flows from operations since our inception. As of March 31, 2018, we had cash and cash equivalents of $2,945,312. The Company anticipates that it will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements were issued. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company&#8217;s continued existence is dependent on its ability to raise additional sufficient funding to cover operating expenses and to invest in operations and development activities. The Company plans to continue to pursue funding through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs or cease operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak84b41835-9589-4c5e-8088-e0f023deca66" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">7</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Restricted Cash</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">A deposit of $4,428 as of both March 31, 2018 and December 31, 2017 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&#8217;s credit cards.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Fair Value Measurements</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%"></td>
<td valign="top" width="6%">
<p style="MARGIN: 0px" align="justify">Level 1:</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Level 2:</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Level 3:</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The warrant liability for the Emerald warrants and the associated put option were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Property and Equipment, Net</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of March 31, 2018 and December 31, 2017, property and equipment, net, was $2,134 and $1,407 respectively, consisting primarily of computers and equipment. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak90b8a783-a0ba-4e35-bd43-29ac41a4db78" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">8</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Income Taxes</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the &#8220;NOLs&#8221;) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#8217;s statement of operations in the period incurred.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Convertible Instruments</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. ASC 815, <i>Derivatives and Hedging Activities</i> (&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> (&#8220;ASC 470-20&#8221;). Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. We account for convertible instruments (when we have determined that the embedded conversion options should be bifurcated from their host instruments) in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We also follow ASC 480-10, <i>Distinguishing Liabilities from Equity</i> (&#8220;ASC 480-10&#8221;) in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in interest expense in the accompanying Consolidated Statements of Operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Warrants Issued in Connection with Financings</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other (income) expense in the Consolidated Statements of Operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak4e72f065-28fe-42b6-a7fb-55dfdebbab92" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">9</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Revenue Recognition</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has not begun planned principal operations and has not generated any revenue since inception.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Research and Development Expenses</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Research and development (&#8220;R&amp;D&#8221;) costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Stock-Based Compensation Expenses</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Volatility - We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Stock-Based Compensation for Non-Employees</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) No. 505-50, <i>Equity - Equity Based Payments to Non-Employees,</i> using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Segment Information</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">FASB ASC No. 280, <i>Segment Reporting</i>, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (&#8220;CODM&#8221;), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Comprehensive Income (Loss)</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three months ended March 31, 2018 and 2017, the comprehensive income (loss) was equal to the net income (loss).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Earnings per share</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company applies FASB ASC No. 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of outstanding warrants and awards granted to employees under stock-based compensation plans. Potentially dilutive shares of the Company&#8217;s common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented. For the three months ended March 31, 2018, warrants to purchase 51,443,250 common shares and stock options exercisable for 1,030,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share. For the three months ended March 31, 2017, 3,625.375 shares of Series B Preferred Stock convertible into 14,501,500 common shares at $0.25 per share, 706 shares of Series D Preferred Stock convertible into 2,824,000 common shares at $0.25 per share, warrants to purchase 11,649,500 common shares and stock options exercisable for 1,130,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak940a9d5e-9869-4f41-ae24-e1afe030a002" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">10</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Recent accounting pronouncements</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In July 2017, the FASB issued ASU 2017-11,<i> Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating<i> Topic 480, Distinguishing Liabilities from Equity</i>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>2. University of Mississippi Agreements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months&#8217; written notice to the other party.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>UM 5050 pro-drug agreements</u>:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM 5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>UM 8930 analogue agreements:</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, an analogue formulation of cannabidiol (&#8220;CBD&#8221;) for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakff7f0624-04a5-470f-9b39-aef1e4c31f72" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">11</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>UM 5070 license agreement:</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On January 10, 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). The license agreement contains certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date and this amount was paid in January, 2018. The aggregate milestone payment under the license agreements, if the milestones are achieved, is $0.7 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>3. Commitments and Contingencies</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Lease Commitments</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the UM campus. The lease term commenced on October 1, 2014 and expired on December 31, 2017. There is annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease were divided by the total number of months in the lease period and the average rent was charged to expense each month during the lease period. The monthly amount charged to rent expense was $9,267. Upon expiration, the Company did not renew the laboratory lease but has retained office space under a month-to-month agreement at the rate of $300 per month.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company maintained its principal executive offices located in a shared office suite located at 600 Anton Blvd., Suite 1100, Costa Mesa, CA, 92626 under a month-to-month agreement. Effective March 1, 2018, the Company moved its corporate offices to 130 North Marina Drive, Long Beach, CA 90803 under a month-to-month agreement at a rate of approximately $2,600 per month.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In November 2015, the Company entered into an operating lease for its office and lab furnishings both in Costa Mesa and the Innovation Hub laboratory. The monthly lease payments were $7,559. In November 2017, the Company bought out the remaining portion of the lease for $32,128 which covered the remaining lease payments as well as the value of the furniture amounting to $19,654. The lab furnishings were donated to the University of Mississippi and the office furnishings were written off due to non-use for a loss on disposal of $1,650.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Total net rent expense related to our operating leases for the three months ended March 31, 2018 and 2017 was $4,311 and $56,449, respectively. There are no future minimum payments under non-cancellable operating leases.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Related Party Matters</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In June 2014, our subsidiary entered into an independent contractor agreement with K2C, Inc. (&#8220;K2C&#8221;), which is wholly owned by the Company&#8217;s then Executive Chairman and Co-Founder, Mr. Cosmas N. Lykos, pursuant to which we paid K2C a monthly fee for services performed by Mr. Lykos for our company. The agreement expired on June 1, 2017 and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In February 2018, we entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted on January 18, 2018, 325,000 shares of restricted common stock granted on October 20, 2015, and 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. The Company recognized additional stock based compensation expense of $112,270 for these restricted stock and option awards. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2018 and 2017, total cash payments made under these agreements was $220,000 (including the previously discussed lump sum payment) and $30,000 respectively. Under the separation agreement, Mr. Lykos is also eligible to participate in our health, death and disability insurance plans for six months subsequent to K2C&#8217;s separation. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak7b8e3882-c513-4db8-bb26-bcb18287a295" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">12</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On February 1, 2018, we entered into an Independent Contractor Agreement with Emerald, pursuant to which Emerald will provide such services as are mutually agreed between the Company and Emerald, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services can include, but are not limited to corporate advisory services and technical expertise in the areas of business development, marketing and product development. The Independent Contractor Agreement specifies a compensation rate as is agreed between our chief executive officer and Emerald&#8217;s chief executive officer on a month-to-month basis. For the three months ended March 31, 2018, the Company incurred expenses of $100,000 under this Agreement. In addition, the Company accrued $15,000 in advisory fees payable directly to Emerald&#8217;s chief executive officer for advisory services rendered and these fees were paid in April 2018. The Independent Contractor Agreement has an initial term of ten years.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Legal Matters</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>General Litigation and Disputes</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations. As of March 31, 2018, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&#8217;s financial position or results of operations, but the Company has filed a petition commencing arbitration as described below. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Pending Series E Preferred Stock Financing and Filing for Arbitration</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On May 3, 2017, the Company entered into a securities purchase agreement with a purchaser to sell 1,000,000 shares of a new Series E Preferred Stock, par value $0.001 per share, at a purchase price of $20.00 for each preferred share for aggregate gross proceeds of $20,000,000. The securities purchase agreement provides for no conditions precedent to the close and that closing is not to occur later than July 10, 2017. The purchaser did not provide funding to close the transaction on July 10, 2017 as required under the securities purchase agreement and requested an extension of the closing date. In connection with the signing of the securities purchase agreement, an affiliate of the purchaser entered into a financial guarantee to the benefit of the Company that provided for payment of the purchase price in full within 90 days of exercise. The Company exercised this guarantee on July 12, 2017. The guarantor has failed to pay the $20,000,000 within 90 days of notice of the purchaser&#8217;s default, as required by the terms of the guaranty. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On November 8, 2017, the Company filed a petition commencing arbitration against the purchaser and guarantor as well as other related individuals. In the petition, the Company asserts, among other things, breach of contract against the purchaser for its failure to close its purchase of Series E Preferred Stock as required by the securities purchase agreement. The Company also asserts a breach of contract claim against the guarantor for its failure to honor its guarantee of the transaction. The petition was filed with Judicial Arbitration and Mediation Services, Inc., ENDISPUTE in Orange County, California, as required by the securities purchase agreement. The Company has engaged its legal counsel in the matter on a contingent-fee basis and intends to purse damages and remedies in connections with these agreements. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Government Proceedings</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of March 31, 2018, the Company had no proceedings or inquiries.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Change in Control Severance Plan</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&#8217;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive&#8217;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&#8217;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak75a3f923-62b2-49b6-8bbf-4f434461e899" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">13</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Contract Manufacturing Organization (&#8220;CMO&#8221;) Agreement</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On February 5, 2016, the Company entered into a letter agreement (&#8220;Agreement&#8221;) with a third party contract manufacturing organization (&#8220;CMO&#8221;) pursuant to which the CMO is to provide services to Nemus for process development and analytical method development and qualification for Nemus&#8217; pro-drug of tetrahydrocannabinol, or THC, as well as for sample production and a stability study.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Pursuant to the terms of the Agreement, Nemus will pay an estimated $154,000 to $183,000 in fees and expenses for the initial evaluation and development of a process for the production of Nemus&#8217; pro-drug of THC to ensure reproducibility, quality and safety and an estimated $142,900 for analytical method development and qualification. The Company did not recognize any research and development expense under this agreement for the three months ended March 31, 2018 and 2017, respectively. After the initial evaluation and development, Nemus has agreed to pay additional fees and expenses for sample production of Nemus&#8217; pro-drug of THC and a stability study, as well as possible extensions to or modifications of the aforementioned projects.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Nemus may at any time cancel or delay any project under the Agreement prior to the scheduled start date. Nemus must reimburse the CMO for costs incurred prior to and including the date of cancellation plus any reasonable and foreseeable costs associated with stopping work on any project, including the CMO&#8217;s loss of revenue incurred as the result of reserving production facilities for Nemus&#8217; exclusive use. Nemus may terminate the Agreement in whole or in part at any time upon 30 days&#8217; written notice.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>4. Stockholders&#8217; Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Common Stock</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In March 2017, the Company issued 605,000 shares of common stock with par value of $0.001 to a third party in exchange for advisory services performed related to raising additional capital. The Company recorded $187,550 as general and administrative expense for the first quarter of 2017 to reflect the fair market value of the common stock issued. The fair market value was determined utilizing the Company&#8217;s closing stock price as of the approval date of the advisory fee by the Company&#8217;s Board of Directors. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the year ended December 31, 2017, a Series C Preferred stockholder converted 386 shares of its preferred stock to common stock as allowed under the Series C Preferred Stock Agreement, resulting in the issuance of 1,544,000 shares of common stock at an effective price of $0.25 per share. This represented the completion of converting all of the original Series C Preferred shares to common stock. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the year ended December 31, 2017, the Series B Preferred stockholders converted 1,197.45 shares of their preferred stock to common stock as allowed under the Series B Preferred Stock Agreement. This resulted in the issuance of&nbsp;5,910,666 shares of common stock at an effective price of $0.25 per share prior to November 1, 2017 and $0.15 per share from&nbsp;November 1, 2017 to December 27, 2017 after issuance of the Series F Preferred Stock. On December 28, 2017, the conversion rate was reset to $0.10 per share as a result of the convertible bridge loan but no conversions occurred from this date through-year end.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the year ended December 31, 2017, the Series D Preferred stockholders converted 1,000 shares of their preferred stock as allowed under the Series D Preferred Stock Agreement, resulting in the issuance of 4,000,000 shares of common stock at an effective price of $0.25 per share. On December 28, 2017, the conversion rate was reset to $0.10 per share as a result of the convertible bridge loan but no conversions occurred from this date through-year end.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On January 19, 2018, the Company entered into a Securities Purchase Agreement in which the Company sold to Emerald 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000 (&#8220;the Emerald Financing&#8221;). This transaction also resulted in the conversion of the $900,000 bridge loan (discussed in note 7 below) at $0.10 per share to 9,000,000 shares of common stock and represented the first of two closings under the Agreement. As a result of this transaction, the Company had a change in control and all Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, tendered their resignation. Emerald has appointed its nominees to the new Board. The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The second closing under the Emerald Financing occurred on February 16, 2018, pursuant to which Nemus issued and sold to Emerald 15,000,000 shares of Nemus&#8217; common stock, and a warrant to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share for a term of five years. In addition, an accredited investor purchased 2,500,000 shares of common stock and a warrant to purchase 3,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. The Company received aggregate gross proceeds of $1,750,000 from this second closing.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakcf9b0934-4aba-4680-86a1-fbdf85d06dcc" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">14</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2018, all remaining Series B, D, and F stockholders converted their shares of preferred stock to common stock at an effective price of $0.10 per share. This resulted in 2,833.55 Series B Preferred Stock being converted into 28,335,500 shares of common stock, 200 shares of Series D Preferred Stock being converted into 2,000,000 shares of common stock, and 2,000 shares of Series F Preferred Stock being converted into 20,000,000 shares of common stock. All such conversions occurred prior to the change in control which took effect on January 19, 2018. In addition, Series B warrant holders exercised warrants with an intrinsic value of $1,125,291 which resulted in the issuance of 4,406,250 shares of common stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Preferred Stock</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Redeemable Convertible Series B Preferred Stock:</u> In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company&#8217;s common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million. Each share of preferred stock was initially convertible into 1,250 shares of common stock which resulted in an effective conversion price of $0.80 per common share and could be converted by the holder at any time. The Series B Preferred Stock also has a &#8220;down-round&#8221; protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. In October 2016, as a result of the Series C Preferred Stock Agreement (as discussed below), the conversion price of the Series B Preferred Stock was reset to $0.40. On December 29, 2016, as a result of the Series D Preferred Stock Agreement, the conversion price of the Series B Preferred Stock was reset to $0.25. On November 1, 2017, as a result of the Series F Preferred Stock Agreement, the conversion price of the Series B Preferred Stock was reset to $0.15 per share. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series B Preferred Stock conversion price was reset to $0.10 per share. The Series B Preferred Stock has liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder&#8217;s preferred stock is convertible as of the record date. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share, subject to reset, and expire five years from the issuance date. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B Preferred stockholders receive an amount per share equal to the conversion price of $0.10, subject to down-round adjustment, multiplied by the as-if converted share amount of 28,335,500 common shares, totaling $2,833,550 as of December 31, 2017. If upon the liquidation, the assets are insufficient to permit payments to the Series B holders, all assets legally available will be distributed in a pro rata basis among the Series B holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Subject to certain trigger events occurring, the Series B Preferred stockholders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top" width="92%">
<p style="MARGIN: 0px" align="justify">Failure of the Series B Registration Statement to be declared effective by the Securities and Exchange Commission, or the SEC, on or prior to the date that is ninety days after the Effectiveness Deadline;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Suspension of the Company&#8217;s common stock from trading for a period of (2) consecutive trading days;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Any default of indebtedness;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Any filing of voluntary or involuntary bankruptcy by the Company;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">A final judgment in excess of $100,000 rendered against the Company;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Breach of representations and warranties in the Stock Purchase Agreement; and</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakc6222010-13f3-4b47-84f9-1081cf48dee3" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">15</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As certain of these triggering events are considered to be outside the control of the Company, the Series B Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In 2017, through October 31st, Series B stockholders converted 777.125 shares at a conversion rate of 4000:1 resulting in the issuance of 3,108,500 shares of common stock. Effective with the Series F Preferred Stock Agreement signed on November 1, 2017, the conversion price for the Series B Preferred Stock was reset to $0.15. From November 1<sup>st</sup> to December 31, 2017, Series B stockholders converted 420.325 shares at a conversion rate of 6666.67:1 resulting in the issuance of 2,802,167 shares of common stock. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series B Preferred Stock conversion price was reset to $0.10 per share.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2018, the Series B stockholders converted all remaining 2,833.55 shares at a conversion rate of 10,000:1 resulting in the issuance of 28,335,500 shares of common stock. As a result, there is no liquidation preference outstanding as of March 31, 2018 related to the Series B Preferred Stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Convertible Series C Preferred Stock:</u> In October 2016, the Company sold 500 shares of Series C convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $500,000 to a healthcare investment fund under the Series C Preferred Stock Agreement. Each share of Series C Preferred Stock was initially convertible into 2,500 shares of common stock which resulted in an effective conversion price of $0.40 per common share. This resulted in the reduction of the conversion price of the Series B Preferred Stock to $0.40 and a reduction in the exercise price of the Series B warrants to $0.40. On December 29, 2016, as a result of the Series D Preferred Stock Agreement (as discussed below), the conversion price of the Series C Preferred Stock was reset to $0.25. As part of the terms of the Series C Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series C Convertible Preferred Stock are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Dividends:</u> Except for stock dividends or other distributions payable in shares of common stock, for which adjustments are to be made to the conversion price, as described below, the stockholder shall be entitled to receive dividends on preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends actually paid on shares of the common stock. No other dividends shall be paid on the preferred stock.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Conversion:</u> The preferred stock may be converted at any time, at the option of the holder, into shares of common stock at a conversion price of $0.25 per share (&#8220;Series C Conversion Price&#8221;). The Series C Conversion Price will be adjusted for customary structural changes such as stock splits or stock dividends. In the event that the Company enters into a merger, consolidation or transaction of a similar effect, the Series C stockholder shall be entitled to receive, upon conversion of the preferred stock, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration that would have been received by a holder of the number of shares of common stock into which the preferred stock is convertible immediately prior to such event.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Down-Round Protection:</u> The Series C Conversion Price is also subject to &#8220;down-round&#8221; anti-dilution adjustment which means that if the Company sells common stock or common stock equivalents at a price below the Series C Conversion Price, the Series C Conversion Price will be reduced to an amount equal to the issuance price of such additional shares of common stock or common stock equivalents.</p></td></tr>
<tr height="15">
<td></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Voting Rights:</u> Except as required by law, the Series C Preferred Stock does not have voting rights.</p></td></tr>
<tr height="15">
<td></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Most Favored Nation Provision:</u> If there is a subsequent financing, the Series C stockholder may elect to exchange its Series C Preferred Stock for the security issued on a dollar for dollar basis.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Participation Rights:</u> For a twelve month period from the date of the financing, the Series C investors will have the right to participate in subsequent financings up to fifty percent of such financing.</p></td></tr>
<tr height="15">
<td></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Liquidation Provision:</u> In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Series C Preferred stockholder receives an amount per share equal to the conversion price of $0.40, subject to down-round adjustment, multiplied by the as-if converted share amount of 1,250,000 common shares. If upon the liquidation, the assets are insufficient to permit payments to the Series C and Series D holders, all assets legally available will be distributed to the Series B Preferred stockholders and then any remaining amount is distributed on a pro rata basis among the Series C and Series D holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak3472cc67-5872-481c-a9f5-3f76bb49e4dd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">16</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company also considered the classification of the Series C Preferred Stock Agreement. Because the Most Favored Nation provision is a redemption feature that is outside the control of the Company, the Series C Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company&#8217;s common stock, a beneficial conversion feature of $325,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in October 2016, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During 2017, all remaining Series C Preferred Stock totaling 386 shares has been converted&nbsp;at a conversion rate of 4000:1 resulting in the issuance of 1,544,000 shares of common stock. As a result, there is no liquidation preference outstanding as of December 31, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition, as a result of the Series D financing and the adjustment in the conversion price, a beneficial conversion feature of $175,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in January 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Convertible Series D Preferred Stock:</u> In January 2017, the Company sold 1,200 shares of Series D convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $1,200,000 to a healthcare investment fund and other private investors under the Series D Preferred Stock Agreement. Each share of Series D Preferred Stock was initially convertible into 4,000 shares of common stock which resulted in an effective conversion price of $0.25 per common share. This resulted in the reduction of the conversion price of the Series B and Series C Preferred Stock to $0.25 and a reduction in the exercise price of the Series B warrants to $0.25. As part of the terms of the Series D Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchasers to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series D Convertible Preferred Stock are identical to those of the Series C Convertible Preferred Stock agreement discussed above with the exception of the initial conversion price which was $0.25 per common share.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company also considered the classification of the Series D Preferred Stock Agreement, the Series D Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet because the Most Favored Nation provision is a redemption feature that is outside the control of the Company.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company&#8217;s common stock, a beneficial conversion feature of $536,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in January 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the year ended December 31, 2017, the Series D stockholders converted 1,000 shares at a conversion rate of 4000:1 and a conversion price of $0.25 per share resulting in the issuance of 4,000,000 shares of common stock. Effective with the Series F Preferred Stock Agreement signed on November 1, 2017, the conversion price for the Series D Preferred Stock was reset to $0.15. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series D Preferred Stock conversion price was reset to $0.10 per share.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">The Series D stock has liquidation preference over common stock. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series D Preferred stockholders receive an amount per share equal to the conversion price of $0.10, subject to down-round adjustment, multiplied by the as-if converted share amount of 2,000,000 common shares, totaling $200,000 as of December 31, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2018, the Series D stockholders converted all remaining 200 shares at a conversion rate of 10,000:1 resulting in the issuance of 2,000,000 shares of common stock. As a result, there is no liquidation preference outstanding as of March 31, 2018 related to the Series D Preferred Stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakd416019f-58d1-4ed3-9381-1507385f5528" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">17</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Convertible Series F Preferred Stock:</u> In November 2017, the Company sold 2,000 shares of Series F convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $2,000,000 to a healthcare investment fund under the Series F Preferred Stock Agreement. Each share of Series F Preferred Stock is convertible into 6,666.67 shares of common stock which results in an effective conversion price of $0.15 per common share. This resulted in the reduction of the conversion price of the Series B and D Preferred Stock to $0.15 and a reduction in the exercise price of the Series B warrants to $0.15. On December 28, 2017, as a result of entering into a Secured Promissory Note for a convertible bridge loan, the conversion price of the Series F Preferred Stock was reset to $0.10. As part of the terms of the Series F Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series F Convertible Preferred Stock are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Dividends:</u> Except for stock dividends or other distributions payable in shares of common stock, for which adjustments are to be made to the conversion price, as described below, the stockholder shall be entitled to receive dividends on preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends actually paid on shares of the common stock. No other dividends shall be paid on the preferred stock.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Conversion:</u> The preferred stock may be converted at any time, at the option of the holder, into shares of common stock at a conversion price of $0.10 per share (&#8220;Series F Conversion Price&#8221;). The Series F Conversion Price will be adjusted for customary structural changes such as stock splits or stock dividends. In the event that the Company enters into a merger, consolidation or transaction of a similar effect, the Series F stockholder shall be entitled to receive, upon conversion of the preferred stock, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration that would have been received by a holder of the number of shares of common stock into which the preferred stock is convertible immediately prior to such event.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Down-Round Protection:</u> The Series F Conversion Price is also subject to &#8220;down-round&#8221; anti-dilution adjustment which means that if the Company sells common stock or common stock equivalents at a price below the Series F Conversion Price, the Series F Conversion Price will be reduced to an amount equal to the issuance price of such additional shares of common stock or common stock equivalents.</p></td></tr>
<tr height="15">
<td></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Voting Rights:</u> Except as required by law, the Series F Preferred Stock does not have voting rights.</p></td></tr>
<tr height="15">
<td></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Discretionary Redemption Provision:</u> If there is a subsequent transaction that results in a change in control, the Series F stockholder may require the Company to redeem the shares for the sum of 150% of the aggregate stated valued of the Series F Shares and all liquidated damages. However, if net proceeds from the triggering transaction are less than $6 million then the redemption amount shall equal 50% of the total proceeds of such transaction.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Participation Rights:</u> For an eighteen month period from the date of the financing, the Series F investors will have the right to participate in subsequent financings up to fifty percent of such financing.</p></td></tr>
<tr height="15">
<td></td>
<td valign="top"></td>
<td valign="top"></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><u>Liquidation Provision:</u> In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Series F stockholder has no liquidation preference.</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Subject to certain trigger events occurring, the Series F Preferred stockholders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 130% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top" width="92%">
<p style="MARGIN: 0px" align="justify">Failure of the Series F Registration Statement to be declared effective by the Securities and Exchange Commission, or the SEC, on or prior to the date that is one hundred and eighty (180) days after the Effectiveness Deadline;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Suspension of the Company&#8217;s common stock from trading for a period of five (5) consecutive trading days;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series F Preferred;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Any default of indebtedness;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Any filing of voluntary or involuntary bankruptcy by the Company;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">A final judgment in excess of $100,000 rendered against the Company;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Breach of representations and warranties in the Stock Purchase Agreement;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Failure to comply with the Series F Certificate of Designation or Rule 144 requirements; and</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font>&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="justify">A change in control that would result in the holder exercising its put option (discussed in Note 5 below).&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakb1138daf-f2e4-429a-9df3-84287faef5a2" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">18</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As certain of these triggering events are considered to be outside the control of the Company, the Series F Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">At the date of the financing, because the conversion of the preferred stock was contingent upon certain events, the conversion feature was determined to not be beneficial. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition, on December 28, 2017, as a result of entering into a Secured Promissory Note for a convertible loan which resulted in the adjustment of the conversion price to $0.10, a beneficial conversion feature of $333,333 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in December 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2018, the Series F stockholders converted all remaining 2,000 shares at a conversion rate of 10,000:1 resulting in the issuance of 20,000,000 shares of common stock. As such, there was no liquidation preference outstanding related to the Series F preferred stock as of March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Warrants</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Warrants vested and outstanding as of March 31, 2018 are summarized as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Amount</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Exercise</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Term</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Issued and</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Source</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Price</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>(Years)</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Outstanding</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Pre 2015 Common Stock Warrants</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.00</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">6-10</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">4,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2015 Common Stock Warrants</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>$</td>
<td>
<p style="MARGIN: 0px" align="right">1.15-$5.00</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">5-10</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">442,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2015 Series B Financing (see Note 6)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 11.25pt" align="justify">Common Stock Warrants to Series B Stockholders</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">1,843,750</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 11.25pt" align="justify">Placement Agent Warrants</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">187,500</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2016 Common Stock Warrants to Service Providers</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.15</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">10</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">40,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2016 Series C Placement Agent Warrants</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.40</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">125,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2017 Series D Placement Agent Warrants</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.25</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">480,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2017 Common Stock Warrants to Service Provider</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.41</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" align="right">125,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px">2018 Emerald Financing Warrants </p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.10</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">44,200,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td>
<p style="MARGIN: 0px 0px 0px 11.25pt" align="justify"><b>Total warrants vested and outstanding as of March 31, 2018</b></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 3px double"><b>51,443,250</b></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>2017 Warrants</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January 2017, the Company issued 480,000 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series D Preferred Stock financing. The warrants vest immediately and have an exercise price of $0.25 per share with a term of five years. The Company estimated the value of the warrants to be $115,200 utilizing the Black-Scholes option pricing model and recorded this amount to issuance costs.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In February 2017, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 125,000 shares of common stock with an exercise price of $0.41 per share with a term of five years. The Company estimated the warrant value to be $30,000 utilizing the Black-Scholes option pricing model and recorded this amount to general and administrative expense for the&nbsp;year due to the immediate vesting.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakfedf844f-e825-4f2e-aad9-04ffd86edf49" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">19</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>2018 Warrants</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock to Emerald Health Sciences and an accredited investor in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10, <i>Distinguishing Liabilities from Equity</i>, and concluded that the Emerald warrants should be classified as a liability. See additional discussion in Note 6 below.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p><b><i>
<p style="MARGIN: 0px" align="justify"><b><i>Stock Option Plan: 2014 Omnibus Incentive Plan</i></b></p></i></b>&nbsp;
<p style="MARGIN: 0px" align="justify">The 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants. As of March 31, 2018, options (net of canceled or expired options) covering an aggregate of 1,030,000 shares of the Company&#8217;s common stock had been granted under the 2014 Plan, and the Company had 1,030,000 options outstanding and 970,000 shares available for future grants under the 2014 Plan.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&#8217;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,030,000 shares net of cancellations and expirations through March 31, 2018 under the 2014 Plan.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following is a summary of activity under the 2014 Plan as of March 31, 2018: </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Shares</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="10">
<p style="MARGIN: 0px" align="center"><b>Options Outstanding</b></p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Available</b></p></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Weighted</b></p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>for Grant of</b></p></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td></td>
<td colspan="2">
<p style="MARGIN: 0px" align="center"><b>Average</b></p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Options &amp; </b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Number of</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Price per</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Exercise</b></p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Shares</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Shares</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Share</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Price</b></p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td></td>
<td></td>
<td colspan="2"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td colspan="2"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify"><b>Balance at December 31, 2017</b></p></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">870,000</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">1,130,000</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">0.42-3.00</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.60</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Options granted</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Options exercised</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">-</p></td>
<td valign="bottom" width="1%"></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Options cancelled</p></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">100,000</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">(100,000</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">0.42-$3.00</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">2.57</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify"><b>Balance at March 31, 2018</b></p></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">970,000</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">1,030,000</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td>
<p style="MARGIN: 0px" align="right">0.42-$3.00</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.42</p></td>
<td valign="bottom" width="1%"></td></tr>
<tr height="15" bgcolor="#ffffff">
<td></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Vested and Exercisable at March 31, 2018</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">668,000</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.42</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.42</p></td>
<td valign="bottom" width="1%"></td></tr></table></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The weighted-average remaining contractual term of options vested and exercisable at March 31, 2018 was approximately 6.62 years.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">During the three months ended March 31, 2018, the Company had cancellations of vested stock options totaling 100,000 options. Stock compensation expense for the three months ended March 31, 2018 and 2017 was $41,005 and $86,544, respectively, and was recorded to general and administrative expense.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak12c3ec84-daca-4901-9a57-c2d06ee5d158" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">20</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#8217;s stock exceeded the exercise price of the stock options at March 31, 2018 for those stock options for which the quoted market price was in excess of the exercise price (&#8220;in-the-money options&#8221;). As of March 31, 2018, the aggregate intrinsic value of options outstanding was $0. As of March 31, 2018, 668,000 options to purchase shares of common stock were exercisable.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The total amount of unrecognized compensation cost related to non-vested stock options was $349,013 as of March 31, 2018. This amount will be recognized over a weighted average period of 1.42 years.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Restricted Stock Awards</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Restricted stock awards (&#8220;RSAs&#8221;) are granted to our Board of Directors and members of senior management and are issued pursuant to the Company&#8217;s 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company&#8217;s senior management and Board of Directors with a fair market value of approximately $900,000. These RSAs vest from one to three years from the grant date as services are rendered to the Company. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On January 18, 2018, the Company entered into Restricted Stock Agreements with each of Dr. Murphy, Elizabeth Berecz, CFO, and Cosmas N. Lykos, the Company&#8217;s Founder granting 900,000, 700,000, and 900,000 shares of restricted common stock, respectively, with a fair market value of $475,000. These agreements were issued outside of the 2014 Omnibus Incentive Plan. The restricted stock vests in equal 50% installments on the first and second anniversaries of the grant date, subject to continued employment with Nemus through the applicable vesting date. Each Restricted Stock Agreement provides that if an executive&#8217;s employment or service is terminated by the Company without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the separation along with accelerated vesting of all outstanding stock awards. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 3 above, Mr. Lykos&#8217; unrestricted stock awards amounting to 1,225,000 shares became immediately vested resulting in the recording of compensation expense of $117,958 which represents the fair market value of those shares as of the separation date.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2018 and 2017, the Company recorded $188,604 and $65,625 during each period, in stock-based compensation expense related to these restricted stock awards. The total amount of unrecognized compensation cost related to non-vested RSAs was $384,396 as of March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Stock-Based Compensation Expense</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statements of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the three months ended March 31, 2018 and 2017, the Company recognized stock-based compensation expense of $229,609 and $152,169 (including compensation expense for RSAs discussed above) which was recorded as a general and administrative expense in the consolidated statements of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>5. Provisions for Conversion of Preferred Stock and Put Option <b>Liability</b></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Series B Preferred Stock Conversion Liability</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of August 20, 2015, in connection with the Series B Preferred Stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company would affect another sale or issuance of common stock, stock options or convertible securities with a price per share below $0.80. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815, <i>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</i>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $75,488 and was booked as a current liability as of September 30, 2015. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of December 31, 2017, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative was classified as a current liability and was adjusted to $6,715 as of December 31, 2017. The change in fair market value was recorded as non-operating income of $102,848 for the year ended December 31, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakb37a9d85-4282-4e57-bb5b-753877f06f96" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">21</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During the three months ended March 31, 2018, all remaining Series B Preferred Stock was converted to common stock by their shareholders and as a result, the Series B conversion liability was reduced to zero as of March 31, 2018. The reduction of this liability totaling $6,715 was recorded as non-operating income for the three months ended March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Series F Preferred Stock Put Option Liability</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of November 1, 2017, in connection with the Series F Preferred Stock financing, the Company recorded a put option liability related to discretionary redemption provided to the stockholders in the event that the Company would undergo a subsequent financing that would result in a change in control. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815, <i>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</i>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $103,364 and was booked as a current liability as of November 1, 2017. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of December 31, 2017, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative was classified as a current liability and was&nbsp;considered de minimis&nbsp;as of December 31, 2017. The change in fair market value was recorded as non-operating income of $103,364 for the year ended December 31, 2017. In March 2018, the Series F Preferred shareholder converted their shares to common stock and as a result, the Company did not record a put option liability as of March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak5e5ffc82-bba6-4b1e-a555-ba630c2b2967" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">22</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>6. Series B Warrant and Emerald Warrant Liabilities</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Series B Warrant Liability</i></b><b><i></i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp; </p>
<p style="MARGIN: 0px" align="justify">In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 common stock warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were initially valued at $2,935,800 utilizing the Black-Scholes pricing model. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also have a &#8220;down-round&#8221; protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The exercise price is automatically adjusted down to the price of the instrument being issued. In October 2016, as a result of the Series C Preferred Stock financing, the exercise price was adjusted to $0.40 and in December 2016, as a result of the Series D Preferred Stock financing, the exercise price was adjusted to $0.25. In November 2017, as a result of the Series F Preferred Stock financing, the exercise price was adjusted to $0.15 and on December 28, 2017, the exercise price was adjusted to $0.10 after the company entered into a Secured Promissory Note for a convertible loan. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10, <i>Distinguishing Liabilities from Equity</i>, and concluded that the Series B warrants should be classified as a liability. The Company then applied the fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the preferred stock. The Company also performed the same valuation as of December 31, 2017 utilizing the Black-Scholes pricing model. This resulted in a warrant value of $551,322 as of December 31, 2017. The change in fair market value at the re-measurement date was recorded as non-operating income totaling $560,986 for the year ended December 31, 2017. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January 2018, Series B warrant holders exercised 987,000 warrants at an exercise price of $0.10 resulting in cash proceeds to the Company of $98,700. On January 19, 2018 as a result of the Emerald Financing, the Series B warrant exercise price was reset to $0.00. The strike price for these warrants is now permanently reset. Subsequent to this date, Series B warrant holders exercised 3,419,250 warrants resulting in the issuance of 3,419,250 shares of common stock with no consideration. The intrinsic value of the warrant exercises for the three months ended March 31, 2018 was $1,125,291. At each of the exercise dates, the Company marked the warrants to fair market value which was determined by a Black Scholes computation which considered the closing trading price on the exercise dates. As of March 31, 2018, the fair market value of the remaining Series B warrants was also determined via a Black Scholes computation. As such, the Company recorded a liability of $483,438 and the change in fair market value for these warrants along with the warrant exercises totaling $1,223,991 was recorded as non-operating expense during the three months ended March 31, 2018. As the remaining warrant holders still held certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants were still considered to require liability classification. The assumptions utilized for the Black Scholes computations are outlined below:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="6">
<p style="MARGIN: 0px" align="center"><b>As of Period End</b></p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>&nbsp;March 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>December 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Dividend yield</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.00</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">%</p></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.00</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">%</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Volatility factor</p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">70.00</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">%&nbsp;</p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">70.00</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">%</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Risk-free interest rate</p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">1.95</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">%&nbsp;</p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">1.947-1.949</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">%</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Expected term (years)</p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">2.25</p></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">2.64-2.65</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Weighted-average fair value of warrants</p></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.238</p></td>
<td valign="bottom"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="justify">$</p></td>
<td valign="bottom">
<p style="MARGIN: 0px 0px 0px 0in" align="right">0.086</p></td>
<td valign="bottom"></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p><b><i>
<p style="MARGIN: 0px" align="justify"><b><i>Emerald Warrant Liabilities</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></i></b><u>Warrant liability</u>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years. The warrants are exercisable in cash or through a cashless exercise provision. The warrants also have an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10 per each warrant. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrant holder has the right to participate in subsequent financing transactions on an as-if converted basis. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10, <i>Distinguishing Liabilities from Equity</i>, and concluded that the Emerald warrants should be classified as a liability and re-measured to fair market value at the end of each reporting period. With the assistance of a third-party valuation specialist, the Company valued the warrant liability utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurement</i>s, as of the closing dates of the financings and as of March 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of January 18, 2018 and February 16, 2018, in connection with the Emerald Financing, the Company recorded a warrant liability related to a discretionary redemption provided to the warrant holders in the event that the Company would undergo a subsequent financing that would result in a change in control. With the assistance of a third-party valuation specialist, the Company valued the warrant liability pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the warrant liability in conjunction with ASC 815, <i>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</i>, and determined that the warrant liability does not requires bifurcation. As of March 31, 2018, the derivative was classified as a current warrant liability valued at $138,630. Because the amount of proceeds related to this financing exceeded the value assigned to the related Emerald warrant liability, the full amount of the&nbsp;warrant liability was&nbsp;charged to&nbsp;non-operating expense and included as part of the fair value in excess of proceeds adjustment discussed below.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Fair Value Computations</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The estimated fair value of the warrants issued on January 19, 2018 (the January Closing Date) and at March 31, 2018 was $4,654,922 and $3,671,089, respectively. The estimated fair value of the warrants issued on February 16, 2018 (the February Closing Date) and at March 31, 2018 was $5,631,051 and $4,296,315, respectively. The change in fair market value from the closing dates to March 31, 2018 amounted to $2,318,569 and was recorded as non-operating income for the three-month period then ended. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Given that the fair value of the derivative warrants issued on the January Closing Date exceeded the total proceeds of the private placement of $1,500,000, as of that date, no net amounts above par value were allocated to common stock. The $3,154,922 amount by which the recorded liabilities exceeded the proceeds was charged to non-operating expense at the January Closing Date. Given that the fair value of the derivative warrants issued on the February Closing Date exceeded the total proceeds of the private placement of $1,750,000, as of that date, no net amounts above par value were allocated to commons stock. The $3,881,051 amount by which the recorded liabilities exceeded the proceeds was charged to non-operating expense at the February Closing Date. In addition, given that there were no amounts allocated to common stock related to these two closings, issuance costs totaling $137,191 were also charged to non-operating expense at the closing dates. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak97eb9266-b86f-4a76-98b4-8a233d8cb774" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">23</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The derivative liabilities were valued based on Monte Carlo simulations conducted at the closing dates of the January and February closings and at March 31, 2018 using the following assumptions:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>March 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>On</b></p>
<p style="MARGIN: 0px" align="center"><b>issuance</b></p></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Dividend yield</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.00</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Volatility factor</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">70.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">70.00</td>
<td valign="bottom" width="1%">%</td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Risk-free interest rate</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">2.54-2.55</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">%</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">2.45-2.6</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">%</p></td></tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Expected term (years)</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">4.8-4.88</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td id="ffcell" valign="bottom" width="9%" align="right">5.0</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Closing price per share of common stock</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px" align="right">0.24</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>$</td>
<td>
<p style="MARGIN: 0px" align="right">0.29-0.30</p></td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>7. Convertible Bridge Loan</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On December 28, 2017, the Company entered into a Secured Promissory Note and Security Agreement for a convertible loan with Emerald. The bridge loan provides for aggregate gross proceeds to Nemus of up to $900,000 and is secured by all of Nemus&#8217; assets. Nemus received proceeds of $500,000 on December 28, 2017 and on January 19, 2018, the Company received the remaining $400,000 in funding as it had satisfied the conditions of the funding. These conditions required receipt of conversion notices from all the existing Series B shareholders to convert their preferred shares to common stock. Such conversions occurred in January and February of 2018. Also, on January 19, 2018, in conjunction with the Emerald Securities Purchase Agreement, the bridge loan was converted at $0.10 per share to common stock resulting in the issuance of 9,000,000 additional shares. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In connection with the convertible bridge loan financing, the Company recorded a liability related to the conversion option of the bridge loan into the Company&#8217;s common stock due to a down-round protection feature present in the loan agreement. The Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <i>Fair Value Measurement</i>s, as of the closing date of the financing utilizing the Black Scholes valuation methodology and the assumptions discussed in Note 6 above. This resulted in a conversion liability value of $265,000 as of the financing close date which was one trading day prior to December 31, 2017. The second funding in January 2018&nbsp;resulted in an additional conversion liability which was $360,000. The Company recorded amortization of this debt discount of $34,608 to non-operating expense prior to the conversion of the debt. In addition, the Company then marked to market the conversion liabilities&nbsp;to $810,000&nbsp;utilizing the assumptions discussed above and recorded a&nbsp;change in fair value&nbsp;on conversion right of $185,000 as a non-operating expense. At the time of the conversion, the Company extinguished the debt and the associated conversion liability and issued the common stock at fair market value resulting in a loss on extinguishment of $590,392 which was recorded as a non-operating expense for the three months ended March 31, 2018. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreakf0030298-5feb-4f4a-89a2-30bbbb4e8934" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">24</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>8. Income Taxes</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">Under the FASB's accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty (50) % likelihood of being sustained. Additionally, the guidance provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at March 31, 2018. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying consolidated statement of operations to offset pre-tax losses.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Company has no material uncertain tax positions as of March 31, 2018.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>9. Subsequent Events</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Separation of Chief Financial Officer </i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On April 30, 2018, the Company entered into a separation agreement and release (the &#8220;Separation Agreement&#8221;) with Elizabeth Berecz, the Company&#8217;s current Chief Financial Officer. Ms. Berecz&#8217;s separation will be effective May 25, 2018 (the &#8220;Separation Date&#8221;), and she will remain the Company&#8217;s principal financial officer until the Separation Date.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Pursuant to the Separation Agreement, Ms. Berecz has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Ms. Berecz compensation and benefits as follows: (i) through the Separation Date, an annualized base salary at the rate in effect for her as of the date of the Separation Agreement; (ii) a lump sum gross payment of $145,833, in consideration for the restrictive covenants contained in the Separation Agreement; (iii) reimbursement for payments made by Ms. Berecz for COBRA coverage for a period of six (6) months following the Separation Date; and (iv) Ms. Berecz&#8217;s unrestricted stock awards amounting to 1,050,000 shares and unvested stock options totaling 100,000 shares became immediately vested.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Appointment of New Chief Financial Officer</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On April 5, 2018, the Company agreed to an offer letter with Doug Cesario, pursuant to which Mr. Cesario joined the Company on April 23, 2018 and will be appointed as Chief Financial Officer of the Company effective May 26, 2018. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak26a8bac3-99e6-4b3e-bfa2-92364dc23ebd" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">25</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt"><i>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements for the three months ended March 31, 2018 and 2017 (unaudited) and the year ended December 31, 2017 together with notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q.</i></p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt"><i>Unless otherwise provided in this Quarterly Report, references to "we," "us," "our" and "Nemus" in this discussion and analysis refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the closing of a reverse merger transaction (the "Merger") pursuant to which a wholly owned subsidiary of LGL formed solely for the purpose of the Merger merged with and into Nemus and LGL changed its name to Nemus Bioscience, Inc.</i></p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt"><i>The Merger has been accounted for as a reverse merger and recapitalization, with Nemus as the acquirer and LGL as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that will be reflected in the historical financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the combined enterprise of LGL and Nemus from and after the closing date of the Merger.</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Overview</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">We are a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics, or cannabinoids, through a number of agreements with the University of Mississippi, or UM. UM has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis extracts. We are currently UM's sole partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px"><b>Recent Events and Significant Contracts</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>UM 5050 pro-drug agreements</u>:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM 5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreaka0cbecd7-6afd-451b-b3fe-6113424d3749" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">26</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>UM 8930 analogue agreements:</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, an analogue formulation of cannabidiol (&#8220;CBD&#8221;) for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>UM 5070 license agreement:</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On January 10, 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). The license agreement contains certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date and this amount was paid in January, 2018. The aggregate milestone payment under the license agreements, if the milestones are achieved, is $0.7 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Critical Accounting Policy and Estimates</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">Our Management's Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">During the three months ended March 31, 2018, there were no significant changes to the items that were disclosed as our critical accounting policies and estimates in Note 1 to our financial statements for the year ended December 31, 2017 contained in our Form 10-K as filed with the SEC on March 19, 2018.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px"><b>Results of Operations</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>For the three months ended March 31, 2018 and 2017</i></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Revenues.</b> To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Operating expenses. </b>For the three months ended March 31, 2018, our total operating expenses were $1,251,361 as compared to $1,380,153 for the three months ended March 31, 2017. The decrease in operating expenses was due to the items noted below:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Research and development.</u> Research and development expenses for the three months ended March 31, 2018 were $25,000 which consisted of license renewal fees for UM 8930. There were no contract research and development expenses due to the limited cash balances available to the Company.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Research and development expenses for the three months ended March 31, 2017, were $92,100 which primarily consisted of up-front license fees for UM 8930 and contract research and development expenses.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak6168ddd1-09ff-4909-a04e-47e2d789f635" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">27</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>General and administrative.</u> General and administrative expenses for the three months ended March 31, 2018 were $1,226,361 which primarily consisted of salaries, stock compensation expense, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. By comparison, general and administrative expenses for the three months ended March 31, 2017 were $1,288,053 which primarily consisted of the same components. Management reduced general and administrative expenses in the areas of investor relations, travel, rent, and office-related expenses resulting in the lower level of expense for 2018.</p>
<p style="MARGIN: 0px"><b><b>&nbsp;</b></b></p>
<p style="MARGIN: 0px" align="justify"><b>Other income and expenses.</b> For the three months ended March 31, 2018, the Company had non-operating expense of $6,959,332 which consisted of the following items:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">$(1,162,493)&nbsp;represented a change in the fair value of the Series B and Emerald warrant liabilities along with the adjustment to fair market value for warrant exercises completed during the quarter; the decrease in the warrant value was primarily attributable to the change in the fair value of the company's common stock.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">$7,174,634 represented a reduction in the fair value of the Emerald warrant liability in excess of proceeds received that was recorded as non-operating expense. In addition, issuance costs totaling $137,191 were also charged to non-operating expense due to the full allocation of the proceeds to the Emerald warrant liability.</p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px" align="justify">$34,608 represented the amortization of debt discount and $185,000 represented the change in fair value of the bridge loan conversion liability prior to conversion.</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td>
<p style="MARGIN: 0px" align="justify">$590,392 represented the loss on extinguishment of the convertible debt.</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For the three months ended March 31, 2017, the Company had non-operating income of $97,766 which consisted of the following components:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">$12,561 represented a change in the fair value of the Series B warrant liability as determined by a third party independent valuation conducted as of March 31, 2017; the decrease in the warrant value was primarily attributable to the change in the fair value of the company's common stock.</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><font face="Symbol">&#183;</font></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">$85,205 represented a change in the fair value of the conversion right related to the Series B preferred stock issuance as estimated from the same valuation referenced above.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Net (income) loss.</b> For the three months ended March 31, 2018, we had a net loss of $8,213,793 as compared to a net loss of $1,283,218 for the three months ended March 31, 2017. The increase in net loss was primarily attributable to the reduction in the fair value of the Emerald warrant liability in excess of proceeds received that was recorded as non-operating expense for the quarter as well as the loss on extinguishment of the convertible bridge loan from Emerald. We expect to incur net losses for the foreseeable future.</p>
<p style="MARGIN: 0px" align="justify">&nbsp; </p>
<p style="MARGIN: 0px"><b>Liquidity and Capital Resources</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt" align="justify">We had cash and cash equivalents of $2,945,312 as of March 31, 2018, as compared to $259,955 as of December 31, 2017. This increase is primarily attributable to the proceeds of $3,250,000 from the Emerald financing along with the $900,000 convertible bridge loan from Emerald as previously discussed. We anticipate that we will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support our corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that we will not have sufficient funds to meet our obligations beyond one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">We have been, and intend to continue, working toward identifying and obtaining new sources of financing. No assurances can be given that we will be successful in obtaining additional financing in the future. Any future financing that we may obtain may cause significant dilution to existing stockholders. Any debt financing or other financing of securities senior to common stock that we are able to obtain will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a negative impact on our business, prospects, financial condition, results of operations and cash flows.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">If adequate funds are not available, we may be required to delay, scale back or eliminate portions of our operations, cease operations or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain of our assets. Accordingly, the inability to obtain such financing could result in a significant loss of ownership and/or control of our assets and could also adversely affect our ability to fund our continued operations and our expansion efforts.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">During the next twelve months, we expect to incur significant research and development expenses with respect to our products. The majority of our research and development activity is focused on development of potential drug candidates and preclinical trials.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak528ee30d-5ea3-401b-a2e5-7ed41fd6417b" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">28</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">We also expect to incur significant legal and accounting costs in connection with being a public company. We expect those fees will be significant and will continue to impact our liquidity. Those fees will be higher as our business volume and activity increases.</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">We also anticipate that we will need to hire additional employees or independent contractors as the Company prepares to enter clinical studies.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><i>Going Concern</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">Our independent registered public accounting firm has issued a report on our audited financial statements for the fiscal year ended December 31, 2017 that included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our unaudited consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/ or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>Off-Balance Sheet Arrangements</u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 3. Quantitative and Qualitative Disclosures about Market Risk.">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">Not applicable.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 4. Controls and Procedures.">Item 4. Controls and Procedures.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Evaluation of disclosure controls and procedures.</b> We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We conducted an evaluation, under the supervision and with the participation of our principal executive and financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2018. Based upon their evaluation and subject to the foregoing, the principal executive and financial officers have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Changes in internal controls.</b> Management determined there were no changes in our internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakdf63a65b-f2bc-4c14-97c2-b82439daf2ce" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">29</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="PART II - OTHER INFORMATION">PART II - OTHER INFORMATION</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 1. Legal Proceeding">Item 1. Legal Proceeding</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">On November 8, 2017, the Company filed a petition commencing arbitration as described in Note 3 under <i>Pending Series E Preferred Stock Financing and Filing for Arbitration</i>.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 1A. Risk Factors.">Item 1A. Risk Factors.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">Investing in our common stock involves a high degree of risk. Our Annual Report on Form 10-K for the year ended December 31, 2017 includes a detailed discussion of our risk factors under the heading "Part I, Item 1A-Risk Factors." There are no changes from the risk factors previously disclosed in our Annual Report on Form 10-K. You should carefully consider the risk factors discussed in our Annual Report on Form 10-K as well as the other information in this report before deciding whether to invest in shares of our common stock. The occurrence of any of the risks discussed in the Annual Report on Form 10-K could harm our business, financial condition, results of operations or growth prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">None</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 3. Defaults Upon Senior Securities.">Item 3. Defaults Upon Senior Securities.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">None.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 4. Mine Safety Disclosures.">Item 4. Mine Safety Disclosures.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">Not applicable.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 5. Other Information.">Item 5. Other Information.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 33.75pt">None.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><u><a name="Item 6. Exhibits.">Item 6. Exhibits.</a></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15" bgcolor="#cceeff">
<td valign="top" width="8%">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex311.htm">31.1</a></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex312.htm">31.2</a></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex321.htm">32.1+</a></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex321.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex322.htm">32.2+</a></p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify"><a href="nmus_ex322.htm">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">101.ins</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Instance Document</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">101.sch</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">XBRL Taxonomy Schema Document</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">101.cal</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">XBRL Taxonomy Calculation Linkbase Document</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">101.def</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">XBRL Taxonomy Definition Linkbase Document</p></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">101.lab</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">XBRL Taxonomy Label Linkbase Document</p></td></tr>
<tr height="15" bgcolor="#ffffff">
<td valign="top">
<p style="MARGIN: 0px" align="justify">101.pre</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">XBRL Taxonomy Presentation Linkbase Document</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">_____________</p>
<p style="MARGIN: 0px"><b>+ </b>Furnished herewith and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakeef52e0d-ccfd-4f3c-a2d1-d0ef75392398" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">30</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td><i><a href="#toc">Table of Contents</a></i></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">In accordance with the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top"></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px" align="justify"><b>Nemus Bioscience, Inc.,</b></p>
<p style="MARGIN: 0px" align="justify"><b>a Nevada corporation</b></p></td>
<td valign="top"></td></tr>
<tr height="15">
<td valign="top" width="50%"></td>
<td valign="top" width="5%"></td>
<td valign="top" width="35%"></td>
<td valign="top" width="10%"></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">May 15, 2018</p></td>
<td>
<p style="MARGIN: 0px" align="justify">By:</p></td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="justify"><i>/s/ Brian Murphy</i></p></td>
<td valign="top"></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">Brian Murphy</p></td>
<td valign="top"></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Its:</p></td>
<td>
<p style="MARGIN: 0px" align="justify">Chief Executive Officer</p>
<p style="MARGIN: 0px" align="justify">(Principal Executive Officer)</p></td>
<td></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="50%">
<p style="MARGIN: 0px" align="justify">May 15, 2018</p></td>
<td width="5%">
<p style="MARGIN: 0px" align="justify">By:</p></td>
<td style="BORDER-BOTTOM: 1px solid" width="35%">
<p style="MARGIN: 0px" align="justify"><i>/s/ Elizabeth Berecz</i></p></td>
<td width="10%"></td></tr>
<tr height="15">
<td valign="top"></td>
<td valign="top"></td>
<td valign="bottom">
<p style="MARGIN: 0px" align="justify">Elizabeth Berecz</p></td>
<td valign="bottom"></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Its:</p></td>
<td>
<p style="MARGIN: 0px" align="justify">Chief Financial Officer</p>
<p style="MARGIN: 0px" align="justify">(Principal Financial and Accounting Officer)</p></td>
<td></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">31&nbsp;</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nmus_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex311.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 31.1</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Certification of Principal Executive Officer,</b></p>
<p style="MARGIN: 0px" align="center"><b>Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</b></p>
<p style="MARGIN: 0px" align="center"><b>As Adopted Pursuant To Section 302 of the Sarbanes-Oxley Act of 2002</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">I, Brian Murphy, certify that:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="4%">
<p style="MARGIN: 0px" align="justify">1.</p></td>
<td>
<p style="MARGIN: 0px" align="justify">I have reviewed this quarterly report on Form 10-Q of Nemus Bioscience, Inc. for the quarter ended March 31, 2018;</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">3.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">4.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">(a)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(b)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(c)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(d)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">5.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">(a)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(b)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Date: May 15, 2018</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="35%">
<p style="MARGIN: 0px" align="justify"><i>/s/ Brian Murphy</i></p></td>
<td valign="top" width="5%"></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Brian Murphy</p>
<p style="MARGIN: 0px" align="justify">Chief Executive Officer</p></td>
<td></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nmus_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex312.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 31.2</b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Certification of Principal Financial Officer,</b></p>
<p style="MARGIN: 0px" align="center"><b>Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</b></p>
<p style="MARGIN: 0px" align="center"><b>As Adopted Pursuant To Section 302 of the Sarbanes-Oxley Act of 2002</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">I, Elizabeth Berecz, certify that:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">1.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">I have reviewed this quarterly report on Form 10-Q of Nemus Bioscience, Inc. for the quarter ended March 31, 2018;</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">2.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">3.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">4.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">(a)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(b)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(c)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr>
<tr height="15">
<td></td>
<td></td>
<td></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">(d)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">5.</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">(a)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="4%"></td>
<td valign="top" width="4%">
<p style="MARGIN: 0px" align="justify">(b)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Date: May 15, 2018</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%">
<p style="MARGIN: 0px" align="justify"><em>/s/ Elizabeth Berecz</em></p></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="55%"></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Elizabeth Berecz</p>
<p style="MARGIN: 0px" align="justify">Chief Financial Officer</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>nmus_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex321.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 32.1</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350,</b></p>
<p style="MARGIN: 0px" align="center"><b>as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">In connection with the Quarterly Report of Nemus Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Brian Murphy, Chief Executive Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="3%">
<p style="MARGIN: 0px" align="justify">(1)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">(2)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%">
<p style="MARGIN: 0px" align="justify"><i>/s/ Brian Murphy</i></p></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="55%"></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Brian Murphy</p>
<p style="MARGIN: 0px" align="justify">Chief Executive Officer</p>
<p style="MARGIN: 0px" align="justify">May 15, 2018</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>nmus_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>nmus_ex322.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 32.2</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350,</b></p>
<p style="MARGIN: 0px" align="center"><b>as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">In connection with the Quarterly Report of Nemus Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Elizabeth Berecz, Chief Financial Officer of the Company, certifies to the best of her knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top" width="3%">
<p style="MARGIN: 0px" align="justify">(1)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px" align="justify">&nbsp;</p></td></tr>
<tr height="15">
<td valign="top" width="3%">
<p style="MARGIN: 0px" align="justify">(2)</p></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%">
<p style="MARGIN: 0px" align="justify"><em>/s/ Elizabeth Berecz</em></p></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="5%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td width="55%"></td></tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Elizabeth Berecz</p>
<p style="MARGIN: 0px" align="justify">Chief Financial Officer</p>
<p style="MARGIN: 0px" align="justify">May 15, 2018</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td></td></tr></table>
<p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>nmus-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.1.0 [05/14/2018 12:36:08 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Tuesday, May 15, 2018 12:04:57 PM -->
<xbrli:xbrl xmlns:nmus="http://www.nemusbioscience.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="nmus-20180331.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_15_Oct_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_MonthAndYearOfAgreementAxis_OctoberTwoThousandFifteenMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:OctoberTwoThousandFifteenMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Aug_2015T00_00_00_TO_20_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:SeriesBPreferredStockConversionLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-01
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:LicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_MonthAndYearOfAgreementAxis_December2015Member_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:December2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:LicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_TypeOfArrangementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-01
</xbrli:startDate>
<xbrli:endDate>
2016-02-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_TypeOfArrangementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-01
</xbrli:startDate>
<xbrli:endDate>
2016-02-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_TypeOfArrangementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:LetterAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:ContractManufacturingOrganizationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-02-01
</xbrli:startDate>
<xbrli:endDate>
2016-02-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-01
</xbrli:startDate>
<xbrli:endDate>
2016-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Dec_2016T00_00_00_TO_29_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Dec_2016T00_00_00_TO_29_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2016T00_00_00_TO_29_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-12-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:Um5070LicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-02-01
</xbrli:startDate>
<xbrli:endDate>
2017-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:IndependentContractorAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2017T00_00_00_TO_01_Apr_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:IndependentContractorAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-25
</xbrli:startDate>
<xbrli:endDate>
2017-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_03_May_2017T00_00_00_TO_03_May_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-03
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_03_May_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-03
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_12_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-01
</xbrli:startDate>
<xbrli:endDate>
2017-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Nov_2017T00_00_00_TO_01_Nov_2017T00_00_00_DerivativeInstrumentRiskAxis_SeriesFPreferredStockOptionLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:SeriesFPreferredStockOptionLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_24_Oct_2017T00_00_00_TO_01_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-24
</xbrli:startDate>
<xbrli:endDate>
2017-11-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_24_Oct_2017T00_00_00_TO_01_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-24
</xbrli:startDate>
<xbrli:endDate>
2017-11-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-03
</xbrli:startDate>
<xbrli:endDate>
2017-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-03
</xbrli:startDate>
<xbrli:endDate>
2017-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-03
</xbrli:startDate>
<xbrli:endDate>
2017-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-03
</xbrli:startDate>
<xbrli:endDate>
2017-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-12-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-12-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-12-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-12-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-12-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember_DerivativeInstrumentRiskAxis_SeriesFPreferredStockOptionLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:SeriesFPreferredStockOptionLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_TypeOfArrangementAxis_SeriesBPreferredStockAgreementMember_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeriesBPreferredStockAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:SeriesBPreferredStockConversionLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:RestrictedStockAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-18
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:RestrictedStockAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-18
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:RestrictedStockAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-18
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:RestrictedStockAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-18
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_ShortTermDebtTypeAxis_BridgeLoanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn19January2018Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:WarrantsIssuanceDateAxis">nmus:WarrantsIssuedOn19January2018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_ShortTermDebtTypeAxis_BridgeLoanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn16February2018Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:WarrantsIssuanceDateAxis">nmus:WarrantsIssuedOn16February2018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember_LegalEntityAxis_K2CIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:RestrictedStockAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-02-01
</xbrli:startDate>
<xbrli:endDate>
2018-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:K2CIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:IndependentContractorAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_TypeOfArrangementAxis_IndependentContractorAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:IndependentContractorAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBWarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmus:SeriesBWarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-01-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn19January2018Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:WarrantsIssuanceDateAxis">nmus:WarrantsIssuedOn19January2018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn16February2018Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:EmeraldWarrantLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:WarrantsIssuanceDateAxis">nmus:WarrantsIssuedOn16February2018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_TypeOfArrangementAxis_IndependentContractorAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:IndependentContractorAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:SeriesBPreferredStockConversionLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_EmeraldPutOptionLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:EmeraldPutOptionLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_EmeraldPutOptionLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmus:EmeraldPutOptionLiabilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:NonoperatingIncomeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-04-01
</xbrli:startDate>
<xbrli:endDate>
2018-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nmus:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-04-01
</xbrli:startDate>
<xbrli:endDate>
2018-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_10_May_2018T00_00_00_TO_10_May_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-05-10
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>MrlsywiI~\FVP645<c444c555cT{h>H8F9:F<F188<;18<6G1E6651;H9GGFFE7;97 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="segment"><xbrli:measure>nmus:segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="License_agreement"><xbrli:measure>nmus:License_agreement</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">Nemus Bioscience, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">0001516551</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">nmus</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_10_May_2018T00_00_00_TO_10_May_2018T00_00_00" unitRef="shares" decimals="INF">132601579</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">2018-03-31</dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">2018</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">Q1</dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">259955</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2945312</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">4428</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4428</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">291428</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">206317</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">555811</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3156057</us-gaap:AssetsCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">100921</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">98757</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedSalariesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">54512</us-gaap:AccruedSalariesCurrent>
<us-gaap:AccruedSalariesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">45704</us-gaap:AccruedSalariesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">143826</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">78237</us-gaap:AccruedLiabilitiesCurrent>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">6715</nmus:ProvisionForConversionOfPreferredStock>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" unitRef="USD" decimals="0">6715</nmus:ProvisionForConversionOfPreferredStock>
<us-gaap:ConvertibleDebtCurrent contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">265000</us-gaap:ConvertibleDebtCurrent>
<us-gaap:ConvertibleDebtCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">235000</us-gaap:ConvertibleDebtCurrent>
<nmus:ProvisionForConversionOfConvertibleDebt contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">265000</nmus:ProvisionForConversionOfConvertibleDebt>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">805974</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">322698</us-gaap:LiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">551322</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">8589472</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">483438</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">551322</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">8589472</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1357296</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">8912170</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">822201</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">169446</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD" decimals="0">1777781</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">33623</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">132414</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">9444831</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">15375360</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">982911</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">551322</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">982911</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">2935800</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-14030871</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-22244664</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">-3569506</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-5753979</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">557218</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3158191</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">1407</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2134</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">557218</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3158191</us-gaap:Assets>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="-6">20000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">2833.55</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">200</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">2000</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">2833.55</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">200</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">2000</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
<us-gaap:TemporaryEquitySharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">347091</nmus:StockIssuanceCosts>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">30557</nmus:StockIssuanceCosts>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD" decimals="0">118855</nmus:StockIssuanceCosts>



<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="-6">236000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="-6">236000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">33622829</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">132414079</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">33622829</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">132414079</us-gaap:CommonStockSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">92100</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">25000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1288053</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">187550</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1226361</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1380153</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1251361</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1380153</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1251361</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3100</us-gaap:InterestExpense>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-12561</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">560986</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1162493</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">1223991</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">2318569</us-gaap:FairValueAdjustmentOfWarrants>
<nmus:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-7174634</nmus:FairValueOfWarrantLiabilityInExcessOfProceeds>
<us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">137191</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
<us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">137191</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1282387</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-8213793</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">831</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1283218</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-8213793</us-gaap:NetIncomeLoss>
<us-gaap:RedeemablePreferredStockDividends contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">711000</us-gaap:RedeemablePreferredStockDividends>
<us-gaap:RedeemablePreferredStockDividends contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD" decimals="0">175000</us-gaap:RedeemablePreferredStockDividends>
<us-gaap:RedeemablePreferredStockDividends contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">536000</us-gaap:RedeemablePreferredStockDividends>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-1994218</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-8213793</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.09</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="2">-0.09</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.09</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="2">-0.09</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="0">23247530</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="0">88632979</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="shares" decimals="0">23247530</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="0">88632979</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:Depreciation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">2428</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">331</us-gaap:Depreciation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">152169</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">86544</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">229609</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">41005</us-gaap:ShareBasedCompensation>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_1">5000</us-gaap:AmortizationOfFinancingCosts>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">85205</nmus:GainLossOnConversionRightPreferredStock>
<nmus:FairValueOfWarrantLiabilityExcessOfProceeds contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-7174634</nmus:FairValueOfWarrantLiabilityExcessOfProceeds>
<nmus:CommonStockIssuedForLicense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">187550</nmus:CommonStockIssuedForLicense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_2">-43994</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_3">-85111</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-47486</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-2164</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-48368</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-8808</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-16250</nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">253042</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-65589</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">-816405</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1053162</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1059</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1059</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_1">1131857</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_01_May_2017T00_00_00_TO_03_May_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember" unitRef="USD" decimals="0">20000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<nmus:CommonStockIssuedForServices contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3240878</nmus:CommonStockIssuedForServices>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">98700</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">98700</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">500000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">400000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1131857</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3739578</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">315452</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2685357</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">102320</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">417772</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">264383</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2949740</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:InterestPaid contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">1631</us-gaap:IncomeTaxesPaid>
<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">880000</us-gaap:ConversionOfStockAmountConverted1>
<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1947227</us-gaap:ConversionOfStockAmountConverted1>
<nmus:ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">405625</nmus:ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock>
<nmus:ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">828916</nmus:ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock>
<nmus:CashAndCashEquivalents contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">380272</nmus:CashAndCashEquivalents>
<nmus:CashAndCashEquivalents contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2945312</nmus:CashAndCashEquivalents>
<nmus:SupplementalRestrictedCash contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">37500</nmus:SupplementalRestrictedCash>
<nmus:SupplementalRestrictedCash contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4428</nmus:SupplementalRestrictedCash>
<nmus:TotalCashEquivalentsAndRestrictedCashShownInConsolidated contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">417772</nmus:TotalCashEquivalentsAndRestrictedCashShownInConsolidated>
<nmus:TotalCashEquivalentsAndRestrictedCashShownInConsolidated contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2949740</nmus:TotalCashEquivalentsAndRestrictedCashShownInConsolidated>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">183343</us-gaap:PaymentsOfStockIssuanceCosts>


<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">9122</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">30000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;1. Nature of Operations, Business Activities and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Nature of Operations and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi (&amp;#8220;UM&amp;#8221;) is federally permitted and licensed to cultivate cannabis for research purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the &amp;#8220;Company,&amp;#8221; &amp;#8220;we&amp;#8221; or &amp;#8220;our&amp;#8221; refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. (&amp;#8220;LGL&amp;#8221;), together with its wholly-owned subsidiary, Nemus, a California corporation (&amp;#8220;Nemus&amp;#8221;). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Long Beach, California.&lt;/div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&amp;#8220;Emerald&amp;#8221;) discussed in note 4 below in which Emerald purchased a majority of the equity interest in Nemus resulting in a change in control. The current Board members, with the exception of Dr. Brian Murphy, the Company&amp;#8217;s CEO/CMO, have tendered their resignation and Emerald has appointed its nominees to the new Board.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman';
 white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense and equity securities with embedded features as discussed below.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has incurred operating losses and negative cash flows from operations since our inception. As of March 31, 2018, we had cash and cash equivalents of $2,945,312. The Company anticipates that it will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements were issued. These conditions give rise to substantial doubt as to the Company&amp;#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s continued existence is dependent on its ability to raise additional sufficient funding to cover operating expenses and to invest in operations and development activities. The Company plans to continue to pursue funding through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce
 spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs or cease operations.&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A deposit of $4,428 as of both March 31, 2018 and December 31, 2017 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&amp;#8217;s credit cards.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on
 three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&lt;/p&gt;&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;/td&gt;&lt;td valign="top" width="6%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Level 1:&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Level 2:&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Level 3:&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The warrant liability for the Emerald warrants and the associated put option were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of March 31, 2018.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018 and December 31, 2017, property and equipment, net, was $2,134 and $1,407 respectively, consisting primarily of computers and equipment. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px;
 font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the &amp;#8220;NOLs&amp;#8221;) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&amp;#8217;s statement of operations in the period incurred.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the
 position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Convertible Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. ASC 815,&amp;#160;&lt;i&gt;Derivatives and Hedging Activities&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 815&amp;#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20,&amp;#160;&lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 470-20&amp;#8221;). Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. We account for convertible instruments (when we have determined that the embedded conversion options should be bifurcated from their host instruments) in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400;
 word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We also follow ASC 480-10,&amp;#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 480-10&amp;#8221;) in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#8217;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#8217;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in interest expense in the accompanying Consolidated Statements of Operations.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other (income) expense in the Consolidated Statements of Operations.&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has not begun planned principal operations and has not generated any revenue since inception.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Research and
 Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:&lt;/p&gt;&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td width="4%"&gt;&lt;/td&gt;&lt;td valign="top" width="4%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Volatility - We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation for Non-Employees&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) No. 505-50,&amp;#160;&lt;i&gt;Equity - Equity Based Payments to Non-Employees,&lt;/i&gt;&amp;#160;using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;FASB ASC No. 280,&amp;#160;&lt;i&gt;Segment Reporting&lt;/i&gt;, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (&amp;#8220;CODM&amp;#8221;), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three months ended March 31, 2018 and 2017, the comprehensive income (loss) was equal to the net income (loss).&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px;
 font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Earnings per share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company applies FASB ASC No. 260,&amp;#160;&lt;i&gt;Earnings per Share&lt;/i&gt;. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of outstanding warrants and awards granted to employees under stock-based compensation plans. Potentially dilutive shares of the Company&amp;#8217;s common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented. For the three months ended March 31, 2018, warrants to purchase 51,443,250 common shares and stock options exercisable for 1,030,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share. For the three months ended March 31, 2017, 3,625.375 shares of Series B Preferred Stock convertible into 14,501,500 common shares at $0.25 per share, 706 shares of Series D Preferred Stock convertible into 2,824,000 common shares at $0.25 per share, warrants to purchase 11,649,500 common shares and stock options exercisable for 1,130,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2017, the FASB issued ASU 2017-11,&lt;i&gt;&amp;#160;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/i&gt;, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating&lt;i&gt;&amp;#160;Topic 480, Distinguishing Liabilities from Equity&lt;/i&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite
 deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<nmus:UniversityOfMississippiAgreementsTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;2. University of Mississippi Agreements&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months&amp;#8217; written notice to the other party.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;UM 5050 pro-drug agreements&lt;/u&gt;:&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&amp;#8217; written notice by the Company to UM.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM 5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify"
 style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;UM 8930 analogue agreements:&lt;/u&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, an analogue formulation of cannabidiol (&amp;#8220;CBD&amp;#8221;) for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&amp;#8217; written notice by the Company to UM.&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.&lt;/div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;UM 5070 license agreement:&lt;/u&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On January 10, 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). The license agreement contains certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date and this amount was paid in January, 2018. The aggregate milestone payment under the license agreements, if the milestones are achieved, is $0.7 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&amp;#8217; written notice by the Company to UM.&lt;/div&gt;&lt;/div&gt;</nmus:UniversityOfMississippiAgreementsTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;3. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Lease Commitments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the UM campus. The lease term commenced on October 1, 2014 and expired on December 31, 2017. There is annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease were divided by the total number of months in the lease period and the average rent was charged to expense each month during the lease period. The monthly amount charged to rent expense was $9,267. Upon expiration, the Company did not renew the laboratory lease but has retained office space under a month-to-month agreement at the rate of $300 per month.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company maintained its principal executive offices located in a shared office suite located at 600 Anton Blvd., Suite 1100, Costa Mesa, CA, 92626 under a month-to-month agreement. Effective March 1, 2018, the Company moved its corporate offices to 130 North Marina Drive, Long Beach, CA 90803 under a month-to-month agreement at a rate of approximately $2,600 per month.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In November 2015, the Company entered into an operating lease for its office and lab furnishings both in Costa Mesa and the Innovation Hub laboratory. The monthly lease payments were $7,559. In November 2017, the Company bought out the remaining portion of the lease for $32,128 which covered the remaining lease payments as well as the value of the furniture amounting to $19,654. The lab furnishings were donated to the University of Mississippi and the office furnishings were written off due to non-use for a loss on disposal of $1,650.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Total net rent expense related to our operating leases for the three months ended March 31, 2018 and 2017 was $4,311 and $56,449, respectively. There are no future minimum payments under non-cancellable operating leases.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Related Party Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In June 2014, our subsidiary entered into an independent contractor agreement with K2C, Inc. (&amp;#8220;K2C&amp;#8221;), which is wholly owned by the Company&amp;#8217;s then Executive Chairman and Co-Founder, Mr. Cosmas N. Lykos, pursuant to which we paid K2C a monthly fee for services performed by Mr. Lykos for our company. The agreement expired on June 1, 2017 and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2018, we entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted on January 18, 2018, 325,000 shares of restricted common stock granted on October 20, 2015, and 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. The Company recognized additional stock based compensation expense of $112,270 for these restricted stock and option awards.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2018 and 2017, total cash payments made under these agreements was $220,000 (including the previously discussed lump sum payment) and $30,000 respectively. Under the separation agreement, Mr. Lykos is also eligible to participate in our health, death and disability insurance plans for six months subsequent to K2C&amp;#8217;s separation.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On February 1, 2018, we entered into an Independent Contractor Agreement with Emerald, pursuant to which Emerald will provide such services as are mutually agreed between the Company and Emerald, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services can include, but are not limited to corporate advisory services and technical expertise in the areas of business development, marketing and product development. The Independent Contractor Agreement specifies a compensation rate as is agreed between our chief executive officer and Emerald&amp;#8217;s chief executive officer on a month-to-month basis. For the three months ended March 31, 2018, the Company incurred expenses of $100,000 under this Agreement. In addition, the Company accrued $15,000 in advisory fees payable directly to Emerald&amp;#8217;s chief executive officer for advisory services rendered and these fees were paid in April 2018. The Independent Contractor Agreement has an initial term of ten years.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;General Litigation and Disputes&lt;/i&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations. As of March 31, 2018, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&amp;#8217;s financial position or results of operations, but the Company has filed a petition commencing arbitration as described below.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;Pending Series E Preferred Stock Financing and Filing for Arbitration&lt;/i&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On May 3, 2017, the Company entered into a securities purchase agreement with a purchaser to sell 1,000,000 shares of a new Series E Preferred Stock, par value $0.001 per share, at a purchase price of $20.00 for each preferred share for aggregate gross proceeds of $20,000,000. The securities purchase agreement provides for no conditions precedent to the close and that closing is not to occur later than July 10, 2017. The purchaser did not provide funding to close the transaction on July 10, 2017 as required under the securities purchase agreement and requested an extension of the closing date. In connection with the signing of the securities purchase agreement, an affiliate of the purchaser entered into a financial guarantee to the benefit of the Company that provided for payment of the purchase price in full within 90 days of exercise. The Company exercised this guarantee on July 12, 2017. The guarantor has failed to pay the $20,000,000 within 90 days of notice of the purchaser&amp;#8217;s default, as required by the terms of the guaranty.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On November 8, 2017, the Company filed a petition commencing arbitration against the purchaser and guarantor as well as other related individuals. In the petition, the Company asserts, among other things, breach of contract against the purchaser for its failure to close its purchase of Series E Preferred Stock as required by the securities purchase agreement. The Company also asserts a breach of contract claim against the guarantor for its failure to honor its guarantee of the transaction. The petition was filed with Judicial Arbitration and Mediation Services, Inc., ENDISPUTE in Orange County, California, as required by the securities purchase agreement. The Company has engaged its legal counsel in the matter on a contingent-fee basis and intends to purse damages and remedies in connections with these agreements.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;i&gt;Government Proceedings&lt;/i&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of March 31, 2018, the Company had no proceedings or inquiries.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Change in Control Severance Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&amp;#8217;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive&amp;#8217;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&amp;#8217;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Contract Manufacturing Organization (&amp;#8220;CMO&amp;#8221;) Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On February 5, 2016, the Company entered into a letter agreement (&amp;#8220;Agreement&amp;#8221;) with a third party contract manufacturing organization (&amp;#8220;CMO&amp;#8221;) pursuant to which the CMO is to provide services to Nemus for process development and analytical method development and qualification for Nemus&amp;#8217; pro-drug of tetrahydrocannabinol, or THC, as well as for sample production and a stability study.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the terms of the Agreement, Nemus will pay an estimated $154,000 to $183,000 in fees and expenses for the initial evaluation and development of a process for the production of Nemus&amp;#8217; pro-drug of THC to ensure reproducibility, quality and safety and an estimated $142,900 for analytical method development and qualification. The Company did not recognize any research and development expense under this agreement for the three months ended March 31, 2018 and 2017, respectively. After the initial evaluation and development, Nemus has agreed to pay additional fees and expenses for sample production of Nemus&amp;#8217; pro-drug of THC and a stability study, as well as possible extensions to or modifications of the aforementioned projects.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Nemus may at any time cancel or delay any project under the Agreement prior to the scheduled start date. Nemus must reimburse the CMO for costs incurred prior to and including the date of cancellation plus any reasonable and foreseeable costs associated with stopping work on any project, including the CMO&amp;#8217;s loss of revenue incurred as the result of reserving production facilities for Nemus&amp;#8217; exclusive use. Nemus may terminate the Agreement in whole or in part at any time upon 30 days&amp;#8217; written notice.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;4. Stockholders&amp;#8217; Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In March 2017, the Company issued 605,000 shares of common stock with par value of $0.001 to a third party in exchange for advisory services performed related to raising additional capital. The Company recorded $187,550 as general and administrative expense for the first quarter of 2017 to reflect the fair market value of the common stock issued. The fair market value was determined utilizing the Company&amp;#8217;s closing stock price as of the approval date of the advisory fee by the Company&amp;#8217;s Board of Directors.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the year ended December 31, 2017, a Series C Preferred stockholder converted 386 shares of its preferred stock to common stock as allowed under the Series C Preferred Stock Agreement, resulting in the issuance of 1,544,000 shares of common stock at an effective price of $0.25 per share. This represented the completion of converting all of the original Series C Preferred shares to common stock.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the year ended December 31, 2017, the Series B Preferred stockholders converted 1,197.45 shares of their preferred stock to common stock as allowed under the Series B Preferred Stock Agreement. This resulted in the issuance of&amp;#160;5,910,666 shares of common stock at an effective price of $0.25 per share prior to November 1, 2017 and $0.15 per share from&amp;#160;November 1, 2017 to December 27, 2017 after issuance of the Series F Preferred Stock. On December 28, 2017, the conversion rate was reset to $0.10 per share as a result of the convertible bridge loan but no conversions occurred from this date through-year end.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the year ended December 31, 2017, the Series D Preferred stockholders converted 1,000 shares of their preferred stock as allowed under the Series D Preferred Stock Agreement, resulting in the issuance of 4,000,000 shares of common stock at an effective price of $0.25 per share. On December 28, 2017, the conversion rate was reset to $0.10 per share as a result of the convertible bridge loan but no conversions occurred from this date through-year end.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On January 19, 2018, the Company entered into a Securities Purchase Agreement in which the Company sold to Emerald 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000 (&amp;#8220;the Emerald Financing&amp;#8221;). This transaction also resulted in the conversion of the $900,000 bridge loan (discussed in note 7 below) at $0.10 per share to 9,000,000 shares of common stock and represented the first of two closings under the Agreement. As a result of this transaction, the Company had a change in control and all Board members, with the exception of Dr. Brian Murphy, the Company&amp;#8217;s CEO/CMO, tendered their resignation. Emerald has appointed its nominees to the new Board. The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The second closing under the Emerald Financing occurred on February 16, 2018, pursuant to which Nemus issued and sold to Emerald 15,000,000 shares of Nemus&amp;#8217; common stock, and a warrant to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share for a term of five years. In addition, an accredited investor purchased 2,500,000 shares of common stock and a warrant to purchase 3,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. The Company received aggregate gross proceeds of $1,750,000 from this second closing.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2018, all remaining Series B, D, and F stockholders converted their shares of preferred stock to common stock at an effective price of $0.10 per share. This resulted in 2,833.55 Series B Preferred Stock being converted into 28,335,500 shares of common stock, 200 shares of Series D Preferred Stock being converted into 2,000,000 shares of common stock, and 2,000 shares of Series F Preferred Stock being converted into 20,000,000 shares of common stock. All such conversions occurred prior to the change in control which took effect on January 19, 2018. In addition, Series B warrant holders exercised warrants with an intrinsic value of $1,125,291 which resulted in the issuance of 4,406,250 shares of common stock.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;Redeemable Convertible Series B Preferred Stock:&lt;/u&gt;&amp;#160;In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company&amp;#8217;s common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million. Each share of preferred stock was initially convertible into 1,250 shares of common stock which resulted in an effective conversion price of $0.80 per common share and could be converted by the holder at any time. The Series B Preferred Stock also has a &amp;#8220;down-round&amp;#8221; protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. In October 2016, as a result of the Series C Preferred Stock Agreement (as discussed below), the conversion price of the Series B Preferred Stock was reset to $0.40. On December 29, 2016, as a result of the Series D Preferred Stock Agreement, the conversion price of the Series B Preferred Stock was reset to $0.25. On November 1, 2017, as a result of the Series F Preferred Stock Agreement, the conversion price of the Series B Preferred Stock was reset to $0.15 per share. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series B Preferred Stock conversion price was reset to $0.10 per share. The Series B Preferred Stock has liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder&amp;#8217;s preferred stock is convertible as of the record date. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share, subject to reset, and expire five years from the issuance date.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B Preferred stockholders receive an amount per share equal to the conversion price of $0.10, subject to down-round adjustment, multiplied by the as-if converted share amount of 28,335,500 common shares, totaling $2,833,550 as of December 31, 2017. If upon the liquidation, the assets are insufficient to permit payments to the Series B holders, all assets legally available will be distributed in a pro rata basis among the Series B holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Subject to certain trigger events occurring, the Series B Preferred stockholders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="92%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Failure of the Series B Registration Statement to be declared effective by the Securities and Exchange Commission, or the SEC, on or prior to the date that is ninety days after the Effectiveness Deadline;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Suspension of the Company&amp;#8217;s common stock from trading for a period of (2) consecutive trading days;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Any default of indebtedness;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Any filing of voluntary or involuntary bankruptcy by the Company;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;A final judgment in excess of $100,000 rendered against the Company;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Breach of representations and warranties in the Stock Purchase Agreement; and&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As certain of these triggering events are considered to be outside the control of the Company, the Series B Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&amp;#8217;s balance sheet.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In 2017, through October 31st, Series B stockholders converted 777.125 shares at a conversion rate of 4000:1 resulting in the issuance of 3,108,500 shares of common stock. Effective with the Series F Preferred Stock Agreement signed on November 1, 2017, the conversion price for the Series B Preferred Stock was reset to $0.15. From November 1&lt;sup&gt;st&lt;/sup&gt;&amp;#160;to December 31, 2017, Series B stockholders converted 420.325 shares at a conversion rate of 6666.67:1 resulting in the issuance of 2,802,167 shares of common stock. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series B Preferred Stock conversion price was reset to $0.10 per share.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2018, the Series B stockholders converted all remaining 2,833.55 shares at a conversion rate of 10,000:1 resulting in the issuance of 28,335,500 shares of common stock. As a result, there is no liquidation preference outstanding as of March 31, 2018 related to the Series B Preferred Stock.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;Convertible Series C Preferred Stock:&lt;/u&gt;&amp;#160;In October 2016, the Company sold 500 shares of Series C convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $500,000 to a healthcare investment fund under the Series C Preferred Stock Agreement. Each share of Series C Preferred Stock was initially convertible into 2,500 shares of common stock which resulted in an effective conversion price of $0.40 per common share. This resulted in the reduction of the conversion price of the Series B Preferred Stock to $0.40 and a reduction in the exercise price of the Series B warrants to $0.40. On December 29, 2016, as a result of the Series D Preferred Stock Agreement (as discussed below), the conversion price of the Series C Preferred Stock was reset to $0.25. As part of the terms of the Series C Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series C Convertible Preferred Stock are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Dividends:&lt;/u&gt;&amp;#160;Except for stock dividends or other distributions payable in shares of common stock, for which adjustments are to be made to the conversion price, as described below, the stockholder shall be entitled to receive dividends on preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends actually paid on shares of the common stock. No other dividends shall be paid on the preferred stock.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Conversion:&lt;/u&gt;&amp;#160;The preferred stock may be converted at any time, at the option of the holder, into shares of common stock at a conversion price of $0.25 per share (&amp;#8220;Series C Conversion Price&amp;#8221;). The Series C Conversion Price will be adjusted for customary structural changes such as stock splits or stock dividends. In the event that the Company enters into a merger, consolidation or transaction of a similar effect, the Series C stockholder shall be entitled to receive, upon conversion of the preferred stock, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration that would have been received by a holder of the number of shares of common stock into which the preferred stock is convertible immediately prior to such event.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Down-Round Protection:&lt;/u&gt;&amp;#160;The Series C Conversion Price is also subject to &amp;#8220;down-round&amp;#8221; anti-dilution adjustment which means that if the Company sells common stock or common stock equivalents at a price below the Series C Conversion Price, the Series C Conversion Price will be reduced to an amount equal to the issuance price of such additional shares of common stock or common stock equivalents.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Voting Rights:&lt;/u&gt;&amp;#160;Except as required by law, the Series C Preferred Stock does not have voting rights.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Most Favored Nation Provision:&lt;/u&gt;&amp;#160;If there is a subsequent financing, the Series C stockholder may elect to exchange its Series C Preferred Stock for the security issued on a dollar for dollar basis.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Participation Rights:&lt;/u&gt;&amp;#160;For a twelve month period from the date of the financing, the Series C investors will have the right to participate in subsequent financings up to fifty percent of such financing.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Liquidation Provision:&lt;/u&gt;&amp;#160;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Series C Preferred stockholder receives an amount per share equal to the conversion price of $0.40, subject to down-round adjustment, multiplied by the as-if converted share amount of 1,250,000 common shares. If upon the liquidation, the assets are insufficient to permit payments to the Series C and Series D holders, all assets legally available will be distributed to the Series B Preferred stockholders and then any remaining amount is distributed on a pro rata basis among the Series C and Series D holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company also considered the classification of the Series C Preferred Stock Agreement. Because the Most Favored Nation provision is a redemption feature that is outside the control of the Company, the Series C Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&amp;#8217;s balance sheet.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company&amp;#8217;s common stock, a beneficial conversion feature of $325,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in October 2016, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During 2017, all remaining Series C Preferred Stock totaling 386 shares has been converted&amp;#160;at a conversion rate of 4000:1 resulting in the issuance of 1,544,000 shares of common stock. As a result, there is no liquidation preference outstanding as of December 31, 2017.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition, as a result of the Series D financing and the adjustment in the conversion price, a beneficial conversion feature of $175,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in January 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;Convertible Series D Preferred Stock:&lt;/u&gt;&amp;#160;In January 2017, the Company sold 1,200 shares of Series D convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $1,200,000 to a healthcare investment fund and other private investors under the Series D Preferred Stock Agreement. Each share of Series D Preferred Stock was initially convertible into 4,000 shares of common stock which resulted in an effective conversion price of $0.25 per common share. This resulted in the reduction of the conversion price of the Series B and Series C Preferred Stock to $0.25 and a reduction in the exercise price of the Series B warrants to $0.25. As part of the terms of the Series D Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchasers to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series D Convertible Preferred Stock are identical to those of the Series C Convertible Preferred Stock agreement discussed above with the exception of the initial conversion price which was $0.25 per common share.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company also considered the classification of the Series D Preferred Stock Agreement, the Series D Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&amp;#8217;s balance sheet because the Most Favored Nation provision is a redemption feature that is outside the control of the Company.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company&amp;#8217;s common stock, a beneficial conversion feature of $536,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in January 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the year ended December 31, 2017, the Series D stockholders converted 1,000 shares at a conversion rate of 4000:1 and a conversion price of $0.25 per share resulting in the issuance of 4,000,000 shares of common stock. Effective with the Series F Preferred Stock Agreement signed on November 1, 2017, the conversion price for the Series D Preferred Stock was reset to $0.15. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series D Preferred Stock conversion price was reset to $0.10 per share.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Series D stock has liquidation preference over common stock. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series D Preferred stockholders receive an amount per share equal to the conversion price of $0.10, subject to down-round adjustment, multiplied by the as-if converted share amount of 2,000,000 common shares, totaling $200,000 as of December 31, 2017.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2018, the Series D stockholders converted all remaining 200 shares at a conversion rate of 10,000:1 resulting in the issuance of 2,000,000 shares of common stock. As a result, there is no liquidation preference outstanding as of March 31, 2018 related to the Series D Preferred Stock.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;Convertible Series F Preferred Stock:&lt;/u&gt;&amp;#160;In November 2017, the Company sold 2,000 shares of Series F convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $2,000,000 to a healthcare investment fund under the Series F Preferred Stock Agreement. Each share of Series F Preferred Stock is convertible into 6,666.67 shares of common stock which results in an effective conversion price of $0.15 per common share. This resulted in the reduction of the conversion price of the Series B and D Preferred Stock to $0.15 and a reduction in the exercise price of the Series B warrants to $0.15. On December 28, 2017, as a result of entering into a Secured Promissory Note for a convertible bridge loan, the conversion price of the Series F Preferred Stock was reset to $0.10. As part of the terms of the Series F Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series F Convertible Preferred Stock are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Dividends:&lt;/u&gt;&amp;#160;Except for stock dividends or other distributions payable in shares of common stock, for which adjustments are to be made to the conversion price, as described below, the stockholder shall be entitled to receive dividends on preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends actually paid on shares of the common stock. No other dividends shall be paid on the preferred stock.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Conversion:&lt;/u&gt;&amp;#160;The preferred stock may be converted at any time, at the option of the holder, into shares of common stock at a conversion price of $0.10 per share (&amp;#8220;Series F Conversion Price&amp;#8221;). The Series F Conversion Price will be adjusted for customary structural changes such as stock splits or stock dividends. In the event that the Company enters into a merger, consolidation or transaction of a similar effect, the Series F stockholder shall be entitled to receive, upon conversion of the preferred stock, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration that would have been received by a holder of the number of shares of common stock into which the preferred stock is convertible immediately prior to such event.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Down-Round Protection:&lt;/u&gt;&amp;#160;The Series F Conversion Price is also subject to &amp;#8220;down-round&amp;#8221; anti-dilution adjustment which means that if the Company sells common stock or common stock equivalents at a price below the Series F Conversion Price, the Series F Conversion Price will be reduced to an amount equal to the issuance price of such additional shares of common stock or common stock equivalents.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Voting Rights:&lt;/u&gt;&amp;#160;Except as required by law, the Series F Preferred Stock does not have voting rights.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Discretionary Redemption Provision:&lt;/u&gt;&amp;#160;If there is a subsequent transaction that results in a change in control, the Series F stockholder may require the Company to redeem the shares for the sum of 150% of the aggregate stated valued of the Series F Shares and all liquidated damages. However, if net proceeds from the triggering transaction are less than $6 million then the redemption amount shall equal 50% of the total proceeds of such transaction.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Participation Rights:&lt;/u&gt;&amp;#160;For an eighteen month period from the date of the financing, the Series F investors will have the right to participate in subsequent financings up to fifty percent of such financing.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;u&gt;Liquidation Provision:&lt;/u&gt;&amp;#160;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Series F stockholder has no liquidation preference.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Subject to certain trigger events occurring, the Series F Preferred stockholders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 130% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" width="92%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Failure of the Series F Registration Statement to be declared effective by the Securities and Exchange Commission, or the SEC, on or prior to the date that is one hundred and eighty (180) days after the Effectiveness Deadline;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Suspension of the Company&amp;#8217;s common stock from trading for a period of five (5) consecutive trading days;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series F Preferred;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Any default of indebtedness;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Any filing of voluntary or involuntary bankruptcy by the Company;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;A final judgment in excess of $100,000 rendered against the Company;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Breach of representations and warranties in the Stock Purchase Agreement;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Failure to comply with the Series F Certificate of Designation or Rule 144 requirements; and&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px;"&gt;A change in control that would result in the holder exercising its put option (discussed in Note 5 below).&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As certain of these triggering events are considered to be outside the control of the Company, the Series F Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&amp;#8217;s balance sheet.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At the date of the financing, because the conversion of the preferred stock was contingent upon certain events, the conversion feature was determined to not be beneficial.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition, on December 28, 2017, as a result of entering into a Secured Promissory Note for a convertible loan which resulted in the adjustment of the conversion price to $0.10, a beneficial conversion feature of $333,333 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in December 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2018, the Series F stockholders converted all remaining 2,000 shares at a conversion rate of 10,000:1 resulting in the issuance of 20,000,000 shares of common stock. As such, there was no liquidation preference outstanding related to the Series F preferred stock as of March 31, 2018.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Warrants vested and outstanding as of March 31, 2018 are summarized as follows:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="hdcell" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a9a43eac9-beac-4204-899e-5a34d4e82535" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="ac7baf135-5153-4261-a990-06c7c412ce8d" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a5265fa22-1e32-409f-b24b-066d20e8f68d" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="ac38763a0-8636-48d2-bf33-67b46e04005d" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" id="a11bb8f1b-f0a4-40c5-a0d6-73ec1ac865f8" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Issued and&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&lt;b&gt;Source&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="a4374344b-7f37-48c0-8135-8d62c6ff387b" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="a04ce2b39-361b-478e-a68c-e779726d2764" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="a9031f512-366c-4812-8062-7d006a2d7a57" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ffcell" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ada8f1772-aef0-4af5-be8b-d940fad0f67e" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a0e192acd-4ea4-4c24-bca5-38f531140503" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Pre 2015 Common Stock Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a07b03888-06f2-4599-9ca6-000f506ff8ce" valign="bottom" width="9%"&gt;1.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;6-10&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ad3de4d37-5d51-49e9-b56d-247ac12e772b" valign="bottom" width="9%"&gt;4,000,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;2015 Common Stock Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;1.15-$5.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;5-10&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ae8924189-b112-49d1-bcf6-89ccca214691" valign="bottom" width="9%"&gt;442,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;2015 Series B Financing (see Note 6)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a459055d6-694c-488c-beb4-ffa0dce5dd6a" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a66ab6e86-f247-4ada-9c5f-fd21450f2d82" valign="bottom" width="9%" colspan="2"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ab4d117ed-50e0-4f73-8611-da06c45d8035" valign="bottom" width="9%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 11.25pt;"&gt;Common Stock Warrants to Series B Stockholders&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a9f69071a-aa8c-4538-9e62-aa8a4b146a0a" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a9e37f238-0476-40cd-9bca-ce6c765d4e58" valign="bottom" width="9%"&gt;5&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a0099a10f-3489-4386-b548-2a5518978f9c" valign="bottom" width="9%"&gt;1,843,750&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 11.25pt;"&gt;Placement Agent Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="aa8cbceb0-4408-4bd7-aeb6-bc94e0774be2" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a9903c0de-ed16-46f9-bb92-942b73491ded" valign="bottom" width="9%"&gt;5&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="aba19c2f4-bb66-4554-8849-6a6f8ba98383" valign="bottom" width="9%"&gt;187,500&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;2016 Common Stock Warrants to Service Providers&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a15810522-8ba1-42fc-adaf-30ad8aac3c8e" valign="bottom" width="9%"&gt;1.15&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a23c16c99-74c3-45bd-9135-a2af7481af01" valign="bottom" width="9%"&gt;10&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="acdf5abc0-f070-49b0-bd00-f475996c76a2" valign="bottom" width="9%"&gt;40,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;2016 Series C Placement Agent Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a4377163f-7937-4bb6-b9c5-03daaefd56e6" valign="bottom" width="9%"&gt;0.40&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ad56722d6-8a83-4964-8b71-253f59d666de" valign="bottom" width="9%"&gt;5&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a013e1b31-24dd-4847-acbb-fb164a047b59" valign="bottom" width="9%"&gt;125,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;2017 Series D Placement Agent Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="ac7498af7-8e5d-4d84-b582-a717f3906957" valign="bottom" width="9%"&gt;0.25&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="acd8fd4ab-d53e-4d4e-bab9-4071b52f4205" valign="bottom" width="9%"&gt;5&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a79b0a49c-3edd-4642-b6eb-def1543aa137" valign="bottom" width="9%"&gt;480,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;2017 Common Stock Warrants to Service Provider&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a4ce0c91c-c69f-4748-acc4-7c339818d0aa" valign="bottom" width="9%"&gt;0.41&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a1367fd42-0445-4468-a318-71bde2152b83" valign="bottom" width="9%"&gt;5&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" style="border-bottom: 1px solid;" id="a2c8ddbb7-a2cb-471f-a535-96c271ea66dd" valign="bottom" width="9%"&gt;125,000&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin: 0px;"&gt;2018 Emerald Financing Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="a1766b6b4-dbaa-40fb-9417-6156d0c6e6ed" valign="bottom" width="9%"&gt;0.10&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a19c6c1e1-79a6-4336-a2ee-6de6f288a15b" valign="bottom" width="9%"&gt;5&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a4df986b0-a65f-43a5-be56-c42a3bb5666a" valign="bottom" width="9%"&gt;44,200,000&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 11.25pt;"&gt;&lt;b&gt;Total warrants vested and outstanding as of March 31, 2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 3px double;"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 3px double;"&gt;&lt;b&gt;51,443,250&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;2017 Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the Company issued 480,000 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series D Preferred Stock financing. The warrants vest immediately and have an exercise price of $0.25 per share with a term of five years. The Company estimated the value of the warrants to be $115,200 utilizing the Black-Scholes option pricing model and recorded this amount to issuance costs.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2017, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 125,000 shares of common stock with an exercise price of $0.41 per share with a term of five years. The Company estimated the warrant value to be $30,000 utilizing the Black-Scholes option pricing model and recorded this amount to general and administrative expense for the&amp;#160;year due to the immediate vesting.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;2018 Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock to Emerald Health Sciences and an accredited investor in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&amp;#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, and concluded that the Emerald warrants should be classified as a liability. See additional discussion in Note 6 below.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#8217;s warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock Option Plan: 2014 Omnibus Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The 2014 Omnibus Incentive Plan (the &amp;#8220;2014 Plan&amp;#8221;) was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants. As of March 31, 2018, options (net of canceled or expired options) covering an aggregate of 1,030,000 shares of the Company&amp;#8217;s common stock had been granted under the 2014 Plan, and the Company had 1,030,000 options outstanding and 970,000 shares available for future grants under the 2014 Plan.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&amp;#8217;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,030,000 shares net of cancellations and expirations through March 31, 2018 under the 2014 Plan.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a summary of activity under the 2014 Plan as of March 31, 2018:&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="10"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Available&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;for Grant of&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Options &amp;amp;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Price per&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td colspan="2"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td colspan="2"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;b&gt;Balance at December 31, 2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;870,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1,130,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.60&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Options granted&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Options exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Options cancelled&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;(100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-$3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;2.57&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;b&gt;Balance at March 31, 2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;970,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1,030,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.42-$3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.42&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Vested and Exercisable at March 31, 2018&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;668,000&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.42&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.42&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The weighted-average remaining contractual term of options vested and exercisable at March 31, 2018 was approximately 6.62 years.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the three months ended March 31, 2018, the Company had cancellations of vested stock options totaling 100,000 options. Stock compensation expense for the three months ended March 31, 2018 and 2017 was $41,005 and $86,544, respectively, and was recorded to general and administrative expense.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&amp;#8217;s stock exceeded the exercise price of the stock options at March 31, 2018 for those stock options for which the quoted market price was in excess of the exercise price (&amp;#8220;in-the-money options&amp;#8221;). As of March 31, 2018, the aggregate intrinsic value of options outstanding was $0. As of March 31, 2018, 668,000 options to purchase shares of common stock were exercisable.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The total amount of unrecognized compensation cost related to non-vested stock options was $349,013 as of March 31, 2018. This amount will be recognized over a weighted average period of 1.42 years.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Restricted stock awards (&amp;#8220;RSAs&amp;#8221;) are granted to our Board of Directors and members of senior management and are issued pursuant to the Company&amp;#8217;s 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company&amp;#8217;s senior management and Board of Directors with a fair market value of approximately $900,000. These RSAs vest from one to three years from the grant date as services are rendered to the Company.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On January 18, 2018, the Company entered into Restricted Stock Agreements with each of Dr. Murphy, Elizabeth Berecz, CFO, and Cosmas N. Lykos, the Company&amp;#8217;s Founder granting 900,000, 700,000, and 900,000 shares of restricted common stock, respectively, with a fair market value of $475,000. These agreements were issued outside of the 2014 Omnibus Incentive Plan. The restricted stock vests in equal 50% installments on the first and second anniversaries of the grant date, subject to continued employment with Nemus through the applicable vesting date. Each Restricted Stock Agreement provides that if an executive&amp;#8217;s employment or service is terminated by the Company without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the separation along with accelerated vesting of all outstanding stock awards.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 3 above, Mr. Lykos&amp;#8217; unrestricted stock awards amounting to 1,225,000 shares became immediately vested resulting in the recording of compensation expense of $117,958 which represents the fair market value of those shares as of the separation date.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the three months ended March 31, 2018 and 2017, the Company recorded $188,604 and $65,625 during each period, in stock-based compensation expense related to these restricted stock awards. The total amount of unrecognized compensation cost related to non-vested RSAs was $384,396 as of March 31, 2018.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statements of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the three months ended March 31, 2018 and 2017, the Company recognized stock-based compensation expense of $229,609 and $152,169 (including compensation expense for RSAs discussed above) which was recorded as a general and administrative expense in the consolidated statements of operations.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:PreferredStockTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;5. Provisions for Conversion of Preferred Stock and Put Option&amp;#160;&lt;b&gt;Liability&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Series B Preferred Stock Conversion Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of August 20, 2015, in connection with the Series B Preferred Stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company would affect another sale or issuance of common stock, stock options or convertible securities with a price per share below $0.80. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&amp;#160;&lt;i&gt;Derivatives and Hedging/Contracts in Entity&amp;#8217;s Own Equity&lt;/i&gt;, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $75,488 and was booked as a current liability as of September 30, 2015. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December 31, 2017, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative was classified as a current liability and was adjusted to $6,715 as of December 31, 2017. The change in fair market value was recorded as non-operating income of $102,848 for the year ended December 31, 2017.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the three months ended March 31, 2018, all remaining Series B Preferred Stock was converted to common stock by their shareholders and as a result, the Series B conversion liability was reduced to zero as of March 31, 2018. The reduction of this liability totaling $6,715 was recorded as non-operating income for the three months ended March 31, 2018.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Series F Preferred Stock Put Option Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of November 1, 2017, in connection with the Series F Preferred Stock financing, the Company recorded a put option liability related to discretionary redemption provided to the stockholders in the event that the Company would undergo a subsequent financing that would result in a change in control. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&amp;#160;&lt;i&gt;Derivatives and Hedging/Contracts in Entity&amp;#8217;s Own Equity&lt;/i&gt;, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $103,364 and was booked as a current liability as of November 1, 2017. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December 31, 2017, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative was classified as a current liability and was&amp;#160;considered de minimis&amp;#160;as of December 31, 2017. The change in fair market value was recorded as non-operating income of $103,364 for the year ended December 31, 2017. In March 2018, the Series F Preferred shareholder converted their shares to common stock and as a result, the Company did not record a put option liability as of March 31, 2018.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
<nmus:SeriesBWarrantsTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;6. Series B Warrant and Emerald Warrant Liabilities&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Series B Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 common stock warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were initially valued at $2,935,800 utilizing the Black-Scholes pricing model. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also have a &amp;#8220;down-round&amp;#8221; protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The exercise price is automatically adjusted down to the price of the instrument being issued. In October 2016, as a result of the Series C Preferred Stock financing, the exercise price was adjusted to $0.40 and in December 2016, as a result of the Series D Preferred Stock financing, the exercise price was adjusted to $0.25. In November 2017, as a result of the Series F Preferred Stock financing, the exercise price was adjusted to $0.15 and on December 28, 2017, the exercise price was adjusted to $0.10 after the company entered into a Secured Promissory Note for a convertible loan. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&amp;#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, and concluded that the Series B warrants should be classified as a liability. The Company then applied the fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the preferred stock. The Company also performed the same valuation as of December 31, 2017 utilizing the Black-Scholes pricing model. This resulted in a warrant value of $551,322 as of December 31, 2017. The change in fair market value at the re-measurement date was recorded as non-operating income totaling $560,986 for the year ended December 31, 2017.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2018, Series B warrant holders exercised 987,000 warrants at an exercise price of $0.10 resulting in cash proceeds to the Company of $98,700. On January 19, 2018 as a result of the Emerald Financing, the Series B warrant exercise price was reset to $0.00. The strike price for these warrants is now permanently reset. Subsequent to this date, Series B warrant holders exercised 3,419,250 warrants resulting in the issuance of 3,419,250 shares of common stock with no consideration. The intrinsic value of the warrant exercises for the three months ended March 31, 2018 was $1,125,291. At each of the exercise dates, the Company marked the warrants to fair market value which was determined by a Black Scholes computation which considered the closing trading price on the exercise dates. As of March 31, 2018, the fair market value of the remaining Series B warrants was also determined via a Black Scholes computation. As such, the Company recorded a liability of $483,438 and the change in fair market value for these warrants along with the warrant exercises totaling $1,223,991 was recorded as non-operating expense during the three months ended March 31, 2018. As the remaining warrant holders still held certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants were still considered to require liability classification. The assumptions utilized for the Black Scholes computations are outlined below:&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="6"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;As of Period End&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;&amp;#160;March 31,&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;70.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;70.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1.95&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1.947-1.949&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;2.25&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;2.64-2.65&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Weighted-average fair value of warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.238&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.086&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;b&gt;&lt;i&gt;Emerald Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;u style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"&gt;Warrant liability&lt;/u&gt;&lt;/div&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years. The warrants are exercisable in cash or through a cashless exercise provision. The warrants also have an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10 per each warrant. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrant holder has the right to participate in subsequent financing transactions on an as-if converted basis. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&amp;#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, and concluded that the Emerald warrants should be classified as a liability and re-measured to fair market value at the end of each reporting period. With the assistance of a third-party valuation specialist, the Company valued the warrant liability utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;s, as of the closing dates of the financings and as of March 31, 2018.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of January 18, 2018 and February 16, 2018, in connection with the Emerald Financing, the Company recorded a warrant liability related to a discretionary redemption provided to the warrant holders in the event that the Company would undergo a subsequent financing that would result in a change in control. With the assistance of a third-party valuation specialist, the Company valued the warrant liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;s, as of the closing date of the financing. The Company also performed a review of the warrant liability in conjunction with ASC 815,&amp;#160;&lt;i&gt;Derivatives and Hedging/Contracts in Entity&amp;#8217;s Own Equity&lt;/i&gt;, and determined that the warrant liability does not requires bifurcation. As of March 31, 2018, the derivative was classified as a current warrant liability valued at $138,630. Because the amount of proceeds related to this financing exceeded the value assigned to the related Emerald warrant liability, the full amount of the&amp;#160;warrant liability was&amp;#160;charged to&amp;#160;non-operating expense and included as part of the fair value in excess of proceeds adjustment discussed below.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;u&gt;Fair Value Computations&lt;/u&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The estimated fair value of the warrants issued on January 19, 2018 (the January Closing Date) and at March 31, 2018 was $4,654,922 and $3,671,089, respectively. The estimated fair value of the warrants issued on February 16, 2018 (the February Closing Date) and at March 31, 2018 was $5,631,051 and $4,296,315, respectively. The change in fair market value from the closing dates to March 31, 2018 amounted to $2,318,569 and was recorded as non-operating income for the three-month period then ended.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Given that the fair value of the derivative warrants issued on the January Closing Date exceeded the total proceeds of the private placement of $1,500,000, as of that date, no net amounts above par value were allocated to common stock. The $3,154,922 amount by which the recorded liabilities exceeded the proceeds was charged to non-operating expense at the January Closing Date. Given that the fair value of the derivative warrants issued on the February Closing Date exceeded the total proceeds of the private placement of $1,750,000, as of that date, no net amounts above par value were allocated to commons stock. The $3,881,051 amount by which the recorded liabilities exceeded the proceeds was charged to non-operating expense at the February Closing Date. In addition, given that there were no amounts allocated to common stock related to these two closings, issuance costs totaling $137,191 were also charged to non-operating expense at the closing dates.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The derivative liabilities were valued based on Monte Carlo simulations conducted at the closing dates of the January and February closings and at March 31, 2018 using the following assumptions:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="hdcell" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom: 1px solid;" id="a65e697b8-51d9-430d-9203-7ab6cb8a824e" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;On&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;issuance&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="ffcell" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a6910fc5f-181b-437b-aa96-491bf8b0607b" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a9755e991-b358-482e-a6f4-5b3b5524bcf9" valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a38e83f6f-9636-4731-ae8d-9af83b620f89" valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;2.54-2.55&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;2.45-2.6&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;4.8-4.88&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" id="a12a52cd1-8040-4b6a-b5cb-6efc9c22ab2c" valign="bottom" width="9%"&gt;5.0&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Closing price per share of common stock&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" id="ac1e5190b-1296-46ae-ba68-df37ca92d069" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.24&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.29-0.30&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</nmus:SeriesBWarrantsTextBlock>
<us-gaap:ShortTermDebtTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;7. Convertible Bridge Loan&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December 28, 2017, the Company entered into a Secured Promissory Note and Security Agreement for a convertible loan with Emerald. The bridge loan provides for aggregate gross proceeds to Nemus of up to $900,000 and is secured by all of Nemus&amp;#8217; assets. Nemus received proceeds of $500,000 on December 28, 2017 and on January 19, 2018, the Company received the remaining $400,000 in funding as it had satisfied the conditions of the funding. These conditions required receipt of conversion notices from all the existing Series B shareholders to convert their preferred shares to common stock. Such conversions occurred in January and February of 2018. Also, on January 19, 2018, in conjunction with the Emerald Securities Purchase Agreement, the bridge loan was converted at $0.10 per share to common stock resulting in the issuance of 9,000,000 additional shares.&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In connection with the convertible bridge loan financing, the Company recorded a liability related to the conversion option of the bridge loan into the Company&amp;#8217;s common stock due to a down-round protection feature present in the loan agreement. The Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;s, as of the closing date of the financing utilizing the Black Scholes valuation methodology and the assumptions discussed in Note 6 above. This resulted in a conversion liability value of $265,000 as of the financing close date which was one trading day prior to December 31, 2017. The second funding in January 2018&amp;#160;resulted in an additional conversion liability which was $360,000. The Company recorded amortization of this debt discount of $34,608 to non-operating expense prior to the conversion of the debt. In addition, the Company then marked to market the conversion liabilities&amp;#160;to $810,000&amp;#160;utilizing the assumptions discussed above and recorded a&amp;#160;change in fair value&amp;#160;on conversion right of $185,000 as a non-operating expense. At the time of the conversion, the Company extinguished the debt and the associated conversion liability and issued the common stock at fair market value resulting in a loss on extinguishment of $590,392 which was recorded as a non-operating expense for the three months ended March 31, 2018.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;8. Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Under the FASB's accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty (50) % likelihood of being sustained. Additionally, the guidance provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.&lt;/p&gt;
&lt;p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at March 31, 2018. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying consolidated statement of operations to offset pre-tax losses.&lt;/p&gt;
&lt;p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has no material uncertain tax positions as of March 31, 2018.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;9. Subsequent Events&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Separation of Chief Financial Officer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 30, 2018, the Company entered into a separation agreement and release (the &amp;#8220;Separation Agreement&amp;#8221;) with Elizabeth Berecz, the Company&amp;#8217;s current Chief Financial Officer. Ms. Berecz&amp;#8217;s separation will be effective May 25, 2018 (the &amp;#8220;Separation Date&amp;#8221;), and she will remain the Company&amp;#8217;s principal financial officer until the Separation Date.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pursuant to the Separation Agreement, Ms. Berecz has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Ms. Berecz compensation and benefits as follows: (i) through the Separation Date, an annualized base salary at the rate in effect for her as of the date of the Separation Agreement; (ii) a lump sum gross payment of $145,833, in consideration for the restrictive covenants contained in the Separation Agreement; (iii) reimbursement for payments made by Ms. Berecz for COBRA coverage for a period of six (6) months following the Separation Date; and (iv) Ms. Berecz&amp;#8217;s unrestricted stock awards amounting to 1,050,000 shares and unvested stock options totaling 100,000 shares became immediately vested.&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Appointment of New Chief Financial Officer&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 5, 2018, the Company agreed to an offer letter with Doug Cesario, pursuant to which Mr. Cesario joined the Company on April 23, 2018 and will be appointed as Chief Financial Officer of the Company effective May 26, 2018.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense and equity securities with embedded features as discussed below.&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<nmus:LiquidityAndGoingConcernPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has incurred operating losses and negative cash flows from operations since our inception. As of March 31, 2018, we had cash and cash equivalents of $2,945,312. The Company anticipates that it will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements were issued. These conditions give rise to substantial doubt as to the Company&amp;#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s continued existence is dependent on its ability to raise additional sufficient funding to cover operating expenses and to invest in operations and development activities. The Company plans to continue to pursue funding through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs or cease operations.&lt;/div&gt;&lt;/div&gt;</nmus:LiquidityAndGoingConcernPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A deposit of $4,428 as of both March 31, 2018 and December 31, 2017 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&amp;#8217;s credit cards.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&lt;/p&gt;&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td valign="top" width="4%"&gt;&lt;/td&gt;&lt;td valign="top" width="6%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Level 1:&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Level 2:&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top"&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Level 3:&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The warrant liability for the Emerald warrants and the associated put option were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of March 31, 2018.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of March 31, 2018 and December 31, 2017, property and equipment, net, was $2,134 and $1,407 respectively, consisting primarily of computers and equipment. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the &amp;#8220;NOLs&amp;#8221;) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&amp;#8217;s statement of operations in the period incurred.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Convertible Instruments&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. ASC 815,&amp;#160;&lt;i&gt;Derivatives and Hedging Activities&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 815&amp;#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20,&amp;#160;&lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 470-20&amp;#8221;). Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. We account for convertible instruments (when we have determined that the embedded conversion options should be bifurcated from their host instruments) in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We also follow ASC 480-10,&amp;#160;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&amp;#160;(&amp;#8220;ASC 480-10&amp;#8221;) in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as
 a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#8217;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#8217;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in interest expense in the accompanying Consolidated Statements of Operations.&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<nmus:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other (income) expense in the Consolidated Statements of Operations.&lt;/div&gt;&lt;/div&gt;</nmus:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has not begun planned principal operations and has not generated any revenue since inception.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:&lt;/p&gt;
&lt;p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="4%"&gt;&lt;/td&gt;
&lt;td valign="top" width="4%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Volatility - We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<nmus:StockBasedCompensationForNonEmployeesPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation for Non-Employees&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) No. 505-50,&amp;#160;&lt;i&gt;Equity - Equity Based Payments to Non-Employees,&lt;/i&gt;&amp;#160;using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.&lt;/div&gt;&lt;/div&gt;</nmus:StockBasedCompensationForNonEmployeesPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;FASB ASC No. 280,&amp;#160;&lt;i&gt;Segment Reporting&lt;/i&gt;, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (&amp;#8220;CODM&amp;#8221;), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three months ended March 31, 2018 and 2017, the comprehensive income (loss) was equal to the net income (loss).&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Earnings per share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company applies FASB ASC No. 260,&amp;#160;&lt;i&gt;Earnings per Share&lt;/i&gt;. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of outstanding warrants and awards granted to employees under stock-based compensation plans. Potentially dilutive shares of the Company&amp;#8217;s common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented. For the three months ended March 31, 2018, warrants to purchase 51,443,250 common shares and stock options exercisable for 1,030,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share. For the three months ended March 31, 2017, 3,625.375 shares of Series B Preferred Stock convertible into 14,501,500 common shares at $0.25 per share, 706 shares of Series D Preferred Stock convertible into 2,824,000 common shares at $0.25 per share, warrants to purchase 11,649,500 common shares and stock options exercisable for 1,130,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share.&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;div&gt;&lt;div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;&lt;p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2017, the FASB issued ASU 2017-11,&lt;i&gt;&amp;#160;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/i&gt;, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating&lt;i&gt;&amp;#160;Topic 480, Distinguishing Liabilities from Equity&lt;/i&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center"  valign="bottom" colspan="2"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center"  valign="bottom" colspan="2"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center"  valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center"  valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center"  valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center"  valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Issued and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&lt;b&gt;Source&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%" colspan="2"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%" colspan="2"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%" colspan="2"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Pre 2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;1.00&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p align="right" style="margin: 0px;"&gt;6-10&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;4,000,000&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p align="right" style="margin: 0px;"&gt;1.15-$5.00&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p align="right" style="margin: 0px;"&gt;5-10&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;442,000&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;2015 Series B Financing (see Note 6)&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%" colspan="2"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 11.25pt;"&gt;Common Stock Warrants to Series B Stockholders&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p
 style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;0.00&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;5&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;1,843,750&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 11.25pt;"&gt;Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;0.00&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;5&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;187,500&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;2016 Common Stock Warrants to Service Providers&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;1.15&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;10&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;40,000&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;2016 Series C Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;0.40&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;5&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;125,000&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;2017 Series D Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;0.25&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;5&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;480,000&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;2017 Common Stock Warrants to Service Provider&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;0.41&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;5&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right" style="border-bottom: 1px solid;"  valign="bottom" width="9%"&gt;125,000&lt;/td&gt;&lt;td style="padding-bottom: 1px;" valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="margin: 0px;"&gt;2018 Emerald Financing Warrants&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;0.10&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom" width="9%"&gt;5&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td align="right"  valign="bottom"
 width="9%"&gt;44,200,000&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td&gt;&lt;p align="justify" style="margin: 0px 0px 0px 11.25pt;"&gt;&lt;b&gt;Total warrants vested and outstanding as of March 31, 2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: black 3px double;"&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: black 3px double;"&gt;&lt;b&gt;51,443,250&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="10"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Available&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;for Grant of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Options &amp;amp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Price per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"&gt;&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;b&gt;Balance at December 31, 2017&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;870,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1,130,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="right" style="margin: 0px;"&gt;0.42-3.00&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.60&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin:
 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Options cancelled&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;100,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;(100,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="right" style="margin: 0px;"&gt;0.42-$3.00&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;2.57&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&lt;b&gt;Balance at March 31, 2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;970,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1,030,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p align="right" style="margin: 0px;"&gt;0.42-$3.00&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.42&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#ffffff"&gt;&lt;td&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td valign="top"&gt;&lt;p align="justify" style="margin: 0px;"&gt;Vested and Exercisable at March 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: 3px double;" valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;668,000&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.42&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="9%"&gt;&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.42&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="6"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;As of Period End&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;&amp;#160;March 31,&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: 1px solid;" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;70.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;70.00&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1.95&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;1.947-1.949&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;2.25&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;2.64-2.65&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Weighted-average fair value of warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.238&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;
&lt;p align="justify" style="margin: 0px 0px 0px 0in;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"&gt;
&lt;p align="right" style="margin: 0px 0px 0px 0in;"&gt;0.086&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;On&lt;/b&gt;&lt;/p&gt;
&lt;p align="center" style="margin: 0px;"&gt;&lt;b&gt;issuance&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1px;" valign="bottom"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;0.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Volatility factor&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;70.00&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;2.54-2.55&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;2.45-2.6&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#ffffff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Expected term (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2"&gt;
&lt;p align="right" style="margin: 0px;"&gt;4.8-4.88&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;5.0&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#cceeff"&gt;
&lt;td valign="top"&gt;
&lt;p align="justify" style="margin: 0px;"&gt;Closing price per share of common stock&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;$&lt;/td&gt;
&lt;td align="right" valign="bottom" width="9%"&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.24&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;$&lt;/td&gt;
&lt;td&gt;
&lt;p align="right" style="margin: 0px;"&gt;0.29-0.30&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock>
<us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">straight-line method</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
<us-gaap:NumberOfReportableSegments contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="segment" decimals="INF">1</us-gaap:NumberOfReportableSegments>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF">11649500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1130000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF">51443250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1030000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">3625.375</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">706</us-gaap:PreferredStockSharesIssued>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">14501500</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">2824000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_20_Aug_2015T00_00_00_TO_20_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_03_May_2017T00_00_00_TO_03_May_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember" unitRef="USD_per_Share" decimals="2">20.00</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:SharesIssuedPricePerShare>
<nmus:TermOfAgreement contextRef="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_LegalEntityAxis_UniversityOfMississippiMember">P5Y</nmus:TermOfAgreement>
<nmus:TermOfAgreement contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_TypeOfArrangementAxis_IndependentContractorAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">P10Y</nmus:TermOfAgreement>
<nmus:NumberOfLicenseAgreements contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="License_agreement" decimals="INF">3</nmus:NumberOfLicenseAgreements>
<nmus:NumberOfLicenseAgreements contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="License_agreement" decimals="INF">2</nmus:NumberOfLicenseAgreements>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_LegalEntityAxis_UniversityOfMississippiMember">P3M</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P60D</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P60D</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P60D</nmus:NoticePeriodForTermination>
<nmus:OneTimeUpfrontPayment contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_15_Oct_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_MonthAndYearOfAgreementAxis_OctoberTwoThousandFifteenMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">10000</nmus:OneTimeUpfrontPayment>
<nmus:OneTimeUpfrontPayment contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_MonthAndYearOfAgreementAxis_December2015Member_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">10000</nmus:OneTimeUpfrontPayment>
<nmus:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">25000</nmus:AnnualFeesForLicenseAgreement>
<nmus:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">25000</nmus:AnnualFeesForLicenseAgreement>
<nmus:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">25000</nmus:AnnualFeesForLicenseAgreement>
<nmus:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="-5">2100000</nmus:AggregateMilestonePaymentsIfMilestonesAchieved>
<nmus:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_14_Dec_2015T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="-5">1400000</nmus:AggregateMilestonePaymentsIfMilestonesAchieved>
<nmus:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="-5">700000</nmus:AggregateMilestonePaymentsIfMilestonesAchieved>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">9267</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00" unitRef="USD" decimals="0">7559</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00" unitRef="USD" decimals="0">56449</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00" unitRef="USD" decimals="0">32128</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4311</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:LeaseAndRentalExpense contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">300</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2600</us-gaap:LeaseAndRentalExpense>
<us-gaap:PaymentsToAcquireFurnitureAndFixtures contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00" unitRef="USD" decimals="0">19654</us-gaap:PaymentsToAcquireFurnitureAndFixtures>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00" unitRef="USD" decimals="0">1650</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<nmus:FeesAndExpensesForServicesProvided contextRef="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_TypeOfArrangementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">154000</nmus:FeesAndExpensesForServicesProvided>
<nmus:FeesAndExpensesForServicesProvided contextRef="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_TypeOfArrangementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember_RangeAxis_MaximumMember" unitRef="USD" decimals="0">183000</nmus:FeesAndExpensesForServicesProvided>
<nmus:AnalyticalMethodDevelopmentAndQualificationExpense contextRef="Context_Custom_01_Feb_2016T00_00_00_TO_05_Feb_2016T00_00_00_TypeOfArrangementAxis_LetterAgreementMember_LegalEntityAxis_ContractManufacturingOrganizationMember" unitRef="USD" decimals="0">142900</nmus:AnalyticalMethodDevelopmentAndQualificationExpense>
<nmus:MonthlyFee contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" unitRef="USD" decimals="0">10000</nmus:MonthlyFee>
<nmus:MonthlyFee contextRef="Context_Custom_25_Mar_2017T00_00_00_TO_01_Apr_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" unitRef="USD" decimals="0">20000</nmus:MonthlyFee>
<nmus:TermsOfAgreementRenewed contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">P1Y</nmus:TermsOfAgreementRenewed>
<nmus:TotalExpenseIncurredUnderAgreement contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" unitRef="USD" decimals="0">30000</nmus:TotalExpenseIncurredUnderAgreement>
<nmus:TotalExpenseIncurredUnderAgreement contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" unitRef="USD" decimals="0">220000</nmus:TotalExpenseIncurredUnderAgreement>
<nmus:TotalExpenseIncurredUnderAgreement contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_TypeOfArrangementAxis_IndependentContractorAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">100000</nmus:TotalExpenseIncurredUnderAgreement>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_03_May_2017T00_00_00_TO_03_May_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember" unitRef="shares" decimals="INF">1000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_03_May_2017T00_00_00_TO_03_May_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<nmus:GuarantorFailedToPay contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_12_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesEPreferredStockMember" unitRef="USD" decimals="0">20000000</nmus:GuarantorFailedToPay>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember" unitRef="USD" decimals="0">180000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember" unitRef="USD" decimals="0">145833</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="shares" decimals="INF">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember" unitRef="shares" decimals="INF">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember" unitRef="shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember" unitRef="shares" decimals="INF">1050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_TypeOfArrangementAxis_IndependentContractorAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">15000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_29_Dec_2016T00_00_00_TO_29_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_29_Dec_2016T00_00_00_TO_29_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember" unitRef="USD_per_Share" decimals="0">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" unitRef="USD_per_Share" decimals="0">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" unitRef="USD_per_Share" decimals="0">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" unitRef="USD_per_Share" decimals="1">0.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" unitRef="USD_per_Share" decimals="2">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandEighteenEmeraldFinancingWarrantsMember" unitRef="USD_per_Share" decimals="1">0.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember_RangeAxis_MinimumMember">P6Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember_RangeAxis_MaximumMember">P10Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MinimumMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember_RangeAxis_MaximumMember">P10Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">P10Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandEighteenEmeraldFinancingWarrantsMember">P5Y</nmus:TermOfWarrant>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">51443250</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_Pre2015CommonStockWarrantsMember" unitRef="USD" decimals="0">4000000</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenCommonStockWarrantsMember" unitRef="USD" decimals="0">442000</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" unitRef="USD" decimals="0">1843750</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" unitRef="USD" decimals="0">187500</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" unitRef="USD" decimals="0">40000</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" unitRef="USD" decimals="0">125000</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" unitRef="USD" decimals="0">480000</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" unitRef="USD" decimals="0">125000</nmus:WarrantsVestedAndOutstanding>
<nmus:WarrantsVestedAndOutstanding contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_TwoThousandEighteenEmeraldFinancingWarrantsMember" unitRef="USD" decimals="0">44200000</nmus:WarrantsVestedAndOutstanding>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">870000</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">970000</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">0</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">0</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">100000</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1030000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1030000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">668000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="0">0</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="0">0</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare>
<nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="1">0.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">2.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">605000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">28335500</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1250</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">777.125</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">420.325</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">386</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">1000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_TypeOfArrangementAxis_SeriesBPreferredStockAgreementMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="2">1197.45</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="2">2833.55</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">200</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">2000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">3108500</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">2802167</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">1544000</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">4000000</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_TypeOfArrangementAxis_SeriesBPreferredStockAgreementMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">5910666</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="0">900000</us-gaap:ConversionOfStockSharesIssued1><us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1710000</us-gaap:DebtConversionConvertedInstrumentAmount1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">28335500</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">2000000</us-gaap:ConversionOfStockSharesIssued1>

<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">20000000</us-gaap:ConversionOfStockSharesIssued1>

<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Mar_2016T00_00_00_TO_31_Mar_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.40</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Dec_2016T00_00_00_TO_29_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_24_Oct_2017T00_00_00_TO_01_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_24_Oct_2017T00_00_00_TO_01_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_TypeOfArrangementAxis_SeriesBPreferredStockAgreementMember_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<nmus:ConversionPrice contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.10</nmus:ConversionPrice>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="shares" decimals="INF">15000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="shares" decimals="INF">15000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" unitRef="shares" decimals="INF">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBWarrantMember" unitRef="shares" decimals="INF">4406250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="0">480000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="shares" decimals="INF">3419250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="shares" decimals="INF">20400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn19January2018Member" unitRef="shares" decimals="INF">4654922</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="shares" decimals="0">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="shares" decimals="INF">20400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" unitRef="shares" decimals="INF">3400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn16February2018Member" unitRef="shares" decimals="INF">5631051</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="shares" decimals="0">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="shares" decimals="INF">6437500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn19January2018Member" unitRef="shares" decimals="0">3671089</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_WarrantsIssuanceDateAxis_WarrantsIssuedOn16February2018Member" unitRef="shares" decimals="INF">4296315</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<nmus:TermOfWarrants contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">P5Y</nmus:TermOfWarrants>
<nmus:TermOfWarrants contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember">P5Y</nmus:TermOfWarrants>
<us-gaap:BridgeLoan contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">900000</us-gaap:BridgeLoan>
<us-gaap:BridgeLoan contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_ShortTermDebtTypeAxis_BridgeLoanMember" unitRef="USD" decimals="0">900000</us-gaap:BridgeLoan>
<us-gaap:BridgeLoan contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">0</us-gaap:BridgeLoan>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_ShortTermDebtTypeAxis_BridgeLoanMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="shares" decimals="INF">9000000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_ShortTermDebtTypeAxis_BridgeLoanMember" unitRef="shares" decimals="INF">9000000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">5000</nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
<nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">500</nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
<nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">1200</nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
<nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="INF">2000</nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
<nmus:CommonStockAggregatePurchasePrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</nmus:CommonStockAggregatePurchasePrice>
<nmus:CommonStockAggregatePurchasePrice contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</nmus:CommonStockAggregatePurchasePrice>
<nmus:CommonStockAggregatePurchasePrice contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</nmus:CommonStockAggregatePurchasePrice>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD" decimals="0">500000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">1200000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD" decimals="0">2000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<nmus:PreferredStockConvertibleConversionPriceDecrease contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:PreferredStockConvertibleConversionPriceDecrease>
<nmus:PreferredStockConvertibleConversionPriceDecrease contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.25</nmus:PreferredStockConvertibleConversionPriceDecrease>
<nmus:PreferredStockConvertibleConversionPriceDecrease contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</nmus:PreferredStockConvertibleConversionPriceDecrease>
<nmus:PreferredStockConvertibleConversionPriceDecrease contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</nmus:PreferredStockConvertibleConversionPriceDecrease>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">2833550</us-gaap:PreferredStockLiquidationPreferenceValue>
<nmus:PercentageOfConversionAmount contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="pure" decimals="2">1.15</nmus:PercentageOfConversionAmount>
<nmus:PercentageOfConversionAmount contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="pure" decimals="2">1.30</nmus:PercentageOfConversionAmount>
<nmus:MinimumLitigationJudgementAmount contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="0">100000</nmus:MinimumLitigationJudgementAmount>
<nmus:MinimumLitigationJudgementAmount contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD" decimals="0">100000</nmus:MinimumLitigationJudgementAmount>
<us-gaap:PreferredStockConversionBasis contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">4000:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockConversionBasis contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">6666.67:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockConversionBasis contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember">4000:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockConversionBasis contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">4000:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockConversionBasis contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">10,000:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockConversionBasis contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">10,000:1</us-gaap:PreferredStockConversionBasis>
<us-gaap:PreferredStockConversionBasis contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">10,000:1</us-gaap:PreferredStockConversionBasis>
<nmus:NumberOfCommonStockIssuedUponConversionOfPreferredStock contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">2500</nmus:NumberOfCommonStockIssuedUponConversionOfPreferredStock>
<nmus:NumberOfCommonStockIssuedUponConversionOfPreferredStock contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">4000</nmus:NumberOfCommonStockIssuedUponConversionOfPreferredStock>
<nmus:NumberOfCommonStockIssuedUponConversionOfPreferredStock contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="shares" decimals="2">6666.67</nmus:NumberOfCommonStockIssuedUponConversionOfPreferredStock>
<nmus:LiquidationProvisionCommonStockEquivalentShares contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="shares" decimals="INF">1250000</nmus:LiquidationProvisionCommonStockEquivalentShares>
<nmus:LiquidationProvisionCommonStockEquivalentShares contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="shares" decimals="INF">2000000</nmus:LiquidationProvisionCommonStockEquivalentShares>
<nmus:LiquidationProvisionCommonStockEquivalentValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">200000</nmus:LiquidationProvisionCommonStockEquivalentValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="USD" decimals="0">325000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">175000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">536000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD" decimals="0">333333</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<nmus:PercentageOfSharesToBeRedeemed contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="pure" decimals="2">1.50</nmus:PercentageOfSharesToBeRedeemed>
<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="USD" decimals="-6">6000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
<nmus:RedemptionAmountPercentage contextRef="Context_Custom_03_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" unitRef="pure" decimals="2">0.50</nmus:RedemptionAmountPercentage>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesDPreferredStockMember" unitRef="USD" decimals="0">115200</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">30000</nmus:ValueOfCommonStockCalledByWarrants>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">970000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<nmus:PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.00</nmus:PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants>
<nmus:CommonStockVotingPercentage contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.10</nmus:CommonStockVotingPercentage>
<nmus:PercentageOfFairValueOptionPriceAtDateOfGrants contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.10</nmus:PercentageOfFairValueOptionPriceAtDateOfGrants>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P6Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">668000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">152169</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2017T00_00_00_TO_31_Mar_2017T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">65625</us-gaap:AllocatedShareBasedCompensationExpense>



<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">229609</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">188604</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">384396</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">349013</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P1Y5M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="0">1200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember_LegalEntityAxis_K2CIncMember" unitRef="USD" decimals="0">1225000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<nmus:FairMarketValueOfSharesGranted contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="0">900000</nmus:FairMarketValueOfSharesGranted>
<nmus:FairMarketValueOfSharesGranted contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember" unitRef="USD" decimals="0">475000</nmus:FairMarketValueOfSharesGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MinimumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_RangeAxis_MaximumMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TitleOfIndividualAxis_ChiefExecutiveOfficerMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" unitRef="shares" decimals="INF">900000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TitleOfIndividualAxis_ChiefFinancialOfficerMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" unitRef="shares" decimals="INF">700000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" unitRef="shares" decimals="INF">900000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember" unitRef="pure" decimals="2">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" unitRef="USD" decimals="0">75488</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
<us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="Context_As_Of_01_Nov_2017T00_00_00_TO_01_Nov_2017T00_00_00_DerivativeInstrumentRiskAxis_SeriesFPreferredStockOptionLiabilityMember" unitRef="USD" decimals="0">103364</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
<us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" unitRef="USD" decimals="0">6715</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
<us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_EmeraldPutOptionLiabilityMember" unitRef="USD" decimals="0">138630</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
<us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_EmeraldPutOptionLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">138630</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember_DerivativeInstrumentRiskAxis_SeriesFPreferredStockOptionLiabilityMember" unitRef="USD" decimals="0">103364</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">102848</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>

<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="2">0.70</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="pure" decimals="2">0.70</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="pure" decimals="2">0.70</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MaximumMember" unitRef="pure" decimals="5">0.01949</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MinimumMember" unitRef="pure" decimals="5">0.01947</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0245</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember" unitRef="pure" decimals="3">0.026</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0254</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0255</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MaximumMember">P2Y7M24D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RangeAxis_MinimumMember">P2Y7M21D</us-gaap:FairValueAssumptionsExpectedTerm>

<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember">P4Y9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember">P4Y10M17D</us-gaap:FairValueAssumptionsExpectedTerm>
<nmus:ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="3">0.086</nmus:ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue>
<nmus:ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="3">0.238</nmus:ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:SharePrice contextRef="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.29</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_28_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.30</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="USD_per_Share" decimals="2">0.24</us-gaap:SharePrice>
<nmus:ExpirationPeriodOfWarrants contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">P5Y</nmus:ExpirationPeriodOfWarrants>
<nmus:ExpirationPeriodOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">P5Y</nmus:ExpirationPeriodOfWarrants>
<nmus:ProceedsFromFinancingBetweenConversionLiabilityAndWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="-6">5000000</nmus:ProceedsFromFinancingBetweenConversionLiabilityAndWarrants>
<nmus:NumberOfWarrantsExercisable contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="shares" decimals="INF">3419250</nmus:NumberOfWarrantsExercisable>
<nmus:NumberOfWarrantsExercisable contextRef="Context_As_Of_31_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="shares" decimals="INF">987000</nmus:NumberOfWarrantsExercisable>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="USD" decimals="0">1500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<nmus:WarrantLiabilitiesMoreThanProceeds contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">3154922</nmus:WarrantLiabilitiesMoreThanProceeds>
<nmus:WarrantLiabilitiesMoreThanProceeds contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember_IncomeStatementLocationAxis_NonoperatingIncomeExpenseMember" unitRef="USD" decimals="0">3881051</nmus:WarrantLiabilitiesMoreThanProceeds>
<us-gaap:RepaymentsOfConvertibleDebt contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">400000</us-gaap:RepaymentsOfConvertibleDebt>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_01_Apr_2018T00_00_00_TO_30_Apr_2018T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember" unitRef="shares" decimals="INF">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">185000</us-gaap:InducedConversionOfConvertibleDebtExpense>
<us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">185000</us-gaap:InducedConversionOfConvertibleDebtExpense>
<nmus:IncreaseInConversionLiability contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">360000</nmus:IncreaseInConversionLiability>
<nmus:IntrinsicValueOfWarrantExercises contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBWarrantMember" unitRef="USD" decimals="0">1125291</nmus:IntrinsicValueOfWarrantExercises>
<nmus:IntrinsicValueOfWarrantExercises contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">1125291</nmus:IntrinsicValueOfWarrantExercises>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">34608</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">34608</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-590392</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" unitRef="USD" decimals="0">590392</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<nmus:SubsequentFinancingPurchasePriceDescription contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_ShortTermDebtTypeAxis_BridgeLoanMember">The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.</nmus:SubsequentFinancingPurchasePriceDescription>
<us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="INF">100000</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
<nmus:ExerciseOfWarrants contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1223991</nmus:ExerciseOfWarrants>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_3" xlink:label="lab_Footnote-1_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">During the three months ended March 31, 2017, warrants issued to service providers for consulting services were valued at $30,000 and were recorded as a Prepaid expense and amortized over the service period.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">During the three months ended March 31, 2017 preferred deemed dividends of $536,000 was recognized on Series D Preferred Stock and $175,000 on Series C Preferred Stock.</link:footnote>
</link:footnoteLink>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember" unitRef="USD" decimals="0">112270</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_28_Feb_2018T00_00_00_ClassOfWarrantOrRightAxis_EmeraldWarrantLiabilityMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="2">0.70</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.0195</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">P2Y3M</us-gaap:FairValueAssumptionsExpectedTerm>
<nmus:MarkedToMarketConversionLiabilities contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">180000</nmus:MarkedToMarketConversionLiabilities>
<nmus:FairValueOfWarrantsIssued contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">10424634</nmus:FairValueOfWarrantsIssued>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nmus-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Tuesday, May 15, 2018 12:04:57 PM -->
<schema targetNamespace="http://www.nemusbioscience.com/20180331" elementFormDefault="qualified" xmlns:nmus="http://www.nemusbioscience.com/20180331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.nemusbioscience.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals" id="Consolidatedbalancesheetsparentheticals">
<link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" id="CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
<link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
<link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals">
<link:definition>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies">
<link:definition>007 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements" id="UniversityOfMississippiAgreements">
<link:definition>008 - Disclosure - University of Mississippi Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES" id="COMMITMENTSANDCONTINGENCIES">
<link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/Stockholdersdeficitandpreferredstocksubjecttoredemption" id="Stockholdersdeficitandpreferredstocksubjecttoredemption">
<link:definition>010 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiability" id="ProvisionsForConversionOfPreferredStockAndPutOptionLiability">
<link:definition>011 - Disclosure - Provisions for Conversion of Preferred Stock and Put Option Liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilities" id="SeriesBWarrantAndEmeraldWarrantLiabilities">
<link:definition>012 - Disclosure - Series B Warrant and Emerald Warrant Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConvertibleBridgeLoan" id="ConvertibleBridgeLoan">
<link:definition>013 - Disclosure - Convertible Bridge Loan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>014 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>015 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>016 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables">
<link:definition>017 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables" id="SeriesBWarrantAndEmeraldWarrantLiabilitiesTables">
<link:definition>018 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<link:definition>019 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/Universityofmississippiagreementsdetailtextuals" id="Universityofmississippiagreementsdetailtextuals">
<link:definition>020 - Disclosure - University of Mississippi Agreements (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals" id="CommitmentsAndContingenciesDetailTextuals">
<link:definition>021 - Disclosure - Commitments and Contingencies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails">
<link:definition>022 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details )</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1">
<link:definition>023 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals">
<link:definition>024 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Common Stock (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1">
<link:definition>025 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Preferred Stock(Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2">
<link:definition>026 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Warrants (Detail Textuals 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3">
<link:definition>027 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Stock Option Plans: 2014 Omnibus Incentive Plan (Detail Textuals 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4" id="StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4">
<link:definition>028 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Restricted Stock Awards (Detail Textuals 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals" id="ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals">
<link:definition>029 - Disclosure - Provisions for Conversion of Preferred Stock and Put Option Liability (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails" id="SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails">
<link:definition>030 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1" id="SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1">
<link:definition>031 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals" id="SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals">
<link:definition>032 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1" id="SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1">
<link:definition>033 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConvertibleBridgeLoanDetailTextuals" id="ConvertibleBridgeLoanDetailTextuals">
<link:definition>034 - Disclosure - Convertible Bridge Loan (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/Subsequenteventsdetailtextuals" id="Subsequenteventsdetailtextuals">
<link:definition>035 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="nmus_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfPreferredStock" id="nmus_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfConvertibleDebt" id="nmus_ProvisionForConversionOfConvertibleDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuanceCosts" id="nmus_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantLiabilityInExcessOfProceeds" id="nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainLossOnConversionRightPreferredStock" id="nmus_GainLossOnConversionRightPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantLiabilityExcessOfProceeds" id="nmus_FairValueOfWarrantLiabilityExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuedForLicense" id="nmus_CommonStockIssuedForLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" id="nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuedForServices" id="nmus_CommonStockIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashAndCashEquivalents" id="nmus_CashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SupplementalRestrictedCash" id="nmus_SupplementalRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TotalCashEquivalentsAndRestrictedCashShownInConsolidated" id="nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashPaidDuringPeriodForAbstract" id="nmus_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" id="nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExerciseOfWarrants" id="nmus_ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsAbstract" id="nmus_UniversityOfMississippiAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsTextBlock" id="nmus_UniversityOfMississippiAgreementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfPreferredStockAbstract" id="nmus_ProvisionForConversionOfPreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" id="nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsTextBlock" id="nmus_SeriesBWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertibleBridgeLoanAbstract" id="nmus_ConvertibleBridgeLoanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LiquidityAndGoingConcernPolicyTextBlock" id="nmus_LiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" id="nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockBasedCompensationForNonEmployeesPolicyTextBlock" id="nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" id="nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="SecuritiesPurchaseAgreementMember" id="nmus_SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" id="nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsTable" id="nmus_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="OptionAgreementMember" id="nmus_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementMember" id="nmus_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Um5070LicenseAgreementMember" id="nmus_Um5070LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiMember" id="nmus_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MonthAndYearOfAgreementAxis" id="nmus_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="MonthAndYearOfAgreementDomain" id="nmus_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="December2015Member" id="nmus_December2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OctoberTwoThousandFifteenMember" id="nmus_OctoberTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsLineItems" id="nmus_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfAgreement" id="nmus_TermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfLicenseAgreements" id="nmus_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoticePeriodForTermination" id="nmus_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OneTimeUpfrontPayment" id="nmus_OneTimeUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualFeesForLicenseAgreement" id="nmus_AnnualFeesForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AggregateMilestonePaymentsIfMilestonesAchieved" id="nmus_AggregateMilestonePaymentsIfMilestonesAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LetterAgreementMember" id="nmus_LetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IndependentContractorAgreementMember" id="nmus_IndependentContractorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RestrictedStockAgreementsMember" id="nmus_RestrictedStockAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeparationAndReleaseAgreementMember" id="nmus_SeparationAndReleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ContractManufacturingOrganizationMember" id="nmus_ContractManufacturingOrganizationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="K2CIncMember" id="nmus_K2CIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmeraldHealthSciencesIncMember" id="nmus_EmeraldHealthSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FeesAndExpensesForServicesProvided" id="nmus_FeesAndExpensesForServicesProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnalyticalMethodDevelopmentAndQualificationExpense" id="nmus_AnalyticalMethodDevelopmentAndQualificationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MonthlyFee" id="nmus_MonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermsOfAgreementRenewed" id="nmus_TermsOfAgreementRenewed" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TotalExpenseIncurredUnderAgreement" id="nmus_TotalExpenseIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GuarantorFailedToPay" id="nmus_GuarantorFailedToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Pre2015CommonStockWarrantsMember" id="nmus_Pre2015CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandFifteenCommonStockWarrantsMember" id="nmus_TwoThousandFifteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" id="nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" id="nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandEighteenEmeraldFinancingWarrantsMember" id="nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrant" id="nmus_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsVestedAndOutstanding" id="nmus_WarrantsVestedAndOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OmnibusIncentivePlan2014Member" id="nmus_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" id="nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTable" id="nmus_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="SeriesBWarrantMember" id="nmus_SeriesBWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBPreferredStockAgreementMember" id="nmus_SeriesBPreferredStockAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityLineItems" id="nmus_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionPrice" id="nmus_ConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrants" id="nmus_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubsequentFinancingPurchasePriceDescription" id="nmus_SubsequentFinancingPurchasePriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IntrinsicValueOfWarrantExercises" id="nmus_IntrinsicValueOfWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" id="nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockAggregatePurchasePrice" id="nmus_CommonStockAggregatePurchasePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockConvertibleConversionPriceDecrease" id="nmus_PreferredStockConvertibleConversionPriceDecrease" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfConversionAmount" id="nmus_PercentageOfConversionAmount" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinimumLitigationJudgementAmount" id="nmus_MinimumLitigationJudgementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfCommonStockIssuedUponConversionOfPreferredStock" id="nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LiquidationProvisionCommonStockEquivalentShares" id="nmus_LiquidationProvisionCommonStockEquivalentShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LiquidationProvisionCommonStockEquivalentValue" id="nmus_LiquidationProvisionCommonStockEquivalentValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfSharesToBeRedeemed" id="nmus_PercentageOfSharesToBeRedeemed" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RedemptionAmountPercentage" id="nmus_RedemptionAmountPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfCommonStockCalledByWarrants" id="nmus_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" id="nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockVotingPercentage" id="nmus_CommonStockVotingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfFairValueOptionPriceAtDateOfGrants" id="nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManagementAndBoardOfDirectorsMember" id="nmus_ManagementAndBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairMarketValueOfSharesGranted" id="nmus_FairMarketValueOfSharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBPreferredStockConversionLiabilityMember" id="nmus_SeriesBPreferredStockConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesFPreferredStockOptionLiabilityMember" id="nmus_SeriesFPreferredStockOptionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsMember" id="nmus_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" id="nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmeraldWarrantLiabilityMember" id="nmus_EmeraldWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExpirationPeriodOfWarrants" id="nmus_ExpirationPeriodOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" id="nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsExercisable" id="nmus_NumberOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuanceDateAxis" id="nmus_WarrantsIssuanceDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="WarrantsIssuanceDateDomain" id="nmus_WarrantsIssuanceDateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedOn19January2018Member" id="nmus_WarrantsIssuedOn19January2018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedOn16February2018Member" id="nmus_WarrantsIssuedOn16February2018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmeraldPutOptionLiabilityMember" id="nmus_EmeraldPutOptionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantLiabilitiesMoreThanProceeds" id="nmus_WarrantLiabilitiesMoreThanProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SecuredPromissoryNoteAndSecurityAgreementMember" id="nmus_SecuredPromissoryNoteAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseInConversionLiability" id="nmus_IncreaseInConversionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarkedToMarketConversionLiabilities" id="nmus_MarkedToMarketConversionLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" nillable="true" xbrli:balance="credit"/>
<element name="FairValueOfWarrantsIssued" id="nmus_FairValueOfWarrantsIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nmus-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Tuesday, May 15, 2018 12:04:57 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleDebtCurrent" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfConvertibleDebt" xlink:label="loc_nmus_ProvisionForConversionOfConvertibleDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_ProvisionForConversionOfConvertibleDebt" order="70" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="30" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/></calculationLink>






<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_InterestExpense" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" order="60" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="70" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="80" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="90" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_RedeemablePreferredStockDividends" order="20" use="optional" weight="-1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xlink:label="loc_nmus_FairValueOfWarrantLiabilityExcessOfProceeds"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_FairValueOfWarrantLiabilityExcessOfProceeds" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockIssuedForLicense" xlink:label="loc_nmus_CommonStockIssuedForLicense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_CommonStockIssuedForLicense" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="120" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="130" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" order="140" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="150" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" order="160" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="170" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockIssuedForServices" xlink:label="loc_nmus_CommonStockIssuedForServices"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_nmus_CommonStockIssuedForServices" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/></calculationLink>



</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nmus-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Tuesday, May 15, 2018 12:04:57 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals"/>

<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals" roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Universityofmississippiagreementsdetailtextuals" roleURI="http://www.nemusbioscience.com/role/Universityofmississippiagreementsdetailtextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals" roleURI="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/ConvertibleBridgeLoanDetailTextuals" xlink:href="nmus-20180331.xsd#ConvertibleBridgeLoanDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Subsequenteventsdetailtextuals" roleURI="http://www.nemusbioscience.com/role/Subsequenteventsdetailtextuals"/>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9" xlink:to="loc_us-gaap_AssetsCurrent_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8" xlink:to="loc_us-gaap_Assets_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableCurrent_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccruedSalariesCurrent_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfConvertibleDebt" xlink:label="loc_nmus_ProvisionForConversionOfConvertibleDebt_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_nmus_ProvisionForConversionOfConvertibleDebt_24" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrent_25" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_26" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_28" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_Liabilities_29" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_CommitmentsAndContingencies_30" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_31" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_StockholdersEquityAbstract_32" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_CommonStockValue_33" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_34" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_35" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_StockholdersEquity_37" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockIssuanceCosts" xlink:label="loc_nmus_StockIssuanceCosts_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_nmus_StockIssuanceCosts_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_12" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_14" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_15" order="90" use="optional"/>
</definitionLink>

<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RedeemablePreferredStockDividends_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" xlink:to="loc_us-gaap_WarrantMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_NumberOfReportableSegments_17" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_18" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_19" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_20" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_21" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Universityofmississippiagreementsdetailtextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_nmus_UniversityOfMississippiAgreementsLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OptionAgreementMember" xlink:label="loc_nmus_OptionAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_OptionAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LicenseAgreementMember" xlink:label="loc_nmus_LicenseAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_LicenseAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_Um5070LicenseAgreementMember" xlink:label="loc_nmus_Um5070LicenseAgreementMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_Um5070LicenseAgreementMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_nmus_UniversityOfMississippiMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_nmus_UniversityOfMississippiMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" xlink:to="loc_us-gaap_IntellectualPropertyMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_nmus_MonthAndYearOfAgreementAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_MonthAndYearOfAgreementAxis_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_December2015Member" xlink:label="loc_nmus_December2015Member_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_December2015Member_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OctoberTwoThousandFifteenMember" xlink:label="loc_nmus_OctoberTwoThousandFifteenMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_OctoberTwoThousandFifteenMember_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfAgreement" xlink:label="loc_nmus_TermOfAgreement_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_TermOfAgreement_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_nmus_NumberOfLicenseAgreements_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_NumberOfLicenseAgreements_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_nmus_NoticePeriodForTermination_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_NoticePeriodForTermination_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OneTimeUpfrontPayment" xlink:label="loc_nmus_OneTimeUpfrontPayment_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_OneTimeUpfrontPayment_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AnnualFeesForLicenseAgreement" xlink:label="loc_nmus_AnnualFeesForLicenseAgreement_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_AnnualFeesForLicenseAgreement_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_22" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LetterAgreementMember" xlink:label="loc_nmus_LetterAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_LetterAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IndependentContractorAgreementMember" xlink:label="loc_nmus_IndependentContractorAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_IndependentContractorAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RestrictedStockAgreementsMember" xlink:label="loc_nmus_RestrictedStockAgreementsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_RestrictedStockAgreementsMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeparationAndReleaseAgreementMember" xlink:label="loc_nmus_SeparationAndReleaseAgreementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_SeparationAndReleaseAgreementMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ContractManufacturingOrganizationMember" xlink:label="loc_nmus_ContractManufacturingOrganizationMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_ContractManufacturingOrganizationMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_nmus_K2CIncMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_K2CIncMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_nmus_EmeraldHealthSciencesIncMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_EmeraldHealthSciencesIncMember_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_16" xlink:to="loc_us-gaap_RangeMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_16" xlink:to="loc_us-gaap_RangeMember_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_17" xlink:to="loc_us-gaap_MinimumMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_17" xlink:to="loc_us-gaap_MaximumMember_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_VestingAxis_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_20" xlink:to="loc_us-gaap_VestingDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_20" xlink:to="loc_us-gaap_VestingDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_25" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26" xlink:to="loc_us-gaap_RestrictedStockMember_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_29" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_LeaseAndRentalExpense_30" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_31" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_32" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FeesAndExpensesForServicesProvided" xlink:label="loc_nmus_FeesAndExpensesForServicesProvided_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_FeesAndExpensesForServicesProvided_33" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:label="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_34" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthlyFee" xlink:label="loc_nmus_MonthlyFee_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_MonthlyFee_35" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermsOfAgreementRenewed" xlink:label="loc_nmus_TermsOfAgreementRenewed_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_TermsOfAgreementRenewed_36" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TotalExpenseIncurredUnderAgreement" xlink:label="loc_nmus_TotalExpenseIncurredUnderAgreement_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_TotalExpenseIncurredUnderAgreement_37" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_38" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_39" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_40" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_41" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GuarantorFailedToPay" xlink:label="loc_nmus_GuarantorFailedToPay_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_GuarantorFailedToPay_42" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_43" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_45" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfAgreement" xlink:label="loc_nmus_TermOfAgreement_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_TermOfAgreement_46" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47" order="190" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_Pre2015CommonStockWarrantsMember" xlink:label="loc_nmus_Pre2015CommonStockWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_Pre2015CommonStockWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_nmus_TwoThousandFifteenCommonStockWarrantsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandFifteenCommonStockWarrantsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember_12" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MinimumMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MaximumMember_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_TermOfWarrant_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsVestedAndOutstanding" xlink:label="loc_nmus_WarrantsVestedAndOutstanding_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_WarrantsVestedAndOutstanding_19" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_12" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_12" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_12" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_12" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare_25" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare_26" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare_27" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_23" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare_28" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_32" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_33" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_34" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantMember" xlink:label="loc_nmus_SeriesBWarrantMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_nmus_SeriesBWarrantMember_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBPreferredStockAgreementMember" xlink:label="loc_nmus_SeriesBPreferredStockAgreementMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_nmus_SeriesBPreferredStockAgreementMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_16" xlink:to="loc_dei_EntityDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_16" xlink:to="loc_dei_EntityDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_nmus_EmeraldHealthSciencesIncMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_nmus_EmeraldHealthSciencesIncMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_nmus_K2CIncMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_nmus_K2CIncMember_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_20" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_20" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_21" xlink:to="loc_us-gaap_BridgeLoanMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23" xlink:to="loc_us-gaap_RelatedPartyDomain_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_24_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23" xlink:to="loc_us-gaap_RelatedPartyDomain_24_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_24" xlink:to="loc_us-gaap_InvestorMember_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_VestingAxis_26" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_26" xlink:to="loc_us-gaap_VestingDomain_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_27_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_26" xlink:to="loc_us-gaap_VestingDomain_27_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_27" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_29" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_30" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_31" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_32" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_33" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ConversionPrice_34" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_35" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_36" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_38" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_39" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrants" xlink:label="loc_nmus_TermOfWarrants_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_TermOfWarrants_40" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_41" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_BridgeLoan_42" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_43" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_44" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_45" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_46" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_nmus_SubsequentFinancingPurchasePriceDescription_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_SubsequentFinancingPurchasePriceDescription_47" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IntrinsicValueOfWarrantExercises" xlink:label="loc_nmus_IntrinsicValueOfWarrantExercises_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_IntrinsicValueOfWarrantExercises_48" order="200" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_CommonStockMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockAggregatePurchasePrice" xlink:label="loc_nmus_CommonStockAggregatePurchasePrice_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_CommonStockAggregatePurchasePrice_16" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ConversionPrice_18" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_19" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_20" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PreferredStockConvertibleConversionPriceDecrease" xlink:label="loc_nmus_PreferredStockConvertibleConversionPriceDecrease_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PreferredStockConvertibleConversionPriceDecrease_22" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_TermOfWarrant_23" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_24" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfConversionAmount" xlink:label="loc_nmus_PercentageOfConversionAmount_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfConversionAmount_25" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MinimumLitigationJudgementAmount" xlink:label="loc_nmus_MinimumLitigationJudgementAmount_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MinimumLitigationJudgementAmount_26" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockConversionBasis_27" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xlink:label="loc_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock_28" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidationProvisionCommonStockEquivalentShares" xlink:label="loc_nmus_LiquidationProvisionCommonStockEquivalentShares_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_LiquidationProvisionCommonStockEquivalentShares_29" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidationProvisionCommonStockEquivalentValue" xlink:label="loc_nmus_LiquidationProvisionCommonStockEquivalentValue_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_LiquidationProvisionCommonStockEquivalentValue_30" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_31" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_32" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfSharesToBeRedeemed" xlink:label="loc_nmus_PercentageOfSharesToBeRedeemed_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfSharesToBeRedeemed_33" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_34" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RedemptionAmountPercentage" xlink:label="loc_nmus_RedemptionAmountPercentage_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_RedemptionAmountPercentage_35" order="240" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8" xlink:to="loc_us-gaap_ClassOfStockDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8" xlink:to="loc_us-gaap_ClassOfStockDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_TermOfWarrant_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_nmus_ValueOfCommonStockCalledByWarrants_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ValueOfCommonStockCalledByWarrants_14" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_nmus_CommonStockVotingPercentage_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_CommonStockVotingPercentage_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_17" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_20" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_21" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_22" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_24" order="140" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_nmus_ManagementAndBoardOfDirectorsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_nmus_ManagementAndBoardOfDirectorsMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RangeAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MinimumMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MaximumMember_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RestrictedStockAgreementsMember" xlink:label="loc_nmus_RestrictedStockAgreementsMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22" xlink:to="loc_nmus_RestrictedStockAgreementsMember_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_VestingAxis_24" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_24" xlink:to="loc_us-gaap_VestingDomain_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_25_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_24" xlink:to="loc_us-gaap_VestingDomain_25_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_25" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_27" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_27" xlink:to="loc_dei_EntityDomain_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_28_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_27" xlink:to="loc_dei_EntityDomain_28_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_nmus_K2CIncMember_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_28" xlink:to="loc_nmus_K2CIncMember_29" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_30" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_nmus_FairMarketValueOfSharesGranted_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_FairMarketValueOfSharesGranted_31" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_34" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_35" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_36" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_nmus_SeriesBPreferredStockConversionLiabilityMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_nmus_SeriesBPreferredStockConversionLiabilityMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesFPreferredStockOptionLiabilityMember" xlink:label="loc_nmus_SeriesFPreferredStockOptionLiabilityMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_nmus_SeriesFPreferredStockOptionLiabilityMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_15" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue_13" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldWarrantLiabilityMember" xlink:label="loc_nmus_EmeraldWarrantLiabilityMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_EmeraldWarrantLiabilityMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharePrice_13" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_11" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_nmus_ExpirationPeriodOfWarrants_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_ExpirationPeriodOfWarrants_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_17" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfWarrantsExercisable" xlink:label="loc_nmus_NumberOfWarrantsExercisable_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_NumberOfWarrantsExercisable_18" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_19" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_20" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_21" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IntrinsicValueOfWarrantExercises" xlink:label="loc_nmus_IntrinsicValueOfWarrantExercises_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_IntrinsicValueOfWarrantExercises_22" order="100" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldWarrantLiabilityMember" xlink:label="loc_nmus_EmeraldWarrantLiabilityMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_EmeraldWarrantLiabilityMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateAxis" xlink:label="loc_nmus_WarrantsIssuanceDateAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_nmus_WarrantsIssuanceDateAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateDomain" xlink:label="loc_nmus_WarrantsIssuanceDateDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_WarrantsIssuanceDateAxis_11" xlink:to="loc_nmus_WarrantsIssuanceDateDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateDomain" xlink:label="loc_nmus_WarrantsIssuanceDateDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_WarrantsIssuanceDateAxis_11" xlink:to="loc_nmus_WarrantsIssuanceDateDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedOn19January2018Member" xlink:label="loc_nmus_WarrantsIssuedOn19January2018Member_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_WarrantsIssuanceDateDomain_12" xlink:to="loc_nmus_WarrantsIssuedOn19January2018Member_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedOn16February2018Member" xlink:label="loc_nmus_WarrantsIssuedOn16February2018Member_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_WarrantsIssuanceDateDomain_12" xlink:to="loc_nmus_WarrantsIssuedOn16February2018Member_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldPutOptionLiabilityMember" xlink:label="loc_nmus_EmeraldPutOptionLiabilityMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16" xlink:to="loc_nmus_EmeraldPutOptionLiabilityMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_nmus_ExpirationPeriodOfWarrants_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_ExpirationPeriodOfWarrants_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantLiabilitiesMoreThanProceeds" xlink:label="loc_nmus_WarrantLiabilitiesMoreThanProceeds_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_WarrantLiabilitiesMoreThanProceeds_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_24" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_25" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConvertibleBridgeLoanDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_BridgeLoanMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_nmus_SecuredPromissoryNoteAndSecurityAgreementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_nmus_SecuredPromissoryNoteAndSecurityAgreementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_nmus_EmeraldHealthSciencesIncMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_EmeraldHealthSciencesIncMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_BridgeLoan_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IncreaseInConversionLiability" xlink:label="loc_nmus_IncreaseInConversionLiability_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_nmus_IncreaseInConversionLiability_17" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_18" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_19" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MarkedToMarketConversionLiabilities" xlink:label="loc_nmus_MarkedToMarketConversionLiabilities"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_nmus_MarkedToMarketConversionLiabilities" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Subsequenteventsdetailtextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_VestingAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_8" xlink:to="loc_us-gaap_VestingDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_8" xlink:to="loc_us-gaap_VestingDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeparationAndReleaseAgreementMember" xlink:label="loc_nmus_SeparationAndReleaseAgreementMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12" xlink:to="loc_nmus_SeparationAndReleaseAgreementMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_16" order="30" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nmus-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Tuesday, May 15, 2018 12:04:57 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_DocumentAndEntityInformationAbstract" xlink:label="loc_2I0HHGGF8208_nmus_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_DocumentAndEntityInformationAbstract" xlink:to="lab_4K2JJIIH0420_nmus_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityRegistrantName" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_2I0HHGGF8208_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_EntityCentralIndexKey" xlink:to="lab_4K2JJIIH0420_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_I9G01G3G9932937HF776_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_TradingSymbol" xlink:to="lab_K1I23I5I1154159JH998_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_2I0HHGGF8208_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_CurrentFiscalYearEndDate" xlink:to="lab_4K2JJIIH0420_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityFilerCategory" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_2I0HHGGF8208_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_4K2JJIIH0420_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_I9G01G3G9932937HF776_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_DocumentType" xlink:to="lab_K1I23I5I1154159JH998_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_2I0HHGGF8208_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_DocumentPeriodEndDate" xlink:to="lab_4K2JJIIH0420_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_I9G01G3G9932937HF776_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_AmendmentFlag" xlink:to="lab_K1I23I5I1154159JH998_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_2I0HHGGF8208_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_DocumentFiscalYearFocus" xlink:to="lab_4K2JJIIH0420_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_I9G01G3G9932937HF776_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_DocumentFiscalPeriodFocus" xlink:to="lab_K1I23I5I1154159JH998_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StatementTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementClassOfStockAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfStockDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_2I0HHGGF8208_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_4K2JJIIH0420_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SeriesCPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Convertible Series C Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SeriesCPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_2I0HHGGF8208_us-gaap_SeriesDPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Convertible Series D Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_4K2JJIIH0420_us-gaap_SeriesDPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SeriesFPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesFPreferredStockMember" xml:lang="en-US">Series F Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesFPreferredStockMember" xml:lang="en-US">Redeemable Convertible Series F Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesFPreferredStockMember" xml:lang="en-US">Series F Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SeriesFPreferredStockMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SeriesFPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AssetsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AssetsCurrentAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_2I0HHGGF8208_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_4K2JJIIH0420_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AssetsCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_2I0HHGGF8208_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_Assets" xlink:to="lab_4K2JJIIH0420_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccountsPayableCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccruedSalariesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccruedSalariesCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccruedSalariesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_I9G01G3G9932937HF776_nmus_ProvisionForConversionOfPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Fair value of the conversion feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ProvisionForConversionOfPreferredStock" xlink:to="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_ConvertibleDebtCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_ConvertibleDebtCurrent"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfConvertibleDebt" xlink:label="loc_I9G01G3G9932937HF776_nmus_ProvisionForConversionOfConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfConvertibleDebt" xml:lang="en-US">Provision For Conversion Of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfConvertibleDebt" xml:lang="en-US">Provision for conversion of convertible debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfConvertibleDebt" xml:lang="en-US">It represent value of provision for conversion of convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ProvisionForConversionOfConvertibleDebt" xlink:to="lab_K1I23I5I1154159JH998_nmus_ProvisionForConversionOfConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_LiabilitiesCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesNoncurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Noncurrent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_2I0HHGGF8208_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_Liabilities" xlink:to="lab_4K2JJIIH0420_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingencies" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_2I0HHGGF8208_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Redeemable Convertible Preferred Stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_4K2JJIIH0420_us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockholdersEquityAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 236 million shares authorized; 132,414,079 issued and outstanding as of March 31, 2018 and 33,622,829 issued and outstanding as of December 31, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockValue" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in-capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_2I0HHGGF8208_us-gaap_WarrantsAndRightsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings during the development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_2I0HHGGF8208_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockholdersEquity" xlink:to="lab_4K2JJIIH0420_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_2I0HHGGF8208_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_4K2JJIIH0420_us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_TemporaryEquitySharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_2I0HHGGF8208_us-gaap_TemporaryEquitySharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_4K2JJIIH0420_us-gaap_TemporaryEquitySharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_TemporaryEquitySharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Balance (Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Balance (Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_TemporaryEquitySharesOutstanding"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockIssuanceCosts" xlink:label="loc_2I0HHGGF8208_nmus_StockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_StockIssuanceCosts" xml:lang="en-US">Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_StockIssuanceCosts" xml:lang="en-US">Issuance costs (in dollars)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_StockIssuanceCosts" xml:lang="en-US">Represents amount of stock issuance costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_StockIssuanceCosts" xlink:to="lab_4K2JJIIH0420_nmus_StockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Par value of common stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Par value of common stock issued (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockSharesIssued" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeStatementAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingExpensesAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_2I0HHGGF8208_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingExpenses" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingIncomeLoss" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_InterestExpense" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other expense (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueAdjustmentOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_2I0HHGGF8208_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xml:lang="en-US">Fair Value Of Warrant Liability In Excess Of Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xml:lang="en-US">Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:to="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_I9G01G3G9932937HF776_nmus_GainLossOnConversionRightPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Gain Loss On Conversion Right Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Change in fair value of conversion rights of Series B preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Loss on conversion right of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Represents the amount related to gain or loss on conversion right of preferred stock during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Change in fair value of conversion rights of Series B preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_GainLossOnConversionRightPreferredStock" xlink:to="lab_K1I23I5I1154159JH998_nmus_GainLossOnConversionRightPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_2I0HHGGF8208_us-gaap_InducedConversionOfConvertibleDebtExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_InducedConversionOfConvertibleDebtExpense" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_InducedConversionOfConvertibleDebtExpense" xml:lang="en-US">Change in fair value of conversion rights of convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="lab_4K2JJIIH0420_us-gaap_InducedConversionOfConvertibleDebtExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Financing transaction costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Issuance costs related to warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Issuance costs related to warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_2I0HHGGF8208_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on extinguishment of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on extinguishment of convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_4K2JJIIH0420_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of convertible debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Net loss before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Net Loss before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Net Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision (Benefit) for Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_2I0HHGGF8208_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetIncomeLoss" xlink:to="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RedeemablePreferredStockDividends"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RedeemablePreferredStockDividends" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RedeemablePreferredStockDividends" xml:lang="en-US">Less: Preferred deemed dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RedeemablePreferredStockDividends" xml:lang="en-US">Preferred deemed dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RedeemablePreferredStockDividends" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RedeemablePreferredStockDividends"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_2I0HHGGF8208_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss applicable to common shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerShareBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic earnings per common share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerShareBasic" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_2I0HHGGF8208_us-gaap_EarningsPerShareDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted earnings per common share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EarningsPerShareDiluted" xlink:to="lab_4K2JJIIH0420_us-gaap_EarningsPerShareDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average shares of common stock outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_2I0HHGGF8208_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_4K2JJIIH0420_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_Depreciation" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensation" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of warrants and stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xlink:label="loc_2I0HHGGF8208_nmus_FairValueOfWarrantLiabilityExcessOfProceeds"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xml:lang="en-US">Fair Value Of Warrant Liability Excess Of Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xml:lang="en-US">Represents amount of fair value of warrant liability in excess of proceeds.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xlink:to="lab_4K2JJIIH0420_nmus_FairValueOfWarrantLiabilityExcessOfProceeds"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockIssuedForLicense" xlink:label="loc_I9G01G3G9932937HF776_nmus_CommonStockIssuedForLicense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForLicense" xml:lang="en-US">Common Stock Issued For License</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForLicense" xml:lang="en-US">Common stock issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForLicense" xml:lang="en-US">Represents amount related to Common stock issued for license.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_CommonStockIssuedForLicense" xlink:to="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForLicense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xml:lang="en-US">Increase (Decrease) in Notes Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_I9G01G3G9932937HF776_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Increase Decrease In Accrued License And Patent Reimbursement Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Represents amount of increase (decrease) in accrued license and patent reimbursement fees.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:to="lab_K1I23I5I1154159JH998_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Cash flows provided from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Aggregate gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Series D preferred stock issuance, net of $183,343 issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockIssuedForServices" xlink:label="loc_I9G01G3G9932937HF776_nmus_CommonStockIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForServices" xml:lang="en-US">Common stock issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForServices" xml:lang="en-US">Proceeds from Common stock issuance, net of $9,122 issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForServices" xml:lang="en-US">Represents amount related to common stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_CommonStockIssuedForServices" xlink:to="lab_K1I23I5I1154159JH998_nmus_CommonStockIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible debt issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_2I0HHGGF8208_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_4K2JJIIH0420_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SupplementalCashFlowElementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SupplementalCashFlowElementsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CashAndCashEquivalents" xlink:label="loc_2I0HHGGF8208_nmus_CashAndCashEquivalents"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_CashAndCashEquivalents" xml:lang="en-US">Cash And Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_CashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_CashAndCashEquivalents" xml:lang="en-US">Represents amount of Cash and cash equivalents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_CashAndCashEquivalents" xlink:to="lab_4K2JJIIH0420_nmus_CashAndCashEquivalents"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SupplementalRestrictedCash" xlink:label="loc_I9G01G3G9932937HF776_nmus_SupplementalRestrictedCash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_SupplementalRestrictedCash" xml:lang="en-US">Supplemental Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SupplementalRestrictedCash" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_SupplementalRestrictedCash" xml:lang="en-US">Represents amount of supplemental restricted cash.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_SupplementalRestrictedCash" xlink:to="lab_K1I23I5I1154159JH998_nmus_SupplementalRestrictedCash"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:label="loc_2I0HHGGF8208_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xml:lang="en-US">Total Cash Equivalents And Restricted Cash Shown In Consolidated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xml:lang="en-US">Represents amount of total cash, cash equivalents and restricted cash shown in the consolidated.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:to="lab_4K2JJIIH0420_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_I9G01G3G9932937HF776_nmus_CashPaidDuringPeriodForAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash Paid During Period For Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash paid during the period for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_CashPaidDuringPeriodForAbstract" xlink:to="lab_K1I23I5I1154159JH998_nmus_CashPaidDuringPeriodForAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_2I0HHGGF8208_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_InterestPaid" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_InterestPaid" xlink:to="lab_4K2JJIIH0420_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxesPaid" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosures of non-cash financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockAmountConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of outstanding preferred stock into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockAmountConverted1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_2I0HHGGF8208_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xml:lang="en-US">Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xml:lang="en-US">Conversion of outstanding preferred stock subject to redemption into common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xml:lang="en-US">Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:to="lab_4K2JJIIH0420_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of convertible debt to equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Number of shares issued in conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExerciseOfWarrants" xlink:label="loc_2I0HHGGF8208_nmus_ExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ExerciseOfWarrants" xml:lang="en-US">Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ExerciseOfWarrants" xml:lang="en-US">Release of warrant liabilities due to exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ExerciseOfWarrants" xml:lang="en-US">The amount express exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ExerciseOfWarrants" xlink:to="lab_4K2JJIIH0420_nmus_ExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Preferred stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_2I0HHGGF8208_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Value of warrants issued to purchase shares of common stock for consulting services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_4K2JJIIH0420_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Warrant issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_2I0HHGGF8208_nmus_UniversityOfMississippiAgreementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsAbstract" xml:lang="en-US">University Of Mississippi Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_UniversityOfMississippiAgreementsAbstract" xlink:to="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_nmus_UniversityOfMississippiAgreementsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">University Of Mississippi Agreements [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">University of Mississippi Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">Represents entire disclosure for University of Mississippi ("UM") Agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_UniversityOfMississippiAgreementsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_nmus_UniversityOfMississippiAgreementsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EquityAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_2I0HHGGF8208_nmus_ProvisionForConversionOfPreferredStockAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ProvisionForConversionOfPreferredStockAbstract" xml:lang="en-US">Provision For Conversion Of Preferred Stock [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:to="lab_4K2JJIIH0420_nmus_ProvisionForConversionOfPreferredStockAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Preferred Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Provisions for Conversion of Preferred Stock and Put Option Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_2I0HHGGF8208_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xml:lang="en-US">Series B Warrant And Emerald Warrant Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:to="lab_4K2JJIIH0420_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_nmus_SeriesBWarrantsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">Series B Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">Series B Warrant and Emerald Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">The entire disclosure for series B warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_SeriesBWarrantsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantsTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConvertibleBridgeLoanAbstract" xlink:label="loc_2I0HHGGF8208_nmus_ConvertibleBridgeLoanAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ConvertibleBridgeLoanAbstract" xml:lang="en-US">Convertible Bridge Loan [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ConvertibleBridgeLoanAbstract" xml:lang="en-US">Represents convertible bridge loan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ConvertibleBridgeLoanAbstract" xlink:to="lab_4K2JJIIH0420_nmus_ConvertibleBridgeLoanAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShortTermDebtTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Convertible Bridge Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShortTermDebtTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_2I0HHGGF8208_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_UseOfEstimates" xlink:to="lab_4K2JJIIH0420_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_nmus_LiquidityAndGoingConcernPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Liquidity And Going Concern [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Entire disclosure of policy for liquidity and going concern.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_nmus_LiquidityAndGoingConcernPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DerivativesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Convertible Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xml:lang="en-US">Warrants Issued In Connection With Financings [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xml:lang="en-US">Warrants Issued in Connection with Financings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xml:lang="en-US">Warrants Issued in Connection with Financings.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_2I0HHGGF8208_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_4K2JJIIH0420_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Stock Based Compensation For Non Employees [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation for Non-Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Represents policy for stock based compensation for Non Employees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of warrants vested and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of summary of stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Schedule of Series B Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xml:lang="en-US">Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xml:lang="en-US">Schedule of derivative liabilities based on Monte Carlo simulations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_I9G01G3G9932937HF776_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Represents Tabular disclosure of nature of operations, business activities and Summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_2I0HHGGF8208_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_WarrantMember" xlink:to="lab_4K2JJIIH0420_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee stock option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EmployeeStockOptionMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_TypeOfArrangementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TypeOfArrangementAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_2I0HHGGF8208_nmus_SecuritiesPurchaseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities purchase agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Represents information regarding securities purchase agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_SecuritiesPurchaseAgreementMember" xlink:to="lab_4K2JJIIH0420_nmus_SecuritiesPurchaseAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_I9G01G3G9932937HF776_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_K1I23I5I1154159JH998_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xml:lang="en-US">Property, plant and equipment, depreciation methods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NumberOfReportableSegments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NumberOfReportableSegments" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NumberOfReportableSegments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive excluded from the calculation of diluted loss per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Number of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockSharesIssued" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_2I0HHGGF8208_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Each share of preferred stock convertible into</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Preferred stock shares convertible into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_4K2JJIIH0420_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_2I0HHGGF8208_nmus_UniversityOfMississippiAgreementsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsTable" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsTable" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_UniversityOfMississippiAgreementsTable" xlink:to="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsTable"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OptionAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_OptionAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_OptionAgreementMember" xml:lang="en-US">Option Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_OptionAgreementMember" xml:lang="en-US">UM 5050 pro-drug agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_OptionAgreementMember" xml:lang="en-US">Option Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_OptionAgreementMember" xml:lang="en-US">Represents information regarding option agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_OptionAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_OptionAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LicenseAgreementMember" xlink:label="loc_2I0HHGGF8208_nmus_LicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_LicenseAgreementMember" xml:lang="en-US">UM 8930 analogue agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_LicenseAgreementMember" xml:lang="en-US">License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_LicenseAgreementMember" xml:lang="en-US">Represents license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_LicenseAgreementMember" xlink:to="lab_4K2JJIIH0420_nmus_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_Um5070LicenseAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_Um5070LicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_Um5070LicenseAgreementMember" xml:lang="en-US">Um 5070 License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_Um5070LicenseAgreementMember" xml:lang="en-US">UM 5070 license agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_Um5070LicenseAgreementMember" xml:lang="en-US">UM 5070 license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_Um5070LicenseAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_Um5070LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_2I0HHGGF8208_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_LegalEntityAxis" xlink:to="lab_4K2JJIIH0420_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityDomain" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_2I0HHGGF8208_nmus_UniversityOfMississippiMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiMember" xml:lang="en-US">University Of Mississippi [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiMember" xml:lang="en-US">University of Mississippi</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiMember" xml:lang="en-US">Represents information regarding university of mississippi.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_UniversityOfMississippiMember" xlink:to="lab_4K2JJIIH0420_nmus_UniversityOfMississippiMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IntellectualPropertyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IntellectualPropertyMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IntellectualPropertyMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_2I0HHGGF8208_nmus_MonthAndYearOfAgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_MonthAndYearOfAgreementAxis" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_MonthAndYearOfAgreementAxis" xml:lang="en-US">Information regarding month and year of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_MonthAndYearOfAgreementAxis" xlink:to="lab_4K2JJIIH0420_nmus_MonthAndYearOfAgreementAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_I9G01G3G9932937HF776_nmus_MonthAndYearOfAgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_MonthAndYearOfAgreementDomain" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_MonthAndYearOfAgreementDomain" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_MonthAndYearOfAgreementDomain" xlink:to="lab_K1I23I5I1154159JH998_nmus_MonthAndYearOfAgreementDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_December2015Member" xlink:label="loc_2I0HHGGF8208_nmus_December2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_December2015Member" xml:lang="en-US">December 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_December2015Member" xml:lang="en-US">December 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_December2015Member" xml:lang="en-US">Represents december 2015 as agreement month and year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_December2015Member" xlink:to="lab_4K2JJIIH0420_nmus_December2015Member"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OctoberTwoThousandFifteenMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_OctoberTwoThousandFifteenMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_OctoberTwoThousandFifteenMember" xml:lang="en-US">October Two Thousand Fifteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_OctoberTwoThousandFifteenMember" xml:lang="en-US">October 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_OctoberTwoThousandFifteenMember" xml:lang="en-US">Represents agreement date of the agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_OctoberTwoThousandFifteenMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_OctoberTwoThousandFifteenMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_2I0HHGGF8208_nmus_UniversityOfMississippiAgreementsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsLineItems" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsLineItems" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_UniversityOfMississippiAgreementsLineItems" xlink:to="lab_4K2JJIIH0420_nmus_UniversityOfMississippiAgreementsLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfAgreement" xlink:label="loc_I9G01G3G9932937HF776_nmus_TermOfAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfAgreement" xml:lang="en-US">Term Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfAgreement" xml:lang="en-US">Term of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfAgreement" xml:lang="en-US">Represents term of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TermOfAgreement" xlink:to="lab_K1I23I5I1154159JH998_nmus_TermOfAgreement"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_2I0HHGGF8208_nmus_NumberOfLicenseAgreements"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Number Of License Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Number of license agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Represents number of license agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_NumberOfLicenseAgreements" xlink:to="lab_4K2JJIIH0420_nmus_NumberOfLicenseAgreements"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_I9G01G3G9932937HF776_nmus_NoticePeriodForTermination"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_NoticePeriodForTermination" xml:lang="en-US">Notice Period For Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_NoticePeriodForTermination" xml:lang="en-US">Notice period for termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_NoticePeriodForTermination" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_NoticePeriodForTermination" xlink:to="lab_K1I23I5I1154159JH998_nmus_NoticePeriodForTermination"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OneTimeUpfrontPayment" xlink:label="loc_2I0HHGGF8208_nmus_OneTimeUpfrontPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One Time Upfront Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One-time up-front option payment under University of Mississippi option agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One time up front payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_4K2JJIIH0420_nmus_OneTimeUpfrontPayment" xml:lang="en-US">One time up front payment payable in four equal monthly installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_OneTimeUpfrontPayment" xml:lang="en-US">This element represents amount of one-time upfront payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_OneTimeUpfrontPayment" xlink:to="lab_4K2JJIIH0420_nmus_OneTimeUpfrontPayment"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AnnualFeesForLicenseAgreement" xlink:label="loc_I9G01G3G9932937HF776_nmus_AnnualFeesForLicenseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_AnnualFeesForLicenseAgreement" xml:lang="en-US">Annual Fees For License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_AnnualFeesForLicenseAgreement" xml:lang="en-US">Annual fees for license agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_AnnualFeesForLicenseAgreement" xml:lang="en-US">Represents annual fees for license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_AnnualFeesForLicenseAgreement" xlink:to="lab_K1I23I5I1154159JH998_nmus_AnnualFeesForLicenseAgreement"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_2I0HHGGF8208_nmus_AggregateMilestonePaymentsIfMilestonesAchieved"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xml:lang="en-US">Aggregate Milestone Payments If Milestones Achieved</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xml:lang="en-US">Aggregate milestone payments if milestones achieved</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xml:lang="en-US">This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:to="lab_4K2JJIIH0420_nmus_AggregateMilestonePaymentsIfMilestonesAchieved"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LetterAgreementMember" xlink:label="loc_2I0HHGGF8208_nmus_LetterAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_LetterAgreementMember" xml:lang="en-US">Letter Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_LetterAgreementMember" xml:lang="en-US">Letter agreement ("Agreement")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_LetterAgreementMember" xml:lang="en-US">Represents letter agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_LetterAgreementMember" xlink:to="lab_4K2JJIIH0420_nmus_LetterAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IndependentContractorAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_IndependentContractorAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_IndependentContractorAgreementMember" xml:lang="en-US">Independent Contractor Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_IndependentContractorAgreementMember" xml:lang="en-US">Independent contractor agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_IndependentContractorAgreementMember" xml:lang="en-US">Represents name of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_IndependentContractorAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_IndependentContractorAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RestrictedStockAgreementsMember" xlink:label="loc_2I0HHGGF8208_nmus_RestrictedStockAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_RestrictedStockAgreementsMember" xml:lang="en-US">Restricted Stock Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_RestrictedStockAgreementsMember" xml:lang="en-US">Restricted Stock Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_RestrictedStockAgreementsMember" xml:lang="en-US">Information of Restricted Stock Agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_RestrictedStockAgreementsMember" xlink:to="lab_4K2JJIIH0420_nmus_RestrictedStockAgreementsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeparationAndReleaseAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_SeparationAndReleaseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeparationAndReleaseAgreementMember" xml:lang="en-US">Separation And Release Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeparationAndReleaseAgreementMember" xml:lang="en-US">Separation Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeparationAndReleaseAgreementMember" xml:lang="en-US">Separation and release agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeparationAndReleaseAgreementMember" xml:lang="en-US">Represents separation and release agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_SeparationAndReleaseAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_SeparationAndReleaseAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ContractManufacturingOrganizationMember" xlink:label="loc_2I0HHGGF8208_nmus_ContractManufacturingOrganizationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ContractManufacturingOrganizationMember" xml:lang="en-US">Contract Manufacturing Organization [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ContractManufacturingOrganizationMember" xml:lang="en-US">Contract manufacturing organization ("CMO")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ContractManufacturingOrganizationMember" xml:lang="en-US">Represents third party, contract manufacturing organization.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ContractManufacturingOrganizationMember" xlink:to="lab_4K2JJIIH0420_nmus_ContractManufacturingOrganizationMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_K2CIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_K2CIncMember" xml:lang="en-US">K2C Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_K2CIncMember" xml:lang="en-US">K2C, Inc.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_K2CIncMember" xml:lang="en-US">Represents name of party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_K2CIncMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_K2CIncMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_2I0HHGGF8208_nmus_EmeraldHealthSciencesIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldHealthSciencesIncMember" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldHealthSciencesIncMember" xml:lang="en-US">Emerald Health Sciences Inc</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldHealthSciencesIncMember" xml:lang="en-US">Represents information about Emerald Health Sciences, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_EmeraldHealthSciencesIncMember" xlink:to="lab_4K2JJIIH0420_nmus_EmeraldHealthSciencesIncMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SeriesEPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SeriesEPreferredStockMember" xml:lang="en-US">Series E Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SeriesEPreferredStockMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SeriesEPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RangeAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RangeMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_2I0HHGGF8208_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_MinimumMember" xlink:to="lab_4K2JJIIH0420_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_MaximumMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_VestingAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_VestingAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_VestingAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_VestingDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_VestingDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_VestingDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Immediate vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">October 20, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">November 21, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AwardTypeAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted stock awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RestrictedStockMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingLeasedAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingLeasedAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_2I0HHGGF8208_us-gaap_LeaseAndRentalExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Lease expenses per month</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_LeaseAndRentalExpense" xlink:to="lab_4K2JJIIH0420_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PaymentsToAcquireFurnitureAndFixtures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquireFurnitureAndFixtures" xml:lang="en-US">Payments to Acquire Furniture and Fixtures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquireFurnitureAndFixtures" xml:lang="en-US">Value of furniture lease payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PaymentsToAcquireFurnitureAndFixtures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_2I0HHGGF8208_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of fixed assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_4K2JJIIH0420_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FeesAndExpensesForServicesProvided" xlink:label="loc_I9G01G3G9932937HF776_nmus_FeesAndExpensesForServicesProvided"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_FeesAndExpensesForServicesProvided" xml:lang="en-US">Fees And Expenses For Services Provided</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_FeesAndExpensesForServicesProvided" xml:lang="en-US">Fees and expenses for the initial evaluation and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_FeesAndExpensesForServicesProvided" xml:lang="en-US">Represents amount of fees and expenses for services provided.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_FeesAndExpensesForServicesProvided" xlink:to="lab_K1I23I5I1154159JH998_nmus_FeesAndExpensesForServicesProvided"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:label="loc_2I0HHGGF8208_nmus_AnalyticalMethodDevelopmentAndQualificationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xml:lang="en-US">Analytical Method Development And Qualification Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xml:lang="en-US">Estimated analytical method development and qualification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xml:lang="en-US">Represents analytical method development and qualification expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:to="lab_4K2JJIIH0420_nmus_AnalyticalMethodDevelopmentAndQualificationExpense"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthlyFee" xlink:label="loc_I9G01G3G9932937HF776_nmus_MonthlyFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_MonthlyFee" xml:lang="en-US">Monthly Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_MonthlyFee" xml:lang="en-US">Monthly fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_MonthlyFee" xml:lang="en-US">Represents amount of monthly fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_MonthlyFee" xlink:to="lab_K1I23I5I1154159JH998_nmus_MonthlyFee"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermsOfAgreementRenewed" xlink:label="loc_2I0HHGGF8208_nmus_TermsOfAgreementRenewed"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TermsOfAgreementRenewed" xml:lang="en-US">Terms Of Agreement Renewed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TermsOfAgreementRenewed" xml:lang="en-US">Terms of agreement renewed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TermsOfAgreementRenewed" xml:lang="en-US">Represents tem of agreement renewed.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TermsOfAgreementRenewed" xlink:to="lab_4K2JJIIH0420_nmus_TermsOfAgreementRenewed"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TotalExpenseIncurredUnderAgreement" xlink:label="loc_I9G01G3G9932937HF776_nmus_TotalExpenseIncurredUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TotalExpenseIncurredUnderAgreement" xml:lang="en-US">Total Expense Incurred Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TotalExpenseIncurredUnderAgreement" xml:lang="en-US">Total expense incurred under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TotalExpenseIncurredUnderAgreement" xml:lang="en-US">Represents total expense incurred under the agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TotalExpenseIncurredUnderAgreement" xlink:to="lab_K1I23I5I1154159JH998_nmus_TotalExpenseIncurredUnderAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_2I0HHGGF8208_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GuarantorFailedToPay" xlink:label="loc_2I0HHGGF8208_nmus_GuarantorFailedToPay"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_GuarantorFailedToPay" xml:lang="en-US">Guarantor Failed To Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_GuarantorFailedToPay" xml:lang="en-US">Guarantor failed to pay within 90 days of notice of purchaser</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_GuarantorFailedToPay" xml:lang="en-US">Represents information the guarantor failed to pay within 90 days of notice of purchaser.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_GuarantorFailedToPay" xlink:to="lab_4K2JJIIH0420_nmus_GuarantorFailedToPay"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Additional fund raised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Common stock gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Common stock gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of unrestricted stock awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of restricted common stock vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued advisory fees payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_2I0HHGGF8208_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recognized stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recognized additional stock based compensation expense of restricted stock and option awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_ClassOfWarrantOrRightAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_Pre2015CommonStockWarrantsMember" xlink:label="loc_2I0HHGGF8208_nmus_Pre2015CommonStockWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_Pre2015CommonStockWarrantsMember" xml:lang="en-US">Pre 2015 Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_Pre2015CommonStockWarrantsMember" xml:lang="en-US">Pre 2015 Common Stock Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_Pre2015CommonStockWarrantsMember" xml:lang="en-US">Represents Pre 2015 Common Stock Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_Pre2015CommonStockWarrantsMember" xlink:to="lab_4K2JJIIH0420_nmus_Pre2015CommonStockWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_TwoThousandFifteenCommonStockWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenCommonStockWarrantsMember" xml:lang="en-US">Two Thousand Fifteen Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenCommonStockWarrantsMember" xml:lang="en-US">2015 Common Stock Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenCommonStockWarrantsMember" xml:lang="en-US">Represents 2015 Common Stock Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TwoThousandFifteenCommonStockWarrantsMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenCommonStockWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_2I0HHGGF8208_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xml:lang="en-US">Two Thousand Fifteen Series B Financing Common Stock Warrants To Series B Stockholders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xml:lang="en-US">2015 series B financing Common Stock Warrants to Series B Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xml:lang="en-US">Represents two thousand fifteen series B financing Common Stock Warrants to Series B Stockholders.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:to="lab_4K2JJIIH0420_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xml:lang="en-US">Two Thousand Fifteen Series B Financing Placement Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xml:lang="en-US">2015 Series B financing Placement Agent Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xml:lang="en-US">Represents two thousand fifteen series B financing Placement Agent Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_2I0HHGGF8208_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xml:lang="en-US">Two Thousand Sixteen Common Stock Warrants To Service Providers [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xml:lang="en-US">2016 Common Stock Warrants to Service Providers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xml:lang="en-US">Represents two thousand sixteen Common Stock Warrants to Service Providers.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:to="lab_4K2JJIIH0420_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xml:lang="en-US">Two Thousand Sixteen Series C Placement Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xml:lang="en-US">2016 Series C Placement Agent Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xml:lang="en-US">Represents 2016 Series C Placement Agent Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_2I0HHGGF8208_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xml:lang="en-US">Two Thousand Seventeen Series D Placement Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xml:lang="en-US">2017 Series D Placement Agent Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xml:lang="en-US">Represents two thousand sixteen Series D Placement Agent Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:to="lab_4K2JJIIH0420_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xml:lang="en-US">Two Thousand Seventeen Common Stock Warrants To Service Providers [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xml:lang="en-US">2017 Common Stock Warrants to Service Provider</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xml:lang="en-US">Represents two thousand seventeen Common Stock Warrants to Service Providers.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_2I0HHGGF8208_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xml:lang="en-US">Two Thousand Eighteen Emerald Financing Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xml:lang="en-US">2018 Emerald Financing Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xml:lang="en-US">Represents 2018 Emerald Financing Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:to="lab_4K2JJIIH0420_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_2I0HHGGF8208_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">common stock par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_I9G01G3G9932937HF776_nmus_TermOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfWarrant" xml:lang="en-US">Term Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfWarrant" xml:lang="en-US">Term of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfWarrant" xml:lang="en-US">Term of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_TermOfWarrant" xml:lang="en-US">Represents term of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_TermOfWarrant" xlink:to="lab_K1I23I5I1154159JH998_nmus_TermOfWarrant"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsVestedAndOutstanding" xlink:label="loc_2I0HHGGF8208_nmus_WarrantsVestedAndOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsVestedAndOutstanding" xml:lang="en-US">Warrants Vested And Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsVestedAndOutstanding" xml:lang="en-US">Warrants vested and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsVestedAndOutstanding" xml:lang="en-US">Represents warrants vested and outstanding as of balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_WarrantsVestedAndOutstanding" xlink:to="lab_4K2JJIIH0420_nmus_WarrantsVestedAndOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PlanNameAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PlanNameDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_2I0HHGGF8208_nmus_OmnibusIncentivePlan2014Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_OmnibusIncentivePlan2014Member" xlink:to="lab_4K2JJIIH0420_nmus_OmnibusIncentivePlan2014Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xlink:label="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments And Options [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xml:lang="en-US">Shares Available for Grant of Option's &amp; Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xlink:to="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xlink:label="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments And Options Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xml:lang="en-US">Represents number of equity-based payment instruments, including stock (or unit) options, that outstanding during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xlink:to="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xlink:label="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments And Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xml:lang="en-US">Options &amp; shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xml:lang="en-US">Represents number of equity-based payment instruments, including stock (or unit) options, that granted during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xlink:to="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xlink:label="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments And Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xml:lang="en-US">Options &amp; shares exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xml:lang="en-US">Represents number of equity-based payment instruments, including stock (or unit) options, that exercised during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xlink:to="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xlink:label="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments And Options Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xml:lang="en-US">Cancellations of vested stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xml:lang="en-US">Represents number of equity-based payment instruments, including stock (or unit) options, that cancelled during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xlink:to="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance at the ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Aggregate number of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options to purchase shares common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Vested and Exercisable at March 31, 2018</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Vested and Exercisable at December 31, 2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xlink:label="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Price Per Share [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xml:lang="en-US">Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xlink:to="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xlink:label="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xml:lang="en-US">Represents the price per share of options outstanding under share-based arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xlink:to="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xlink:label="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xml:lang="en-US">Represents the price per share of options granted under share-based arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xlink:to="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xlink:label="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xml:lang="en-US">Options exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xml:lang="en-US">Represents the price per share of options exercised under share-based arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xlink:to="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xlink:label="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xml:lang="en-US">Represents the price per share of options cancelled under share-based arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xlink:to="lab_K1I23I5I1154159JH998_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xlink:label="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xml:lang="en-US">Vested and Exercisable at March 31, 2018</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xml:lang="en-US">Vested and Exercisable at December 31, 2016</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xml:lang="en-US">Represents the price per share of options vested and exercisable under share-based arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xlink:to="lab_4K2JJIIH0420_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance at the ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Vested and Exercisable at March 31, 2018</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Vested and Exercisable at December 31, 2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_I9G01G3G9932937HF776_nmus_EquityTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_EquityTable" xml:lang="en-US">Equity [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_EquityTable" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_EquityTable" xlink:to="lab_K1I23I5I1154159JH998_nmus_EquityTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EquityComponentDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockMember" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_SeriesBWarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantMember" xml:lang="en-US">Series B Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantMember" xml:lang="en-US">Series B warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantMember" xml:lang="en-US">Represents information regarding Series B warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_SeriesBWarrantMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_SeriesBWarrantMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBPreferredStockAgreementMember" xlink:label="loc_2I0HHGGF8208_nmus_SeriesBPreferredStockAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockAgreementMember" xml:lang="en-US">Series B Preferred Stock Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockAgreementMember" xml:lang="en-US">Series B Preferred stock agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockAgreementMember" xml:lang="en-US">Represents information regarding Series B Preferred Stock Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_SeriesBPreferredStockAgreementMember" xlink:to="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShortTermDebtTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_ShortTermDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_BridgeLoanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoanMember" xml:lang="en-US">Bridge Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoanMember" xml:lang="en-US">Bridge Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_BridgeLoanMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RelatedPartyDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_2I0HHGGF8208_us-gaap_InvestorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_InvestorMember" xml:lang="en-US">Accredited investor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_InvestorMember" xlink:to="lab_4K2JJIIH0420_us-gaap_InvestorMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_I9G01G3G9932937HF776_nmus_EquityLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_EquityLineItems" xml:lang="en-US">Equity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_EquityLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_EquityLineItems" xlink:to="lab_K1I23I5I1154159JH998_nmus_EquityLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Common stock issued for services (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Number of common shares issued to founders and one board member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockSharesConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Number of shares converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockSharesConverted1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionPrice" xlink:label="loc_2I0HHGGF8208_nmus_ConversionPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ConversionPrice" xml:lang="en-US">Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ConversionPrice" xml:lang="en-US">Conversion price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ConversionPrice" xml:lang="en-US">Represents conversion price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ConversionPrice" xlink:to="lab_4K2JJIIH0420_nmus_ConversionPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Shares issued, price per share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common shares issued to individual investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of shares called by warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of common stock called by warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrants" xlink:label="loc_2I0HHGGF8208_nmus_TermOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_TermOfWarrants" xml:lang="en-US">Term Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_TermOfWarrants" xml:lang="en-US">Term of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_TermOfWarrants" xml:lang="en-US">Represents term of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_TermOfWarrants" xlink:to="lab_4K2JJIIH0420_nmus_TermOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_BridgeLoan"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoan" xml:lang="en-US">Bridge Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoan" xml:lang="en-US">Aggregate gross proceeds secured by all of Nemus' assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoan" xml:lang="en-US">Aggregate gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_BridgeLoan" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_BridgeLoan"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_2I0HHGGF8208_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price, per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Initial conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_4K2JJIIH0420_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Shares converted into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_2I0HHGGF8208_nmus_SubsequentFinancingPurchasePriceDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_SubsequentFinancingPurchasePriceDescription" xml:lang="en-US">Subsequent Financing Purchase Price Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_SubsequentFinancingPurchasePriceDescription" xml:lang="en-US">Subsequent financing purchase price, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_SubsequentFinancingPurchasePriceDescription" xml:lang="en-US">Represents subsequent financing purchase price description to protect against aniti-dilution.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_SubsequentFinancingPurchasePriceDescription" xlink:to="lab_4K2JJIIH0420_nmus_SubsequentFinancingPurchasePriceDescription"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IntrinsicValueOfWarrantExercises" xlink:label="loc_I9G01G3G9932937HF776_nmus_IntrinsicValueOfWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_IntrinsicValueOfWarrantExercises" xml:lang="en-US">Intrinsic Value Of Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_IntrinsicValueOfWarrantExercises" xml:lang="en-US">Intrinsic value of warrant exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_IntrinsicValueOfWarrantExercises" xml:lang="en-US">Represents intrinsic value of warrant exercises .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_IntrinsicValueOfWarrantExercises" xlink:to="lab_K1I23I5I1154159JH998_nmus_IntrinsicValueOfWarrantExercises"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_2I0HHGGF8208_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Stock And Warrants Issued During Period Shares Preferred Stock And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Number of preferred stock and warrants sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Number of preferred stock and warrants for common stock issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:to="lab_4K2JJIIH0420_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockAggregatePurchasePrice" xlink:label="loc_I9G01G3G9932937HF776_nmus_CommonStockAggregatePurchasePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockAggregatePurchasePrice" xml:lang="en-US">Common Stock Aggregate Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockAggregatePurchasePrice" xml:lang="en-US">Aggregate purchase price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_CommonStockAggregatePurchasePrice" xml:lang="en-US">Represents common stock aggregate purchase price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_CommonStockAggregatePurchasePrice" xlink:to="lab_K1I23I5I1154159JH998_nmus_CommonStockAggregatePurchasePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from issuance of preferred stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds received from the Series B financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PreferredStockConvertibleConversionPriceDecrease" xlink:label="loc_I9G01G3G9932937HF776_nmus_PreferredStockConvertibleConversionPriceDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_PreferredStockConvertibleConversionPriceDecrease" xml:lang="en-US">Preferred Stock Convertible Conversion Price Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_PreferredStockConvertibleConversionPriceDecrease" xml:lang="en-US">Reduction of conversion price of preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_PreferredStockConvertibleConversionPriceDecrease" xml:lang="en-US">Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_PreferredStockConvertibleConversionPriceDecrease" xlink:to="lab_K1I23I5I1154159JH998_nmus_PreferredStockConvertibleConversionPriceDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_2I0HHGGF8208_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Liquidation preference value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_4K2JJIIH0420_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfConversionAmount" xlink:label="loc_I9G01G3G9932937HF776_nmus_PercentageOfConversionAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfConversionAmount" xml:lang="en-US">Percentage Of Conversion Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfConversionAmount" xml:lang="en-US">Percentage of conversion amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfConversionAmount" xml:lang="en-US">Represents percentage of conversion amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_PercentageOfConversionAmount" xlink:to="lab_K1I23I5I1154159JH998_nmus_PercentageOfConversionAmount"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MinimumLitigationJudgementAmount" xlink:label="loc_2I0HHGGF8208_nmus_MinimumLitigationJudgementAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_MinimumLitigationJudgementAmount" xml:lang="en-US">Minimum Litigation Judgement Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_MinimumLitigationJudgementAmount" xml:lang="en-US">Value of final judgment rendered against company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_MinimumLitigationJudgementAmount" xml:lang="en-US">Represents minimum litigation judgement amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_MinimumLitigationJudgementAmount" xlink:to="lab_4K2JJIIH0420_nmus_MinimumLitigationJudgementAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockConversionBasis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred stock, conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockConversionBasis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockConversionBasis"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xlink:label="loc_2I0HHGGF8208_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xml:lang="en-US">Number Of Common Stock Issued Upon Conversion Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xml:lang="en-US">Number of common stock issued upon conversion of preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xml:lang="en-US">Represents number of common stock issued upon conversion of preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xlink:to="lab_4K2JJIIH0420_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidationProvisionCommonStockEquivalentShares" xlink:label="loc_I9G01G3G9932937HF776_nmus_LiquidationProvisionCommonStockEquivalentShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_LiquidationProvisionCommonStockEquivalentShares" xml:lang="en-US">Liquidation Provision Common Stock Equivalent Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_LiquidationProvisionCommonStockEquivalentShares" xml:lang="en-US">Liquidation provision common stock equivalent shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_LiquidationProvisionCommonStockEquivalentShares" xml:lang="en-US">Represents liquidation provision common stock equivalent shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_LiquidationProvisionCommonStockEquivalentShares" xlink:to="lab_K1I23I5I1154159JH998_nmus_LiquidationProvisionCommonStockEquivalentShares"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidationProvisionCommonStockEquivalentValue" xlink:label="loc_2I0HHGGF8208_nmus_LiquidationProvisionCommonStockEquivalentValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_LiquidationProvisionCommonStockEquivalentValue" xml:lang="en-US">Liquidation provision common stock equivalent value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_LiquidationProvisionCommonStockEquivalentValue" xml:lang="en-US">Represents liquidation provision common stock equivalent value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_LiquidationProvisionCommonStockEquivalentValue" xlink:to="lab_4K2JJIIH0420_nmus_LiquidationProvisionCommonStockEquivalentValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Beneficial conversion feature upon issuance of Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfSharesToBeRedeemed" xlink:label="loc_2I0HHGGF8208_nmus_PercentageOfSharesToBeRedeemed"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_PercentageOfSharesToBeRedeemed" xml:lang="en-US">Percentage Of Shares To Be Redeemed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_PercentageOfSharesToBeRedeemed" xml:lang="en-US">Percentage of shares to be redeemed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_PercentageOfSharesToBeRedeemed" xml:lang="en-US">Represents percentage of shares to be redeemed.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_PercentageOfSharesToBeRedeemed" xlink:to="lab_4K2JJIIH0420_nmus_PercentageOfSharesToBeRedeemed"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from triggering transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from triggering transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RedemptionAmountPercentage" xlink:label="loc_2I0HHGGF8208_nmus_RedemptionAmountPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_RedemptionAmountPercentage" xml:lang="en-US">Redemption Amount Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_RedemptionAmountPercentage" xml:lang="en-US">Redemption amount percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_RedemptionAmountPercentage" xml:lang="en-US">Represents redemption amount percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_RedemptionAmountPercentage" xlink:to="lab_4K2JJIIH0420_nmus_RedemptionAmountPercentage"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_I9G01G3G9932937HF776_nmus_ValueOfCommonStockCalledByWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Value of common stock called by warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ValueOfCommonStockCalledByWarrants" xlink:to="lab_K1I23I5I1154159JH998_nmus_ValueOfCommonStockCalledByWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_2I0HHGGF8208_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares reserved for future grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiry period of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_I9G01G3G9932937HF776_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">Percentage Of Option Price At Least Of Fair Value On Date Of Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">Percentage of option price at least of fair value on date of grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">This element represents percentage of option price least of fair value on the date of grants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:to="lab_K1I23I5I1154159JH998_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_2I0HHGGF8208_nmus_CommonStockVotingPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_CommonStockVotingPercentage" xml:lang="en-US">Common Stock Voting Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_CommonStockVotingPercentage" xml:lang="en-US">Voting percentage of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_CommonStockVotingPercentage" xml:lang="en-US">Percentage of vesting of share-based compensation awards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_CommonStockVotingPercentage" xlink:to="lab_4K2JJIIH0420_nmus_CommonStockVotingPercentage"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_I9G01G3G9932937HF776_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">Percentage Of Fair Value Option Price At Date Of Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">Percentage of fair value option price at date of grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">This element represents percentage of option price least of fair value on the date of grants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:to="lab_K1I23I5I1154159JH998_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining contractual term of options vested and exercisable (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options to purchase shares of common stock, exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options to purchase shares of common stock, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_2I0HHGGF8208_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_4K2JJIIH0420_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Recognized period of non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TitleOfIndividualAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_2I0HHGGF8208_nmus_ManagementAndBoardOfDirectorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Management And Board Of Directors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Senior management and board of directors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Person or persons controlling and directing the affairs of an entity and person serving on the board of directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ManagementAndBoardOfDirectorsMember" xlink:to="lab_4K2JJIIH0420_nmus_ManagementAndBoardOfDirectorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Dr. Brian S. Murphy</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_2I0HHGGF8208_us-gaap_ChiefFinancialOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ChiefFinancialOfficerMember" xml:lang="en-US">Chief Financial Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ChiefFinancialOfficerMember" xml:lang="en-US">Elizabeth Berecz, CFO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ChiefFinancialOfficerMember" xlink:to="lab_4K2JJIIH0420_us-gaap_ChiefFinancialOfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_BoardOfDirectorsChairmanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Cosmas N. Lykos</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_BoardOfDirectorsChairmanMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_BoardOfDirectorsChairmanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Compensation expense from issuance of restricted common stock to employees and board members</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Shares used for restricted stock awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Number of restricted stock awards granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Shares used for restricted stock awards (see discussion below)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_I9G01G3G9932937HF776_nmus_FairMarketValueOfSharesGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair Market Value Of Shares Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair market value of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair value of shares granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_FairMarketValueOfSharesGranted" xlink:to="lab_K1I23I5I1154159JH998_nmus_FairMarketValueOfSharesGranted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vested period of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vested period of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Shares of restricted common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Compensation expense from issuance of restricted common stock to employees and board members (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Restricted stock vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockTable" xml:lang="en-US">Conversion of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_DerivativeInstrumentRiskAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_DerivativeInstrumentRiskAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DerivativeContractTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DerivativeContractTypeDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_2I0HHGGF8208_nmus_SeriesBPreferredStockConversionLiabilityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockConversionLiabilityMember" xml:lang="en-US">Series BPreferred Stock Conversion Liability Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockConversionLiabilityMember" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockConversionLiabilityMember" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_SeriesBPreferredStockConversionLiabilityMember" xlink:to="lab_4K2JJIIH0420_nmus_SeriesBPreferredStockConversionLiabilityMember"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesFPreferredStockOptionLiabilityMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_SeriesFPreferredStockOptionLiabilityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesFPreferredStockOptionLiabilityMember" xml:lang="en-US">Series FPreferred Stock Option Liability Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesFPreferredStockOptionLiabilityMember" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_SeriesFPreferredStockOptionLiabilityMember" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_SeriesFPreferredStockOptionLiabilityMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_SeriesFPreferredStockOptionLiabilityMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_2I0HHGGF8208_us-gaap_NonoperatingIncomeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseMember" xml:lang="en-US">Nonoperating Income (Expense) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseMember" xml:lang="en-US">Non-operating income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseMember" xml:lang="en-US">Non-operating expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NonoperatingIncomeExpenseMember" xlink:to="lab_4K2JJIIH0420_us-gaap_NonoperatingIncomeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockLineItems" xml:lang="en-US">Conversion of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConversionOfStockLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConversionOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_2I0HHGGF8208_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xml:lang="en-US">Fair value of embedded derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_4K2JJIIH0420_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Change in fair value of conversion rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Change in fair market value of embedded derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Change in fair value of conversion rights of Series B preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_2I0HHGGF8208_nmus_SeriesBWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_SeriesBWarrantsMember" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_SeriesBWarrantsMember" xlink:to="lab_4K2JJIIH0420_nmus_SeriesBWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_I9G01G3G9932937HF776_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Class Of Warrant Or Right In Period Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average fair value of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Represents the weighted-average fair value of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_K1I23I5I1154159JH998_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldWarrantLiabilityMember" xlink:label="loc_2I0HHGGF8208_nmus_EmeraldWarrantLiabilityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldWarrantLiabilityMember" xml:lang="en-US">Emerald Warrant Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldWarrantLiabilityMember" xml:lang="en-US">Emerald Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldWarrantLiabilityMember" xml:lang="en-US">Emerald Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_EmeraldWarrantLiabilityMember" xml:lang="en-US">Represents the information about Emerald Warrant Liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_EmeraldWarrantLiabilityMember" xlink:to="lab_4K2JJIIH0420_nmus_EmeraldWarrantLiabilityMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharePrice" xml:lang="en-US">Closing price per share of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharePrice" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_2I0HHGGF8208_nmus_ExpirationPeriodOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_ExpirationPeriodOfWarrants" xml:lang="en-US">Expiration Period Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_ExpirationPeriodOfWarrants" xml:lang="en-US">Warrants, expiration period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_ExpirationPeriodOfWarrants" xml:lang="en-US">Represents expiration period of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_ExpirationPeriodOfWarrants" xlink:to="lab_4K2JJIIH0420_nmus_ExpirationPeriodOfWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_I9G01G3G9932937HF776_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xml:lang="en-US">Proceeds From Financing Between Conversion Liability And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xml:lang="en-US">Proceeds from financing between conversion liability and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xml:lang="en-US">Represents the amount related to proceeds from financing between the conversion liability and the warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:to="lab_K1I23I5I1154159JH998_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfWarrantsExercisable" xlink:label="loc_2I0HHGGF8208_nmus_NumberOfWarrantsExercisable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfWarrantsExercisable" xml:lang="en-US">Number Of Warrants Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_NumberOfWarrantsExercisable" xml:lang="en-US">Number of warrants exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_NumberOfWarrantsExercisable" xlink:to="lab_4K2JJIIH0420_nmus_NumberOfWarrantsExercisable"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateAxis" xlink:label="loc_I9G01G3G9932937HF776_nmus_WarrantsIssuanceDateAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuanceDateAxis" xml:lang="en-US">Warrants Issuance Date [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuanceDateAxis" xml:lang="en-US">Represents the information about warrants issuance date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_WarrantsIssuanceDateAxis" xlink:to="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuanceDateAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateDomain" xlink:label="loc_2I0HHGGF8208_nmus_WarrantsIssuanceDateDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuanceDateDomain" xml:lang="en-US">Warrants Issuance Date [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuanceDateDomain" xml:lang="en-US">Represents the information about warrants issuance date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_WarrantsIssuanceDateDomain" xlink:to="lab_4K2JJIIH0420_nmus_WarrantsIssuanceDateDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedOn19January2018Member" xlink:label="loc_I9G01G3G9932937HF776_nmus_WarrantsIssuedOn19January2018Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuedOn19January2018Member" xml:lang="en-US">Warrants Issued On 19 January 2018 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuedOn19January2018Member" xml:lang="en-US">Warrants issued on January 19, 2018</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuedOn19January2018Member" xml:lang="en-US">Warrants issued on January 19, 2018.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_WarrantsIssuedOn19January2018Member" xlink:to="lab_K1I23I5I1154159JH998_nmus_WarrantsIssuedOn19January2018Member"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedOn16February2018Member" xlink:label="loc_2I0HHGGF8208_nmus_WarrantsIssuedOn16February2018Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuedOn16February2018Member" xml:lang="en-US">Warrants Issued On 16 February 2018 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuedOn16February2018Member" xml:lang="en-US">Warrants issued on February 16, 2018</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_WarrantsIssuedOn16February2018Member" xml:lang="en-US">Warrants issued on February 16, 2018.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_WarrantsIssuedOn16February2018Member" xlink:to="lab_4K2JJIIH0420_nmus_WarrantsIssuedOn16February2018Member"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldPutOptionLiabilityMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_EmeraldPutOptionLiabilityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_EmeraldPutOptionLiabilityMember" xml:lang="en-US">Emerald Put Option Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_EmeraldPutOptionLiabilityMember" xml:lang="en-US">Emerald Put Option Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_EmeraldPutOptionLiabilityMember" xml:lang="en-US">Represents information about Emerald Put Option Liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_EmeraldPutOptionLiabilityMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_EmeraldPutOptionLiabilityMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Total proceeds from Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantLiabilitiesMoreThanProceeds" xlink:label="loc_I9G01G3G9932937HF776_nmus_WarrantLiabilitiesMoreThanProceeds"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantLiabilitiesMoreThanProceeds" xml:lang="en-US">Warrant Liabilities More Than Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantLiabilitiesMoreThanProceeds" xml:lang="en-US">Warrant liabilities more than proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_WarrantLiabilitiesMoreThanProceeds" xml:lang="en-US">Represents the information about warrant liabilities more than proceeds.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_WarrantLiabilitiesMoreThanProceeds" xlink:to="lab_K1I23I5I1154159JH998_nmus_WarrantLiabilitiesMoreThanProceeds"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfShortTermDebtTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfShortTermDebtTable"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_nmus_SecuredPromissoryNoteAndSecurityAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xml:lang="en-US">Secured Promissory Note And Security Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xml:lang="en-US">Secured Promissory Note and Security Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xml:lang="en-US">Represents Secured Promissory Note and Security Agreement for a convertible loan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_nmus_SecuredPromissoryNoteAndSecurityAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_ShortTermDebtLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShortTermDebtLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_ShortTermDebtLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RepaymentsOfConvertibleDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Payments received from convertible bridge loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Funds received under the Secured Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Funding of remaining bridge loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RepaymentsOfConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IncreaseInConversionLiability" xlink:label="loc_2I0HHGGF8208_nmus_IncreaseInConversionLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_nmus_IncreaseInConversionLiability" xml:lang="en-US">Increase In Conversion Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_nmus_IncreaseInConversionLiability" xml:lang="en-US">Increase in conversion liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_nmus_IncreaseInConversionLiability" xml:lang="en-US">Represents information about increase in conversion liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_nmus_IncreaseInConversionLiability" xlink:to="lab_4K2JJIIH0420_nmus_IncreaseInConversionLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventMember" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of unvested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Fair value of common stock issued in extinguishment of convertible debt</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Number of shares issued in conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MarkedToMarketConversionLiabilities" xlink:label="loc_nmus_MarkedToMarketConversionLiabilities_1"/>
<label xlink:type="resource" xlink:label="lab_nmus_MarkedToMarketConversionLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Marked To Market Conversion Liabilities</label>
<label xlink:type="resource" xlink:label="lab_nmus_MarkedToMarketConversionLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Marked to market the conversion liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nmus_MarkedToMarketConversionLiabilities_1" xlink:to="lab_nmus_MarkedToMarketConversionLiabilities"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nmus_MarkedToMarketConversionLiabilities" xml:lang="en-US">Represents marked to market the conversion liabilities.</label>

<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantsIssued" xlink:label="loc_nmus_FairValueOfWarrantsIssued_1"/>
<label xlink:type="resource" xlink:label="lab_nmus_FairValueOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Fair Value Of Warrants Issued</label>
<label xlink:type="resource" xlink:label="lab_nmus_FairValueOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Fair value of warrants issued in connection with Emerald financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nmus_FairValueOfWarrantsIssued_1" xlink:to="lab_nmus_FairValueOfWarrantsIssued"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nmus_FairValueOfWarrantsIssued" xml:lang="en-US">The fair value of warrants issued in noncash investing or financing activities.</label>

</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nmus-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Tuesday, May 15, 2018 12:04:57 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#DocumentAndEntityInformation" roleURI="http://www.nemusbioscience.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals" roleURI="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#UniversityOfMississippiAgreements" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#COMMITMENTSANDCONTINGENCIES" roleURI="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Stockholdersdeficitandpreferredstocksubjecttoredemption" roleURI="http://www.nemusbioscience.com/role/Stockholdersdeficitandpreferredstocksubjecttoredemption"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ProvisionsForConversionOfPreferredStockAndPutOptionLiability" roleURI="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiability"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilities" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilities"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ConvertibleBridgeLoan" roleURI="http://www.nemusbioscience.com/role/ConvertibleBridgeLoan"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#IncomeTaxes" roleURI="http://www.nemusbioscience.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SubsequentEvents" roleURI="http://www.nemusbioscience.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesTables" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Universityofmississippiagreementsdetailtextuals" roleURI="http://www.nemusbioscience.com/role/Universityofmississippiagreementsdetailtextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals" roleURI="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/ConvertibleBridgeLoanDetailTextuals" xlink:href="nmus-20180331.xsd#ConvertibleBridgeLoanDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20180331.xsd#Subsequenteventsdetailtextuals" roleURI="http://www.nemusbioscience.com/role/Subsequenteventsdetailtextuals"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_DocumentAndEntityInformationAbstract" xlink:label="loc_nmus_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AssetsAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_10" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_10" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_10" xlink:to="loc_us-gaap_AssetsCurrent_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9" xlink:to="loc_us-gaap_Assets_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccountsPayableCurrent_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccruedSalariesCurrent_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfConvertibleDebt" xlink:label="loc_nmus_ProvisionForConversionOfConvertibleDebt_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_nmus_ProvisionForConversionOfConvertibleDebt_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrent_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_27" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_Liabilities_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommitmentsAndContingencies_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquityAbstract_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33" xlink:to="loc_us-gaap_CommonStockValue_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_35" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_36" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_37" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_33" xlink:to="loc_us-gaap_StockholdersEquity_38" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_39" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockIssuanceCosts" xlink:label="loc_nmus_StockIssuanceCosts_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_nmus_StockIssuanceCosts_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesIssued_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_InterestExpense_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_RedeemablePreferredStockDividends_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_22" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_22" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>












<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_Depreciation_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensation_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantLiabilityExcessOfProceeds" xlink:label="loc_nmus_FairValueOfWarrantLiabilityExcessOfProceeds_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_nmus_FairValueOfWarrantLiabilityExcessOfProceeds_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockIssuedForLicense" xlink:label="loc_nmus_CommonStockIssuedForLicense_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_nmus_CommonStockIssuedForLicense_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_28" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_28" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockIssuedForServices" xlink:label="loc_nmus_CommonStockIssuedForServices_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_nmus_CommonStockIssuedForServices_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_37" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_40" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CashAndCashEquivalents" xlink:label="loc_nmus_CashAndCashEquivalents_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_40" xlink:to="loc_nmus_CashAndCashEquivalents_41" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SupplementalRestrictedCash" xlink:label="loc_nmus_SupplementalRestrictedCash_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_40" xlink:to="loc_nmus_SupplementalRestrictedCash_42" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:label="loc_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_40" xlink:to="loc_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_43" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_nmus_CashPaidDuringPeriodForAbstract_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_40" xlink:to="loc_nmus_CashPaidDuringPeriodForAbstract_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_44" xlink:to="loc_us-gaap_InterestPaid_45" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_44" xlink:to="loc_us-gaap_IncomeTaxesPaid_46" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_40" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_48" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" xlink:to="loc_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_50" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExerciseOfWarrants" xlink:label="loc_nmus_ExerciseOfWarrants_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" xlink:to="loc_nmus_ExerciseOfWarrants_51" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairValueOfWarrantsIssued" xlink:label="loc_nmus_FairValueOfWarrantsIssued"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" xlink:to="loc_nmus_FairValueOfWarrantsIssued" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_RedeemablePreferredStockDividends_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_nmus_UniversityOfMississippiAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsTextBlock" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Stockholdersdeficitandpreferredstocksubjecttoredemption">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiability">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0" xlink:to="loc_us-gaap_PreferredStockTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilities">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsTextBlock" xlink:label="loc_nmus_SeriesBWarrantsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_nmus_SeriesBWarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConvertibleBridgeLoan">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConvertibleBridgeLoanAbstract" xlink:label="loc_nmus_ConvertibleBridgeLoanAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ConvertibleBridgeLoanAbstract_0" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_nmus_LiquidityAndGoingConcernPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_LiquidityAndGoingConcernPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" xlink:to="loc_us-gaap_WarrantMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_NumberOfReportableSegments_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_PreferredStockSharesIssued_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_13" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Universityofmississippiagreementsdetailtextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_nmus_UniversityOfMississippiAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OptionAgreementMember" xlink:label="loc_nmus_OptionAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_OptionAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LicenseAgreementMember" xlink:label="loc_nmus_LicenseAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_LicenseAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_Um5070LicenseAgreementMember" xlink:label="loc_nmus_Um5070LicenseAgreementMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_Um5070LicenseAgreementMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_nmus_UniversityOfMississippiMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_nmus_UniversityOfMississippiMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" xlink:to="loc_us-gaap_IntellectualPropertyMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_nmus_MonthAndYearOfAgreementAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_MonthAndYearOfAgreementAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_December2015Member" xlink:label="loc_nmus_December2015Member_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_December2015Member_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OctoberTwoThousandFifteenMember" xlink:label="loc_nmus_OctoberTwoThousandFifteenMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_OctoberTwoThousandFifteenMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_nmus_UniversityOfMississippiAgreementsLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfAgreement" xlink:label="loc_nmus_TermOfAgreement_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_TermOfAgreement_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_nmus_NumberOfLicenseAgreements_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_NumberOfLicenseAgreements_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_nmus_NoticePeriodForTermination_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_NoticePeriodForTermination_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OneTimeUpfrontPayment" xlink:label="loc_nmus_OneTimeUpfrontPayment_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_OneTimeUpfrontPayment_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AnnualFeesForLicenseAgreement" xlink:label="loc_nmus_AnnualFeesForLicenseAgreement_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_AnnualFeesForLicenseAgreement_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_17" xlink:to="loc_nmus_AggregateMilestonePaymentsIfMilestonesAchieved_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LetterAgreementMember" xlink:label="loc_nmus_LetterAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_LetterAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IndependentContractorAgreementMember" xlink:label="loc_nmus_IndependentContractorAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_IndependentContractorAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RestrictedStockAgreementsMember" xlink:label="loc_nmus_RestrictedStockAgreementsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_RestrictedStockAgreementsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeparationAndReleaseAgreementMember" xlink:label="loc_nmus_SeparationAndReleaseAgreementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3" xlink:to="loc_nmus_SeparationAndReleaseAgreementMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ContractManufacturingOrganizationMember" xlink:label="loc_nmus_ContractManufacturingOrganizationMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_ContractManufacturingOrganizationMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_nmus_K2CIncMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_K2CIncMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_nmus_EmeraldHealthSciencesIncMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_EmeraldHealthSciencesIncMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_14" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_16" xlink:to="loc_us-gaap_RangeMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_17" xlink:to="loc_us-gaap_MinimumMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_17" xlink:to="loc_us-gaap_MaximumMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_VestingAxis_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_20" xlink:to="loc_us-gaap_VestingDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_21" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26" xlink:to="loc_us-gaap_RestrictedStockMember_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_LeaseAndRentalExpense_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FeesAndExpensesForServicesProvided" xlink:label="loc_nmus_FeesAndExpensesForServicesProvided_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_FeesAndExpensesForServicesProvided_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_AnalyticalMethodDevelopmentAndQualificationExpense" xlink:label="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_AnalyticalMethodDevelopmentAndQualificationExpense_35" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MonthlyFee" xlink:label="loc_nmus_MonthlyFee_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_MonthlyFee_36" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermsOfAgreementRenewed" xlink:label="loc_nmus_TermsOfAgreementRenewed_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_TermsOfAgreementRenewed_37" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TotalExpenseIncurredUnderAgreement" xlink:label="loc_nmus_TotalExpenseIncurredUnderAgreement_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_TotalExpenseIncurredUnderAgreement_38" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_39" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_41" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_42" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_GuarantorFailedToPay" xlink:label="loc_nmus_GuarantorFailedToPay_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_GuarantorFailedToPay_43" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_44" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_45" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_46" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfAgreement" xlink:label="loc_nmus_TermOfAgreement_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_nmus_TermOfAgreement_47" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_29" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_48" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_Pre2015CommonStockWarrantsMember" xlink:label="loc_nmus_Pre2015CommonStockWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_Pre2015CommonStockWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_nmus_TwoThousandFifteenCommonStockWarrantsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandFifteenCommonStockWarrantsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_13" xlink:to="loc_us-gaap_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MinimumMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_14" xlink:to="loc_us-gaap_MaximumMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_nmus_TermOfWarrant_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsVestedAndOutstanding" xlink:label="loc_nmus_WarrantsVestedAndOutstanding_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_nmus_WarrantsVestedAndOutstanding_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward_13" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare_31" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward_26" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_35" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_37" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_38" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_39" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantMember" xlink:label="loc_nmus_SeriesBWarrantMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_nmus_SeriesBWarrantMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBPreferredStockAgreementMember" xlink:label="loc_nmus_SeriesBPreferredStockAgreementMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_nmus_SeriesBPreferredStockAgreementMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_16" xlink:to="loc_dei_EntityDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_nmus_EmeraldHealthSciencesIncMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_nmus_EmeraldHealthSciencesIncMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_nmus_K2CIncMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_nmus_K2CIncMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_20" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_21" xlink:to="loc_us-gaap_BridgeLoanMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_23" xlink:to="loc_us-gaap_RelatedPartyDomain_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_24" xlink:to="loc_us-gaap_InvestorMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_VestingAxis_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_26" xlink:to="loc_us-gaap_VestingDomain_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_27" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_nmus_ConversionPrice_35" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_36" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_37" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_39" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrants" xlink:label="loc_nmus_TermOfWarrants_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_nmus_TermOfWarrants_41" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_42" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_BridgeLoan_43" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_44" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_45" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_46" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_47" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_nmus_SubsequentFinancingPurchasePriceDescription_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_nmus_SubsequentFinancingPurchasePriceDescription_48" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IntrinsicValueOfWarrantExercises" xlink:label="loc_nmus_IntrinsicValueOfWarrantExercises_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_29" xlink:to="loc_nmus_IntrinsicValueOfWarrantExercises_49" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_CommonStockMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockAggregatePurchasePrice" xlink:label="loc_nmus_CommonStockAggregatePurchasePrice_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_CommonStockAggregatePurchasePrice_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_ConversionPrice_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PreferredStockConvertibleConversionPriceDecrease" xlink:label="loc_nmus_PreferredStockConvertibleConversionPriceDecrease_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_PreferredStockConvertibleConversionPriceDecrease_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_TermOfWarrant_24" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_25" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfConversionAmount" xlink:label="loc_nmus_PercentageOfConversionAmount_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_PercentageOfConversionAmount_26" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MinimumLitigationJudgementAmount" xlink:label="loc_nmus_MinimumLitigationJudgementAmount_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_MinimumLitigationJudgementAmount_27" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_PreferredStockConversionBasis_28" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xlink:label="loc_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock_29" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidationProvisionCommonStockEquivalentShares" xlink:label="loc_nmus_LiquidationProvisionCommonStockEquivalentShares_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_LiquidationProvisionCommonStockEquivalentShares_30" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_LiquidationProvisionCommonStockEquivalentValue" xlink:label="loc_nmus_LiquidationProvisionCommonStockEquivalentValue_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_LiquidationProvisionCommonStockEquivalentValue_31" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_32" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_33" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfSharesToBeRedeemed" xlink:label="loc_nmus_PercentageOfSharesToBeRedeemed_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_PercentageOfSharesToBeRedeemed_34" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_35" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RedemptionAmountPercentage" xlink:label="loc_nmus_RedemptionAmountPercentage_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_12" xlink:to="loc_nmus_RedemptionAmountPercentage_36" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8" xlink:to="loc_us-gaap_ClassOfStockDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_nmus_TermOfWarrant_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_nmus_ValueOfCommonStockCalledByWarrants_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_nmus_ValueOfCommonStockCalledByWarrants_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_nmus_CommonStockVotingPercentage_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_nmus_CommonStockVotingPercentage_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled" xlink:label="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensation_25" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_nmus_ManagementAndBoardOfDirectorsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_nmus_ManagementAndBoardOfDirectorsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_9" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_14" xlink:to="loc_us-gaap_RangeMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MinimumMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_15" xlink:to="loc_us-gaap_MaximumMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_RestrictedStockAgreementsMember" xlink:label="loc_nmus_RestrictedStockAgreementsMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22" xlink:to="loc_nmus_RestrictedStockAgreementsMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_VestingAxis_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_24" xlink:to="loc_us-gaap_VestingDomain_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_25" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_27" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_27" xlink:to="loc_dei_EntityDomain_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_K2CIncMember" xlink:label="loc_nmus_K2CIncMember_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_28" xlink:to="loc_nmus_K2CIncMember_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_nmus_FairMarketValueOfSharesGranted_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_nmus_FairMarketValueOfSharesGranted_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_36" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_37" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0" xlink:to="loc_us-gaap_ConversionOfStockTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_nmus_SeriesBPreferredStockConversionLiabilityMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_nmus_SeriesBPreferredStockConversionLiabilityMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesFPreferredStockOptionLiabilityMember" xlink:label="loc_nmus_SeriesFPreferredStockOptionLiabilityMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_nmus_SeriesFPreferredStockOptionLiabilityMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_ConversionOfStockLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_12" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_12" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_12" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_12" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldWarrantLiabilityMember" xlink:label="loc_nmus_EmeraldWarrantLiabilityMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_EmeraldWarrantLiabilityMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9" xlink:to="loc_us-gaap_SharePrice_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_11" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_nmus_ExpirationPeriodOfWarrants_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_nmus_ExpirationPeriodOfWarrants_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_NumberOfWarrantsExercisable" xlink:label="loc_nmus_NumberOfWarrantsExercisable_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_nmus_NumberOfWarrantsExercisable_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IntrinsicValueOfWarrantExercises" xlink:label="loc_nmus_IntrinsicValueOfWarrantExercises_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_nmus_IntrinsicValueOfWarrantExercises_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract" xlink:label="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldWarrantLiabilityMember" xlink:label="loc_nmus_EmeraldWarrantLiabilityMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_EmeraldWarrantLiabilityMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuritiesPurchaseAgreementMember" xlink:label="loc_nmus_SecuritiesPurchaseAgreementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_nmus_SecuritiesPurchaseAgreementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateAxis" xlink:label="loc_nmus_WarrantsIssuanceDateAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_nmus_WarrantsIssuanceDateAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuanceDateDomain" xlink:label="loc_nmus_WarrantsIssuanceDateDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_WarrantsIssuanceDateAxis_11" xlink:to="loc_nmus_WarrantsIssuanceDateDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedOn19January2018Member" xlink:label="loc_nmus_WarrantsIssuedOn19January2018Member_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_WarrantsIssuanceDateDomain_12" xlink:to="loc_nmus_WarrantsIssuedOn19January2018Member_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantsIssuedOn16February2018Member" xlink:label="loc_nmus_WarrantsIssuedOn16February2018Member_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_WarrantsIssuanceDateDomain_12" xlink:to="loc_nmus_WarrantsIssuedOn16February2018Member_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldPutOptionLiabilityMember" xlink:label="loc_nmus_EmeraldPutOptionLiabilityMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_16" xlink:to="loc_nmus_EmeraldPutOptionLiabilityMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ExpirationPeriodOfWarrants" xlink:label="loc_nmus_ExpirationPeriodOfWarrants_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_nmus_ExpirationPeriodOfWarrants_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_WarrantLiabilitiesMoreThanProceeds" xlink:label="loc_nmus_WarrantLiabilitiesMoreThanProceeds_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_nmus_WarrantLiabilitiesMoreThanProceeds_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConvertibleBridgeLoanDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_ConvertibleBridgeLoanAbstract" xlink:label="loc_nmus_ConvertibleBridgeLoanAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ConvertibleBridgeLoanAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_BridgeLoanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_nmus_SecuredPromissoryNoteAndSecurityAgreementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_nmus_SecuredPromissoryNoteAndSecurityAgreementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_EmeraldHealthSciencesIncMember" xlink:label="loc_nmus_EmeraldHealthSciencesIncMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_EmeraldHealthSciencesIncMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_BridgeLoan_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_IncreaseInConversionLiability" xlink:label="loc_nmus_IncreaseInConversionLiability_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_nmus_IncreaseInConversionLiability_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_MarkedToMarketConversionLiabilities" xlink:label="loc_nmus_MarkedToMarketConversionLiabilities"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_11" xlink:to="loc_nmus_MarkedToMarketConversionLiabilities" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Subsequenteventsdetailtextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_VestingAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_8" xlink:to="loc_us-gaap_VestingDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20180331.xsd#nmus_SeparationAndReleaseAgreementMember" xlink:label="loc_nmus_SeparationAndReleaseAgreementMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_12" xlink:to="loc_nmus_SeparationAndReleaseAgreementMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771730752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>May 10, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nemus Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">nmus<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,601,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772481744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,945,312<span></span>
</td>
<td class="nump">$ 259,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">4,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">206,317<span></span>
</td>
<td class="nump">291,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,156,057<span></span>
</td>
<td class="nump">555,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,158,191<span></span>
</td>
<td class="nump">557,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">98,757<span></span>
</td>
<td class="nump">100,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">45,704<span></span>
</td>
<td class="nump">54,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">78,237<span></span>
</td>
<td class="nump">143,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Provision for conversion of Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfConvertibleDebt', window );">Provision for conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">322,698<span></span>
</td>
<td class="nump">805,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">8,589,472<span></span>
</td>
<td class="nump">551,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">8,589,472<span></span>
</td>
<td class="nump">551,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,912,170<span></span>
</td>
<td class="nump">1,357,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 236 million shares authorized; 132,414,079 issued and outstanding as of March 31, 2018 and 33,622,829 issued and outstanding as of December 31, 2017</a></td>
<td class="nump">132,414<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">15,375,360<span></span>
</td>
<td class="nump">9,444,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">982,911<span></span>
</td>
<td class="nump">982,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(22,244,664)<span></span>
</td>
<td class="num">(14,030,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(5,753,979)<span></span>
</td>
<td class="num">(3,569,506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 3,158,191<span></span>
</td>
<td class="nump">557,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Redeemable Convertible Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable Convertible Preferred Stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Convertible Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable Convertible Preferred Stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Redeemable Convertible Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable Convertible Preferred Stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,777,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent value of provision for conversion of convertible debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772413104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock issued (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">236,000,000<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">132,414,079<span></span>
</td>
<td class="nump">33,622,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">132,414,079<span></span>
</td>
<td class="nump">33,622,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Redeemable Convertible Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,833.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,833.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockIssuanceCosts', window );">Issuance costs (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Convertible Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockIssuanceCosts', window );">Issuance costs (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Redeemable Convertible Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockIssuanceCosts', window );">Issuance costs (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771695184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 92,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,226,361<span></span>
</td>
<td class="nump">1,288,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,251,361<span></span>
</td>
<td class="nump">1,380,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(1,251,361)<span></span>
</td>
<td class="num">(1,380,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(1,162,493)<span></span>
</td>
<td class="num">(12,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of warrant liability in excess of proceeds</a></td>
<td class="nump">7,174,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Change in fair value of conversion rights of convertible debt</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Financing transaction costs</a></td>
<td class="nump">137,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible debt</a></td>
<td class="nump">590,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="nump">34,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net Loss before income taxes</a></td>
<td class="num">(8,213,793)<span></span>
</td>
<td class="num">(1,282,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,213,793)<span></span>
</td>
<td class="num">(1,283,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Less: Preferred deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders</a></td>
<td class="num">$ (8,213,793)<span></span>
</td>
<td class="num">$ (1,994,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common share (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per common share (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares of common stock outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">88,632,979<span></span>
</td>
<td class="nump">23,247,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">88,632,979<span></span>
</td>
<td class="nump">23,247,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FairValueOfWarrantLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FairValueOfWarrantLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=77886427&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773245344">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,213,793)<span></span>
</td>
<td class="num">$ (1,283,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">331<span></span>
</td>
<td class="nump">2,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229,609<span></span>
</td>
<td class="nump">152,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of warrants and stock issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of Series B preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Change in fair value of conversion rights of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,162,493)<span></span>
</td>
<td class="num">(12,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairValueOfWarrantLiabilityExcessOfProceeds', window );">Fair value of warrant liability in excess of proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,174,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">590,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockIssuedForLicense', window );">Common stock issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">85,111<span></span>
</td>
<td class="nump">43,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,164)<span></span>
</td>
<td class="num">(47,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,808)<span></span>
</td>
<td class="num">(48,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees', window );">Accrued license and patent reimbursement fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(65,589)<span></span>
</td>
<td class="nump">253,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,053,162)<span></span>
</td>
<td class="num">(816,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Series D preferred stock issuance, net of $183,343 issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,131,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockIssuedForServices', window );">Proceeds from Common stock issuance, net of $9,122 issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,240,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible debt issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,739,578<span></span>
</td>
<td class="nump">1,131,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,685,357<span></span>
</td>
<td class="nump">315,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">264,383<span></span>
</td>
<td class="nump">102,320<span></span>
</td>
<td class="nump">$ 102,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,949,740<span></span>
</td>
<td class="nump">417,772<span></span>
</td>
<td class="nump">$ 264,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosures of cash-flow information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,945,312<span></span>
</td>
<td class="nump">380,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SupplementalRestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated', window );">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,949,740<span></span>
</td>
<td class="nump">417,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of outstanding preferred stock into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,947,227<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock', window );">Conversion of outstanding preferred stock subject to redemption into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">828,916<span></span>
</td>
<td class="nump">$ 405,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Fair value of common stock issued in extinguishment of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairValueOfWarrantsIssued', window );">Fair value of warrants issued in connection with Emerald financing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,424,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ExerciseOfWarrants', window );">Release of warrant liabilities due to exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,223,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the three months ended March 31, 2017, warrants issued to service providers for consulting services were valued at $30,000 and were recorded as a Prepaid expense and amortized over the service period.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During the three months ended March 31, 2017 preferred deemed dividends of $536,000 was recognized on Series D Preferred Stock and $175,000 on Series C Preferred Stock.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of Cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CommonStockIssuedForLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to Common stock issued for license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CommonStockIssuedForLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CommonStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to common stock issued for services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CommonStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount express exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FairValueOfWarrantLiabilityExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FairValueOfWarrantLiabilityExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of increase (decrease) in accrued license and patent reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SupplementalRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of supplemental restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SupplementalRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of total cash, cash equivalents and restricted cash shown in the consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TotalCashEquivalentsAndRestrictedCashShownInConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=77886427&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772458192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Value of warrants issued to purchase shares of common stock for consulting services</a></td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Preferred deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Preferred deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Preferred deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762849104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Operations, Business Activities and Summary of Significant Accounting Policies</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>1. Nature of Operations, Business Activities and Summary of Significant Accounting Policies</b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Nature of Operations and Basis of Presentation</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi (&#8220;UM&#8221;) is federally permitted and licensed to cultivate cannabis for research purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;our&#8221; refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. (&#8220;LGL&#8221;), together with its wholly-owned subsidiary, Nemus, a California corporation (&#8220;Nemus&#8221;). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Long Beach, California.</div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald&#8221;) discussed in note 4 below in which Emerald purchased a majority of the equity interest in Nemus resulting in a change in control. The current Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, have tendered their resignation and Emerald has appointed its nominees to the new Board.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman';
 white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Use of Estimates</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense and equity securities with embedded features as discussed below.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Liquidity and Going Concern</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has incurred operating losses and negative cash flows from operations since our inception. As of March 31, 2018, we had cash and cash equivalents of $2,945,312. The Company anticipates that it will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements were issued. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s continued existence is dependent on its ability to raise additional sufficient funding to cover operating expenses and to invest in operations and development activities. The Company plans to continue to pursue funding through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce
 spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs or cease operations.</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Cash and Cash Equivalents</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Restricted Cash</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A deposit of $4,428 as of both March 31, 2018 and December 31, 2017 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&#8217;s credit cards.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Fair Value Measurements</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on
 three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</p><p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr><td valign="top" width="4%"></td><td valign="top" width="6%"><p align="justify" style="margin: 0px;">Level 1:</p></td><td valign="top"><p align="justify" style="margin: 0px;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr><tr><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr><td valign="top"></td><td valign="top"><p align="justify" style="margin: 0px;">Level 2:</p></td><td valign="top"><p align="justify" style="margin: 0px;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr><tr><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr><td valign="top"></td><td valign="top"><p align="justify" style="margin: 0px;">Level 3:</p></td><td valign="top"><p align="justify" style="margin: 0px;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The warrant liability for the Emerald warrants and the associated put option were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of March 31, 2018.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Property and Equipment, Net</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018 and December 31, 2017, property and equipment, net, was $2,134 and $1,407 respectively, consisting primarily of computers and equipment. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px;
 font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Income Taxes</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the &#8220;NOLs&#8221;) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#8217;s statement of operations in the period incurred.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the
 position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Convertible Instruments</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. ASC 815,&#160;<i>Derivatives and Hedging Activities</i>&#160;(&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20,&#160;<i>Debt with Conversion and Other Options</i>&#160;(&#8220;ASC 470-20&#8221;). Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. We account for convertible instruments (when we have determined that the embedded conversion options should be bifurcated from their host instruments) in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400;
 word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We also follow ASC 480-10,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480-10&#8221;) in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in interest expense in the accompanying Consolidated Statements of Operations.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrants Issued in Connection with Financings</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other (income) expense in the Consolidated Statements of Operations.</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Revenue Recognition</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has not begun planned principal operations and has not generated any revenue since inception.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Research and
 Development Expenses</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock-Based Compensation Expenses</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</p><p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr><td width="4%"></td><td valign="top" width="4%"><p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p></td><td valign="top"><p align="justify" style="margin: 0px;">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</p></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td valign="top"><p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p></td><td valign="top"><p align="justify" style="margin: 0px;">Volatility - We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</p></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td valign="top"><p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p></td><td valign="top"><p align="justify" style="margin: 0px;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</p></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td valign="top"><p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p></td><td valign="top"><p align="justify" style="margin: 0px;">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.</p></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td valign="top"><p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p></td><td valign="top"><p align="justify" style="margin: 0px;">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.</p></td></tr></table><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color:
 initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock-Based Compensation for Non-Employees</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) No. 505-50,&#160;<i>Equity - Equity Based Payments to Non-Employees,</i>&#160;using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Segment Information</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">FASB ASC No. 280,&#160;<i>Segment Reporting</i>, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (&#8220;CODM&#8221;), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Comprehensive Income (Loss)</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three months ended March 31, 2018 and 2017, the comprehensive income (loss) was equal to the net income (loss).</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px;
 font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Earnings per share</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company applies FASB ASC No. 260,&#160;<i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of outstanding warrants and awards granted to employees under stock-based compensation plans. Potentially dilutive shares of the Company&#8217;s common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented. For the three months ended March 31, 2018, warrants to purchase 51,443,250 common shares and stock options exercisable for 1,030,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share. For the three months ended March 31, 2017, 3,625.375 shares of Series B Preferred Stock convertible into 14,501,500 common shares at $0.25 per share, 706 shares of Series D Preferred Stock convertible into 2,824,000 common shares at $0.25 per share, warrants to purchase 11,649,500 common shares and stock options exercisable for 1,130,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share.</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Recent accounting pronouncements</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2017, the FASB issued ASU 2017-11,<i>&#160;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating<i>&#160;Topic 480, Distinguishing Liabilities from Equity</i>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite
 deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915074064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>University of Mississippi Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsAbstract', window );"><strong>University Of Mississippi Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsTextBlock', window );">University of Mississippi Agreements</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>2. University of Mississippi Agreements</b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2013, the Company entered into a Memorandum of Understanding (MOU) with UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months&#8217; written notice to the other party.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>UM 5050 pro-drug agreements</u>:</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $2.1 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. The agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM 5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify"
 style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>UM 8930 analogue agreements:</u></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 14, 2015, the Company executed two license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM 8930, an analogue formulation of cannabidiol (&#8220;CBD&#8221;) for products administered through each of ocular or rectal delivery. The license agreements contain certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date. The aggregate milestone payments under the license agreements, if the milestones are achieved, is $1.4 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 14, 2015, we signed a renewable option agreement for the rights to explore other routes of delivery of UM8930 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment of $10,000 for a six-month option period that has subsequently been renewed under the same financial terms and conditions. The most recent renewal occurred for the period from December 15, 2017 to June 14, 2018.</div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>UM 5070 license agreement:</u></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On January 10, 2017, the Company entered into a license agreement with UM pursuant to which UM granted the Company an exclusive, perpetual license, including the right to sublicense, under intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like methicillin-resistant Staphylococcus aureus (MRSA). The license agreement contains certain milestone and royalty payments, as defined therein. There is an annual fee of $25,000 per license agreement, payable on the anniversary of each effective date and this amount was paid in January, 2018. The aggregate milestone payment under the license agreements, if the milestones are achieved, is $0.7 million. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days&#8217; written notice by the Company to UM.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents entire disclosure for University of Mississippi ("UM") Agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762868288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>3. Commitments and Contingencies</b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Lease Commitments</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the UM campus. The lease term commenced on October 1, 2014 and expired on December 31, 2017. There is annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease were divided by the total number of months in the lease period and the average rent was charged to expense each month during the lease period. The monthly amount charged to rent expense was $9,267. Upon expiration, the Company did not renew the laboratory lease but has retained office space under a month-to-month agreement at the rate of $300 per month.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company maintained its principal executive offices located in a shared office suite located at 600 Anton Blvd., Suite 1100, Costa Mesa, CA, 92626 under a month-to-month agreement. Effective March 1, 2018, the Company moved its corporate offices to 130 North Marina Drive, Long Beach, CA 90803 under a month-to-month agreement at a rate of approximately $2,600 per month.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In November 2015, the Company entered into an operating lease for its office and lab furnishings both in Costa Mesa and the Innovation Hub laboratory. The monthly lease payments were $7,559. In November 2017, the Company bought out the remaining portion of the lease for $32,128 which covered the remaining lease payments as well as the value of the furniture amounting to $19,654. The lab furnishings were donated to the University of Mississippi and the office furnishings were written off due to non-use for a loss on disposal of $1,650.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Total net rent expense related to our operating leases for the three months ended March 31, 2018 and 2017 was $4,311 and $56,449, respectively. There are no future minimum payments under non-cancellable operating leases.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Related Party Matters</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In June 2014, our subsidiary entered into an independent contractor agreement with K2C, Inc. (&#8220;K2C&#8221;), which is wholly owned by the Company&#8217;s then Executive Chairman and Co-Founder, Mr. Cosmas N. Lykos, pursuant to which we paid K2C a monthly fee for services performed by Mr. Lykos for our company. The agreement expired on June 1, 2017 and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2018, we entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted on January 18, 2018, 325,000 shares of restricted common stock granted on October 20, 2015, and 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. The Company recognized additional stock based compensation expense of $112,270 for these restricted stock and option awards.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2018 and 2017, total cash payments made under these agreements was $220,000 (including the previously discussed lump sum payment) and $30,000 respectively. Under the separation agreement, Mr. Lykos is also eligible to participate in our health, death and disability insurance plans for six months subsequent to K2C&#8217;s separation.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On February 1, 2018, we entered into an Independent Contractor Agreement with Emerald, pursuant to which Emerald will provide such services as are mutually agreed between the Company and Emerald, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services can include, but are not limited to corporate advisory services and technical expertise in the areas of business development, marketing and product development. The Independent Contractor Agreement specifies a compensation rate as is agreed between our chief executive officer and Emerald&#8217;s chief executive officer on a month-to-month basis. For the three months ended March 31, 2018, the Company incurred expenses of $100,000 under this Agreement. In addition, the Company accrued $15,000 in advisory fees payable directly to Emerald&#8217;s chief executive officer for advisory services rendered and these fees were paid in April 2018. The Independent Contractor Agreement has an initial term of ten years.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Legal Matters</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>General Litigation and Disputes</i></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations. As of March 31, 2018, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&#8217;s financial position or results of operations, but the Company has filed a petition commencing arbitration as described below.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Pending Series E Preferred Stock Financing and Filing for Arbitration</i></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On May 3, 2017, the Company entered into a securities purchase agreement with a purchaser to sell 1,000,000 shares of a new Series E Preferred Stock, par value $0.001 per share, at a purchase price of $20.00 for each preferred share for aggregate gross proceeds of $20,000,000. The securities purchase agreement provides for no conditions precedent to the close and that closing is not to occur later than July 10, 2017. The purchaser did not provide funding to close the transaction on July 10, 2017 as required under the securities purchase agreement and requested an extension of the closing date. In connection with the signing of the securities purchase agreement, an affiliate of the purchaser entered into a financial guarantee to the benefit of the Company that provided for payment of the purchase price in full within 90 days of exercise. The Company exercised this guarantee on July 12, 2017. The guarantor has failed to pay the $20,000,000 within 90 days of notice of the purchaser&#8217;s default, as required by the terms of the guaranty.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On November 8, 2017, the Company filed a petition commencing arbitration against the purchaser and guarantor as well as other related individuals. In the petition, the Company asserts, among other things, breach of contract against the purchaser for its failure to close its purchase of Series E Preferred Stock as required by the securities purchase agreement. The Company also asserts a breach of contract claim against the guarantor for its failure to honor its guarantee of the transaction. The petition was filed with Judicial Arbitration and Mediation Services, Inc., ENDISPUTE in Orange County, California, as required by the securities purchase agreement. The Company has engaged its legal counsel in the matter on a contingent-fee basis and intends to purse damages and remedies in connections with these agreements.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><i>Government Proceedings</i></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of March 31, 2018, the Company had no proceedings or inquiries.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Change in Control Severance Plan</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&#8217;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive&#8217;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&#8217;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Contract Manufacturing Organization (&#8220;CMO&#8221;) Agreement</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On February 5, 2016, the Company entered into a letter agreement (&#8220;Agreement&#8221;) with a third party contract manufacturing organization (&#8220;CMO&#8221;) pursuant to which the CMO is to provide services to Nemus for process development and analytical method development and qualification for Nemus&#8217; pro-drug of tetrahydrocannabinol, or THC, as well as for sample production and a stability study.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the terms of the Agreement, Nemus will pay an estimated $154,000 to $183,000 in fees and expenses for the initial evaluation and development of a process for the production of Nemus&#8217; pro-drug of THC to ensure reproducibility, quality and safety and an estimated $142,900 for analytical method development and qualification. The Company did not recognize any research and development expense under this agreement for the three months ended March 31, 2018 and 2017, respectively. After the initial evaluation and development, Nemus has agreed to pay additional fees and expenses for sample production of Nemus&#8217; pro-drug of THC and a stability study, as well as possible extensions to or modifications of the aforementioned projects.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Nemus may at any time cancel or delay any project under the Agreement prior to the scheduled start date. Nemus must reimburse the CMO for costs incurred prior to and including the date of cancellation plus any reasonable and foreseeable costs associated with stopping work on any project, including the CMO&#8217;s loss of revenue incurred as the result of reserving production facilities for Nemus&#8217; exclusive use. Nemus may terminate the Agreement in whole or in part at any time upon 30 days&#8217; written notice.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915093168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>4. Stockholders&#8217; Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Common Stock</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In March 2017, the Company issued 605,000 shares of common stock with par value of $0.001 to a third party in exchange for advisory services performed related to raising additional capital. The Company recorded $187,550 as general and administrative expense for the first quarter of 2017 to reflect the fair market value of the common stock issued. The fair market value was determined utilizing the Company&#8217;s closing stock price as of the approval date of the advisory fee by the Company&#8217;s Board of Directors.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the year ended December 31, 2017, a Series C Preferred stockholder converted 386 shares of its preferred stock to common stock as allowed under the Series C Preferred Stock Agreement, resulting in the issuance of 1,544,000 shares of common stock at an effective price of $0.25 per share. This represented the completion of converting all of the original Series C Preferred shares to common stock.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the year ended December 31, 2017, the Series B Preferred stockholders converted 1,197.45 shares of their preferred stock to common stock as allowed under the Series B Preferred Stock Agreement. This resulted in the issuance of&#160;5,910,666 shares of common stock at an effective price of $0.25 per share prior to November 1, 2017 and $0.15 per share from&#160;November 1, 2017 to December 27, 2017 after issuance of the Series F Preferred Stock. On December 28, 2017, the conversion rate was reset to $0.10 per share as a result of the convertible bridge loan but no conversions occurred from this date through-year end.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the year ended December 31, 2017, the Series D Preferred stockholders converted 1,000 shares of their preferred stock as allowed under the Series D Preferred Stock Agreement, resulting in the issuance of 4,000,000 shares of common stock at an effective price of $0.25 per share. On December 28, 2017, the conversion rate was reset to $0.10 per share as a result of the convertible bridge loan but no conversions occurred from this date through-year end.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On January 19, 2018, the Company entered into a Securities Purchase Agreement in which the Company sold to Emerald 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000 (&#8220;the Emerald Financing&#8221;). This transaction also resulted in the conversion of the $900,000 bridge loan (discussed in note 7 below) at $0.10 per share to 9,000,000 shares of common stock and represented the first of two closings under the Agreement. As a result of this transaction, the Company had a change in control and all Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, tendered their resignation. Emerald has appointed its nominees to the new Board. The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The second closing under the Emerald Financing occurred on February 16, 2018, pursuant to which Nemus issued and sold to Emerald 15,000,000 shares of Nemus&#8217; common stock, and a warrant to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share for a term of five years. In addition, an accredited investor purchased 2,500,000 shares of common stock and a warrant to purchase 3,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. The Company received aggregate gross proceeds of $1,750,000 from this second closing.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2018, all remaining Series B, D, and F stockholders converted their shares of preferred stock to common stock at an effective price of $0.10 per share. This resulted in 2,833.55 Series B Preferred Stock being converted into 28,335,500 shares of common stock, 200 shares of Series D Preferred Stock being converted into 2,000,000 shares of common stock, and 2,000 shares of Series F Preferred Stock being converted into 20,000,000 shares of common stock. All such conversions occurred prior to the change in control which took effect on January 19, 2018. In addition, Series B warrant holders exercised warrants with an intrinsic value of $1,125,291 which resulted in the issuance of 4,406,250 shares of common stock.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Preferred Stock</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>Redeemable Convertible Series B Preferred Stock:</u>&#160;In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company&#8217;s common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million. Each share of preferred stock was initially convertible into 1,250 shares of common stock which resulted in an effective conversion price of $0.80 per common share and could be converted by the holder at any time. The Series B Preferred Stock also has a &#8220;down-round&#8221; protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. In October 2016, as a result of the Series C Preferred Stock Agreement (as discussed below), the conversion price of the Series B Preferred Stock was reset to $0.40. On December 29, 2016, as a result of the Series D Preferred Stock Agreement, the conversion price of the Series B Preferred Stock was reset to $0.25. On November 1, 2017, as a result of the Series F Preferred Stock Agreement, the conversion price of the Series B Preferred Stock was reset to $0.15 per share. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series B Preferred Stock conversion price was reset to $0.10 per share. The Series B Preferred Stock has liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder&#8217;s preferred stock is convertible as of the record date. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share, subject to reset, and expire five years from the issuance date.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B Preferred stockholders receive an amount per share equal to the conversion price of $0.10, subject to down-round adjustment, multiplied by the as-if converted share amount of 28,335,500 common shares, totaling $2,833,550 as of December 31, 2017. If upon the liquidation, the assets are insufficient to permit payments to the Series B holders, all assets legally available will be distributed in a pro rata basis among the Series B holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Subject to certain trigger events occurring, the Series B Preferred stockholders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top" width="92%">
<p align="justify" style="margin: 0px;">Failure of the Series B Registration Statement to be declared effective by the Securities and Exchange Commission, or the SEC, on or prior to the date that is ninety days after the Effectiveness Deadline;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Suspension of the Company&#8217;s common stock from trading for a period of (2) consecutive trading days;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Any default of indebtedness;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Any filing of voluntary or involuntary bankruptcy by the Company;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">A final judgment in excess of $100,000 rendered against the Company;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Breach of representations and warranties in the Stock Purchase Agreement; and</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.</p>
</td>
</tr>
</table>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As certain of these triggering events are considered to be outside the control of the Company, the Series B Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In 2017, through October 31st, Series B stockholders converted 777.125 shares at a conversion rate of 4000:1 resulting in the issuance of 3,108,500 shares of common stock. Effective with the Series F Preferred Stock Agreement signed on November 1, 2017, the conversion price for the Series B Preferred Stock was reset to $0.15. From November 1<sup>st</sup>&#160;to December 31, 2017, Series B stockholders converted 420.325 shares at a conversion rate of 6666.67:1 resulting in the issuance of 2,802,167 shares of common stock. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series B Preferred Stock conversion price was reset to $0.10 per share.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2018, the Series B stockholders converted all remaining 2,833.55 shares at a conversion rate of 10,000:1 resulting in the issuance of 28,335,500 shares of common stock. As a result, there is no liquidation preference outstanding as of March 31, 2018 related to the Series B Preferred Stock.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>Convertible Series C Preferred Stock:</u>&#160;In October 2016, the Company sold 500 shares of Series C convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $500,000 to a healthcare investment fund under the Series C Preferred Stock Agreement. Each share of Series C Preferred Stock was initially convertible into 2,500 shares of common stock which resulted in an effective conversion price of $0.40 per common share. This resulted in the reduction of the conversion price of the Series B Preferred Stock to $0.40 and a reduction in the exercise price of the Series B warrants to $0.40. On December 29, 2016, as a result of the Series D Preferred Stock Agreement (as discussed below), the conversion price of the Series C Preferred Stock was reset to $0.25. As part of the terms of the Series C Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series C Convertible Preferred Stock are as follows:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Dividends:</u>&#160;Except for stock dividends or other distributions payable in shares of common stock, for which adjustments are to be made to the conversion price, as described below, the stockholder shall be entitled to receive dividends on preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends actually paid on shares of the common stock. No other dividends shall be paid on the preferred stock.</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Conversion:</u>&#160;The preferred stock may be converted at any time, at the option of the holder, into shares of common stock at a conversion price of $0.25 per share (&#8220;Series C Conversion Price&#8221;). The Series C Conversion Price will be adjusted for customary structural changes such as stock splits or stock dividends. In the event that the Company enters into a merger, consolidation or transaction of a similar effect, the Series C stockholder shall be entitled to receive, upon conversion of the preferred stock, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration that would have been received by a holder of the number of shares of common stock into which the preferred stock is convertible immediately prior to such event.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Down-Round Protection:</u>&#160;The Series C Conversion Price is also subject to &#8220;down-round&#8221; anti-dilution adjustment which means that if the Company sells common stock or common stock equivalents at a price below the Series C Conversion Price, the Series C Conversion Price will be reduced to an amount equal to the issuance price of such additional shares of common stock or common stock equivalents.</p>
</td>
</tr>
<tr>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Voting Rights:</u>&#160;Except as required by law, the Series C Preferred Stock does not have voting rights.</p>
</td>
</tr>
<tr>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Most Favored Nation Provision:</u>&#160;If there is a subsequent financing, the Series C stockholder may elect to exchange its Series C Preferred Stock for the security issued on a dollar for dollar basis.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Participation Rights:</u>&#160;For a twelve month period from the date of the financing, the Series C investors will have the right to participate in subsequent financings up to fifty percent of such financing.</p>
</td>
</tr>
<tr>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Liquidation Provision:</u>&#160;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Series C Preferred stockholder receives an amount per share equal to the conversion price of $0.40, subject to down-round adjustment, multiplied by the as-if converted share amount of 1,250,000 common shares. If upon the liquidation, the assets are insufficient to permit payments to the Series C and Series D holders, all assets legally available will be distributed to the Series B Preferred stockholders and then any remaining amount is distributed on a pro rata basis among the Series C and Series D holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</p>
</td>
</tr>
</table>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company also considered the classification of the Series C Preferred Stock Agreement. Because the Most Favored Nation provision is a redemption feature that is outside the control of the Company, the Series C Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company&#8217;s common stock, a beneficial conversion feature of $325,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in October 2016, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During 2017, all remaining Series C Preferred Stock totaling 386 shares has been converted&#160;at a conversion rate of 4000:1 resulting in the issuance of 1,544,000 shares of common stock. As a result, there is no liquidation preference outstanding as of December 31, 2017.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition, as a result of the Series D financing and the adjustment in the conversion price, a beneficial conversion feature of $175,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in January 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>Convertible Series D Preferred Stock:</u>&#160;In January 2017, the Company sold 1,200 shares of Series D convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $1,200,000 to a healthcare investment fund and other private investors under the Series D Preferred Stock Agreement. Each share of Series D Preferred Stock was initially convertible into 4,000 shares of common stock which resulted in an effective conversion price of $0.25 per common share. This resulted in the reduction of the conversion price of the Series B and Series C Preferred Stock to $0.25 and a reduction in the exercise price of the Series B warrants to $0.25. As part of the terms of the Series D Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchasers to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series D Convertible Preferred Stock are identical to those of the Series C Convertible Preferred Stock agreement discussed above with the exception of the initial conversion price which was $0.25 per common share.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company also considered the classification of the Series D Preferred Stock Agreement, the Series D Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet because the Most Favored Nation provision is a redemption feature that is outside the control of the Company.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company&#8217;s common stock, a beneficial conversion feature of $536,000 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in January 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the year ended December 31, 2017, the Series D stockholders converted 1,000 shares at a conversion rate of 4000:1 and a conversion price of $0.25 per share resulting in the issuance of 4,000,000 shares of common stock. Effective with the Series F Preferred Stock Agreement signed on November 1, 2017, the conversion price for the Series D Preferred Stock was reset to $0.15. On December 28, 2017 as a result of entering into a Secured Promissory Note for a convertible loan, the Series D Preferred Stock conversion price was reset to $0.10 per share.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Series D stock has liquidation preference over common stock. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series D Preferred stockholders receive an amount per share equal to the conversion price of $0.10, subject to down-round adjustment, multiplied by the as-if converted share amount of 2,000,000 common shares, totaling $200,000 as of December 31, 2017.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2018, the Series D stockholders converted all remaining 200 shares at a conversion rate of 10,000:1 resulting in the issuance of 2,000,000 shares of common stock. As a result, there is no liquidation preference outstanding as of March 31, 2018 related to the Series D Preferred Stock.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>Convertible Series F Preferred Stock:</u>&#160;In November 2017, the Company sold 2,000 shares of Series F convertible preferred stock with a purchase price of $1,000 per share for gross proceeds of $2,000,000 to a healthcare investment fund under the Series F Preferred Stock Agreement. Each share of Series F Preferred Stock is convertible into 6,666.67 shares of common stock which results in an effective conversion price of $0.15 per common share. This resulted in the reduction of the conversion price of the Series B and D Preferred Stock to $0.15 and a reduction in the exercise price of the Series B warrants to $0.15. On December 28, 2017, as a result of entering into a Secured Promissory Note for a convertible bridge loan, the conversion price of the Series F Preferred Stock was reset to $0.10. As part of the terms of the Series F Preferred Stock Agreement, the Company entered into a Registration Rights Agreement with the purchaser to file a registration statement to register for resale the shares of common stock underlying the preferred shares within 30 days following the closing of the agreement. Each Preferred Stock is convertible into common stock at any time at the election of the investor. The terms of the Series F Convertible Preferred Stock are as follows:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Dividends:</u>&#160;Except for stock dividends or other distributions payable in shares of common stock, for which adjustments are to be made to the conversion price, as described below, the stockholder shall be entitled to receive dividends on preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends actually paid on shares of the common stock. No other dividends shall be paid on the preferred stock.</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Conversion:</u>&#160;The preferred stock may be converted at any time, at the option of the holder, into shares of common stock at a conversion price of $0.10 per share (&#8220;Series F Conversion Price&#8221;). The Series F Conversion Price will be adjusted for customary structural changes such as stock splits or stock dividends. In the event that the Company enters into a merger, consolidation or transaction of a similar effect, the Series F stockholder shall be entitled to receive, upon conversion of the preferred stock, the number of shares of common stock of the successor or acquiring corporation of the Company, if it is the surviving corporation, and any additional consideration that would have been received by a holder of the number of shares of common stock into which the preferred stock is convertible immediately prior to such event.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Down-Round Protection:</u>&#160;The Series F Conversion Price is also subject to &#8220;down-round&#8221; anti-dilution adjustment which means that if the Company sells common stock or common stock equivalents at a price below the Series F Conversion Price, the Series F Conversion Price will be reduced to an amount equal to the issuance price of such additional shares of common stock or common stock equivalents.</p>
</td>
</tr>
<tr>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Voting Rights:</u>&#160;Except as required by law, the Series F Preferred Stock does not have voting rights.</p>
</td>
</tr>
<tr>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Discretionary Redemption Provision:</u>&#160;If there is a subsequent transaction that results in a change in control, the Series F stockholder may require the Company to redeem the shares for the sum of 150% of the aggregate stated valued of the Series F Shares and all liquidated damages. However, if net proceeds from the triggering transaction are less than $6 million then the redemption amount shall equal 50% of the total proceeds of such transaction.</p>
</td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Participation Rights:</u>&#160;For an eighteen month period from the date of the financing, the Series F investors will have the right to participate in subsequent financings up to fifty percent of such financing.</p>
</td>
</tr>
<tr>
<td></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;"><u>Liquidation Provision:</u>&#160;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Series F stockholder has no liquidation preference.</p>
</td>
</tr>
</table>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Subject to certain trigger events occurring, the Series F Preferred stockholders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 130% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top" width="92%">
<p align="justify" style="margin: 0px;">Failure of the Series F Registration Statement to be declared effective by the Securities and Exchange Commission, or the SEC, on or prior to the date that is one hundred and eighty (180) days after the Effectiveness Deadline;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Suspension of the Company&#8217;s common stock from trading for a period of five (5) consecutive trading days;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series F Preferred;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Any default of indebtedness;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Any filing of voluntary or involuntary bankruptcy by the Company;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">A final judgment in excess of $100,000 rendered against the Company;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Breach of representations and warranties in the Stock Purchase Agreement;</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Failure to comply with the Series F Certificate of Designation or Rule 144 requirements; and</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font>&#160;</p>
</td>
<td>
<p align="justify" style="margin: 0px;">A change in control that would result in the holder exercising its put option (discussed in Note 5 below).&#160;</p>
</td>
</tr>
</table>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As certain of these triggering events are considered to be outside the control of the Company, the Series F Preferred Stock is considered to be contingently redeemable convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the date of the financing, because the conversion of the preferred stock was contingent upon certain events, the conversion feature was determined to not be beneficial.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition, on December 28, 2017, as a result of entering into a Secured Promissory Note for a convertible loan which resulted in the adjustment of the conversion price to $0.10, a beneficial conversion feature of $333,333 has been recorded as a discount to the preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual, in December 2017, the Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statement of operations.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2018, the Series F stockholders converted all remaining 2,000 shares at a conversion rate of 10,000:1 resulting in the issuance of 20,000,000 shares of common stock. As such, there was no liquidation preference outstanding related to the Series F preferred stock as of March 31, 2018.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrants</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Warrants vested and outstanding as of March 31, 2018 are summarized as follows:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="hdcell" valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a9a43eac9-beac-4204-899e-5a34d4e82535" valign="bottom" colspan="2"></td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="ac7baf135-5153-4261-a990-06c7c412ce8d" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Amount</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a5265fa22-1e32-409f-b24b-066d20e8f68d" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Exercise</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="ac38763a0-8636-48d2-bf33-67b46e04005d" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Term</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" id="a11bb8f1b-f0a4-40c5-a0d6-73ec1ac865f8" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Issued and</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td style="border-bottom: 1px solid;" valign="bottom">
<p style="margin: 0px;"><b>Source</b></p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="a4374344b-7f37-48c0-8135-8d62c6ff387b" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>Price</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="a04ce2b39-361b-478e-a68c-e779726d2764" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>(Years)</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="a9031f512-366c-4812-8062-7d006a2d7a57" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>Outstanding</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ffcell" valign="bottom" width="9%" colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ada8f1772-aef0-4af5-be8b-d940fad0f67e" valign="bottom" width="9%" colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a0e192acd-4ea4-4c24-bca5-38f531140503" valign="bottom" width="9%" colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Pre 2015 Common Stock Warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a07b03888-06f2-4599-9ca6-000f506ff8ce" valign="bottom" width="9%">1.00</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">6-10</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ad3de4d37-5d51-49e9-b56d-247ac12e772b" valign="bottom" width="9%">4,000,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">2015 Common Stock Warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">1.15-$5.00</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">5-10</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ae8924189-b112-49d1-bcf6-89ccca214691" valign="bottom" width="9%">442,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">2015 Series B Financing (see Note 6)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a459055d6-694c-488c-beb4-ffa0dce5dd6a" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a66ab6e86-f247-4ada-9c5f-fd21450f2d82" valign="bottom" width="9%" colspan="2">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ab4d117ed-50e0-4f73-8611-da06c45d8035" valign="bottom" width="9%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px 0px 0px 11.25pt;">Common Stock Warrants to Series B Stockholders</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a9f69071a-aa8c-4538-9e62-aa8a4b146a0a" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a9e37f238-0476-40cd-9bca-ce6c765d4e58" valign="bottom" width="9%">5</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a0099a10f-3489-4386-b548-2a5518978f9c" valign="bottom" width="9%">1,843,750</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px 0px 0px 11.25pt;">Placement Agent Warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="aa8cbceb0-4408-4bd7-aeb6-bc94e0774be2" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a9903c0de-ed16-46f9-bb92-942b73491ded" valign="bottom" width="9%">5</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="aba19c2f4-bb66-4554-8849-6a6f8ba98383" valign="bottom" width="9%">187,500</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">2016 Common Stock Warrants to Service Providers</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a15810522-8ba1-42fc-adaf-30ad8aac3c8e" valign="bottom" width="9%">1.15</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a23c16c99-74c3-45bd-9135-a2af7481af01" valign="bottom" width="9%">10</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="acdf5abc0-f070-49b0-bd00-f475996c76a2" valign="bottom" width="9%">40,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">2016 Series C Placement Agent Warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a4377163f-7937-4bb6-b9c5-03daaefd56e6" valign="bottom" width="9%">0.40</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ad56722d6-8a83-4964-8b71-253f59d666de" valign="bottom" width="9%">5</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a013e1b31-24dd-4847-acbb-fb164a047b59" valign="bottom" width="9%">125,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">2017 Series D Placement Agent Warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="ac7498af7-8e5d-4d84-b582-a717f3906957" valign="bottom" width="9%">0.25</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="acd8fd4ab-d53e-4d4e-bab9-4071b52f4205" valign="bottom" width="9%">5</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a79b0a49c-3edd-4642-b6eb-def1543aa137" valign="bottom" width="9%">480,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">2017 Common Stock Warrants to Service Provider</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a4ce0c91c-c69f-4748-acc4-7c339818d0aa" valign="bottom" width="9%">0.41</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a1367fd42-0445-4468-a318-71bde2152b83" valign="bottom" width="9%">5</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" style="border-bottom: 1px solid;" id="a2c8ddbb7-a2cb-471f-a535-96c271ea66dd" valign="bottom" width="9%">125,000</td>
<td style="padding-bottom: 1px;" valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p style="margin: 0px;">2018 Emerald Financing Warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="a1766b6b4-dbaa-40fb-9417-6156d0c6e6ed" valign="bottom" width="9%">0.10</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a19c6c1e1-79a6-4336-a2ee-6de6f288a15b" valign="bottom" width="9%">5</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a4df986b0-a65f-43a5-be56-c42a3bb5666a" valign="bottom" width="9%">44,200,000</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td>
<p align="justify" style="margin: 0px 0px 0px 11.25pt;"><b>Total warrants vested and outstanding as of March 31, 2018</b></p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 3px double;">
<p style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: black 3px double;"><b>51,443,250</b></td>
<td>
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>2017 Warrants</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the Company issued 480,000 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series D Preferred Stock financing. The warrants vest immediately and have an exercise price of $0.25 per share with a term of five years. The Company estimated the value of the warrants to be $115,200 utilizing the Black-Scholes option pricing model and recorded this amount to issuance costs.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2017, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 125,000 shares of common stock with an exercise price of $0.41 per share with a term of five years. The Company estimated the warrant value to be $30,000 utilizing the Black-Scholes option pricing model and recorded this amount to general and administrative expense for the&#160;year due to the immediate vesting.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>2018 Warrants</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock to Emerald Health Sciences and an accredited investor in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&#160;<i>Distinguishing Liabilities from Equity</i>, and concluded that the Emerald warrants should be classified as a liability. See additional discussion in Note 6 below.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px;"><font style="font-family: times new roman,times;" size="2"><b><i>Stock Option Plan: 2014 Omnibus Incentive Plan</i></b></font></p>
<div>&#160;</div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants. As of March 31, 2018, options (net of canceled or expired options) covering an aggregate of 1,030,000 shares of the Company&#8217;s common stock had been granted under the 2014 Plan, and the Company had 1,030,000 options outstanding and 970,000 shares available for future grants under the 2014 Plan.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&#8217;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,030,000 shares net of cancellations and expirations through March 31, 2018 under the 2014 Plan.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of activity under the 2014 Plan as of March 31, 2018:</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Shares</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="10">
<p align="center" style="margin: 0px;"><b>Options Outstanding</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Available</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Weighted</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>for Grant of</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom" colspan="2"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td></td>
<td colspan="2">
<p align="center" style="margin: 0px;"><b>Average</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Options &amp;</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Number of</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Price per</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>Exercise</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>Shares</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>Shares</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>Share</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>Price</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td></td>
<td></td>
<td colspan="2"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td colspan="2"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;"><b>Balance at December 31, 2017</b></p>
</td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">870,000</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">1,130,000</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td>
<p align="right" style="margin: 0px;">0.42-3.00</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.60</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Options granted</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Options exercised</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">-</p>
</td>
<td valign="bottom" width="1%"></td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Options cancelled</p>
</td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 1px solid;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">100,000</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 1px solid;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">(100,000</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">)</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td>
<p align="right" style="margin: 0px;">0.42-$3.00</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">2.57</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;"><b>Balance at March 31, 2018</b></p>
</td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">970,000</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">1,030,000</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td>
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td>
<p align="right" style="margin: 0px;">0.42-$3.00</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.42</p>
</td>
<td valign="bottom" width="1%"></td>
</tr>
<tr bgcolor="#ffffff">
<td></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Vested and Exercisable at March 31, 2018</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="9%"></td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%"></td>
<td style="border-bottom: 3px double;" valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 3px double;" valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">668,000</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.42</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.42</p>
</td>
<td valign="bottom" width="1%"></td>
</tr>
</table>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The weighted-average remaining contractual term of options vested and exercisable at March 31, 2018 was approximately 6.62 years.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the three months ended March 31, 2018, the Company had cancellations of vested stock options totaling 100,000 options. Stock compensation expense for the three months ended March 31, 2018 and 2017 was $41,005 and $86,544, respectively, and was recorded to general and administrative expense.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#8217;s stock exceeded the exercise price of the stock options at March 31, 2018 for those stock options for which the quoted market price was in excess of the exercise price (&#8220;in-the-money options&#8221;). As of March 31, 2018, the aggregate intrinsic value of options outstanding was $0. As of March 31, 2018, 668,000 options to purchase shares of common stock were exercisable.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The total amount of unrecognized compensation cost related to non-vested stock options was $349,013 as of March 31, 2018. This amount will be recognized over a weighted average period of 1.42 years.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Restricted Stock Awards</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Restricted stock awards (&#8220;RSAs&#8221;) are granted to our Board of Directors and members of senior management and are issued pursuant to the Company&#8217;s 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company&#8217;s senior management and Board of Directors with a fair market value of approximately $900,000. These RSAs vest from one to three years from the grant date as services are rendered to the Company.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On January 18, 2018, the Company entered into Restricted Stock Agreements with each of Dr. Murphy, Elizabeth Berecz, CFO, and Cosmas N. Lykos, the Company&#8217;s Founder granting 900,000, 700,000, and 900,000 shares of restricted common stock, respectively, with a fair market value of $475,000. These agreements were issued outside of the 2014 Omnibus Incentive Plan. The restricted stock vests in equal 50% installments on the first and second anniversaries of the grant date, subject to continued employment with Nemus through the applicable vesting date. Each Restricted Stock Agreement provides that if an executive&#8217;s employment or service is terminated by the Company without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the separation along with accelerated vesting of all outstanding stock awards.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 3 above, Mr. Lykos&#8217; unrestricted stock awards amounting to 1,225,000 shares became immediately vested resulting in the recording of compensation expense of $117,958 which represents the fair market value of those shares as of the separation date.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the three months ended March 31, 2018 and 2017, the Company recorded $188,604 and $65,625 during each period, in stock-based compensation expense related to these restricted stock awards. The total amount of unrecognized compensation cost related to non-vested RSAs was $384,396 as of March 31, 2018.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock-Based Compensation Expense</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statements of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the three months ended March 31, 2018 and 2017, the Company recognized stock-based compensation expense of $229,609 and $152,169 (including compensation expense for RSAs discussed above) which was recorded as a general and administrative expense in the consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762873904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions for Conversion of Preferred Stock and Put Option Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStockAbstract', window );"><strong>Provision For Conversion Of Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Provisions for Conversion of Preferred Stock and Put Option Liability</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>5. Provisions for Conversion of Preferred Stock and Put Option&#160;<b>Liability</b></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Series B Preferred Stock Conversion Liability</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of August 20, 2015, in connection with the Series B Preferred Stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company would affect another sale or issuance of common stock, stock options or convertible securities with a price per share below $0.80. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&#160;<i>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</i>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $75,488 and was booked as a current liability as of September 30, 2015. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December 31, 2017, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative was classified as a current liability and was adjusted to $6,715 as of December 31, 2017. The change in fair market value was recorded as non-operating income of $102,848 for the year ended December 31, 2017.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the three months ended March 31, 2018, all remaining Series B Preferred Stock was converted to common stock by their shareholders and as a result, the Series B conversion liability was reduced to zero as of March 31, 2018. The reduction of this liability totaling $6,715 was recorded as non-operating income for the three months ended March 31, 2018.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;"><b><i>Series F Preferred Stock Put Option Liability</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of November 1, 2017, in connection with the Series F Preferred Stock financing, the Company recorded a put option liability related to discretionary redemption provided to the stockholders in the event that the Company would undergo a subsequent financing that would result in a change in control. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&#160;<i>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</i>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $103,364 and was booked as a current liability as of November 1, 2017. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December 31, 2017, the Company engaged a third-party valuation specialist to re-measure the conversion liability to fair market value as of that date utilizing the same methodology previously performed. The derivative was classified as a current liability and was&#160;considered de minimis&#160;as of December 31, 2017. The change in fair market value was recorded as non-operating income of $103,364 for the year ended December 31, 2017. In March 2018, the Series F Preferred shareholder converted their shares to common stock and as a result, the Company did not record a put option liability as of March 31, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762910032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrant and Emerald Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract', window );"><strong>Series B Warrant And Emerald Warrant Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsTextBlock', window );">Series B Warrant and Emerald Warrant Liabilities</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>6. Series B Warrant and Emerald Warrant Liabilities</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Series B Warrant Liability</i></b><b><i></i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 common stock warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were initially valued at $2,935,800 utilizing the Black-Scholes pricing model. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also have a &#8220;down-round&#8221; protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The exercise price is automatically adjusted down to the price of the instrument being issued. In October 2016, as a result of the Series C Preferred Stock financing, the exercise price was adjusted to $0.40 and in December 2016, as a result of the Series D Preferred Stock financing, the exercise price was adjusted to $0.25. In November 2017, as a result of the Series F Preferred Stock financing, the exercise price was adjusted to $0.15 and on December 28, 2017, the exercise price was adjusted to $0.10 after the company entered into a Secured Promissory Note for a convertible loan. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&#160;<i>Distinguishing Liabilities from Equity</i>, and concluded that the Series B warrants should be classified as a liability. The Company then applied the fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the preferred stock. The Company also performed the same valuation as of December 31, 2017 utilizing the Black-Scholes pricing model. This resulted in a warrant value of $551,322 as of December 31, 2017. The change in fair market value at the re-measurement date was recorded as non-operating income totaling $560,986 for the year ended December 31, 2017.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2018, Series B warrant holders exercised 987,000 warrants at an exercise price of $0.10 resulting in cash proceeds to the Company of $98,700. On January 19, 2018 as a result of the Emerald Financing, the Series B warrant exercise price was reset to $0.00. The strike price for these warrants is now permanently reset. Subsequent to this date, Series B warrant holders exercised 3,419,250 warrants resulting in the issuance of 3,419,250 shares of common stock with no consideration. The intrinsic value of the warrant exercises for the three months ended March 31, 2018 was $1,125,291. At each of the exercise dates, the Company marked the warrants to fair market value which was determined by a Black Scholes computation which considered the closing trading price on the exercise dates. As of March 31, 2018, the fair market value of the remaining Series B warrants was also determined via a Black Scholes computation. As such, the Company recorded a liability of $483,438 and the change in fair market value for these warrants along with the warrant exercises totaling $1,223,991 was recorded as non-operating expense during the three months ended March 31, 2018. As the remaining warrant holders still held certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants were still considered to require liability classification. The assumptions utilized for the Black Scholes computations are outlined below:</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="6">
<p align="center" style="margin: 0px;"><b>As of Period End</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>&#160;March 31,</b></p>
<p align="center" style="margin: 0px;"><b>2018</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>December 31,</b></p>
<p align="center" style="margin: 0px;"><b>2017</b></p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.00</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.00</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Volatility factor</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">70.00</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%&#160;</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">70.00</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">1.95</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%&#160;</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">1.947-1.949</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Expected term (years)</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">2.25</p>
</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">2.64-2.65</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Weighted-average fair value of warrants</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">0.238</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">0.086</p>
</td>
<td valign="bottom"></td>
</tr>
</table>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<div>
<p align="justify" style="margin: 0px;"><b><i>Emerald Warrant Liabilities</i></b></p>
<p align="justify" style="margin: 0px;">&#160;</p>
<u style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Warrant liability</u></div>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years. The warrants are exercisable in cash or through a cashless exercise provision. The warrants also have an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10 per each warrant. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrant holder has the right to participate in subsequent financing transactions on an as-if converted basis. The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&#160;<i>Distinguishing Liabilities from Equity</i>, and concluded that the Emerald warrants should be classified as a liability and re-measured to fair market value at the end of each reporting period. With the assistance of a third-party valuation specialist, the Company valued the warrant liability utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurement</i>s, as of the closing dates of the financings and as of March 31, 2018.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of January 18, 2018 and February 16, 2018, in connection with the Emerald Financing, the Company recorded a warrant liability related to a discretionary redemption provided to the warrant holders in the event that the Company would undergo a subsequent financing that would result in a change in control. With the assistance of a third-party valuation specialist, the Company valued the warrant liability pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurement</i>s, as of the closing date of the financing. The Company also performed a review of the warrant liability in conjunction with ASC 815,&#160;<i>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</i>, and determined that the warrant liability does not requires bifurcation. As of March 31, 2018, the derivative was classified as a current warrant liability valued at $138,630. Because the amount of proceeds related to this financing exceeded the value assigned to the related Emerald warrant liability, the full amount of the&#160;warrant liability was&#160;charged to&#160;non-operating expense and included as part of the fair value in excess of proceeds adjustment discussed below.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><u>Fair Value Computations</u></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The estimated fair value of the warrants issued on January 19, 2018 (the January Closing Date) and at March 31, 2018 was $4,654,922 and $3,671,089, respectively. The estimated fair value of the warrants issued on February 16, 2018 (the February Closing Date) and at March 31, 2018 was $5,631,051 and $4,296,315, respectively. The change in fair market value from the closing dates to March 31, 2018 amounted to $2,318,569 and was recorded as non-operating income for the three-month period then ended.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Given that the fair value of the derivative warrants issued on the January Closing Date exceeded the total proceeds of the private placement of $1,500,000, as of that date, no net amounts above par value were allocated to common stock. The $3,154,922 amount by which the recorded liabilities exceeded the proceeds was charged to non-operating expense at the January Closing Date. Given that the fair value of the derivative warrants issued on the February Closing Date exceeded the total proceeds of the private placement of $1,750,000, as of that date, no net amounts above par value were allocated to commons stock. The $3,881,051 amount by which the recorded liabilities exceeded the proceeds was charged to non-operating expense at the February Closing Date. In addition, given that there were no amounts allocated to common stock related to these two closings, issuance costs totaling $137,191 were also charged to non-operating expense at the closing dates.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The derivative liabilities were valued based on Monte Carlo simulations conducted at the closing dates of the January and February closings and at March 31, 2018 using the following assumptions:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="hdcell" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>March 31,</b></p>
<p align="center" style="margin: 0px;"><b>2018</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom: 1px solid;" id="a65e697b8-51d9-430d-9203-7ab6cb8a824e" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>On</b></p>
<p align="center" style="margin: 0px;"><b>issuance</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="ffcell" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a6910fc5f-181b-437b-aa96-491bf8b0607b" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Volatility factor</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a9755e991-b358-482e-a6f4-5b3b5524bcf9" valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a38e83f6f-9636-4731-ae8d-9af83b620f89" valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">2.54-2.55</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">%</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">2.45-2.6</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Expected term (years)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">4.8-4.88</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" id="a12a52cd1-8040-4b6a-b5cb-6efc9c22ab2c" valign="bottom" width="9%">5.0</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Closing price per share of common stock</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" id="ac1e5190b-1296-46ae-ba68-df37ca92d069" valign="bottom" width="9%">
<p align="right" style="margin: 0px;">0.24</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">0.29-0.30</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for series B warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762986832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Bridge Loan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConvertibleBridgeLoanAbstract', window );"><strong>Convertible Bridge Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Convertible Bridge Loan</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>7. Convertible Bridge Loan</b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December 28, 2017, the Company entered into a Secured Promissory Note and Security Agreement for a convertible loan with Emerald. The bridge loan provides for aggregate gross proceeds to Nemus of up to $900,000 and is secured by all of Nemus&#8217; assets. Nemus received proceeds of $500,000 on December 28, 2017 and on January 19, 2018, the Company received the remaining $400,000 in funding as it had satisfied the conditions of the funding. These conditions required receipt of conversion notices from all the existing Series B shareholders to convert their preferred shares to common stock. Such conversions occurred in January and February of 2018. Also, on January 19, 2018, in conjunction with the Emerald Securities Purchase Agreement, the bridge loan was converted at $0.10 per share to common stock resulting in the issuance of 9,000,000 additional shares.</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the convertible bridge loan financing, the Company recorded a liability related to the conversion option of the bridge loan into the Company&#8217;s common stock due to a down-round protection feature present in the loan agreement. The Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<i>Fair Value Measurement</i>s, as of the closing date of the financing utilizing the Black Scholes valuation methodology and the assumptions discussed in Note 6 above. This resulted in a conversion liability value of $265,000 as of the financing close date which was one trading day prior to December 31, 2017. The second funding in January 2018&#160;resulted in an additional conversion liability which was $360,000. The Company recorded amortization of this debt discount of $34,608 to non-operating expense prior to the conversion of the debt. In addition, the Company then marked to market the conversion liabilities&#160;to $810,000&#160;utilizing the assumptions discussed above and recorded a&#160;change in fair value&#160;on conversion right of $185,000 as a non-operating expense. At the time of the conversion, the Company extinguished the debt and the associated conversion liability and issued the common stock at fair market value resulting in a loss on extinguishment of $590,392 which was recorded as a non-operating expense for the three months ended March 31, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConvertibleBridgeLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents convertible bridge loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConvertibleBridgeLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762981984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>8. Income Taxes</b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Under the FASB's accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a fifty (50) % likelihood of being sustained. Additionally, the guidance provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p>
<p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at March 31, 2018. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying consolidated statement of operations to offset pre-tax losses.</p>
<p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has no material uncertain tax positions as of March 31, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764701168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>9. Subsequent Events</b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Separation of Chief Financial Officer</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 30, 2018, the Company entered into a separation agreement and release (the &#8220;Separation Agreement&#8221;) with Elizabeth Berecz, the Company&#8217;s current Chief Financial Officer. Ms. Berecz&#8217;s separation will be effective May 25, 2018 (the &#8220;Separation Date&#8221;), and she will remain the Company&#8217;s principal financial officer until the Separation Date.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pursuant to the Separation Agreement, Ms. Berecz has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Ms. Berecz compensation and benefits as follows: (i) through the Separation Date, an annualized base salary at the rate in effect for her as of the date of the Separation Agreement; (ii) a lump sum gross payment of $145,833, in consideration for the restrictive covenants contained in the Separation Agreement; (iii) reimbursement for payments made by Ms. Berecz for COBRA coverage for a period of six (6) months following the Separation Date; and (iv) Ms. Berecz&#8217;s unrestricted stock awards amounting to 1,050,000 shares and unvested stock options totaling 100,000 shares became immediately vested.</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Appointment of New Chief Financial Officer</i></b></p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 5, 2018, the Company agreed to an offer letter with Doug Cesario, pursuant to which Mr. Cesario joined the Company on April 23, 2018 and will be appointed as Chief Financial Officer of the Company effective May 26, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758356944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Use of Estimates</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense and equity securities with embedded features as discussed below.&#160;</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Liquidity and Going Concern</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has incurred operating losses and negative cash flows from operations since our inception. As of March 31, 2018, we had cash and cash equivalents of $2,945,312. The Company anticipates that it will continue to incur net losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements were issued. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s continued existence is dependent on its ability to raise additional sufficient funding to cover operating expenses and to invest in operations and development activities. The Company plans to continue to pursue funding through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs or cease operations.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Cash and Cash Equivalents</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Restricted Cash</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A deposit of $4,428 as of both March 31, 2018 and December 31, 2017 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&#8217;s credit cards.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Fair Value Measurements</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</p><p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr><td valign="top" width="4%"></td><td valign="top" width="6%"><p align="justify" style="margin: 0px;">Level 1:</p></td><td valign="top"><p align="justify" style="margin: 0px;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr><tr><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr><td valign="top"></td><td valign="top"><p align="justify" style="margin: 0px;">Level 2:</p></td><td valign="top"><p align="justify" style="margin: 0px;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr><tr><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr><tr><td valign="top"></td><td valign="top"><p align="justify" style="margin: 0px;">Level 3:</p></td><td valign="top"><p align="justify" style="margin: 0px;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. The warrant liability for the Emerald warrants and the associated put option were valued utilizing Level 3 inputs primarily from a third party independent appraisal conducted as of March 31, 2018.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Property and Equipment, Net</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of March 31, 2018 and December 31, 2017, property and equipment, net, was $2,134 and $1,407 respectively, consisting primarily of computers and equipment. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Income Taxes</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the &#8220;NOLs&#8221;) and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#8217;s statement of operations in the period incurred.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result, there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Convertible Instruments</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We account for hybrid contracts that feature conversion options in accordance with generally accepted accounting principles in the United States. ASC 815,&#160;<i>Derivatives and Hedging Activities</i>&#160;(&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We account for convertible instruments when we have determined that the embedded conversion options should not be bifurcated from their host instruments, in accordance with ASC 470-20,&#160;<i>Debt with Conversion and Other Options</i>&#160;(&#8220;ASC 470-20&#8221;). Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. We account for convertible instruments (when we have determined that the embedded conversion options should be bifurcated from their host instruments) in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.</p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We also follow ASC 480-10,&#160;<i>Distinguishing Liabilities from Equity</i>&#160;(&#8220;ASC 480-10&#8221;) in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as
 a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives, and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in interest expense in the accompanying Consolidated Statements of Operations.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock', window );">Warrants Issued in Connection with Financings</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Warrants Issued in Connection with Financings</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and record changes in fair value in other (income) expense in the Consolidated Statements of Operations.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Revenue Recognition</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has not begun planned principal operations and has not generated any revenue since inception.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Research and Development Expenses</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation Expenses</a></td>
<td class="text"><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock-Based Compensation Expenses</i></b></p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</p>
<p style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="4%"></td>
<td valign="top" width="4%">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Volatility - We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the period in which the awards were granted.</p>
</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td valign="top">
<p align="justify" style="margin: 0px;"><font style="font-family: symbol;">&#183;</font></p>
</td>
<td valign="top">
<p align="justify" style="margin: 0px;">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends.</p>
</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock', window );">Stock-Based Compensation for Non-Employees</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Stock-Based Compensation for Non-Employees</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for warrants and options issued to non-employees under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) No. 505-50,&#160;<i>Equity - Equity Based Payments to Non-Employees,</i>&#160;using the Black-Scholes option-pricing model. The value of such non-employee awards is periodically re-measured over the vesting terms and at each quarter end.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Segment Information</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">FASB ASC No. 280,&#160;<i>Segment Reporting</i>, establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (&#8220;CODM&#8221;), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Comprehensive Income (Loss)</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), net of their related tax effect, arrived at a comprehensive income (loss). For the three months ended March 31, 2018 and 2017, the comprehensive income (loss) was equal to the net income (loss).</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Earnings per share</i></b></p><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company applies FASB ASC No. 260,&#160;<i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted earnings or loss per share would include the dilutive effect of outstanding warrants and awards granted to employees under stock-based compensation plans. Potentially dilutive shares of the Company&#8217;s common stock are excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive for the periods presented. For the three months ended March 31, 2018, warrants to purchase 51,443,250 common shares and stock options exercisable for 1,030,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share. For the three months ended March 31, 2017, 3,625.375 shares of Series B Preferred Stock convertible into 14,501,500 common shares at $0.25 per share, 706 shares of Series D Preferred Stock convertible into 2,824,000 common shares at $0.25 per share, warrants to purchase 11,649,500 common shares and stock options exercisable for 1,130,000 common shares outstanding at the end of the period are excluded from the calculation of diluted loss per common share.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div><div style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Recent accounting pronouncements</i></b></div><p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><div align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2017, the FASB issued ASU 2017-11,<i>&#160;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating<i>&#160;Topic 480, Distinguishing Liabilities from Equity</i>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for stock based compensation for Non Employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued in Connection with Financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659400176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants vested and outstanding</a></td>
<td class="text"><table style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; width: 100%; font: 10pt 'times new roman'; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center"  valign="bottom" colspan="2"></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center"  valign="bottom" colspan="2"></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center"  valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Amount</b></p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td></tr><tr><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center"  valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Exercise</b></p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center"  valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Term</b></p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center"  valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Issued and</b></p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td></tr><tr><td style="border-bottom: 1px solid;" valign="bottom"><p style="margin: 0px;"><b>Source</b></p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>Price</b></p></td><td style="padding-bottom: 1px;" valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>(Years)</b></p></td><td style="padding-bottom: 1px;" valign="bottom"><p style="margin: 0px;">&#160;</p></td><td valign="bottom"><p style="margin: 0px;">&#160;</p></td><td align="center" style="border-bottom: 1px solid;"  valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>Outstanding</b></p></td><td style="padding-bottom: 1px;" valign="bottom"><p style="margin: 0px;">&#160;</p></td></tr><tr><td><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%" colspan="2"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%" colspan="2"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%" colspan="2"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;">Pre 2015 Common Stock Warrants</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">1.00</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td colspan="2"><p align="right" style="margin: 0px;">6-10</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">4,000,000</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p align="justify" style="margin: 0px;">2015 Common Stock Warrants</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td>$</td><td><p align="right" style="margin: 0px;">1.15-$5.00</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td colspan="2"><p align="right" style="margin: 0px;">5-10</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">442,000</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;">2015 Series B Financing (see Note 6)</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%" colspan="2"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p align="justify" style="margin: 0px 0px 0px 11.25pt;">Common Stock Warrants to Series B Stockholders</p></td><td valign="bottom" width="1%"><p
 style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">0.00</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">5</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">1,843,750</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px 0px 0px 11.25pt;">Placement Agent Warrants</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">0.00</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">5</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">187,500</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p align="justify" style="margin: 0px;">2016 Common Stock Warrants to Service Providers</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">1.15</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">10</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">40,000</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;">2016 Series C Placement Agent Warrants</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">0.40</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">5</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">125,000</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p align="justify" style="margin: 0px;">2017 Series D Placement Agent Warrants</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">0.25</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">5</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">480,000</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;">2017 Common Stock Warrants to Service Provider</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">0.41</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">5</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right" style="border-bottom: 1px solid;"  valign="bottom" width="9%">125,000</td><td style="padding-bottom: 1px;" valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p style="margin: 0px;">2018 Emerald Financing Warrants</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%">$</td><td align="right"  valign="bottom" width="9%">0.10</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom" width="9%">5</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td><td align="right"  valign="bottom"
 width="9%">44,200,000</td><td valign="bottom" width="1%"><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td><p align="justify" style="margin: 0px 0px 0px 11.25pt;"><b>Total warrants vested and outstanding as of March 31, 2018</b></p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td><p style="margin: 0px;">&#160;</p></td><td style="border-bottom: black 3px double;"><p style="margin: 0px;">&#160;</p></td><td style="border-bottom: black 3px double;"><b>51,443,250</b></td><td><p style="margin: 0px;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Shares</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" colspan="10"><p align="center" style="margin: 0px;"><b>Options Outstanding</b></p></td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Available</b></p></td><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Weighted</b></p></td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>for Grant of</b></p></td><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"></td><td valign="bottom"></td><td valign="bottom" colspan="2"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td></td><td colspan="2"><p align="center" style="margin: 0px;"><b>Average</b></p></td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Options &amp;</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Number of</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Price per</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" colspan="2"><p align="center" style="margin: 0px;"><b>Exercise</b></p></td><td valign="bottom"></td></tr><tr><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>Shares</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>Shares</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>Share</b></p></td><td valign="bottom"></td><td valign="bottom"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="9%" colspan="2"><p align="center" style="margin: 0px;"><b>Price</b></p></td><td valign="bottom"></td></tr><tr><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td><p align="justify" style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;"><b>Balance at December 31, 2017</b></p></td><td valign="bottom" width="1%"></td><td style="border-bottom: 3px double;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 3px double;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">870,000</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="border-bottom: 3px double;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 3px double;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">1,130,000</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td><p align="right" style="margin: 0px;">0.42-3.00</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">0.60</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#ffffff"><td valign="top"><p align="justify" style="margin: 0px;">Options granted</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;">Options exercised</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="9%"><p align="right" style="margin:
 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">-</p></td><td valign="bottom" width="1%"></td></tr><tr bgcolor="#ffffff"><td valign="top"><p align="justify" style="margin: 0px;">Options cancelled</p></td><td valign="bottom" width="1%"></td><td style="border-bottom: 1px solid;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">100,000</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="border-bottom: 1px solid;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 1px solid;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">(100,000</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">)</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td><p align="right" style="margin: 0px;">0.42-$3.00</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">2.57</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;"><b>Balance at March 31, 2018</b></p></td><td valign="bottom" width="1%"></td><td style="border-bottom: 3px double;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 3px double;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">970,000</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="border-bottom: 3px double;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 3px double;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">1,030,000</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td><p align="right" style="margin: 0px;">0.42-$3.00</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">0.42</p></td><td valign="bottom" width="1%"></td></tr><tr bgcolor="#ffffff"><td></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="9%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="9%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="9%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="9%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td></tr><tr bgcolor="#cceeff"><td valign="top"><p align="justify" style="margin: 0px;">Vested and Exercisable at March 31, 2018</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="9%"></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"></td><td style="border-bottom: 3px double;" valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td style="border-bottom: 3px double;" valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">668,000</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">0.42</p></td><td valign="bottom" width="1%"></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px;">&#160;</p></td><td valign="bottom" width="1%"><p align="justify" style="margin: 0px 0px 0px 0in;">$</p></td><td valign="bottom" width="9%"><p align="right" style="margin: 0px 0px 0px 0in;">0.42</p></td><td valign="bottom" width="1%"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6705964272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrant and Emerald Warrant Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract', window );"><strong>Series B Warrant And Emerald Warrant Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Series B Warrants</a></td>
<td class="text"><table style="text-align: justify; width: 100%; font: 10pt 'times new roman'; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="6">
<p align="center" style="margin: 0px;"><b>As of Period End</b></p>
</td>
<td valign="bottom"></td>
</tr>
<tr>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>&#160;March 31,</b></p>
<p align="center" style="margin: 0px;"><b>2018</b></p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="border-bottom: 1px solid;" valign="bottom" colspan="2">
<p align="center" style="margin: 0px;"><b>December 31,</b></p>
<p align="center" style="margin: 0px;"><b>2017</b></p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.00</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
<td valign="bottom" width="1%"></td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="9%">
<p align="right" style="margin: 0px 0px 0px 0in;">0.00</p>
</td>
<td valign="bottom" width="1%">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Volatility factor</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">70.00</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%&#160;</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">70.00</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">1.95</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%&#160;</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">1.947-1.949</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Expected term (years)</p>
</td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">2.25</p>
</td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">2.64-2.65</p>
</td>
<td valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="top">
<p align="justify" style="margin: 0px;">Weighted-average fair value of warrants</p>
</td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">0.238</p>
</td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom"></td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom">
<p align="justify" style="margin: 0px;">&#160;</p>
</td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom">
<p align="justify" style="margin: 0px 0px 0px 0in;">$</p>
</td>
<td style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" valign="bottom">
<p align="right" style="margin: 0px 0px 0px 0in;">0.086</p>
</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock', window );">Schedule of derivative liabilities based on Monte Carlo simulations</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>March 31,</b></p>
<p align="center" style="margin: 0px;"><b>2018</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2">
<p align="center" style="margin: 0px;"><b>On</b></p>
<p align="center" style="margin: 0px;"><b>issuance</b></p>
</td>
<td style="padding-bottom: 1px;" valign="bottom">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Dividend yield</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">0.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Volatility factor</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">70.00</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Risk-free interest rate</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">2.54-2.55</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">%</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">2.45-2.6</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">%</p>
</td>
</tr>
<tr bgcolor="#ffffff">
<td valign="top">
<p align="justify" style="margin: 0px;">Expected term (years)</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td colspan="2">
<p align="right" style="margin: 0px;">4.8-4.88</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td align="right" valign="bottom" width="9%">5.0</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p align="justify" style="margin: 0px;">Closing price per share of common stock</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td align="right" valign="bottom" width="9%">
<p align="right" style="margin: 0px;">0.24</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td valign="bottom" width="1%">
<p style="margin: 0px;">&#160;</p>
</td>
<td>$</td>
<td>
<p align="right" style="margin: 0px;">0.29-0.30</p>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantAndEmeraldWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all information related to the key inputs and assumptions (including, at a minimum, but not limited to, and if applicable, quantitative information about discount rates, expected prepayments including the expected weighted-average life of prepayable financial assets, and anticipated credit losses) used in measuring the fair value of assets or liabilities that relate to the transferor's continuing involvement with transferred financial assets, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=d3e107314-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773171664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2015 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="nump">$ 2,945,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash | $</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net | $</a></td>
<td class="nump">$ 2,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, plant and equipment, depreciation methods</a></td>
<td class="text">straight-line method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">51,443,250<span></span>
</td>
<td class="nump">11,649,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">1,030,000<span></span>
</td>
<td class="nump">1,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Number of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625.375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock shares convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Number of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock shares convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771933296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>University of Mississippi Agreements (Detail Textuals) - University of Mississippi<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 10, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 14, 2015 </div>
<div>USD ($) </div>
<div>License_agreement</div>
</th>
<th class="th">
<div>Oct. 15, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2014 </div>
<div>USD ($) </div>
<div>License_agreement</div>
</th>
<th class="th"><div>Jul. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_OptionAgreementMember', window );">UM 5050 pro-drug agreements | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfLicenseAgreements', window );">Number of license agreements | License_agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_OptionAgreementMember', window );">UM 5050 pro-drug agreements | Intellectual Property | October 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OneTimeUpfrontPayment', window );">One time up front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_LicenseAgreementMember', window );">UM 8930 analogue agreements | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfLicenseAgreements', window );">Number of license agreements | License_agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_LicenseAgreementMember', window );">UM 8930 analogue agreements | Intellectual Property | December 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OneTimeUpfrontPayment', window );">One time up front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_Um5070LicenseAgreementMember', window );">UM 5070 license agreement | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AggregateMilestonePaymentsIfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AggregateMilestonePaymentsIfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AnnualFeesForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual fees for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AnnualFeesForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OneTimeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of one-time upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OneTimeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_OctoberTwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_OctoberTwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_December2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_December2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_Um5070LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_Um5070LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775418752">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 12, 2017</div></th>
<th class="th"><div>May 03, 2017</div></th>
<th class="th"><div>Apr. 01, 2017</div></th>
<th class="th"><div>Feb. 05, 2016</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,128<span></span>
</td>
<td class="nump">$ 7,559<span></span>
</td>
<td class="nump">$ 9,267<span></span>
</td>
<td class="nump">$ 4,311<span></span>
</td>
<td class="nump">$ 56,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expenses per month</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireFurnitureAndFixtures', window );">Value of furniture lease payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Aggregate gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,131,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized additional stock based compensation expense of restricted stock and option awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,604<span></span>
</td>
<td class="nump">65,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Aggregate gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GuarantorFailedToPay', window );">Guarantor failed to pay within 90 days of notice of purchaser</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_LetterAgreementMember', window );">Letter agreement ("Agreement") | Contract manufacturing organization ("CMO")</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AnalyticalMethodDevelopmentAndQualificationExpense', window );">Estimated analytical method development and qualification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_LetterAgreementMember', window );">Letter agreement ("Agreement") | Contract manufacturing organization ("CMO") | Minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FeesAndExpensesForServicesProvided', window );">Fees and expenses for the initial evaluation and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_LetterAgreementMember', window );">Letter agreement ("Agreement") | Contract manufacturing organization ("CMO") | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FeesAndExpensesForServicesProvided', window );">Fees and expenses for the initial evaluation and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_IndependentContractorAgreementMember', window );">Independent contractor agreement | K2C, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MonthlyFee', window );">Monthly fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermsOfAgreementRenewed', window );">Terms of agreement renewed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TotalExpenseIncurredUnderAgreement', window );">Total expense incurred under agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_IndependentContractorAgreementMember', window );">Independent contractor agreement | Emerald Health Sciences Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TotalExpenseIncurredUnderAgreement', window );">Total expense incurred under agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued advisory fees payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfAgreement', window );">Term of agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized additional stock based compensation expense of restricted stock and option awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc. | Immediate vesting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc. | October 20, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc. | November 21, 2014</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the three months ended March 31, 2017 preferred deemed dividends of $536,000 was recognized on Series D Preferred Stock and $175,000 on Series C Preferred Stock.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AnalyticalMethodDevelopmentAndQualificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents analytical method development and qualification expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AnalyticalMethodDevelopmentAndQualificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FeesAndExpensesForServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of fees and expenses for services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FeesAndExpensesForServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GuarantorFailedToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information the guarantor failed to pay within 90 days of notice of purchaser.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GuarantorFailedToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermsOfAgreementRenewed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents tem of agreement renewed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermsOfAgreementRenewed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TotalExpenseIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total expense incurred under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TotalExpenseIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireFurnitureAndFixtures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireFurnitureAndFixtures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_ContractManufacturingOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_ContractManufacturingOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_K2CIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_K2CIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760641520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details ) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 51,443,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember', window );">2015 series B financing Common Stock Warrants to Series B Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 1,843,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember', window );">2015 Series B financing Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember', window );">2016 Common Stock Warrants to Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember', window );">2016 Series C Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember', window );">2017 Series D Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember', window );">2017 Common Stock Warrants to Service Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsVestedAndOutstanding', window );">Warrants vested and outstanding</a></td>
<td class="nump">$ 44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_WarrantsVestedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants vested and outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_WarrantsVestedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_Pre2015CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_Pre2015CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772412880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details 1) - Stock Option - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward', window );"><strong>Shares Available for Grant of Option's &amp; Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding', window );">Balance at the beginning | shares</a></td>
<td class="nump">870,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted', window );">Options &amp; shares granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised', window );">Options &amp; shares exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled', window );">Options cancelled | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding', window );">Balance at the ending | shares</a></td>
<td class="nump">970,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning | shares</a></td>
<td class="nump">1,130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled | shares</a></td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending | shares</a></td>
<td class="nump">1,030,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and Exercisable at March 31, 2018 | shares</a></td>
<td class="nump">668,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare', window );">Options granted</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare', window );">Vested and Exercisable at March 31, 2018</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled</a></td>
<td class="nump">2.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the ending</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and Exercisable at March 31, 2018</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare', window );">Balance at the beginning</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare', window );">Options cancelled</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare', window );">Balance at the ending</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare', window );">Balance at the beginning</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare', window );">Options cancelled</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare', window );">Balance at the ending</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of equity-based payment instruments, including stock (or unit) options, that cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of equity-based payment instruments, including stock (or unit) options, that exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of equity-based payment instruments, including stock (or unit) options, that granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of equity-based payment instruments, including stock (or unit) options, that outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share of options cancelled under share-based arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share of options exercised under share-based arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share of options granted under share-based arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share of options outstanding under share-based arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPricePerShareRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per share of options vested and exercisable under share-based arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisablePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779693168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Common Stock (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2017</div></th>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2016</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Aug. 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,226,361<span></span>
</td>
<td class="nump">$ 1,288,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued, price per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400,000<span></span>
</td>
<td class="nump">20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrants', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement | Emerald Health Sciences Inc | Accredited investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrants', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement | Emerald Health Sciences Inc | Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price, per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SubsequentFinancingPurchasePriceDescription', window );">Subsequent financing purchase price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,335,500<span></span>
</td>
<td class="nump">2,833.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420.325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,335,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,802,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock shares convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Series B Preferred stock agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,910,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Convertible Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Convertible Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock shares convertible into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nmus_SeriesBWarrantMember', window );">Series B warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,406,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IntrinsicValueOfWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents intrinsic value of warrant exercises .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IntrinsicValueOfWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SubsequentFinancingPurchasePriceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents subsequent financing purchase price description to protect against aniti-dilution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SubsequentFinancingPurchasePriceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SeriesBPreferredStockAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SeriesBPreferredStockAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nmus_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nmus_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779902576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Preferred Stock(Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2017</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2016</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Aug. 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Number of preferred stock and warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,335,500<span></span>
</td>
<td class="nump">2,833.55<span></span>
</td>
<td class="nump">420.325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,335,500<span></span>
</td>
<td class="nump">2,802,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PreferredStockConvertibleConversionPriceDecrease', window );">Reduction of conversion price of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,833,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfConversionAmount', window );">Percentage of conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumLitigationJudgementAmount', window );">Value of final judgment rendered against company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4000:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10,000:1<span></span>
</td>
<td class="text">6666.67:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Convertible Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Number of preferred stock and warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PreferredStockConvertibleConversionPriceDecrease', window );">Reduction of conversion price of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10,000:1<span></span>
</td>
<td class="text">4000:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock', window );">Number of common stock issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_LiquidationProvisionCommonStockEquivalentShares', window );">Liquidation provision common stock equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_LiquidationProvisionCommonStockEquivalentValue', window );">Liquidation provision common stock equivalent value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature upon issuance of Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Convertible Series D Preferred Stock | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Redeemable Convertible Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Number of preferred stock and warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfConversionAmount', window );">Percentage of conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumLitigationJudgementAmount', window );">Value of final judgment rendered against company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10,000:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock', window );">Number of common stock issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature upon issuance of Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfSharesToBeRedeemed', window );">Percentage of shares to be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from triggering transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_RedemptionAmountPercentage', window );">Redemption amount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Convertible Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Number of preferred stock and warrants sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PreferredStockConvertibleConversionPriceDecrease', window );">Reduction of conversion price of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock, conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4000:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock', window );">Number of common stock issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_LiquidationProvisionCommonStockEquivalentShares', window );">Liquidation provision common stock equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature upon issuance of Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CommonStockAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents common stock aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CommonStockAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_LiquidationProvisionCommonStockEquivalentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents liquidation provision common stock equivalent shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_LiquidationProvisionCommonStockEquivalentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_LiquidationProvisionCommonStockEquivalentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents liquidation provision common stock equivalent value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_LiquidationProvisionCommonStockEquivalentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MinimumLitigationJudgementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum litigation judgement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MinimumLitigationJudgementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of common stock issued upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfCommonStockIssuedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfConversionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of conversion amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfConversionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfSharesToBeRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of shares to be redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfSharesToBeRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PreferredStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PreferredStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_RedemptionAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents redemption amount percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_RedemptionAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=96868398&amp;loc=d3e34017-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775631648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Warrants (Detail Textuals 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ValueOfCommonStockCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of common stock called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ValueOfCommonStockCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761032080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Stock Option Plans: 2014 Omnibus Incentive Plan (Detail Textuals 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,609<span></span>
</td>
<td class="nump">$ 152,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,609<span></span>
</td>
<td class="nump">152,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,005<span></span>
</td>
<td class="nump">$ 86,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized period of non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="nump">970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">1,030,000<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiry period of options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants', window );">Percentage of option price at least of fair value on date of grants</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockVotingPercentage', window );">Voting percentage of common stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants', window );">Percentage of fair value option price at date of grants</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term of options vested and exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options to purchase shares of common stock, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled', window );">Cancellations of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CommonStockVotingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CommonStockVotingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of option price least of fair value on the date of grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfFairValueOptionPriceAtDateOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of option price least of fair value on the date of grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of equity-based payment instruments, including stock (or unit) options, that cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsAndOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760933248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Restricted Stock Awards (Detail Textuals 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Jan. 18, 2018</div></th>
<th class="th"><div>Oct. 20, 2015</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_RestrictedStockAgreementsMember', window );">Restricted Stock Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairMarketValueOfSharesGranted', window );">Fair market value of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nmus_RestrictedStockAgreementsMember', window );">Restricted Stock Agreements | Immediate vesting | K2C, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restricted stock awards granted</a></td>
<td class="nump">$ 1,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,609<span></span>
</td>
<td class="nump">$ 152,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Dr. Brian S. Murphy | Restricted Stock Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember', window );">Elizabeth Berecz, CFO | Restricted Stock Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember', window );">Cosmas N. Lykos | Restricted Stock Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,604<span></span>
</td>
<td class="nump">$ 65,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards | Senior management and board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restricted stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairMarketValueOfSharesGranted', window );">Fair market value of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards | Senior management and board of directors | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Restricted stock awards | Senior management and board of directors | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FairMarketValueOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FairMarketValueOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_RestrictedStockAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_RestrictedStockAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_K2CIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_K2CIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nmus_ManagementAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nmus_ManagementAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776078336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions for Conversion of Preferred Stock and Put Option Liability (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Nov. 01, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Aug. 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Provision for conversion of Series B preferred stock</a></td>
<td class="nump">$ 6,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesBPreferredStockConversionLiabilityMember', window );">Series B Preferred Stock Conversion Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative</a></td>
<td class="nump">6,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesBPreferredStockConversionLiabilityMember', window );">Series B Preferred Stock Conversion Liability | Non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Provision for conversion of Series B preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesFPreferredStockOptionLiabilityMember', window );">Series F Preferred Stock Put Option Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesFPreferredStockOptionLiabilityMember', window );">Series F Preferred Stock Put Option Liability | Non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair market value of embedded derivative</a></td>
<td class="nump">103,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair market value of embedded derivative</a></td>
<td class="nump">$ 102,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesBPreferredStockConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesBPreferredStockConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesFPreferredStockOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=nmus_SeriesFPreferredStockOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761237632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrant and Emerald Warrant Liabilities (Details) - Series B Warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of warrants</a></td>
<td class="nump">$ 0.238<span></span>
</td>
<td class="nump">$ 0.086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.949%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.947%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted-average fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ClassOfWarrantOrRightInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917246496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrant and Emerald Warrant Liabilities (Details 1) - Emerald Warrant Liabilities - $ / shares<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price per share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price per share of common stock</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price per share of common stock</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761600560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrant and Emerald Warrant Liabilities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 29, 2016</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,589,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair market value at the re-measurement date recorded as non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,162,493)<span></span>
</td>
<td class="num">$ (12,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Convertible Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Redeemable Convertible Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ExpirationPeriodOfWarrants', window );">Warrants, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,935,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants', window );">Proceeds from financing between conversion liability and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfWarrantsExercisable', window );">Number Of Warrants Exercisable</a></td>
<td class="nump">987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="nump">$ 98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants | Non-operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair market value at the re-measurement date recorded as non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,223,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants | Convertible Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants | Redeemable Convertible Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ExpirationPeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ExpirationPeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IntrinsicValueOfWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents intrinsic value of warrant exercises .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IntrinsicValueOfWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to proceeds from financing between the conversion liability and the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761218096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrant and Emerald Warrant Liabilities (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair market value at the re-measurement date recorded as non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,162,493)<span></span>
</td>
<td class="num">$ (12,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Issuance costs related to warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_EmeraldPutOptionLiabilityMember', window );">Emerald Put Option Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember', window );">Non-operating expense | Emerald Put Option Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Emerald Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Total proceeds from Private Placement</a></td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Emerald Warrant Liability | Warrants issued on January 19, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,654,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,671,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Emerald Warrant Liability | Warrants issued on February 16, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">5,631,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,296,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Emerald Warrant Liability | Non-operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair market value at the re-measurement date recorded as non-operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,318,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantLiabilitiesMoreThanProceeds', window );">Warrant liabilities more than proceeds</a></td>
<td class="nump">$ 3,881,051<span></span>
</td>
<td class="nump">$ 3,154,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Issuance costs related to warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember', window );">Emerald Warrant Liability | Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ExpirationPeriodOfWarrants', window );">Warrants, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ExpirationPeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ExpirationPeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_WarrantLiabilitiesMoreThanProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information about warrant liabilities more than proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_WarrantLiabilitiesMoreThanProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=nmus_EmeraldPutOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=nmus_EmeraldPutOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_EmeraldWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_WarrantsIssuanceDateAxis=nmus_WarrantsIssuedOn19January2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_WarrantsIssuanceDateAxis=nmus_WarrantsIssuedOn19January2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_WarrantsIssuanceDateAxis=nmus_WarrantsIssuedOn16February2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_WarrantsIssuanceDateAxis=nmus_WarrantsIssuedOn16February2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761485184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Bridge Loan (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Change in fair value of conversion rights of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MarkedToMarketConversionLiabilities', window );">Marked to market the conversion liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Secured Promissory Note and Security Agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Funds received under the Secured Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseInConversionLiability', window );">Increase in conversion liability</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible debt discount</a></td>
<td class="nump">$ 34,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Change in fair value of conversion rights of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseInConversionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information about increase in conversion liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseInConversionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MarkedToMarketConversionLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents marked to market the conversion liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MarkedToMarketConversionLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=77886427&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SecuredPromissoryNoteAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SecuredPromissoryNoteAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657970816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - Subsequent Event - Elizabeth Berecz, CFO - Separation Agreement<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds | $</a></td>
<td class="nump">$ 145,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Immediate vesting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of unrestricted stock awards</a></td>
<td class="nump">1,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of unvested stock options</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nmus_SeparationAndReleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M=.@I R\Y,#E-C,>A:^$"F&"$R>7O IJ%.%?_Q,X=8*?DD.V2ZON^[.LY-^[
MX?WYZ75>M[ ^D_(:QU_9"CI&7+/SY+?Z_F'SR.2JXG=%U12\V52W@M>BN?Z8
M7'_X781=,'9K_['Q65"V\.LNY!=02P,$%     @ V3FO3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MU]@;8[4SRAZ<Q:-K/Z^#6N_M<%NX^V[JP::!-:>YOTRN3>[J/U!+ P04
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M;.LG1YH(; LHRH5U2;<"NEA1L&[O$]N3H=*=NXYAQ@!FI!'#%F942AE$GS"
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M/,%4SS4E4_%?X0(2PX,2S%$:Z>)*RMYYHR86E*+X^[@+'?=AO$GW$VP=D$R
M9 ;L8QXV)HK*'[CG16;-0.S8^XZ')]X>$NQ-&9RQ%?$.Q3OT7HIM>IVQ2R":
M8HYC3+*,F2,8LL\IDK44Q^0?>+(.WZTJW$7X[@^%-^L$Z2I!&@G2_Y:X%G/[
M5Q*VZ*D"V\1I<J0TO8Z3O/#. WN7Q#?Y'3Y.^S=N&Z$=.1N/+QO[7QOC :5L
MKG"$6OQ@LR&A]N%XBV<[CMEH>---/XC-W[CX %!+ P04    " #9.:],G;PS
MS[4!  #2 P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U3;8^4,!#^
M*TU_P)5E65TW0')[QFBBR>:,Y^<N#-!<7[ MR_GOG18.48E?VLYTGF>>F4[S
MT=AGUP%X\J*D=@7MO.]/C+FJ \7=G>E!XTUCK.(>3=LRUUO@=00IR=(D><,4
M%YJ6>?1=;)F;P4NAX6*)&Y3B]N<9I!D+NJ.OCD?1=CXX6)GWO(6OX+_U%XL6
M6UAJH4 [832QT!3T?G<Z9R$^!CP)&-WJ3$(E5V.>@_&I+F@2!(&$R@<&CML-
M'D#*0(0R?LR<=$D9@.OS*_N'6#O6<N4.'HS\+FK?%?1(20T-'Z1_-.-'F.LY
M4#(7_QEN(#$\*,$<E9$NKJ0:G#=J9D$IBK],N]!Q'Z>;0SK#M@'I#$@7P#'F
M85.BJ/P]][S,K1F)G7K?\_#$NU.*O:F",[8BWJ%XA]Y;N<N..;L%HCGF/,6D
MZY@E@B'[DB+=2G%._X&GV_#]IL)]A.__4/ANFR#;),@B0?;?$C=B#LE?2=BJ
MIPIL&Z?)D<H,.D[RRKL,['U\1/8[?)KV+]RV0CMR-1Y?-O:_,<8#2DGN<(0Z
M_&"+(:'QX?@6SW8:L\GPII]_$%N^<?D+4$L#!!0    ( -DYKTQET3K$L $
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M,]IV7+/1\::;7A";GW'Q!E!+ P04    " #9.:],(%F\$K,!  #2 P  &0
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M11]>-O6_1O00I&SNP@BUX8/-AH+:Q^-].-MQS$;#8S?](#9_X^(74$L#!!0
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MYQ,NN5;*@K.2W#@OK9OB)1!06[^]<WL]O>4IL*J?QY0L_Q7%;U!+ P04
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M<0_''0X;*37%54[)@ _PL7_BN,HI?+SA%%<DQ13I-KP!=5LP)2.RI;AL*?M
MJQM0-PZ-*!^5$L7U31%]#SK=@-[I] :'N6T*.E>[3!:'ZIY=>EMUSK6]^G1V
MV[O\+;570V=_!3?K^D;^ZJ;^0/@1%X<D+[U'I<W%L[H>[I72TI D$U.QH_DF
M:1>IW&O[.C7O17TQKQ=:G9J/CJ#]\EG^!U!+ P04    " #9.:],<PC(2>0"
M  #^#   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R55^UNVC 4?94H
M#]#8SB<5(*V4:I,VJ>JT[;<+!J(F<988Z-Y^MI-&))Q0^$-L<^XYOO8]B3T]
MRNJMW@FAG/<\*^J9NU.JO/>\>K43.:_O9"D*_<]&5CE7NEMMO;JL!%_;H#SS
M&"&1E_.T<.=3._9<S:=RK[*T$,^54^_SG%?_'D0FCS.7NA\#+^EVI\R -Y^6
M?"M^"O6K?*YTS^M8UFDNBCJ5A5.)S<S]0N^?6&P"+.)W*H[U2=LQJ;Q*^68Z
MW]8SEY@9B4RLE*'@^G$0"Y%EADG/XV]+ZG::)O"T_<'^9)/7R;SR6BQD]B==
MJ]W,35QG+39\GZD7>?PJVH1"UVFS_RX.(M-P,Q.ML9)9;7^=U;Y6,F]9]%1R
M_MX\T\(^CRW_1Q@.8&T ZP(8O1C@MP%^%^ G%P."-B"X5B%L \)K%:(V(.H"
M:&#WHUDLN_J/7/'YM))'IVH*J.2F3NE]I/=W90;M=MK_] ;4>O0P9SZ=>@=#
MU&(>&@SK85@?LT 8OX]Y1)B@CUDB3-C'/"%,U&$\G6^7-(-),TO@]PAB3.!#
M M\2!#V"9#!+A)E@D0"*!.<$ 1F(( S%(B$4"0$!PP01)(BN7\L8$L1@!H/*
M63:8T&(*B_&Q1 (EDL]7<HDP 1:90)$)(!A4[K+!Q"=YL) 0@F4HP8XE0"@:
MVHB<*U%"QK5&W@X4:(WL+L5>HS>8C6*W46"E(!F^7/RSC.F%?+'E*/+3B&DI
M-A0-;\@76XI&GUMBT8)./3'B6XI]1Y'QR% %@49L0;'Y*')6.-1);G(&=B!%
M%HR&2I.S=:/!!6<P[$(&7!B.46!S,7I]I;"1#QG[W!F+%G2E,QCV( ,>#$>^
M- R;BP4WY(O-Q=#G:E"S#Q T4K,,.Y A!X9#G>B6FF78A0P9+!HJQ6=*,2I9
M[^349VX&/WBU38O:>95*'R#M,6\CI1*:D]SI5=KIRTC7R<1&F6:LVU5S(F\Z
M2I;M;</KKCSS_U!+ P04    " #9.:],PP]J<K($   @&0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6R5F>MNHS@4QU\ER@,4?&R#J9)(VV8ZF6E7
MJF:TNY]IXEPT$+) F]FW7T.<--CG1- /#9?_N=G^V08FQZ+\56VUKD>_\VQ?
M3<?;NC[<!T&UW.H\K>Z*@]Z;.^NBS-/:G):;H#J4.EVU1GD60!A&09[N]N/9
MI+WV6LXFQ7N=[?;ZM1Q5[WF>EO\]Z*PX3L=L?+[P8[?9ULV%8#8YI!O]4]=_
M'5Y+<Q9<O*QVN=Y7NV(_*O5Z.OZ#W;](: Q:Q=\[?:RNCD=-*6]%\:LY^;::
MCL,F(YWI9=VX2,W/AW[46=9X,GG\:YV.+S$;P^OCL_>GMGA3S%M:Z<<B^V>W
MJK?3L1J/5GJ=OF?UC^*XT+8@.1[9ZE_TA\Z,O,G$Q%@66=7^'RW?J[K(K1>3
M2I[^/OWN]NWOT?H_F^$&8 V@KP&W!OQBP,1- V$-Q*<!OVD@K8'L&R&R!E%?
M@]@:Q'T-E#50?0T2:Y#T-6#AN>?"WB:7SF:]3<[=S< Q"4X#JQVI\[1.9Y.R
M.([*$VR'M&&:W1LKX[RYVH[]]J89K96Y^C$#"9/@H_%D-8\G#70TO*N98QK1
MU7S!-+*K><(T45?S%=/$7<T"TZBNYANF2;J:[X@F"KN:9T335;SXBOC326!Z
MZ-)-@'<3M YX)PV&>^"X!]YZ$!T/3IJ+DR9N-?M6PX&!VVR^*I9>N_FB!"*G
MDYY]D>",.6WGBV0D1((7+_#B!5*\,X*_"[_XT.UI7V-& ]&3$D]%(JDXH"Q.
M&GD5AB71%4Z=.!$>)T+B.+ M(J\<%DFBG!@/$WMA/#QBKQJS2VC_\$@*CZ20
M@IR9X<'7L-!E4?F-RSA35S-()YL$SR9!LB$\-"L!.O6&_:%FU/3-D#R4.S\Q
MOY^5BD+ASE+,:YI(1B")E(BIB@&2$H$K(R8KQ@<T#<$\\Z%WA^;<:CJ#X=;0
M9 34S*?:A6UN->HJ5G@7AE15!-8,X3KVRO+!!JHB@FOF@^WA-K>BN#?:C&";
M(7#'SD+P:$4#HA'L,@3>&' ?0, + ^ % EY X(V=9>D)$'@%)%3-0&T@$"IC
M8D4!@DH80"405 *R%,?N)A 0+*4@^QD(*@%9:^.(\$'P!M& F@F6 &')K]EG
MB2E.UTR0!!A)Q,($!!^0#-AM$GSP$,G#69B^6)%'M+L#]&6,IIX3M'&,ML0-
MA8@4%8A C2.H*6<R>[:BSJX(K1VP;2E9.[7Y1W;_BICQ.$$N%P-&!4$D1XCT
MFP;9_MZ8Y3E!+D=62L7=6,@66-*A", Y CAW=V&82!$S,"?HY@C=BMB?<8)N
M/H!N0= M$+J5^Y@N$&P5W8^"X%;TV.)^%<@JR0"HIVQ!H"LP=(G94Q"LB0&K
MI*">5Y%54GDU^ZMD<H,303 I,":IQVN"-3%@E10$1 +CPZO9?YCD0 ,K"(X$
MPE%"^2 X$@,XD@1'$N/(K=F*.O/AC9JEQU'W-C'TI3_TO6?G!TS$W3DLN'KY
MF.MRT[YFKT;+XGU?-^UU=?7R*O^A??'N7I?L_EEB=TPBYD[[]C_X#''Z=O!G
M6FYV^VKT5M1UD;?O-M=%46N3?WAG&G&KT]7E)-/KNCF,S7%Y>F=_.JF+@_T>
M$5P^BLS^!U!+ P04    " #9.:],NW:S-Q0$  "H%P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6R5F.UNHS@4AF\%<0$%?Q%2)9&:CD:[TJY4S6IW
M?]/$2=  S@!I9NY^C*%I$MXS8_JC@//Z')]C/_Y:G$W]M3EHW0;?RZ)JEN&A
M;8^/4=1L#KK,F@=SU)7]96?J,FOM9[V/FF.MLZVK5!81C^,D*K.\"E<+5_92
MKQ;FU!9YI5_JH#F595;_6.O"G)<A"]\+ON3[0]L51*O%,=OK?W3[[_&EME_1
MQ<HV+W75Y*8*:KU;AD_L\3EQ%9SBOUR?FZOWH OEU9BOW<>?VV48=RW2A=ZT
MG8G,/M[TLRZ*SI)MQ[?!:'CQV56\?G^W_MD%;X-YS1K];(K_\VU[6(9I&&SU
M+CL5[1=S_D,/ :DP&*+_2[_IPLJ[EE@?&U,T[G^P.36M*0<KMBEE]KU_YI5[
MG@?[[]5P!3Y4X)<*UO>O*HBA@OBH(%WP?<M<J)^R-ELM:G,.ZKZWCEDW*-BC
ML,G<=(4N=^XW&VUC2]]6?,X6T5MG:-"L>PV_TGPH(FO]XH(C%VL^JLYO'3P#
MQ9QC%P)&(9P!<6- 8 ,2&I#.@+PQ(.]:V6M8[$25$\4/7&$W"KI1P(VZRW:O
MF5UY44Q*P56,/2704P(\)=C #!J8^:<TA0;2WZ=TG8YB)4;6'+J8>Z1S/G(A
M8_>''77=BS")@:L988(@C?EGE$&2GA@'K4CO:46B.>$'X\3$R(0@$X:!8G)"
MM!@6AF@910M$J23\8%38F!41$^.085C8!%H8QH4A7NX',QL#(R6G!S/&AHVY
M$3$QWW+, X_] ^:8!\X\)HA!=#/IL@=&3+H<8\-]L$$B06##,38<84,E!6/#
M)V##,38<83/**UAE""\8&HX6F%%.@8B"DV.R^ SDE#*!R>+IA)QB8CA::48Y
M'2\U!)<"0R70(G.?4R2BQJG Y E$WOU4,XANUN94BAFU#1&8/3'&2L3$4!/$
MYF["[DY@K(3'_FX]B'SZ#Y,G?!8L)"+[#[,G$'NC_DM _]G>HT+"^ F$'[&/
M%!@_,0$_@?$3/O@-(L^E0F($I0^"2$1-:Q(C*'T0E&,$);USE1A B0 D=JX2
M RBG'*^(\Y4/@(.(\9L3%I58S*#T81")* 8E9E#Z,"@!@_8<1_8@9E B!E/"
M!&903F!08@:E#X,2,/B+,S)F4/DPB$14%RK,H/)A4 $&4QI"A2%4"$*JM1A"
M-0%"A2%4/A J>,TAB?.0(NXY?"A$(K(+,87*AT(UC4*%*52 0D:9P!2J"10J
M3*'RH7 0W<VC1 \F&,+$!T(DHGHPP1 F/A F $)W[!WU871U[UGJ>N^NB)M@
M8TZ5NY^^*KU<0S]Q=V_Z(>_OL/_.ZGU>-<&K:5M3NCO2G3&MM@V*'^S0/>AL
M>_DH]*[M7F?VO>[OCON/UAR'>_'H<CF_^@E02P,$%     @ V3FO3*SYM>].
M P  S@\  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE9=A;]HP$(;_
M2I3O(_$9$J@ J72:-FF3JDW;/J=@(&H2L\1 ]^_G."Z%^'65]4,3F_.]MN\>
M.S<_R_JYV0NA@I>RJ)I%N%?J<!=%S7HORJP9R8.H]"];69>9TLUZ%S6'6F0;
M,Z@L(HKC)"JSO J7<]/W6"_G\JB*O!*/== <RS*K_ZY$(<^+D(6O'=_SW5ZU
M'=%R?LAVXH=0/P^/M6Y%%R^;O!15D\LJJ,5V$=ZSNQ5/V@'&XE<NSLW5>] N
MY4G*Y[;Q9;,(XW9&HA!KU;K(].,D'D11M)[T//Y8I^%%LQUX_?[J_9-9O%[,
M4]:(!UG\SC=JOPBG8; 1V^Q8J._R_%G8!4W"P*[^JSB)0INW,]$::UDTYG^P
M/C9*EM:+GDJ9O73/O#+/L_7_.@P/(#N +@.X&1!U0F;F'S.5+>>U/ =UM_F'
MK(TQNR.]-^NVTVR%^4U/OM&]IR5G;!Z=6D?69M79T)7-FT6DO5\D"$FLR!G.
M&6$'',Z1&P?\Q@''#L;0P=@X&-\X&/<6V=E,C$UE;*9IK/^PS@3J3(#.I*<S
M<70\$@F42(!$TI-(ADJD4"(%$FE/(G4D6.S?K2G4F0*=:4]GZNC,WHG*#.K,
M0/K,L ,68TCB 0EDC6[VA''_9)D'2.9J4=S78D-#S""3]XR BL,]#5;!X#(^
M()6LT;7*A_>2B6'&&8*\GT[,I9S%[\4(<\X Z$1]+9?T))GZI3#O+'&SESR'
M'\,\,P T.=G;&:4#8HUI9@!GZA]^S.79IX)99C.@TC__K-'L6F4T]EPYA)&G
M&.Q[ZG&!229$<C\CK1'C-Y--/$(89D(P]P-,@V$F##,!F)T DPNS3P5C3 !C
MFO55QDZ :33Q10<S3(!AWC]GK=' 3,($$[BRG92U1@.%,.<$..>^+S4,,4V'
MGS:$"25$J)/U_T,HQX1R<"D[F6*-!@IACCG@V,D4:S10"'/, <?<Y\+SJ0R^
ME7T!Y)A C@CL!Y"[%ZE/!>/'T17J1,^]0GTJF#T.V'-#ESA77U\ENBJG2E'O
M3"'9!&MYK$P5>]5[*5;OR91C;^9=I?LMJW=YU01/4NFBSI1>6RF5T#.)1WJE
M>UU<7QJ%V*KV-=7O=5=A=@TE#[9ZCBXE_/(?4$L#!!0    ( -DYKTSSX(AO
MFP8  ,LG   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)5:Z7+:2!!^
M%8H' ,TMN;"KUE=BQQ@G6[O[6[9EFPH@5I+MY.U7Q\"B/F#(CX#PU\=,=W_3
M:FGRF1<_R[<LJP:_EHM5>3I\JZKUR7A</KUER[0<Y>ML5?_E)2^6:55?%J_C
M<EUDZ7,KM%R,9139\3*=KX9GD_:WA^)LDK]7B_DJ>R@&Y?MRF1:_S[-%_GDZ
M%,/-#S_FKV]5\\/X;+).7[,_L^JO]4-17XVW6I[GRVQ5SO/5H,A>3H=_B)/O
M3C<"+>+O>?99[GP?-$MYS/.?S<7-\^DP:CS*%ME3U:A(ZX^/[");+!I-M1__
M>J7#K<U&</?[1OMUN_AZ,8]IF5WDBW_FS]7;Z3 >#IZSE_1]4?W(/[]F?D%F
M./"KO\L^LD4-;SRI;3SEB[+]?_#T7E;YTFNI75FFO[K/^:K]_/3Z-V*T@/0"
M<BL@]%X!Y054J(#V CK4)>,%3*@%ZP5LJ(#S BY4(/8"<:A X@624 $1;2(7
M!8ML@RV"13;A%L'Q%IN B^"(BTW(A0X6V01=!$==;,(N@N,N-H$7,/+CKJ[:
M0KU,J_1L4N2?@Z+CFG7:4)HXJ:5JY<VO;>FW?ZR+M:Q__3A32DW&'XTFCSGO
M,+*'T7W,!84Q?<PEA;%]S!6%<7W,-<9($_<Q7R@] /.5PB1]S V!T5$?<TMA
M1!_SC<+(/N:.PH!83(FU]Q'W&.& PS-J _N0!P*2 $O?*7__SXMQG7C;[)-T
M]LE6@^II,+0&16M0K0:]H\&"K9]VD+B%K%I(-(HB@)H=0O6<T;0S&CFC-$CP
M:8=Q.W:$E%9!K^\I7!Q'1M$>&=HC0W@$RFG:8<R.I21J_M&&+&W($H9 O3UT
MF.9<V-ECR<3;T78<CC?([JE#ZY%1M&=%,6TI)E:4T!H26D,2GMW-II#T'!W,
M[PN/"4Q=P1T$ J_71)#!!=I;8?;MK6 *7TAD34*:NO0@D##<NAB"$)@AE$%;
MJ(Y=%\, @J  (Z$U362H[EOS.Q" [/O%\("@B""&?IEC]ILA D$P@5'0$@9)
MQ1278)A 8"J0L84;Z#"-FGW[QY"!(-C ,&>=8.A ',$'DN$#B?D 9[,'];)F
MWZ(E0PF2H@28S!)3@MJ7H9)K!3 CX R5QS""9!A!4HP ,Y0 L1DJ&3*0F Q0
MAEY(XJ!W9L_^,14NB0HW7'8QM2OM$1G*E*4DRM+"LI2X+/?U')*I2DE5);(5
M'Y,S3.W*A+#DH*6$Z:2892FFR!55Y* 4+DD0DZ"**7"%"UQ*Q^A@ZE8=T\-S
M33Q1D;"M^^)!0NQLKW-N)."]RYW"I[F,Z]M1 \_7J4<F #DR0.6,,JYE-%)<
M^ZH83E#4/8*#2\7'OA)13/A/] ?D2F<D,I+"<N%F:$81- ,[TG-%-Q)@4Z\8
M&+C;#T+=T"B8&K<T# PSOM&H&*99B&/3(-3LH/O]X##\K8BV"G;5]^K0;5AW
M<T_#8L8AYC!0^#! A_JU!R5<LO0M,4>!PD>!E E<>HS;?&TB85B&9HX#11P'
M5M(Z-,/R.@HG3LT0N"8Z-$B<,P_:W5\A$C=BC3%,KZD.S4%C$FVQ241D=UJ
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MND5.#UR^AN*];@?E=L%9I3\"G.Y+9/,/4$L#!!0    ( -DYKTQ=#\>X,0,
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MU;>AOB_;2;)]4/+03<E>/ZHO_@-02P,$%     @ V3FO3"VN@$+8 @  7 L
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MVQ-L.5=,IQ->Z/NXUZUN.RG85IEAJL>BZ?>:B>*UZV6#MJ%>_@=02P,$%
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MSE %F>N!7>'[#(DTC6F(V^DZ 3LH0B36D6XF(V<-F1XM0<^ 6P(3XC6@9&K
M./D(10(>\Q:G'V%?"!BG%D&XE3'[@'8Y0Y(H5!_K>,2 &C>6&IQ>!./7R(E!
M<.:0Y NIP;E#4O=TB\"..'6:G\61ZERPF\8%TC@AX> VO'8*YR-!")G%N K
MF0;A]-0 SC0@_Y^:E0$-(XYB2L*(6*E!@ PR!1TI.>#<!82[63*B N<D?.%&
M!)R3X-Z)[F5E0$.> "5I%(\T ^#D!8R\J5T&EY,T3=TRK#$@N6[E:Z=P\L*4
MR]& DHFW(^ D!^Q^'$LA3G+XP@T)."7!I:1#ACMP+TG&X).CD>+DI>XUZ?SE
MNC,@ZS_72&XI3G'J4IRE=E0("*A=@& P*U2\V>O1L/4VXE3++O.#W<OX>0O=
MK&'MK\AL39#]>S)[Z(?+#_7]K/MWWNR+NO5>A%03CIY#=D)(KGP/;U0M#FJ\
MOBQ*OI/=:Z+>FW[&[!=2',W\'%R&^.5O4$L#!!0    ( -DYKTQKN\P2$P,
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MW;JV!8%6F6FFYV*YP,M"\7'M36AKD-4?4$L#!!0    ( -DYKTQI%A0$XFL
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MF!F;U8S(OO+:Y &PD+<!!+YE\FQ_F Z'0[HD] @%FQIGS>#F)"UK,RM_+&+
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MXW4 HH)*PHJ<,4QC^RC;0PYSBFFF*T:*-+]Q>GIPF.XC7[3 (N%#$D-2%][
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M83Q'2!]0_4UV36C'^\NW+K#!!)OC;%YE-A^KO;M8YG.FYHZNK!H5'(&G,"&
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M6@]9 N-3)WQ%(,Q$+ \Y_PROCG97J&HIML+NDQ4'VXY^XFYILVIP/+SA"_(
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M!" F7GP(MHBNIH GQT%#PB,**UC69&<)PFV]_23.^W5Y#>[.2]PB73AD2;+
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M7'1IFU* W;/"6 H6$!GAXE2T5VV<^KAG6"SAR>EK,URG5HUH5-V]F@##!$E
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M'A=165!MM-;DJ2OBK:I5R51>LO+I6%@(PWUA;R[?.1CB%B]]'&(A^L2R<[6
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M&D9%N_%0C4$(ZDB&TG@N\X$GV$Y\Y6YG'*7$>U'[Y@<3JO#.NK7HAA*OZY2
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MQ@=\-MG,\$99O1>>XK+@U_EMP?VN!-=)OW1Y8K-'B35U+;WDG/!W)D/D+9(
M:3,$O2R60:G'TTCTC@81XFG,I0G'5=?8KNG+BQTN3K[S6D+.0D/,2Z"DMV+@
MI;5J.RVNI3G-)S/*[?;B@] 2HQ]0UH9:J:EF0M/0?1=9Z.KB/$TTGL=P1=''
MN4<:;"3Z'RE>,G.^.9?E3;'WK_)LBIU=O],U7:V:11CF&MF"K22DY;:G&FOM
M0AH0E\;/J=:UBRN1]Q"B[WHVT=P/.2B-. BM."$8Z*C+/N?>&@V[@EL1)J41
MS9+@ECFV;9$HFUB/CF^X@_>,BJ.Z4AZ8.'L-U 9W,WCGAN//X94^K@94L_R,
M>1&3QY:!W ]$>MXL^<MJ>JNV$-1KFS"1QJ>IQ)$W;JR7+J[2:>ZF68J(.29.
MCB]IK*E2)Y'VZ;&$O)@]>OW;[2$6<F8?:L[LS4<TP89\Q*H^HX,#C8F4@,(S
M7SZGT@[5\8ULM;;G&X:!*1A0(62,A,.VP+'6;%PT\: ^BI(R?)VH9.UGI'S9
M<$+?OG,&/$IZA&*SV[_]+</;J47L>[HO!EV02')5NQ^7T=-\U?U1LS0B4H^2
M<WQ\/  I5:^1%'4/J3R*IX!0+T;K+9O[Z6AXLD89L;4DVO@0:PLF]XWKO=C,
MVE&/L9/9BGK->H\R,H<>#CA=RD\ (#\UO6W35H=ZJ%/Y-NP\9W1OVON-FF!G
M TC*O;"BHT@2.8UJ(KFZ^J>WJB;U[O:@TP4<*0Y*.UQO#_<7WV?.OX22.!>F
M_\"&)_OTIXJVZ2,5X7-_?8<5Y5YCWA?,^9Z7^T&+[+BW/KB(47S>&N*MV2G_
M:1RV;ND$(JC<<U]N>SO7X2!YF7/D)[[?!;\K$L2]XKRTXGI&*MM_(OF+H?J#
MDK^S91"NPB9G,2-B>RZ_?UZRZKAE+.^V%.3,VDGQC2[G^CI!B(I94R@Q)0V8
M>?5XD%]K50*W,2Y:@/9-VXCK/8MT 8XDTW(/%-O@3;6:CNK"$BQ*M8<J&EM0
MMK"U#]I!E*BE474F..:_"9X[2%N48<,6B$3.I>5=*Y^NKB@]36@'R2M6&B0*
MH,O>%R.T4[5-*(#'34^U?P%'W.3<_S6(<I==(+ >Q]X]9P6\"7(C.3Y#[1H=
M[B3BKMOA].CX#XO3:OSKR./Z0^%T!]>,[+:_D/>L]6*O?>\/R0T"<O];L\O_
M)UC/X?[1/Z[I+[NF7Q&?LDU4R@:VPQZ]'K-U$'?TBX)1_KM4MIC@=*EL7?$O
M;7Y',26\>A]4DI/:@.8S#$5\7RW5?VE)%49);*""T3+6Q=FHN]\B 5V\/E9_
MS_F1YC#^&WPKO=%4?UC?BD/I?M>*O- K0'V=XM][L5N*_^9+OJ7.O]ES^ONH
M_-'%Z!1>(GKQVZO\6*.XIN!7Q/"/GMW_.GK_U[J(7O_1743[PW^XB'Y_%]'K
M/XJ+",M3WL%%TQ)7U(KX$4X8.T[^]SF.**AH]_#OW'OT^A_>HP[OT?:>H]=?
MXSD*O%-G'6%"A/H/MFR"0"QW7R)_B!-3_1/7+R6,HR59\E#B:']/?U4LC?\A
M5?2G:,WQ%>I2D_V2Y.+)?O/>1NJ&JGZM1"<J0(<&!*,QM@QI56>T_:^J;O3$
MB1FC7,R5F4VJNK&EQ7E_/X7__HAJO]_BOQ.]_VDZ0F^P:=LYN(4I8$LM88L
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MFT9X6;WH[EO9.[8)X>RDGYESMSY:"F6R?A8NJ<,TH*J\^FQJAM$=(L\B$8=
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M/G^1O!E8LD=9IV+,]734VBXE@_*A3#Y219378MG[+GGS!AW&00DU7/6;DH@
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M%7TK4X3]9+U5[]NF6?[Y_P)02P,$%     @ V3FO3&U[2V)F @  X0T   T
M  !X;"]S='EL97,N>&ULU9=M:]LP$,>_BE#&:&'4=M*DZVH;MD)AL(Y"\V+O
MBF++MD /GBQG3C_]),M/\4BV9NM(WD2G.]W_?K+D</8+M:'X,<-8@8I17@0P
M4RK_X#A%E&&&B@N18ZXCB9 ,*3V5J5/D$J.X,$F,.E/773@,$0Y#GY?LCJD"
M1*+D*H"+S@5L_JV(<0"?SMY^+X6Z>0/L.'DWF;A/YS=C_UD=.(? :GR. ^@M
M+J'SYZ(7KKM;V 1'XO,7BN_3'DDO=D@/.7=R7;V,:P_62/C]?JH!TRCQVB0Z
MS7F'?B)X?^PS:!U:&3$,UH@&\!91LI+$9"6($;JQ[JEQ1((*"92^;[JR9SS%
MLPU[=F:N8J/#"!>RKFTKV-]5LWP4:&<&D%#: 4ZA=81^CI3"DM_I2;VX=OX2
M HV]W.2:,)5HXTWGL$^H!UUD)62,95?&@ZTK]"E.#(XD:69&)7+'!)423!LQ
M0:G@J&9H,QI#RT:8TD?SGGY+MK2K!-@UYDA<" Q%:^I=-V9_:FZ-/%2SVD/9
MRX-T04[60GTJ]79X/3=W#C](G)"JGE=)!Z#549[3S4=*4LZPW<QO"WH'%@Q]
MU-8!F9#D6>N9JQ)I!Y80K+%4)!IZ?DB4+W&EVNM4)8<R3T^0^5\_YQ1S+!$=
M0NN[?\Q/^3\3SZ[^'KG^5QD#']=3?6U$TQB< .3\^"%GU\?/:-JI$X \@5?;
MM( G /G:=])I^J!!L[75:G5>L"H)580WN!F)8VQY3*\;P*^FB:9;#4_?<6EY
MA5;Z>VM+7^?&.$$E50]FBW4P@+W]Q8![BV[5LI,(8&_?XYB4S+;E_4==^!-0
M2P,$%     @ V3FO3*+2J^<* P  >!<   \   !X;"]W;W)K8F]O:RYX;6S%
MF%MOVR 4@/\*\LOZ,,T!)^E%3:5</#52FT1UMCT3FR2H-GB >_GW@T313J7I
M:"\TDB5LS.43B/,!MZ_:/&^T?B9O3:WL*-D[U]ZDJ2WWHN'VFVZ%\G^VVC3<
M^4^S2VUK!*_L7@C7U"GK]89IPZ5*[FY/;:U,>G<;7GY*\6K_YH=/PDLG7\2:
M;T9)+_'E4E#PT.@I/1+=F/]ATMNM+,5,EUTCE#M"&5%S)[6R>]G:A"C>B%%R
M*D*XJDBNG'3O9*Z.3?FR"3ET/:]&"?7OCCM?YT5:N:E%0LR-]#_,O*(!/![D
M=+DHE@_SV7B=S\AD_#!>3'-2W.?YN@" # %D9P,D%RL.(#,$,OM$R&+MD\=\
MX0&7W\ERE3\!R#X"V3\;Y'1<W /( 0(Y."?D$$ .$<AA7,@%=YT11&_)LA7F
M^/\KF716*F$M 9"7".1E7,@?RL<^8T/4\:"/TMKPM*TDXYT1 D!>(9!7D:=;
M-XUTH9 ]A,FI]G%2[80JI;  \1I!O(Z+6#A=/N]U7?G!_$)FPE>3QYC^)*H/
MXTA[6!SOQ<5<&1TZ];G$UP\#>9A]K<+LKPS$1'43V3>%,'YFR83\XL;PDQP;
MOXKJRN=!3$PZ-+9U#L/G0J]D8F2U$^1!\P_.QG1#(_MFKDK="++F;Q]6"<7L
M0B/KI>@V5OSNPH8G?PD+&H)A1J&1E8)&:PJ50C&GT,A20>,,O828F%5H9*V@
M"YA>04S,*S2R6/!)OX:8F%MH9+F@DF8]N 7'Y,(BRP75-+F F)A<6&RY8$N(
M,8B)GF@BRP7'S" F)AD663(X9A]B8MYAL;V#8@X@)F8A%ME".":T$,,LQ,YI
M(08MQ# +L=@60C&AA1AF(1;90NBFG$$+,<Q"+/81!W-Z!BV481;*(EL(QZ00
M$[-0=LXC3@8ME&$6RF);",6$%LK0F[785VO_/HF1BYEP7-80$[-0]MFGGQ,@
M68LWUT%,S$+9P4+IZ7*Z\H%-B6KAN[ ^O^1UN3(D),<3<G\0=J_;KJZG/F^I
M_,@<KI-#&Z>;\+L_4$L#!!0    ( -DYKTQE0E[)B $  /X5   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V$UNPC 0AN&KH!P 9\;\5L"*#=NV
M%[""22+R)]M5X?9-LVF0P-,%^M@$1:"9=\,CRYMW6YE0MHTORLY/+G75^&U2
MA-"]*>6SPM;&3]O.-OTWI];5)O2O+E>=R<XFMXK3=*'<>$:RVXQG3@[';>(.
M1THFG\;E-FP3=:G4=^O.OK V>#5\T+1?T/_DVMG_K&]/IS*S^S;[JFT3[E3\
M+4C4_2".!S$\2,>#-#QH%@^:P8/F\: Y/&@1#UK @Y;QH"4\:!4/6L&#UO&@
M-3R(4D'&%)\D88W7F@2N">\U"6 37FP2R":\V22@37BU26";\&Z3 #?AY2:!
M;L+;30+>A->;!;T9KS<+>O,+SMK281NO-PMZ,UYO%O1FO-XLZ,UXO5G0F_%Z
MLZ WX_5F06_&Z\V"WHS76PMZ:[S>6M!;X_76@M[Z!7<ETF4)7F\MZ*WQ>FM!
M;XW76X_T]H5Q]O@17-GD_MDE-\,?UHS@]N%:V>=G#%,?[A\I'?HM5@W/I__%
MAZF_$>KFNG?W U!+ P04    " #9.:],"3F(>YD!  "!%@  $P   %M#;VYT
M96YT7U1Y<&5S72YX;6S-F-]NPB 4AU_%]':Q"-W<GZ@WVVXWD^T%6'MJB2T0
M0*=O/UIUR98N<5&3WTTI'#CG@Y+OHI/WK24_V#2U]M.D"L$^,.;SBAKI4V-)
MQTAI7"-#[+H%LS)?R@4Q,1J-66YT(!V&H<V1S"9/5,I5'0:/N_$V]321UM8J
MET$9S=:Z^)5TN$^8.JJ[.;Y2UE_%"<G@>1.S^#@V36+4)^R("K\7MOVX[G5-
MSJF"_H5FRE+E5)A\U<0EJ;>.9.$KHM#4J:^DH^(M.*47>]ZY=.%%-C$QV]3L
MQX3T<AQA6U,_0!<Y9^40KP7UE>H"NR<_J>#A-N3&T="Z&'5!]6PO(LUCU+-V
MXCFW2.W5*:@XJGA,?;D/^VG<LGOO._#OH&==<]JIGX]#@'!D(!S7(!PW(!QC
M$(Y;$(X[$(Y[$ X^0@%!,2I'42I'<2I'D2I'L2I'T2I'\2I'$2M',:M ,:M
M,:M ,:M ,:M ,:M ,:M ,:M ,:M ,:M ,6N&8M8,Q:P9BEDS%+-F*&;-+FC6
MKDT;J?1?)!_&+ _U6??G>?8%4$L! A0#%     @ V3FO3!\CSP/     $P(
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M4$L! A0#%     @ V3FO3(+S2#P< P  9@X  !@              ( !\P\
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -DYKTP2P.;;
MA ,  / .   8              "  443  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #9.:],^$9'M'X%  #_&@  &
M@ '_%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ V3FO
M3-T[7+LQ @  BP8  !@              ( !LQP  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( -DYKTRF)UTGKP$  -(#   8
M      "  1H?  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #9.:],<CFA8K4!  #2 P  &               @ '_(   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ V3FO3)V\,\^U 0  T@,  !@
M             ( !ZB(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( -DYKTQET3K$L $  -(#   9              "  =4D  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ V3FO3"!9O!*S 0
MT@,  !D              ( !O"8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #9.:],Z:4S@+0!  #2 P  &0              @ &F
M*   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -DYKTQ*
MB3H>LP$  -(#   9              "  9$J  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ V3FO3*7:/$&T 0  T@,  !D
M     ( !>RP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -DYKTRF=P^B,P,   4-   9              "
M 0LW  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ V3FO
M3',(R$GD @  _@P  !D              ( !=3H  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #9.:],PP]J<K($   @&0  &0
M        @ &0/0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( -DYKTR[=K,W% 0  *@7   9              "  7E"  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ V3FO3*SYM>]. P  S@\
M !D              ( !Q$8  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #9.:],\^"(;YL&  #+)P  &0              @ %)2@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -DYKTQ/SUGM
M30<  (<M   9              "  1M1  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ V3FO3$3L,[\$ P  E0P  !D
M ( !GU@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #9
M.:],70_'N#$#  !!#0  &0              @ ':6P  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -DYKTP242(#90,  +8/   9
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M970S,BYX;6Q02P$"% ,4    " #9.:],IJ*H()0#  #0#P  &0
M    @ 'W;P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M -DYKTQKN\P2$P,  #P,   9              "  <)S  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ V3FO3$^B/S'R 0  + 4  !D
M             ( !#'<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #9.:],:184!.)K   =LP$ %               @ $U>0  >&PO
M<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #9.:],;7M+8F8"  #A#0
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:+GAM;%!+!08     +  L .8+  ";[@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>201</ContextCount>
  <ElementCount>240</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnauditedParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - University of Mississippi Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements</Role>
      <ShortName>University of Mississippi Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/Stockholdersdeficitandpreferredstocksubjecttoredemption</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Provisions for Conversion of Preferred Stock and Put Option Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiability</Role>
      <ShortName>Provisions for Conversion of Preferred Stock and Put Option Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Series B Warrant and Emerald Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilities</Role>
      <ShortName>Series B Warrant and Emerald Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Convertible Bridge Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConvertibleBridgeLoan</Role>
      <ShortName>Convertible Bridge Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/Stockholdersdeficitandpreferredstocksubjecttoredemption</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables</Role>
      <ShortName>Series B Warrant and Emerald Warrant Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - University of Mississippi Agreements (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/Universityofmississippiagreementsdetailtextuals</Role>
      <ShortName>University of Mississippi Agreements (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/UniversityOfMississippiAgreements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Commitments and Contingencies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals</Role>
      <ShortName>Commitments and Contingencies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockDetails1</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Common Stock (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockCommonStockDetailTextuals</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Common Stock (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Preferred Stock(Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockPreferredStockdetailTextuals1</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Preferred Stock(Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Warrants (Detail Textuals 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockWarrantsDetailTextuals2</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Warrants (Detail Textuals 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Stock Option Plans: 2014 Omnibus Incentive Plan (Detail Textuals 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockStockOptionPlans2014OmnibusIncentivePlanDetailTextuals3</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Stock Option Plans: 2014 Omnibus Incentive Plan (Detail Textuals 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Restricted Stock Awards (Detail Textuals 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockRestrictedStockAwardsDetailTextuals4</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Restricted Stock Awards (Detail Textuals 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndRedeemableConvertibleSeriesBAndConvertibleSeriesCDAndFPreferredStockTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Provisions for Conversion of Preferred Stock and Put Option Liability (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiabilityDetailTextuals</Role>
      <ShortName>Provisions for Conversion of Preferred Stock and Put Option Liability (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/ProvisionsForConversionOfPreferredStockAndPutOptionLiability</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails</Role>
      <ShortName>Series B Warrant and Emerald Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetails1</Role>
      <ShortName>Series B Warrant and Emerald Warrant Liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals</Role>
      <ShortName>Series B Warrant and Emerald Warrant Liabilities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Series B Warrant and Emerald Warrant Liabilities (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesDetailTextuals1</Role>
      <ShortName>Series B Warrant and Emerald Warrant Liabilities (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantAndEmeraldWarrantLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Convertible Bridge Loan (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConvertibleBridgeLoanDetailTextuals</Role>
      <ShortName>Convertible Bridge Loan (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/ConvertibleBridgeLoan</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nmus-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/Subsequenteventsdetailtextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SubsequentEvents</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nmus-20180331.xml</File>
    <File>nmus-20180331.xsd</File>
    <File>nmus-20180331_cal.xml</File>
    <File>nmus-20180331_def.xml</File>
    <File>nmus-20180331_lab.xml</File>
    <File>nmus-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001640334-18-000968-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-18-000968-xbrl.zip
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M/Y[G2C</GTGU6E-UGS[?4[3=IY._X9F?FN@9,QL$_$G@GK%[YH>41B0JPA?
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MZGI(0,Y*%K%OF'"5PZ5NT89VRE>CH0U0__F!Z3\ ]=IO81KI/Q*A^(9J=FC
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MMLS(^(=>!2N8+5[+=3V=G?>,><KHMO'0%Y%P5PSWP:18%VRI#/I]ZR+[S<M
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M132.L$(!#<C+FW<2#YR#U@2R!1O7SJ5>/L)P%?#H7Q0OC>PQ2Q-0I$;,11L
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M>948HGEF7G+2"W_UV,SS@4X+^E)!<VJ)J %$5*(WM7AM %[7K21.<=$W:^Q
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MM'OS?71!WE>,D2AD,W<VI#-K)$#P CI)F[P5YGQD]$'>1 D- :/"T]B/?I4
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M+B;?($[7%4L";);?#>JH!0<O; =I#0X/'XS*MN:06V+#SE1T14B8SV)@P/O
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M_;HVEY(3T381E"$I:K,+I"6'!I!#A5K7XO6\\5K,\P6)+!H%927@(F.?+GV
MW: H=,3B&V..L3$I2[.4_]BCNC 0^?@'TK8HAK>6&MPQ[CAU6Z*7X>OI#R@T
M0<QSJ>>\['>F0[LSL/KY'@A8I(&)"S2'5A:+D,]$Z&*BI(-.0W,%Y2'2AAY
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M%/1C  %M:/S;:A)-P7]K!C82K[F6:\H9-*=N+G)"O38YOB)1+/6XB6ZSG Q
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MW!?[D)RWBC$#=,/Y'-VBRXAWZ3S41Z-ES8VZPJUKL*F8+3)GTO^05VC\0$2
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M)A;C9UX6]U>_POWG*GR4"2!R$VA&8%&FZ?M7[^@9.Q+>JT-0WLY4][J*ZL#
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MLL/IQA6GTSY_Y%;>W)>_X.*[%__YATA4_$15H3H<:>#>.ABMT7!JFV8&S8/
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M.OGL=!"J-;_;"T+[6&(/S.EH!E3+LUR>-/NE!6S-TXK.%27E0=Z*X&\UCY5
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M<)[:0:."F^FY+MB^""]H52!:F*AQH$& OTN#XQ=SJ887+0KZA#YAQM4H?IM
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M[%G V,I-)?07=OXWPOV/9O[R;U!+ P04    " #9.:],A5!NMW\)  "6?@
M%0   &YM=7,M,C Q.# S,S%?8V%L+GAM;.U=;7/BMA;^WIG^!U_ZM820[=[L
M9C;MD$!ZF4E"!MBVWSJ*?0BZM24JR03ZZZ]D["POMBP#L07<Z4QWU^C(YSS/
MT=&1=&Q_^646^,X4&,>47->:9^<U!XA+/4Q>KFM?AW?U3[5??O[^NR__JM?_
MN.G?.VWJA@$0X3S(-B,,GO.*Q=CI_%/O>%A0YORVZ,MIGEV>G9\U'?G780C<
M0_,?G0<T=YH??W0NSIN?G.;%U?E/5Q\OG:<'IUY7]_ Q^>L9<7"D3H1?U\9"
M3*X:C=?7U[/9,_//*'MI7)R??V@D#6N+EE<SCE=:OWY(VC8;?SS<#]PQ!*B.
M"1>(N-^D5#=I<LW/GS\WHE]E4XZO>"1_3UTD(I1R]7(R6ZA_U9-F=76IWKRH
M?VB>S;A74Q@PZD,?1DYT^RLQG\!UC>-@XBNUHVMC!J/K&@E"7E<XGG]82/]P
M2PFG/O:0 .\&^<K2P1A \)JC.OW:[ZYH3D#V\(PI=[$D',Y<&C14NT9V/PVE
MH(M\-_0C).ZE.BN*PDP \<!+5%7][7K3R#&HNW(?7U%!V2HB\6TBO$>(/T>@
M2Y!>$)I(\)N7#? %3ZXH["[KY\T8^Q_BRW^V.)=WO0T9DTZ>W,!'S^!'M_TS
MO5VC9"UO$1^WB*?^Z/P=XBGRI1:\)6X18W,Y=']#?@@:[<WDU_ENL54#$7.3
M>\B_;I"]ZOEQBP8/@R#JK8X%!(G\B-% !W!R7[J-'0YE'C 9W61P"[E4DDZ4
M LBO.:^ 7\9"_E0ZA7W@@F%7^ONN9!;MR7Y:"V,3$WQA$\%/#"8(>YW9! B'
M_(B2WMY^LC+LC"GY8!,E"WMRH[K4JV+(L[!>(\0LKI7K]'0"3,R?Y!0NY,!5
M@W:B\L5'T/N^1LQ:-O3&FL6D,LFYQ^@9^UA@,$AP4AJ7JVW+=6DH@_T3FJ-G
MWR" 9@A4Z#[9@&\,[ QC[1OA:YKVP5<Y^Q-B9FYE)'Z(E&4 85\4D'JS$+R!
M7&4Q4\K2! Z%I%1CS;*3"F@I%*.S90Z)G#2!F)^?]L'/YE:)NJ)F[RE66U5W
ME-U2$N^!]48RGQV!5,,;".K^E8)^$6FK>2@$0\S(1WM&S$);@67P;<.SR!\N
M&0)6<Y1G;$S+ORL8*&LJ%1TIZ^)6TU ,B)B42WO&RI*%CY2X1;+_I?;EZMP&
MAJ>2OBD4U3Y/T@Y7VS1E?=#G(F#?\F!)43/WLH2,+ HTR4D>ZH=A58H[6;18
MB9*/,?6E7EQMKXBYQJM2&I>=D00!)9$:N2<PZTTK=)ALD#>SD'4#[8M +<_#
M"QV>$/:ZY!9-L$#^DNJZ%56^\$$090*"?:/]=\084N<[Q.LK#7@O%.K,7E4C
M:$C3BAT$77K#[=NLZ(- F(#708Q(%;E<R8=!&&V M6&$7:S+S@R$#X(T$Q#V
MN8^Q]P1->ENA^357U(ZD1VN6)A.R<3)3 1N+ !:Q02XTA?0T(*X^O=9)'2!'
M6A#LF\6&$$PH0VR^L"HI56@%ZKB@)03#SZ%01P9#^H1R5K+%^SI ?K< S'!*
M/#0DTEH:3B&-M<*\G[__;OF_70H+>X^#WGVWW1IVVH.A_/]#YW$XZ-WUGCK]
MUK K?_U*4"CS357X5ZS4L$#/[UE\6$"-DBM6>A-@2(6[N+Q&%_4WVU90TP9R
MJ*B*K39,P:=1-42LCKZ"32-7:0E4)@$I-6LZVVTL0?P5B#3.EQJWO  3S 6+
M-AOS"<N3/ S*<NVWL:SPS;HND0$,[BDWB@E+K2N<%S7*KY.3PF+^&*J7G>M]
ML^-.&KM(34.I=*P])?P&1I3!HMT0S8 _8$*9G-F[1  #K@K'5GM93/P/(,94
M_C*53:+45\-RF5I4Z#T5@)WIE<L.;-^R,3$W/Y*OMSQM>C=PRY\!2@\Y=PBS
M:/.]Y?TW7-C3&R4;B!JF]7*GS7L.IOFKS0)>D%%E\:;"VXV31:2TLC-S@7-5
ME$-= "^-YBTZ.4W.MT&[A'*T7Q$FRI(>^59:$IT%F-6CF8J?,.?&"-M7ZM8E
M7NB"IRDZ,IGI3?LX31_9 NO\XKO2LP.E7UR*_FW;_ ZB?4CU6Y?S4#U=>TNY
M-ELHUL]I>TQ!S/.K TOW&A4:N;(>9'3LS-0")\1\O,B#,HH[S65/VSL,L(T]
MXI,]$TXKH#+>_1-!M-"RC7GTO(N<+ ,<!AJ'R)<];8<PP#9VB,\6A8A'$$8[
MCJOM*F0Z5>'-R;Y$=[!QGR@V*TYI;H# 2%N\DR5Q&$2G6&KA#L^*0:TIPO[B
M\'NI>B\^([Y!'+NF@]&@)UM8-#=ZG><U9[!OR/7! PB4;:O+SC:>8@](ZMZ.
MN>SA$VB C^F0U91$O$,YQ&UK\)^[^][O>Z^&2.FX@F*(%"U*/OF4#J;> Q,]
MA25-NYE_Y2 GV+<CF98KI(]$3VJDS./Z*+E+QV6? &^;B55X)+\?ZO82Z\OE
MJ@T3!BZ.[-#NMBPU.T*F5F&PL:QB,$8,Y,04;>&H##&/L@R!(R0O"QHKW_"T
MLK:^PP015QJ9M]NI%3M"2O4PF9UVF1);]7G7T9"W[T.L>OG#L^QSK*/A_ET.
MI\KG_[UJ5XZ.9[."E)P73.P8H34U$GNH1TFI1CD:%HO#EW\"5$&T?N]3P:/A
MN_A17][)3I59\_Y/^XZ.:/,CO.;YN\;HI<U5564 WAUE]]C-2*%R18Z(JGQX
M$H:LVC#J$I>!7&NW8?%GEZR^7UE_-*<7/2)VS>%*6,X[+:B:YK77B1;B>5WV
M)(C> "QAVJH-J4V]'ZF ;=^>NTUO)^$,!J F[K&G;:WW<H].,/'I'!(KS-ZG
M5JB;DW ('8R))^04>.^8FJ5&K,7[;J,$I$6DBPKIFGW P7/(."1EHUF9VPX]
M'A'G.X.;T)]7MEUU)-A\/;*TJB?&P-Z0VS8Z%.SZB+QG?W G;K2G3;AWK9%8
ME"&^0XV$:<<E?X4$S:.2RR%MN7^'F$'FESHT%A?HI-JJJST0OO%EDP( 6OA4
M?@8H;^><^QX%IAV7_BV>:'=9U20GCZ"LO]==S9/1!54$EO=RS"T[M&]T%'2$
ME._^; 7L/HM1"^P'#H!-95:4F59J98Z&/ -X['N5W+*GQ8=(G1DP%^O?!*45
M.QI&S4"R[^6IR_KF?T/!1.JH*<WZNH)%[U15"*Q]HG+C$Y:K%Y9:/@'#ZD&A
MU?5(9^;ZH1>]_L@=(_("?;F<[8Q&X&J_<%*N(A7Z7360IU0@[[0VM?Q+ E:#
M;+S$,9S6_P_R+G'<<)K-?"3GR]O'T^6E_P%02P,$%     @ V3FO3,K6VJ(L
M-@  // # !4   !N;75S+3(P,3@P,S,Q7V1E9BYX;6SM?5ESXSB6[ON-F/_@
MF_TZN5AR=F563-T)><OVM-/RV*[*F2<&34(2NRC2Q<69KE]_ 5*B2 HK"1"'
M+D5T5#MM #SG?%@.SH;_^,\?Z_#H&25I$$>_O#E^]^'-$8J\V ^BY2]O?GVX
M?/OIS7_^OW_[/__Q?]^^_9_3N^NC\]C+URC*CK[B-HL ^4??@VQU=/'GVPL_
MR.+DZ+=RK*/C=S^]^_#N^ C_^)"CU'=?_OWHJ_MR=/SQWX\F'XX_'1U/?OYP
M\O/'GXYNOQZ]?4N^$0;1[X]NBHXP35'ZRYM5ECW]_/[]]^_?W_UX3,)W<;)\
M/_GP8?I^V_!-V?+G'VG0:/U]NFU[_/Y_OE[?>RNT=M\&49JYD;?K18:A]3O^
M_/GS^^*ON&D:_)P6_:]CS\T**0GI.F*V(/]ZNVWVEOSJ[?'D[?3XW8_4K^C"
M;?RL^DQ]@(_ORS^^(>)R$R^)0W2'%D>;'W^]N]KO%D39>S]8O]^T>>^&(?X2
MH>'G[.4)_?(F#=9/(=K^;I6@!9/%[?<)Y1\)S7\CH[WO00W^&45DPKSUT<+-
MPTPC;?MC:Z(T7KM!9(;0<NA>=!9#O%VC]2-*=!+9&+</A2M,3.+EC^AMQ;A&
M.FFC]Z$VBK.9UB6S&;"@:4N0:/!HG:=OR;;Y85IN%G\[BZ,T#@/?S9!_ZH9D
M8[M?(92E;X[:K!&2(H1'> SBU OP_H[>>?'Z?<$>>QR-!#Z6 Z?%P$]N@@^0
M%<H"SPW[D,L;E1#?C_SYS?W\^NI\]G!Q?O^ __OUXN;A?GYY-KO_Q^7U_-O]
MKY&;XR,/^;>]^.GZF9[HW+A9GJ#Y8HX72W&LI:=Y&D0H36=>%CP'68#26>3?
MY^NUF[S,%_?!,L+GO>=&V<SSXCS*L(9PBY' #*7G*'.#\ ']R')U"9BDI*>0
M?HV"0C7*7N+%.DA3\K^GI\!=)@@1)2CUB\]EW1A7';WW>ERO@ZP8&(L3KR,B
M-TQ17_SDQ^W)P'T6>[^OXM#'0CM'> 8$&?[@'?*QN-S'$.%/8WEF ?[Q'B7X
M\Z<E/<U?GIWCWU[>XF^@)$%^,6A)IRKCYNF!+K!C:!([ABLRLDSBJ$9LQ^5F
M@T*P0FW^RV]0#6=R\JD$*]QO;I+@0[:UBT_ B)5%'UB!%O^9/Q$=YQ9KKBG^
M[,E\'06/>7J%988/SF=$_M!D: I&X%WI!PO('4JS)/"RS3]GW]W$;TVG$S#2
MER*VIZAOD_@Y(#?F]#).2JK(O^:+)BF8N-L\*V?"=> ^!B%68GN=:AH_W'>V
ME:AL-A?\P8LUOI>$_N87VZ]6VJWR^:T\_M ,*1^<ZA\8F*6NJE;7SUABSS1P
M"CJ+JDUGN_V=)H&_1-=Q^Q"1,#8)A^B+2OZ8HC]R?,RAY]YW?\%@!:D^/CZB
MH-SJHM\;%.-V*/*1OZ69C-G7W%=X8&*O\9V0^#SBA&KH+(R<"S=]+"R=6%I+
MUWUZCT7VTWL49NGV-T2(/[W]<+QQ<OQM\VOG/L,D$*L!9@Y=X1\KC$/W$87%
MMQUV8^=#*20;%#^0@UR&VJ*A<]R&<Y8T:783;SO:QNBLY,59)/%:0ES;3\8"
M8H_B!"LOO[S!/?(44Q(7IZU+/E<8LG_VXHA,U(NPZ(:7#UJ2'W9_#^,4^;^\
MR9(<V0/I+'33=+XHU88?@=3L:O=Q)B:@X[@_.%!6\ A@I/# 1'1H<.JTG3><
M:!14]AL[4Q-PL/QZ'"QH,J;#0F7B]>#AG-<=J\9P:7J&C0%3<0,&H(V&UKP$
M?6UX=FG[&;N7<V($*IK+>1\F^F)@[&=<'H !=-8)(&HOY^.H &+QL 7H& A"
MYYT0HO9R_CXJA%@\;!&: $'HLA-"U%[.3Z-"B,7#%J&I=81F:8IOB+/'-$M<
M+^. TFSH?+*(@\H=:(]L.-M72=I9GI#@#VD$6NV=SQ:!V!<N#X1]RL&<]6=N
MNB+&>OQ_%W_DP;,;%C$/V9F;)"]!M/S-#7.>64"JOW/\P3I6% P82K0L1V P
MW#E1^J*I.))S;,0,9 ;7#KS!V3'Q:?KD!O[%CR=\?40;GCE 4ML[QT9,/V;@
M8G( 1\=K<"1[?#G'9@P^1D#8HQR.^G:;Q$\HR5Z(;[YP\^"5_$14HQO$7QCL
M;LZQ34."K$HAX@#.IE5R)%P8SK%-\X":)D=HA;,!U9R9))BX%J5!)D7V(J%:
MRP[A'-NT$*C<>U0X @FE_+V(W<DYMFDN4() B"*%-3"J]R98/[UU7XI *+$N
M0.W@'-NT*@ADS=@/F8Q !><.A6Z9<E+C5!XJ:G?GV*850@=P3+8 Z1&>E^3(
MOW=#-Y%%CM+!F=BT0G3%BL$(G)-K0^,^?V* ]OLX$YL6A3X8T7G1<5_:C]HB
MOW&JZ%)N<"D%!(7>SL2FQ4 )#D6NML"<6%\_M2B_<_28B1</O8,SL6E7Z+1R
MV(QLT?DXW+)I$:.Z;EK=G8E-4X*^A4-A:XO-WZVO'*4CA[8_V[0[=%HQ=":V
MB/P$"9&;./*Z7&3W^SD3FZ8'O7=9.G=P5.USE 3/+LEYHA+-@5#0TYD ,4@P
M$* C)\$4F-NN*F ,CH 8(I1@8K("9V'52)3#Q)D L2QHV/4(+W NK)S:#ERM
MF]G+F0(Q+'2%2L ;'*?? UH_Q8F;O)2L;1WVLS6Q:,VR+ D>\XQ8M1[BLK(,
M!U#EL9PI$-M$5Y@[<0SGHMS)O\41U!2(;:,KG'S6=%RA]>VWFQ(<PFBR5E-G
M:M.H(1 P>R]MLP!&1YSY?E!^^M8-_*OHS'T*,C>LT<PSV@H[.U.;5H].<,DQ
M!4>/W-8'(?47@N4J2^=Y1BJ DMJF'.QXW9RI33M()]1$[,!1-N](#G2$_ LW
MB3!QZ<SS\G5>N-PVE32XX9BBSL[4;EA&!^SDF(*C<^XSJ:1N.%.;AH]."-&9
M@*,(BG2G'N%.SA2(_4/#K9O)H,""_[Y9HV&0J@V\JJ>'&@ZR%!]J.!QJ.!QJ
M.!QJ.!QJ.!QJ.!C>S0XU',90PT%GA8!QU7!@\0#'DJ._0L"X:CBP>(!CNVGY
M2V[=9)X4.[I?6'9O47*_PE<5>1\3:P2KM1U4=')Y?N"LLQ;-!8'I+,]6<1+\
MN;NWBM%K]QQ-)0@Q'V#77$GK59KFZDB5O:R6B>B-4L4#''LHE4XY+X2HJ]TZ
M$;W!:G&BPV#*"&(N3DPR-XC1["Q.J5FVC)9VBS;(")E#.$BO=@?%0**WW6H-
M*HM!DADX@>,U@A74 4XONT4=.F)%8P).*/D>H4(E@-'#;E6'7MCL&-CB\@D>
M+G)'/Z^;W0(0O1!J<;&%Z;.L9\V8;ZWK"WP'9]O!V79PMAV<;9"=.P=G&RP\
M#LZV(3P%.NMQC\O9QN(!&$ '9QM<9]NM^U*D-VW8$IG.9+I9=;>IZ'8")N"
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M9EF>K0*TN/B!O)S<R^>+1>"A1*C<<'K9R3_2!J(DAW NSP6AET'D1E[@ADH
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M#*7A:#[N6@3#*<&R(4RH]C?:.1/+1M.V.+E"W]$,;98K2QW(@=%-_/ N3XS
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M_;&!'8? _U-,0>6NN^!GC!FX7V@LDX95*,T$$LA7/'WVPHBO[C%I5('?)E'
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MLUV/-_PB5)86/7OYZ/TM2<\C+U,5F=.7_[8 #7W]:$>&3MU[,?M$3"?U_+(
M\M,+$2"(@ 'HS4RV7397>?9L@(+[ZY5I*[WUYBK8@H5**;)'WX[S5T=\#UX*
M;I*]TNGW<?N_'-OS2M-11/W\X$7E6QNWXB0:2- J78MDFX^;@TDY&E=H:3J\
MT)F>87XTLC2#S#CB:,5KY&]/X^"_J)?>KJL@CTG097 ^R+%*CU";C\1H\=Z?
MC^<'JT8 MM>? 3B)V*%TW7OXV E$^>O+%XXH.X!@NZLPX$3UX6.8#:>7$;MP
ME $DT'N+(22M)$?A# $&^FW1:YSF-:+#:R!\WH;^EN<6[WD5!"J:700BX1C9
MI8 1&P_?"ICP\ AANZ"^,&WL+[^U"/#U3 ,Q/[W+;S-7.8CP48C"=_:+1V =
MC1;=$.?@B/A>UI#F8TE'8A?5 J$VATII&)/0Z.<) _3X.7G<)H>,4>DJ7.>4
M6I8J-H(%F^0XB&@GL4[.(&P**>>08A*NP]9(!/G5'"*C;H](0P_48A\4?=WX
M>V:L-_J&TF>00F@D>G.^0[C15+YSR/N^6;**G4,^^8VFPI?9FX0;P#)H$R-\
M4Y8TJRN:J:[+OJ:W"1V6'_$^H<WO(T3UD::[A@MO9<+;<T%-=A>1SJL8-N+H
MD(K''!LNOGGN1&2#AU??L+EY&Q%D5E8A$,-6M5\:QM2:+>H5M;/OS(RF>C:(
MC=0AHZA(P42UDQ*+(+/= 1/&[IUTT>DQL;?C-J@T1#C68(7$' _*CMKZ#@G.
M&(E.<OG>-TR"JR3E&B.,>[=+7\94#0:VBK,.O8YHB,%$CB9L.&F,QV.977#:
M2YQX._%\1IQ&E"^V0>IQ&V:$1O*<W'#9/Z=AGM.8Q#JDR2$.F*JH#]I/+X2&
M[)2=DKV7YB_(C/^P@!H4^1V2SC$!N)@^ACOZ\YXA$^=WWHO"9^\JQ/Z9(*Z
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MFP07-5>Q3_^?@Q>%:_97S@>&YWA7L# ],%S0[S:?*8$0"84TP C-=01HMJ"
M=0&I2;"_S/)PQ[T1)JP5'7:2#@T=)43Y'TV0".I63$* H_X\5A0H51N2HA;N
MND#3Y\)5$8S0:1]E*SBF/JV<I\8T4"?I:/F=-V)%FSOV5P2Q#O/UKF=8K[N7
MHEURKS>RJ_% YG%TN7W8L^BP^@AIXVU6LT;[]7L:T\^&;;)4<T%\ 34BG6Y(
M?"3ODE[7T"T&0]>5LL6A696>I#/A8&^7S=%H5GBDNUY\D%C7 3E1FU"]D(R1
MW*2^!KF._0.OB_,S[]3EUBG3 !RH735"MR,F?%+IL9-R&A'S,-:9'H%DX8R2
ML$2RU4$<D?UVPK*I*G0(\Y@+UJK3YB([[ 08R^N"=Z-'Y;E$HFMV>F#GAC3\
MY[!+80@%ZDIE$+G.M>=Q;;85D7-(/0G%M<D(O#*)5R;Q\I1X@5TIF#&D]BK!
MB!NA1.S.2V_3AYR';\2]\QU-Q0JM\P_,H((G()@B/RB*;"[AMQ!B-I%W]FR^
M%%$4[L"$.!=BNF<X/PM,WX0Q"9(H\E*9(20$N%,J'CXSP8K7S5(3;!A]A&_^
MX>"E7LQ&7WEA1(/'Y,Y[,3I2]TX$.4\K4.@D#)3#B!Q''A/>11KZ)&V]^K5<
M?9[P1!WR.<RW3$C>OR6!]R+.V7&2A[XL8,Z6OO4RFB(X:1NBJ:C7S%WES1@*
M(#F;ZZ1-?3#7B-J2]CSQ*0VR*X;>=98=/(;Z[?H\V>V26.@H>U,^!!#>B@^C
MW#5F<@[A;$#*69P7Y;R9GC:-2!]T0/(T"$2F%3O;K@^\AY(79D@2(\:@5>R0
M?+>U27DZTKX ,SEN,EGM&25R"/PI0UUCZ$J9*1I$C\A5CV_E:^;K.,M387^S
M6V89T\>M%]_N.8B,%RNCP77,',0P,0YD++8>M(_-IR.X>>F3^NODZ84TQQ4K
M**NC%&_8&ZL@8AG,+?)B4BQD1>12F-]$Y&(0/ 8!I/NG@ZBZP@SO(4[-'N6"
M1+50D*A!(+]I)YX%"'#?&4IOCBNA,*W27+!.CN^G![;D-%G3+!-N'L\0/.>!
M>Y%-\RF147SS>SL7T-#>OQT9.BZRG$V:TWDRS>)*9P$<O> YS)+T1:;2LC.Y
M]Q3A>P3KP-9F]8BL>7I!48X$<!KT*RO+%[.&T*"</&-D.WQ<3B1*9PW/^UIG
M+.^IGVQB?A<DC7N!IM]$4_& '<0QF@)1KPY42(=&C7/+#2K\Q#@@R5X^A0"K
MXS)&%DT<&2NQ7DYWG4=>EMVN_^)QCRJ_3>_#S39_Y*;%UNO00()V,K1(=D(X
M?##GTV(XOQ@4$\BO8@J^*G_#>VAD8@<W$)@K;3H_J % V4T=2A8LB*M/Q. ^
M:57BT"8!\YM;1PD=*)1Z4%G44<.%6/M/&.RCNRJTKK^H2 :X2RFO-MX(C1??
MR2QZ.P\" 4D2,$"M)R]%%%\_NKDK62[#T#9N'LP09 LXX-3('-"CAR05P%36
MU&D!AH(V)G'_<_*X30Z9QZNAK'-*8QO5H,DNMH +F\IO18!.NOOGA)3323$?
ME3*9"W%$NF4N%!OJ!IFJF4;L3'P21UF>5"')?MMG5V'LQ7X8;WH^_I@4@\1O
MMTD4,)FP<&@F_RC,J\/I26>D[XH.\&>D^HY"!3XF]=CFY] X6@M04*B2K*3"
M>H!BN8)B"!RX!6C5?&;%&"\O&6]=,-YH,B)Q%.?2>9J'H/,HO%GU_EWD^>+6
M_73#_F=2W]3J4\C<54LRN6KT"BP1<%^37SN20D)C/W15C8HBJ!W@D;1PT,@J
M,J'WG%WTCXLS[:!\IM&S#^$7A3,O-#TO#U94!W-UIAV^ .TY.Q%%JU0+B%J?
MF(,E%5R,_O D=&'L^#NMBW9,!UQ>[B044"G03,LD?<3!Y[NZZQ,C1]59F4RJ
M+:6V/I_#&;7X A8?U(HH1EJR<+3.7Z7#.8H<0CD.HH_3NQR%^'&@U8 &>%U'
M>R5AY3%::XB)5!]]9A^H/GQAJ?ST1L,&-KAS:$<(O<(K897\?H%-Y<U)"IX+
M,XPX,@=P',I#KM\@-1!Z? Z*P<S7L]<*$ZNZ<:=B,V/A\BTTGI\;H0Q5(OJS
M\I(T$KK2^&"(U$&<AA1*'3K .6@.T/,I!B=_TET#3:-N+WEN(_O^Y8ZF7A14
M,=!Q/J4A5&AOTAAYK=(LH9 "3./.9G[_T;I/P!3H<X[28(O+:73&\OA4K$,8
MGU]H)]9&'J&53 ,G[]]HFE/;IY#?+-FDVCXS_4;3K%J3Q7\#VZYZS#:86%JK
M'05FU\LO-/7#C!GZD)?-*26J^&OV;LC\C@..ZDV4 2F,>7Q%2FA$@&N,R:I!
M"[<9G9421W5%J@J?*%X:3X5BN<>TW-F]V%FS(J:C,2\KBCV";7$__N#^QR3J
MS?ZYH*%N&]D1I0)L%V<ZF@D;-6HAT=<_A+= *4:@">28+)OI],\S+=N]<0/P
MPD<$C 96?M2BY0@);,&</KDU",WT".T([5$J)%EMZC0.;@]YEK/#%#LW&<54
MM ! PB<#*"GL5596SN,=%!LSH._37+&11=MD[9(9L;$/?%@BU)#GSWK<B"=\
M["<O$L5VLRVE.0F\'$O#0Q-14\<Y#.1LP=*E_I8&!]ZJ>K#^7:8J@.=4Q&6Z
M#T,'2J8D8:?:: &;BX-)Y=%,6WH4;5V9R;G0*%PS-0LN6+R=,<DG;T=M"M4<
MS0'K972\\$XA _8OPO^.K?Q,'\'UW7NZU%Z>/=SJRK1F0ZO7#C(:IL%:+:9_
M0\RJG??MQHACPNTN#I\.V35#)N;A)0Z?C?K)XO)U  3(46$0K3;7%!-(-8,(
M/N)S$-V@3HD6@A.#-3J*_C',&](@BN248"9IZG."D9B]@B8'SA>D$WP1VGA-
M0K3)6Q#@OI"=CM',3@%3<=D(HSQ=[7D>3I!5Y^^3*+I*4C[*R*K/O080MV!^
MPO8*)SG3"^=9(9S%N&/A[&D/(B*9\NOD5_Y]4BP @8L"1&)&E&<OC/CQFS#'
M@'R0U_'K@DZ_R<C_\G;[?RUZWR+P?9:GTRE).:NLY0 29L0C*>6J.8S"RI'R
M2*&L98LSWIKOB6["..:!6/'WO>A;P=-J^1\IC]76OT;B;"VD0=7>VC+J$YF-
MT5\QJ6_,YEX+Z WX_(1>W.;,>8OF?/.]/)W/B@LI+R\UX1P$D7KU(??2_!42
MI;(=,]'E,@Y>(55F8A7WY(OE*=((Y<15HS(JH!5GU'VADL(:^(K]PX\.XE)8
MIAJ^8;[>(0[S;XM&'FQ(OF54;EX?!X>4_X<3/J7[),WYOP#=%3A#:)R,LHQ%
M1N:^B#,#A3L>E]__:H[&-4$7=U&*3W^=YV$U74OTY6$WDR?CS4RTP''H51-C
M9A-3D!6=>5E668&<A(\U)3(S4F:&]QF294U_O9*O[@3<)/+BQJ7Z^-=]^M71
MN-?0T-GH@NMDHR/,S$:G(C$ZLP.EVD#/-&T-B\P4G?.@0Q0!GFGJ%7PUIYHF
M41<W/=7'H9\O+$W9XF^>) /3J<5; :DN"R7Y=1[W=&0I^<*?C2]PG/)T-)C9
MY%:D16=REU;A(&>]M@5Y!2ENW8"G/OMFGOPG_2I>;2K<$'$G3X];E<9WU;SX
M!$Z\P4';3Y6Z[<^K>;W)@T8B/&]"H8G\ODIE*+G&]*'2]!^&>NTT!PD7TG8K
M(K^(H&+-$E0LO>HY'UB[E++Y6G WR&D!PQ]/ @L6$O1GJX ]OIS-$FE?<,YE
MAEZ/!1>7;MEU?"?X]D.:9,L]X=$LX;4?9/K)JM+*<]WEV]=)6A;_T\TFI1LO
MIXT0S\SI#9 G,#NFR!.R9]AM&;"2*$?U^!04>O6G,XU&6N1HIE9'"VIUOL/7
M67:@P84(3\K%R/.X^*-!6D*_G;6'#':R<B'"G$>G\CO\G3*1B\%Q@)B"4*7:
M45[WP[F&SL*@]_U<)>'U.'=72;JF87Y@")7Z;&GGKF\)K]VYZR?KG)JG\<49
M=0^<NVA&T?FO12&]0SL:K.7H*6GP7M(@%AZYW0,<9'SPZGU@C>)>Q =6:^W7
M8_RJTHN77_;49S\^)OQ7A37G;\J7O;(P7L]KO<FP(/B<MO*7NMQHN1!^EN:_
MKEQXOIBOZ/9C!.6/J%4-YT'BCTP1;LF/[U:B6PV.@PY&.EU07Q1K*DGU.SP'
MIX4UZ*RA=DOU"9&S6ZQ4- ]@1E,,<L@1FG<1K_/1R#!IIT_:+=U,V>N%?;48
MBS!':&GBMDCR-;P,L2?"UUMZ!T MF9QNEE",@':C<9E\M,AYGWD,??QUO? 8
M)N5\=J*91SJW@ESJ78<]/9<IBK+<$X[1%)@[U\@\X>HK)X1ITM77*1$+ONBQ
M)T&SS=.V[+%7]=7C_D[235 DAS@HAQ0Q'Z]>W&M_FV-H]&=XEF-F\0$=H:(0
MQ) 3-)^7VKN 5WUP5I!T/F>H^.#LCA#8:=F0HG.G^,&=E T)8*[ZR]([^-3^
MPIIFL;.P1L\!JO\JWV;Y4[#BTZ_R#*PDXWQ*O_HDM-H'I.9@'MTK]/2-D3=7
M]G7)&WSJ?C&],KN/K]5G@"J^>OX/Y^,KEO"JO7PE6>=3^=4GH54^ JK"EVU!
M0 1S$U"78,%G A;7.XOY_%J]!V@2&OD=54;'\@> X56\RK. "7'GLQ&-5NW-
MW*FO[([,A<:O(OL.(74&<^Y>X2'+A4+FQO:YIB5MT!*?Y870Z;.?PTS-RNO)
MKF_<'OV%AILM1X\I%6]#RS.GP(\GV*S!2Z29KO"U/TQSVI3%B@V52R+%FJIP
M8>$)_'KZE.6IY^<X<BI1;<H [= <D>#5R]+EV^QTRU>GX)=Z/66ZG-?Z>,J<
MW%CT-7@Z&SSID2:XH2/,UUMKS$0U+E6!S$ O(C(_F549'DL3-,XWF7!IZ$\4
MDVZ#BVG*3&V37$E=_F)Y S7K*6+6C1C(0L-_7)A>6TQS3IA<5;PB#5V5PW)4
MTFZV>=I5H3TN3$W\655S3V$T=-H9YS8@KKH&HA[&^<ISZ(97I)![JO:@\IMM
MU_?JG6?[#9E53?=6D4.GJ+%OR5=0?6PF1;*,2^VF11"I\=&%;C#$XT>N$JW?
M/??FX*A\MK3*QU@2S7*C7D6JUBNDWG_G\FG@MP>3:/$12<.R0^0C_Y#5XX_F
M/- 7&\<(M+F^:/O[J_C[]%DM[J\!],MN9A5Z3X?(2TD09GZ49 >95"BG(TO,
M[^&EX6SZ+B,MV>3!RX60RD5P"4YB3O73+V%?$QY%<7P=$+C6#7K4%()2CR._
M\I&+)X(MB@Q@0P4#QAOHG3#,=<L)4FL1%\G."SOZ<.C0W \$.@2E0FV(Y\BO
M<BBN5,K)L0$/M6A9SR@>HN.[Y43H7'26$EU//E*;JNC=B5 VIP^%-F/),40,
M(K_*83B,C.WJT1@3)>=H#8B*;<8\0*1I2+.SOX@'++F2BS4O._L P+X'[T>I
M$T,2P\@9*0:"<?9TF'R6 Q$=F0PQ:)R=PGB=I#L9S>-M#E-1U*Z-(K)3E$Z*
M#!XGJT5HO&3?L3$T36D@U,;I)J7"!36S5^: 8![XFJ&HE)=J8F';JJGSZ0+;
MY[6382C;7WKE5 Q//]UP,]<5RNW%\D330D(UKRS-Q7/)Z[PDS1]INKN@3_DC
M^YHB.C-P(]L'!/IPJ4*M>T?%QITP>=\1/G)%^%C H(8#J>UNJ-6;!<AWRK"&
MXO*B?SK<Q:L*'4-N XP 6!'8[-I&MSG+\=A9&@8;>I-XL=UQ23D?6J/U(-1Y
MFB2&$#X&R#>:$ -TVE?%44:*5\%.R\G#/8UXZ\L[+\U?'MD))O-\<4UZ]M+\
MB\WUC 5$*,ULA737A15#B!B#[9[#?CNU6MMZ+V$8U^WZHP<"M#+O16J  ;'>
M$Z@WR$@S*G=G.1:[CGD)H22UNQYHS8+2<9W%M]FH'( A7&*\Z%/?9Z=DW@2:
MA,58-+JWGUVT^K675T8G%]V$,;W.Z<[XS-X[%T&241,15:(1'T/$('S91KKU
MBW6'_(\D+8-B9!W&7NR'7E1VT.-A,C\Z!(+?B<>3DR+Z'7G<LO'U&%[X[)#)
MU-<B;8ERJ.S()7(.FZ$V+\L2]@4N09_#?$L"H5O)3G!@1@+*UB"_EK %,O6P
M\^(7XGVA6=FN3ZX!C;W1,;YI-E2;ZY?,B$K\OU]GV8$&%X>4-Z:1)4%X"F,F
M?W^5I \T?0Y]:I$B9045+F?*$OE.X$2$AN5((D%4;WPDE%7Y5R8!I(2$P-*-
M1KVX&9<W V&-8U9,(6^8"(LJA]FW**[[1V,LFQWS9$R_P%U,+9%GVFF=B.*.
MF4BZYNKK*>%%6:5N0^,GN(G\0'*:@[POF6K#_)PT8^;G=BV6*A<F?\TLT3O;
MH]LP0.B3G G*79$NYW F%[-*-4:JB2@2',9@68MQ(;^^"C7P(ZPQWQJ=:$V9
M=H3_7W_"Z&5<[QR09(#NPC7" 5],P7[-^UG6;']O/[SHQA6]WUI_76<9R26\
M@M_5]^W]S+Z@N^]%M)!^J0?9/QI&^CIN1%FM;]QM8$/;1TM"=!Q_-KUA)&N;
M4IC+PNEG+G ##J([K['H-SW?5:<(NL;U![>I+A)@EL-@S_Y(COF?Z&?QIVF.
M]S4TE,?Z)K(NQWDV7XY ?XK78<K_(,J%-DZS GEVBBT#VZ)B"1-M=JAGUI@'
M.U_5D5Z'_O!1/HR#\#D,#EY4TV/Z&K-)%N;A\T)(]T1LP+TH-_WD'HMH*Z<%
M8Q"1EV6WZR)/^S:]YX^\*T-!?;;4/&2G,8_7MSE[*<9EQ4#K],>QGX/VS\:3
M:_C<+^;R2A_%NX"%-?K"^)=#N';;,T2V7D9+4K2M0*$'11BSKG:,*_0S(X.4
M_*#0DI/I_4=$[-$UB8(3.D*"SJ&?2+&:A= FT:HC FP\@[7Z_J"_WC<%)+S6
M67:;^_@ <KLNG]-!^M86"VZH"@2AM<$U-XN,M):/))[6S][J<%HO;T,D<]NZ
M9XV9T)[6$1(6B<^ SI%VR:>;#7_.E5.R29,L8R?8Q*<TR$C&];.T94P_<^[_
M1!D3_8:GI- 9)'B,=^.$(3K3W)4/RZ3TQ26:OPZYCK,\%;JWN!H+GR+:"MSW
MW1CW'FS- 4)%RVQ0;G,BGTOJR2O2F%[^8\8K,_N V1ADV[=IJU;$.TBBR$NS
M^K<X@F1C4+Z.F3\KLP&U%XE@<2-K>=6&CFR%=5F]5"^BNK*O%]N\:K!.9[&$
M#NVQ6!.C5VW5$%9U=LN1,CNZRT/D_HS&_Z&5^$+".$^.SOWH7 DW 3!R-YRX
M?TQMC<-31O]Q8("O9+IUO+DKXG%"NUS0S$_#O>(*OJ<2@ 4\F$H;5@AWF+6:
M3:KII)Q?]+%M0(#/RYD,W76%;A6O+1R/8$9\'6IQC$*X$97(AG%OHBXBV6F2
M4S\GWL8+F< 2CWLL)T$8'?@()&$-!XG7E.RP%O<1NNHZSE-&U]#_Q8L.M JU
M5%U=3#T-,V"@3WX,4.VZQ\44(N8T IAU?R84887Q"#X+!.N(8=4^:?G(YZ08
M'A4$&D:6('MW9"J?PP^1#(5SC-\C:@O%01FN5=W1MXH1U1/,O*'17X'QD28@
M3G\Z$QM37:OTYC:5YYQ.Q:O&1 1>U0P$JN\\]^U29PSWZA8X2Z+ICW\.;A8<
M!?C#KIX$ 2SNU52*1>-T3:151KVMJ.JW5A< 1XZ?E2\V# W4&3-!5EMIN+XC
M.3XJXG''7%"LL3H^%2'RP5S0.GKRT= RG@)=9$Z8L60.>V&F8KE<Y/FNN%R\
M8H0HLX9OU\=Z3OZ+LK_8NFP3?07J[FPT<=J24 (DG.](,TN[Y9VM2 VW_(TW
MI\-F?]<V,W'"!G%TS@N*2[CY:)%2GX;/_/$])PJOCU&5L*UB:.!NVK3*1'N'
M-XDF&>&F'7])?8=X0?V4,JUNY;59 P=UXAQ(T67SXS-I T@GO8"4</#X>!-0
MX)X&!_%F3*;FMA[$=G4?(E=PBOVO,BR"8A!_E-1'!K_!&2V2?$<NOX@B1LR]
MW/(V?20X4'YY(!+;>84.)OIA>6? KQ2>PPSJ]F!"X3?V.AW5RI).:'.!-^$_
M#F$@^+'6Y")L:>YN&L*#<RR-$1Y0F2O2F-UP&E?RS@*%G^B,:Q.U?>T//_=A
M!NCTV#'O@'MCQ;EC'!G*=IZI_0USGVH]<+I+#G%NY[3H ,$Z*'H4>XQ1,9S?
M]#7<#SD#D=OAC->QC^'-@]<(C\(.L49<::_'$9NI-Y ] [,^+'@C],/', YW
MA]U-F(<;L9/_<0AD!V2ECNB&[@>!@%S&&:#69K5B"JGGD&H2D'Z8!*]?RJMP
M'DR(R-_8!($2LS0!Y4Y&F7CC)[N]%[\@N"=SP+*A*';%1D;U1OZMVDA 9>$@
M.X.W6H;2!^7GUSKKS,OL.P#I@4$G,0^A.NC6-_P/,0>%^S$>NTQBU[#0J9>#
M./,CF,O$1-NPZ0@S7;Y.;MPLR<OKG_=ELK,L"7B\#B/K[0H;Q*B[$T*1-"'.
M (TKYR*WAH-K"N=MY^X&WA&8G!:* A('3HN&*",(5\Y)C(8;$8^D"Q(?8Z3V
M4+L>XU3'"'UX%#(I KV-1?!Z[,]>5+WZL(ITV,(&#7[8$T(7?:M '.O$&DJ1
M98C"2YD!_^K2X%C>:8U_-@_^[L&4\01HZ+O(@1;(@BZ.FF$X#N.F%I;0<4:7
M)BX@03P\:[3'"73O+0. _S(:;6<Q%A1 XJFX\;S:07%B^.4B):?!WPY9SADE
M>TQ.@R#D"_6B.R\,KN-S;Q_F7M2XR.5O7/\2YMO:L[JB7GY(C=-/)O\N=/QE
M0@)VLG1KT#S+H 9..'2>P%# /ZJ7(5KORIY(C=-C\15$K\]G)-P9C>DZ]%L5
M)]9RO#PT-;/^BD2W\Z'S-7BP:&IA-8HK32RI$]TD2Q?G,3FC]S3@7>8#(_=C
M  2(NS&(EO[^N'AU]9B0,TK*6=!U[\;@5%=694KOB3> FPDG>Q?)&BWES7$O
MADA<(#,Y4[L\1D(&_?*@H;(&(]8#$7P[\- .BSTY]/GS>1IN-E2\ \U1]JB
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MNF825%5K!<5Q;$I*=/K>I4WLUQ+[3>\9#=P4.PN'63<O1\E8L&TO7\^3E]&
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M+OD\2C)1'X/_G5?)D+> [9[O:/P%-3.9]V=O<M(8:_YE'Z9"FT@'HG(L!BL
M#$V'L>,Z='K.UL7@\C!2'U5@"XG;XU+^:<6?,918[>>I.^E@\VQ0:1B\#B[@
M_K^5" S;MB'Q&2'9=VGB4QID5VSM13N7>'-&\\^4QCUO6T_C0"/YZF//B,^
M!CM&D:<GS5D (QP:J<"1 E[_DWG>"Q%*VRQ-%U'!;UW1Y:F@2R.[+ZKHPNOV
M(8QZ3$J8EE,O$XI(RGN3\EAOPEP9/>7X+"7U1! %9Y1DO%8:CI",5DDCM*YL
M7%'K\<LO-/7#3%'4JVM-=/-!/"H]0HJ^'0T_BC0F(/!$G-!I.!W,):DF('%
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M5U%\@SW.*596!=K%[X!;C604C'F- 6I*R*#%R$W(\;OX;W.8R!*9JJCQE=N
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MRBB:F'>-8C?P=UX?U=+!\$*%E3\EFT+Z+9FXE&U_57X%XY6'G!:M1HYU\Q*
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M$""/ZC@KIPOII9]?"=I9O U_;$D08[334?PV"E/JK?<_R(WGS_4*R=D(9%5
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M0RW;F.3?4)ZVWI^1O<-=HJT\GY2RYT,ZA"EVQID.U-QV8&<QC>&$/H(,:E[
M3P9G.AHKG8Z0@LX8.N86*..@\_HQO9[ZFBWF>N%,1V/>.\",,3ONT#I"2Z9,
M-2[@LT:K(\YTH-9%*R>.]M!#:R\MF3L,AS&HV:/9%6<*F_9N7/.GQ> ?KS8#
MN]H YQL<U'PQ-^;PRET[)HK<K0UH_G3KF#,=:("EC=.J.Q6]::''\;9+XQG=
MXIF7!>EEY@;)&!][X1BUBA9Y[Z_L%K'\^11&=X>=R?61#'&^5!2@Z#H2A?0
M*TFK+*P']#H*BQS.PBGI_; YW0$ES3O/+ _\W(B4(3:Q/"C#)K2QC4A3^.Z5
M!7XOA,L(FT!6]T>1@KD6Z/*1O1RBZB*[6P?H"9 6"RRCYP./*&\BDBZM^X6!
MG_40$L.9DBP,PUY0RV/\]F%=NK0*:@&_"<*FB#,UA2C&L=86%[)6]#)K ;\=
MHD\O#\48GD O$%ZT8I=9"_CM$'UV>2AZ>VGWX.Q>M6*760OZV1%]>KDPH$U
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MIO<>UH8*5X_VERXJ)R;DZ["(W?^&Z+^0/R/?=)<H3R9S082YQLO3375K%=P
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M,#$X,#,S,5]D968N>&UL4$L! A0#%     @ V3FO3 LB*0 ::P  )DD& !4
M             ( !=#H! &YM=7,M,C Q.# S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( -DYKTSAK#Z*@D8  (X<!0 5              "  <&E 0!N;75S+3(P
D,3@P,S,Q7W!R92YX;6Q02P4&      8 !@"* 0  =NP!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
